{
  "version": "https://jsonfeed.org/version/1.1",
  "title": "medRxiv: new health research",
  "home_page_url": "https://www.medrxiv.org/",
  "description": "Events collected by UnlimitedPipe 0.10.62",
  "_unlimitedpipe": {
    "schema": "unlimitedpipe.event/1",
    "generator": "UnlimitedPipe 0.10.62"
  },
  "items": [
    {
      "id": "8e2d51d54fa44b772e61",
      "title": "Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
      "content_text": "Wildfire smoke has become an increasing public health concern in the contiguous United States (CONUS). Previous studies have provided high-resolution estimates of either total PM2.5 or wildfire-related PM2.5 during the past two decades, but few have focused on the most recent wildfire-intensive years, and jointly estimated both to quantify wildfire contributions to total PM2.5 exposure. This study developed a high-resolution machine learning framework to estimate daily 1-km concentrations of…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "8e2d51d54fa44b772e61",
          "source": "web",
          "type": "change",
          "key": "#f77b70fc283a32d70eec",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T11:28:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
            "item_type": "record",
            "summary": "added: Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
            "after": {
              "title": "Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
              "authors": "Liu, N.; Cheong, Y.; Larson, T.; Austin, E.; Seto, E.",
              "author_corresponding": "Ningrui Liu",
              "author_corresponding_institution": "University of Washington",
              "doi": "10.64898/2026.11.11.26367854",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "occupational and environmental health",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.11.26367854.source.xml",
              "abstract": "Wildfire smoke has become an increasing public health concern in the contiguous United States (CONUS). Previous studies have provided high-resolution estimates of either total PM2.5 or wildfire-related PM2.5 during the past two decades, but few have focused on the most recent wildfire-intensive years, and jointly estimated both to quantify wildfire contributions to total PM2.5 exposure. This study developed a high-resolution machine learning framework to estimate daily 1-km concentrations of total and wildfire-related PM2.5 across the CONUS from 2018 to 2024. This framework incorporates chemical precursors and wildfire smoke density as predictors and relies on publicly accessible data sources enabling future updates. The model achieved high performance with cross-validated R2 of 0.72 and 0.89 for daily and annual estimates, respectively. Elevated total PM2.5 concentrations were observed along the west coast and in several metropolitan areas across the CONUS. Wildfire smoke contributed substantially to total PM2.5 concentrations during major wildfire years, accounting for approximately 35% of PM2.5 along the west coast in 2020, and over 25% in the eastern U.S. in 2023. Wildfire-related PM2.5 mortality accounted for 20% of PM2.5-attributable deaths along the west coast in 2020 (30 times that in 2019), and 24% in the northeastern U.S. in 2023 (14 times that in 2019). These findings highlight the growing role of wildfire smoke as a major driver of total PM2.5 exposure and associated health risks in both western and eastern U.S., underscoring the need for sustained nationwide public health interventions to reduce wildfire smoke exposure.\n\n\n\nO_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=73 SRC=\"FIGDIR/small/26367854v1_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (32K):\norg.highwire.dtl.DTLVardef@1b05c54org.highwire.dtl.DTLVardef@17dc815org.highwire.dtl.DTLVardef@daece7org.highwire.dtl.DTLVardef@f73d69_HPS_FORMAT_FIGEXP  M_FIG Graphical Abstract\n\nC_FIG HighlightsO_LIDaily 1-km concentrations of total and wildfire PM2.5 were predicted for the CONUS.\nC_LIO_LIElevated PM2.5 was observed along the U.S. west coast and metropolitan areas.\nC_LIO_LIWildfire was a major driver of PM2.5 variability in both western and eastern U.S.\nC_LIO_LIWildfire contributed over 20% to PM2.5-related mortality in severe wildfire years.\nC_LI",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Wildfire smoke has become an increasing public health concern in the contiguous United States (CONUS). Previous studies have provided high-resolution estimates of either total PM2.5 or wildfire-related PM2.5 during the past two decades, but few have focused on the most recent wildfire-intensive years, and jointly estimated both to quantify wildfire contributions to total PM2.5 exposure. This study developed a high-resolution machine learning framework to estimate daily 1-km concentrations of total and wildfire-related PM2.5 across the CONUS from 2018 to 2024. This framework incorporates chemical precursors and wildfire smoke density as predictors and relies on publicly accessible data sources enabling future updates. The model achieved high performance with cross-validated R2 of 0.72 and 0.89 for daily and annual estimates, respectively. Elevated total PM2.5 concentrations were observed along the west coast and in several metropolitan areas across the CONUS. Wildfire smoke contributed substantially to total PM2.5 concentrations during major wildfire years, accounting for approximately 35% of PM2.5 along the west coast in 2020, and over 25% in the eastern U.S. in 2023. Wildfire-related PM2.5 mortality accounted for 20% of PM2.5-attributable deaths along the west coast in 2020 (30 times that in 2019), and 24% in the northeastern U.S. in 2023 (14 times that in 2019). These findings highlight the growing role of wildfire smoke as a major driver of total PM2.5 exposure and associated health risks in both western and eastern U.S., underscoring the need for sustained nationwide public health interventions to reduce wildfire smoke exposure.\n\n\n\nO_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=73 SRC=\"FIGDIR/small/26367854v1_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (32K):\norg.highwire.dtl.DTLVardef@1b05c54org.highwire.dtl.DTLVardef@17dc815org.highwire.dtl.DTLVardef@daece7org.highwire.dtl.DTLVardef@f73d69_HPS_FORMAT_FIGEXP  M_FIG Graphical Abstract\n\nC_FIG HighlightsO_LIDaily 1-km concentrations of total and wildfire PM2.5 were predicted for the CONUS.\nC_LIO_LIElevated PM2.5 was observed along the U.S. west coast and metropolitan areas.\nC_LIO_LIWildfire was a major driver of PM2.5 variability in both western and eastern U.S.\nC_LIO_LIWildfire contributed over 20% to PM2.5-related mortality in severe wildfire years.\nC_LI",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.11.26367854v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 215,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.11.26367854v1?rss=1"
    },
    {
      "id": "3e292d0eb7fe32d9e668",
      "title": "Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
      "content_text": "Wildfire smoke has become an increasing public health concern in the contiguous United States (CONUS). Previous studies have provided high-resolution estimates of either total PM2.5 or wildfire-related PM2.5 during the past two decades, but few have focused on the most recent wildfire-intensive years, and jointly estimated both to quantify wildfire contributions to total PM2.5 exposure. This study developed a high-resolution machine learning framework to estimate daily 1-km concentrations of…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "3e292d0eb7fe32d9e668",
          "source": "web",
          "type": "change",
          "key": "#2556feaa1f8fc09a35ba",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T10:30:37Z",
          "data": {
            "change": "added",
            "label": "Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
            "item_type": "record",
            "summary": "added: Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
            "after": {
              "title": "Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
              "authors": "Liu, N.; Cheong, Y.; Larson, T.; Austin, E.; Seto, E.",
              "author_corresponding": "Ningrui Liu",
              "author_corresponding_institution": "University of Washington",
              "doi": "10.64898/2026.11.11.26367854",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "occupational and environmental health",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.11.26367854.source.xml",
              "abstract": "Wildfire smoke has become an increasing public health concern in the contiguous United States (CONUS). Previous studies have provided high-resolution estimates of either total PM2.5 or wildfire-related PM2.5 during the past two decades, but few have focused on the most recent wildfire-intensive years, and jointly estimated both to quantify wildfire contributions to total PM2.5 exposure. This study developed a high-resolution machine learning framework to estimate daily 1-km concentrations of total and wildfire-related PM2.5 across the CONUS from 2018 to 2024. This framework incorporates chemical precursors and wildfire smoke density as predictors and relies on publicly accessible data sources enabling future updates. The model achieved high performance with cross-validated R2 of 0.72 and 0.89 for daily and annual estimates, respectively. Elevated total PM2.5 concentrations were observed along the west coast and in several metropolitan areas across the CONUS. Wildfire smoke contributed substantially to total PM2.5 concentrations during major wildfire years, accounting for approximately 35% of PM2.5 along the west coast in 2020, and over 25% in the eastern U.S. in 2023. Wildfire-related PM2.5 mortality accounted for 20% of PM2.5-attributable deaths along the west coast in 2020 (30 times that in 2019), and 24% in the northeastern U.S. in 2023 (14 times that in 2019). These findings highlight the growing role of wildfire smoke as a major driver of total PM2.5 exposure and associated health risks in both western and eastern U.S., underscoring the need for sustained nationwide public health interventions to reduce wildfire smoke exposure.\n\n\n\nO_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=73 SRC=\"FIGDIR/small/26367854v1_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (32K):\norg.highwire.dtl.DTLVardef@14e3615org.highwire.dtl.DTLVardef@1c0d0a8org.highwire.dtl.DTLVardef@1c2fff0org.highwire.dtl.DTLVardef@130fafb_HPS_FORMAT_FIGEXP  M_FIG Graphical Abstract\n\nC_FIG HighlightsO_LIDaily 1-km concentrations of total and wildfire PM2.5 were predicted for the CONUS.\nC_LIO_LIElevated PM2.5 was observed along the U.S. west coast and metropolitan areas.\nC_LIO_LIWildfire was a major driver of PM2.5 variability in both western and eastern U.S.\nC_LIO_LIWildfire contributed over 20% to PM2.5-related mortality in severe wildfire years.\nC_LI",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Wildfire smoke has become an increasing public health concern in the contiguous United States (CONUS). Previous studies have provided high-resolution estimates of either total PM2.5 or wildfire-related PM2.5 during the past two decades, but few have focused on the most recent wildfire-intensive years, and jointly estimated both to quantify wildfire contributions to total PM2.5 exposure. This study developed a high-resolution machine learning framework to estimate daily 1-km concentrations of total and wildfire-related PM2.5 across the CONUS from 2018 to 2024. This framework incorporates chemical precursors and wildfire smoke density as predictors and relies on publicly accessible data sources enabling future updates. The model achieved high performance with cross-validated R2 of 0.72 and 0.89 for daily and annual estimates, respectively. Elevated total PM2.5 concentrations were observed along the west coast and in several metropolitan areas across the CONUS. Wildfire smoke contributed substantially to total PM2.5 concentrations during major wildfire years, accounting for approximately 35% of PM2.5 along the west coast in 2020, and over 25% in the eastern U.S. in 2023. Wildfire-related PM2.5 mortality accounted for 20% of PM2.5-attributable deaths along the west coast in 2020 (30 times that in 2019), and 24% in the northeastern U.S. in 2023 (14 times that in 2019). These findings highlight the growing role of wildfire smoke as a major driver of total PM2.5 exposure and associated health risks in both western and eastern U.S., underscoring the need for sustained nationwide public health interventions to reduce wildfire smoke exposure.\n\n\n\nO_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=73 SRC=\"FIGDIR/small/26367854v1_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (32K):\norg.highwire.dtl.DTLVardef@14e3615org.highwire.dtl.DTLVardef@1c0d0a8org.highwire.dtl.DTLVardef@1c2fff0org.highwire.dtl.DTLVardef@130fafb_HPS_FORMAT_FIGEXP  M_FIG Graphical Abstract\n\nC_FIG HighlightsO_LIDaily 1-km concentrations of total and wildfire PM2.5 were predicted for the CONUS.\nC_LIO_LIElevated PM2.5 was observed along the U.S. west coast and metropolitan areas.\nC_LIO_LIWildfire was a major driver of PM2.5 variability in both western and eastern U.S.\nC_LIO_LIWildfire contributed over 20% to PM2.5-related mortality in severe wildfire years.\nC_LI",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.11.26367854v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 199,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.11.26367854v1?rss=1"
    },
    {
      "id": "e84c3e7da94029837f55",
      "title": "Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
      "content_text": "Wildfire smoke has become an increasing public health concern in the contiguous United States (CONUS). Previous studies have provided high-resolution estimates of either total PM2.5 or wildfire-related PM2.5 during the past two decades, but few have focused on the most recent wildfire-intensive years, and jointly estimated both to quantify wildfire contributions to total PM2.5 exposure. This study developed a high-resolution machine learning framework to estimate daily 1-km concentrations of…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "e84c3e7da94029837f55",
          "source": "web",
          "type": "change",
          "key": "#e380f498d4df75efc171",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T09:28:33Z",
          "data": {
            "change": "added",
            "label": "Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
            "item_type": "record",
            "summary": "added: Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
            "after": {
              "title": "Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
              "authors": "Liu, N.; Cheong, Y.; Larson, T.; Austin, E.; Seto, E.",
              "author_corresponding": "Ningrui Liu",
              "author_corresponding_institution": "University of Washington",
              "doi": "10.64898/2026.11.11.26367854",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "occupational and environmental health",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.11.26367854.source.xml",
              "abstract": "Wildfire smoke has become an increasing public health concern in the contiguous United States (CONUS). Previous studies have provided high-resolution estimates of either total PM2.5 or wildfire-related PM2.5 during the past two decades, but few have focused on the most recent wildfire-intensive years, and jointly estimated both to quantify wildfire contributions to total PM2.5 exposure. This study developed a high-resolution machine learning framework to estimate daily 1-km concentrations of total and wildfire-related PM2.5 across the CONUS from 2018 to 2024. This framework incorporates chemical precursors and wildfire smoke density as predictors and relies on publicly accessible data sources enabling future updates. The model achieved high performance with cross-validated R2 of 0.72 and 0.89 for daily and annual estimates, respectively. Elevated total PM2.5 concentrations were observed along the west coast and in several metropolitan areas across the CONUS. Wildfire smoke contributed substantially to total PM2.5 concentrations during major wildfire years, accounting for approximately 35% of PM2.5 along the west coast in 2020, and over 25% in the eastern U.S. in 2023. Wildfire-related PM2.5 mortality accounted for 20% of PM2.5-attributable deaths along the west coast in 2020 (30 times that in 2019), and 24% in the northeastern U.S. in 2023 (14 times that in 2019). These findings highlight the growing role of wildfire smoke as a major driver of total PM2.5 exposure and associated health risks in both western and eastern U.S., underscoring the need for sustained nationwide public health interventions to reduce wildfire smoke exposure.\n\n\n\nO_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=73 SRC=\"FIGDIR/small/26367854v1_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (32K):\norg.highwire.dtl.DTLVardef@176959corg.highwire.dtl.DTLVardef@5866c1org.highwire.dtl.DTLVardef@1c221b2org.highwire.dtl.DTLVardef@326c98_HPS_FORMAT_FIGEXP  M_FIG Graphical Abstract\n\nC_FIG HighlightsO_LIDaily 1-km concentrations of total and wildfire PM2.5 were predicted for the CONUS.\nC_LIO_LIElevated PM2.5 was observed along the U.S. west coast and metropolitan areas.\nC_LIO_LIWildfire was a major driver of PM2.5 variability in both western and eastern U.S.\nC_LIO_LIWildfire contributed over 20% to PM2.5-related mortality in severe wildfire years.\nC_LI",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Wildfire smoke has become an increasing public health concern in the contiguous United States (CONUS). Previous studies have provided high-resolution estimates of either total PM2.5 or wildfire-related PM2.5 during the past two decades, but few have focused on the most recent wildfire-intensive years, and jointly estimated both to quantify wildfire contributions to total PM2.5 exposure. This study developed a high-resolution machine learning framework to estimate daily 1-km concentrations of total and wildfire-related PM2.5 across the CONUS from 2018 to 2024. This framework incorporates chemical precursors and wildfire smoke density as predictors and relies on publicly accessible data sources enabling future updates. The model achieved high performance with cross-validated R2 of 0.72 and 0.89 for daily and annual estimates, respectively. Elevated total PM2.5 concentrations were observed along the west coast and in several metropolitan areas across the CONUS. Wildfire smoke contributed substantially to total PM2.5 concentrations during major wildfire years, accounting for approximately 35% of PM2.5 along the west coast in 2020, and over 25% in the eastern U.S. in 2023. Wildfire-related PM2.5 mortality accounted for 20% of PM2.5-attributable deaths along the west coast in 2020 (30 times that in 2019), and 24% in the northeastern U.S. in 2023 (14 times that in 2019). These findings highlight the growing role of wildfire smoke as a major driver of total PM2.5 exposure and associated health risks in both western and eastern U.S., underscoring the need for sustained nationwide public health interventions to reduce wildfire smoke exposure.\n\n\n\nO_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=73 SRC=\"FIGDIR/small/26367854v1_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (32K):\norg.highwire.dtl.DTLVardef@176959corg.highwire.dtl.DTLVardef@5866c1org.highwire.dtl.DTLVardef@1c221b2org.highwire.dtl.DTLVardef@326c98_HPS_FORMAT_FIGEXP  M_FIG Graphical Abstract\n\nC_FIG HighlightsO_LIDaily 1-km concentrations of total and wildfire PM2.5 were predicted for the CONUS.\nC_LIO_LIElevated PM2.5 was observed along the U.S. west coast and metropolitan areas.\nC_LIO_LIWildfire was a major driver of PM2.5 variability in both western and eastern U.S.\nC_LIO_LIWildfire contributed over 20% to PM2.5-related mortality in severe wildfire years.\nC_LI",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.11.26367854v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 397,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.11.26367854v1?rss=1"
    },
    {
      "id": "5613a9a10f2fd4cd0915",
      "title": "Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
      "content_text": "Wildfire smoke has become an increasing public health concern in the contiguous United States (CONUS). Previous studies have provided high-resolution estimates of either total PM2.5 or wildfire-related PM2.5 during the past two decades, but few have focused on the most recent wildfire-intensive years, and jointly estimated both to quantify wildfire contributions to total PM2.5 exposure. This study developed a high-resolution machine learning framework to estimate daily 1-km concentrations of…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "5613a9a10f2fd4cd0915",
          "source": "web",
          "type": "change",
          "key": "#e6bf6c1278d662c875a4",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T07:34:39Z",
          "data": {
            "change": "added",
            "label": "Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
            "item_type": "record",
            "summary": "added: Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
            "after": {
              "title": "Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
              "authors": "Liu, N.; Cheong, Y.; Larson, T.; Austin, E.; Seto, E.",
              "author_corresponding": "Ningrui Liu",
              "author_corresponding_institution": "University of Washington",
              "doi": "10.64898/2026.11.11.26367854",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "occupational and environmental health",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.11.26367854.source.xml",
              "abstract": "Wildfire smoke has become an increasing public health concern in the contiguous United States (CONUS). Previous studies have provided high-resolution estimates of either total PM2.5 or wildfire-related PM2.5 during the past two decades, but few have focused on the most recent wildfire-intensive years, and jointly estimated both to quantify wildfire contributions to total PM2.5 exposure. This study developed a high-resolution machine learning framework to estimate daily 1-km concentrations of total and wildfire-related PM2.5 across the CONUS from 2018 to 2024. This framework incorporates chemical precursors and wildfire smoke density as predictors and relies on publicly accessible data sources enabling future updates. The model achieved high performance with cross-validated R2 of 0.72 and 0.89 for daily and annual estimates, respectively. Elevated total PM2.5 concentrations were observed along the west coast and in several metropolitan areas across the CONUS. Wildfire smoke contributed substantially to total PM2.5 concentrations during major wildfire years, accounting for approximately 35% of PM2.5 along the west coast in 2020, and over 25% in the eastern U.S. in 2023. Wildfire-related PM2.5 mortality accounted for 20% of PM2.5-attributable deaths along the west coast in 2020 (30 times that in 2019), and 24% in the northeastern U.S. in 2023 (14 times that in 2019). These findings highlight the growing role of wildfire smoke as a major driver of total PM2.5 exposure and associated health risks in both western and eastern U.S., underscoring the need for sustained nationwide public health interventions to reduce wildfire smoke exposure.\n\n\n\nO_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=73 SRC=\"FIGDIR/small/26367854v1_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (32K):\norg.highwire.dtl.DTLVardef@17dc815org.highwire.dtl.DTLVardef@daece7org.highwire.dtl.DTLVardef@f73d69org.highwire.dtl.DTLVardef@1e0f99e_HPS_FORMAT_FIGEXP  M_FIG Graphical Abstract\n\nC_FIG HighlightsO_LIDaily 1-km concentrations of total and wildfire PM2.5 were predicted for the CONUS.\nC_LIO_LIElevated PM2.5 was observed along the U.S. west coast and metropolitan areas.\nC_LIO_LIWildfire was a major driver of PM2.5 variability in both western and eastern U.S.\nC_LIO_LIWildfire contributed over 20% to PM2.5-related mortality in severe wildfire years.\nC_LI",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Wildfire smoke has become an increasing public health concern in the contiguous United States (CONUS). Previous studies have provided high-resolution estimates of either total PM2.5 or wildfire-related PM2.5 during the past two decades, but few have focused on the most recent wildfire-intensive years, and jointly estimated both to quantify wildfire contributions to total PM2.5 exposure. This study developed a high-resolution machine learning framework to estimate daily 1-km concentrations of total and wildfire-related PM2.5 across the CONUS from 2018 to 2024. This framework incorporates chemical precursors and wildfire smoke density as predictors and relies on publicly accessible data sources enabling future updates. The model achieved high performance with cross-validated R2 of 0.72 and 0.89 for daily and annual estimates, respectively. Elevated total PM2.5 concentrations were observed along the west coast and in several metropolitan areas across the CONUS. Wildfire smoke contributed substantially to total PM2.5 concentrations during major wildfire years, accounting for approximately 35% of PM2.5 along the west coast in 2020, and over 25% in the eastern U.S. in 2023. Wildfire-related PM2.5 mortality accounted for 20% of PM2.5-attributable deaths along the west coast in 2020 (30 times that in 2019), and 24% in the northeastern U.S. in 2023 (14 times that in 2019). These findings highlight the growing role of wildfire smoke as a major driver of total PM2.5 exposure and associated health risks in both western and eastern U.S., underscoring the need for sustained nationwide public health interventions to reduce wildfire smoke exposure.\n\n\n\nO_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=73 SRC=\"FIGDIR/small/26367854v1_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (32K):\norg.highwire.dtl.DTLVardef@17dc815org.highwire.dtl.DTLVardef@daece7org.highwire.dtl.DTLVardef@f73d69org.highwire.dtl.DTLVardef@1e0f99e_HPS_FORMAT_FIGEXP  M_FIG Graphical Abstract\n\nC_FIG HighlightsO_LIDaily 1-km concentrations of total and wildfire PM2.5 were predicted for the CONUS.\nC_LIO_LIElevated PM2.5 was observed along the U.S. west coast and metropolitan areas.\nC_LIO_LIWildfire was a major driver of PM2.5 variability in both western and eastern U.S.\nC_LIO_LIWildfire contributed over 20% to PM2.5-related mortality in severe wildfire years.\nC_LI",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.11.26367854v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 243,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.11.26367854v1?rss=1"
    },
    {
      "id": "df0f0b702181e45ec9be",
      "title": "Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
      "content_text": "Wildfire smoke has become an increasing public health concern in the contiguous United States (CONUS). Previous studies have provided high-resolution estimates of either total PM2.5 or wildfire-related PM2.5 during the past two decades, but few have focused on the most recent wildfire-intensive years, and jointly estimated both to quantify wildfire contributions to total PM2.5 exposure. This study developed a high-resolution machine learning framework to estimate daily 1-km concentrations of…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "df0f0b702181e45ec9be",
          "source": "web",
          "type": "change",
          "key": "#a0ed0eda7e062fd0eb5f",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T06:36:46Z",
          "data": {
            "change": "added",
            "label": "Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
            "item_type": "record",
            "summary": "added: Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
            "after": {
              "title": "Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
              "authors": "Liu, N.; Cheong, Y.; Larson, T.; Austin, E.; Seto, E.",
              "author_corresponding": "Ningrui Liu",
              "author_corresponding_institution": "University of Washington",
              "doi": "10.64898/2026.11.11.26367854",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "occupational and environmental health",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.11.26367854.source.xml",
              "abstract": "Wildfire smoke has become an increasing public health concern in the contiguous United States (CONUS). Previous studies have provided high-resolution estimates of either total PM2.5 or wildfire-related PM2.5 during the past two decades, but few have focused on the most recent wildfire-intensive years, and jointly estimated both to quantify wildfire contributions to total PM2.5 exposure. This study developed a high-resolution machine learning framework to estimate daily 1-km concentrations of total and wildfire-related PM2.5 across the CONUS from 2018 to 2024. This framework incorporates chemical precursors and wildfire smoke density as predictors and relies on publicly accessible data sources enabling future updates. The model achieved high performance with cross-validated R2 of 0.72 and 0.89 for daily and annual estimates, respectively. Elevated total PM2.5 concentrations were observed along the west coast and in several metropolitan areas across the CONUS. Wildfire smoke contributed substantially to total PM2.5 concentrations during major wildfire years, accounting for approximately 35% of PM2.5 along the west coast in 2020, and over 25% in the eastern U.S. in 2023. Wildfire-related PM2.5 mortality accounted for 20% of PM2.5-attributable deaths along the west coast in 2020 (30 times that in 2019), and 24% in the northeastern U.S. in 2023 (14 times that in 2019). These findings highlight the growing role of wildfire smoke as a major driver of total PM2.5 exposure and associated health risks in both western and eastern U.S., underscoring the need for sustained nationwide public health interventions to reduce wildfire smoke exposure.\n\n\n\nO_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=73 SRC=\"FIGDIR/small/26367854v1_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (32K):\norg.highwire.dtl.DTLVardef@6f7492org.highwire.dtl.DTLVardef@14e3615org.highwire.dtl.DTLVardef@1c0d0a8org.highwire.dtl.DTLVardef@1c2fff0_HPS_FORMAT_FIGEXP  M_FIG Graphical Abstract\n\nC_FIG HighlightsO_LIDaily 1-km concentrations of total and wildfire PM2.5 were predicted for the CONUS.\nC_LIO_LIElevated PM2.5 was observed along the U.S. west coast and metropolitan areas.\nC_LIO_LIWildfire was a major driver of PM2.5 variability in both western and eastern U.S.\nC_LIO_LIWildfire contributed over 20% to PM2.5-related mortality in severe wildfire years.\nC_LI",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Wildfire smoke has become an increasing public health concern in the contiguous United States (CONUS). Previous studies have provided high-resolution estimates of either total PM2.5 or wildfire-related PM2.5 during the past two decades, but few have focused on the most recent wildfire-intensive years, and jointly estimated both to quantify wildfire contributions to total PM2.5 exposure. This study developed a high-resolution machine learning framework to estimate daily 1-km concentrations of total and wildfire-related PM2.5 across the CONUS from 2018 to 2024. This framework incorporates chemical precursors and wildfire smoke density as predictors and relies on publicly accessible data sources enabling future updates. The model achieved high performance with cross-validated R2 of 0.72 and 0.89 for daily and annual estimates, respectively. Elevated total PM2.5 concentrations were observed along the west coast and in several metropolitan areas across the CONUS. Wildfire smoke contributed substantially to total PM2.5 concentrations during major wildfire years, accounting for approximately 35% of PM2.5 along the west coast in 2020, and over 25% in the eastern U.S. in 2023. Wildfire-related PM2.5 mortality accounted for 20% of PM2.5-attributable deaths along the west coast in 2020 (30 times that in 2019), and 24% in the northeastern U.S. in 2023 (14 times that in 2019). These findings highlight the growing role of wildfire smoke as a major driver of total PM2.5 exposure and associated health risks in both western and eastern U.S., underscoring the need for sustained nationwide public health interventions to reduce wildfire smoke exposure.\n\n\n\nO_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=73 SRC=\"FIGDIR/small/26367854v1_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (32K):\norg.highwire.dtl.DTLVardef@6f7492org.highwire.dtl.DTLVardef@14e3615org.highwire.dtl.DTLVardef@1c0d0a8org.highwire.dtl.DTLVardef@1c2fff0_HPS_FORMAT_FIGEXP  M_FIG Graphical Abstract\n\nC_FIG HighlightsO_LIDaily 1-km concentrations of total and wildfire PM2.5 were predicted for the CONUS.\nC_LIO_LIElevated PM2.5 was observed along the U.S. west coast and metropolitan areas.\nC_LIO_LIWildfire was a major driver of PM2.5 variability in both western and eastern U.S.\nC_LIO_LIWildfire contributed over 20% to PM2.5-related mortality in severe wildfire years.\nC_LI",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.11.26367854v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 676,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.11.26367854v1?rss=1"
    },
    {
      "id": "7ec0388f2651d4a081b7",
      "title": "Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
      "content_text": "Wildfire smoke has become an increasing public health concern in the contiguous United States (CONUS). Previous studies have provided high-resolution estimates of either total PM2.5 or wildfire-related PM2.5 during the past two decades, but few have focused on the most recent wildfire-intensive years, and jointly estimated both to quantify wildfire contributions to total PM2.5 exposure. This study developed a high-resolution machine learning framework to estimate daily 1-km concentrations of…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "7ec0388f2651d4a081b7",
          "source": "web",
          "type": "change",
          "key": "#3bc5ac23ea4ca7815cae",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T05:37:40Z",
          "data": {
            "change": "added",
            "label": "Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
            "item_type": "record",
            "summary": "added: Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
            "after": {
              "title": "Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
              "authors": "Liu, N.; Cheong, Y.; Larson, T.; Austin, E.; Seto, E.",
              "author_corresponding": "Ningrui Liu",
              "author_corresponding_institution": "University of Washington",
              "doi": "10.64898/2026.11.11.26367854",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "occupational and environmental health",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.11.26367854.source.xml",
              "abstract": "Wildfire smoke has become an increasing public health concern in the contiguous United States (CONUS). Previous studies have provided high-resolution estimates of either total PM2.5 or wildfire-related PM2.5 during the past two decades, but few have focused on the most recent wildfire-intensive years, and jointly estimated both to quantify wildfire contributions to total PM2.5 exposure. This study developed a high-resolution machine learning framework to estimate daily 1-km concentrations of total and wildfire-related PM2.5 across the CONUS from 2018 to 2024. This framework incorporates chemical precursors and wildfire smoke density as predictors and relies on publicly accessible data sources enabling future updates. The model achieved high performance with cross-validated R2 of 0.72 and 0.89 for daily and annual estimates, respectively. Elevated total PM2.5 concentrations were observed along the west coast and in several metropolitan areas across the CONUS. Wildfire smoke contributed substantially to total PM2.5 concentrations during major wildfire years, accounting for approximately 35% of PM2.5 along the west coast in 2020, and over 25% in the eastern U.S. in 2023. Wildfire-related PM2.5 mortality accounted for 20% of PM2.5-attributable deaths along the west coast in 2020 (30 times that in 2019), and 24% in the northeastern U.S. in 2023 (14 times that in 2019). These findings highlight the growing role of wildfire smoke as a major driver of total PM2.5 exposure and associated health risks in both western and eastern U.S., underscoring the need for sustained nationwide public health interventions to reduce wildfire smoke exposure.\n\n\n\nO_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=73 SRC=\"FIGDIR/small/26367854v1_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (32K):\norg.highwire.dtl.DTLVardef@1b9af7dorg.highwire.dtl.DTLVardef@1b05c54org.highwire.dtl.DTLVardef@17dc815org.highwire.dtl.DTLVardef@daece7_HPS_FORMAT_FIGEXP  M_FIG Graphical Abstract\n\nC_FIG HighlightsO_LIDaily 1-km concentrations of total and wildfire PM2.5 were predicted for the CONUS.\nC_LIO_LIElevated PM2.5 was observed along the U.S. west coast and metropolitan areas.\nC_LIO_LIWildfire was a major driver of PM2.5 variability in both western and eastern U.S.\nC_LIO_LIWildfire contributed over 20% to PM2.5-related mortality in severe wildfire years.\nC_LI",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Wildfire smoke has become an increasing public health concern in the contiguous United States (CONUS). Previous studies have provided high-resolution estimates of either total PM2.5 or wildfire-related PM2.5 during the past two decades, but few have focused on the most recent wildfire-intensive years, and jointly estimated both to quantify wildfire contributions to total PM2.5 exposure. This study developed a high-resolution machine learning framework to estimate daily 1-km concentrations of total and wildfire-related PM2.5 across the CONUS from 2018 to 2024. This framework incorporates chemical precursors and wildfire smoke density as predictors and relies on publicly accessible data sources enabling future updates. The model achieved high performance with cross-validated R2 of 0.72 and 0.89 for daily and annual estimates, respectively. Elevated total PM2.5 concentrations were observed along the west coast and in several metropolitan areas across the CONUS. Wildfire smoke contributed substantially to total PM2.5 concentrations during major wildfire years, accounting for approximately 35% of PM2.5 along the west coast in 2020, and over 25% in the eastern U.S. in 2023. Wildfire-related PM2.5 mortality accounted for 20% of PM2.5-attributable deaths along the west coast in 2020 (30 times that in 2019), and 24% in the northeastern U.S. in 2023 (14 times that in 2019). These findings highlight the growing role of wildfire smoke as a major driver of total PM2.5 exposure and associated health risks in both western and eastern U.S., underscoring the need for sustained nationwide public health interventions to reduce wildfire smoke exposure.\n\n\n\nO_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=73 SRC=\"FIGDIR/small/26367854v1_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (32K):\norg.highwire.dtl.DTLVardef@1b9af7dorg.highwire.dtl.DTLVardef@1b05c54org.highwire.dtl.DTLVardef@17dc815org.highwire.dtl.DTLVardef@daece7_HPS_FORMAT_FIGEXP  M_FIG Graphical Abstract\n\nC_FIG HighlightsO_LIDaily 1-km concentrations of total and wildfire PM2.5 were predicted for the CONUS.\nC_LIO_LIElevated PM2.5 was observed along the U.S. west coast and metropolitan areas.\nC_LIO_LIWildfire was a major driver of PM2.5 variability in both western and eastern U.S.\nC_LIO_LIWildfire contributed over 20% to PM2.5-related mortality in severe wildfire years.\nC_LI",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.11.26367854v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 1328,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.11.26367854v1?rss=1"
    },
    {
      "id": "5c9eff322e8a12f03de6",
      "title": "Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
      "content_text": "Wildfire smoke has become an increasing public health concern in the contiguous United States (CONUS). Previous studies have provided high-resolution estimates of either total PM2.5 or wildfire-related PM2.5 during the past two decades, but few have focused on the most recent wildfire-intensive years, and jointly estimated both to quantify wildfire contributions to total PM2.5 exposure. This study developed a high-resolution machine learning framework to estimate daily 1-km concentrations of…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "5c9eff322e8a12f03de6",
          "source": "web",
          "type": "change",
          "key": "#c0a66dfecff63281e584",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T01:45:22Z",
          "data": {
            "change": "added",
            "label": "Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
            "item_type": "record",
            "summary": "added: Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
            "after": {
              "title": "Preprint: High-resolution spatiotemporal estimates of total and wildfire PM2.5 in the contiguous United States, 2018-2024: Implications for population exposure and mortality burden",
              "authors": "Liu, N.; Cheong, Y.; Larson, T.; Austin, E.; Seto, E.",
              "author_corresponding": "Ningrui Liu",
              "author_corresponding_institution": "University of Washington",
              "doi": "10.64898/2026.11.11.26367854",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "occupational and environmental health",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.11.26367854.source.xml",
              "abstract": "Wildfire smoke has become an increasing public health concern in the contiguous United States (CONUS). Previous studies have provided high-resolution estimates of either total PM2.5 or wildfire-related PM2.5 during the past two decades, but few have focused on the most recent wildfire-intensive years, and jointly estimated both to quantify wildfire contributions to total PM2.5 exposure. This study developed a high-resolution machine learning framework to estimate daily 1-km concentrations of total and wildfire-related PM2.5 across the CONUS from 2018 to 2024. This framework incorporates chemical precursors and wildfire smoke density as predictors and relies on publicly accessible data sources enabling future updates. The model achieved high performance with cross-validated R2 of 0.72 and 0.89 for daily and annual estimates, respectively. Elevated total PM2.5 concentrations were observed along the west coast and in several metropolitan areas across the CONUS. Wildfire smoke contributed substantially to total PM2.5 concentrations during major wildfire years, accounting for approximately 35% of PM2.5 along the west coast in 2020, and over 25% in the eastern U.S. in 2023. Wildfire-related PM2.5 mortality accounted for 20% of PM2.5-attributable deaths along the west coast in 2020 (30 times that in 2019), and 24% in the northeastern U.S. in 2023 (14 times that in 2019). These findings highlight the growing role of wildfire smoke as a major driver of total PM2.5 exposure and associated health risks in both western and eastern U.S., underscoring the need for sustained nationwide public health interventions to reduce wildfire smoke exposure.\n\n\n\nO_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=73 SRC=\"FIGDIR/small/26367854v1_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (32K):\norg.highwire.dtl.DTLVardef@9dc0a8org.highwire.dtl.DTLVardef@d36a6dorg.highwire.dtl.DTLVardef@1f020aforg.highwire.dtl.DTLVardef@1f1c748_HPS_FORMAT_FIGEXP  M_FIG Graphical Abstract\n\nC_FIG HighlightsO_LIDaily 1-km concentrations of total and wildfire PM2.5 were predicted for the CONUS.\nC_LIO_LIElevated PM2.5 was observed along the U.S. west coast and metropolitan areas.\nC_LIO_LIWildfire was a major driver of PM2.5 variability in both western and eastern U.S.\nC_LIO_LIWildfire contributed over 20% to PM2.5-related mortality in severe wildfire years.\nC_LI",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Wildfire smoke has become an increasing public health concern in the contiguous United States (CONUS). Previous studies have provided high-resolution estimates of either total PM2.5 or wildfire-related PM2.5 during the past two decades, but few have focused on the most recent wildfire-intensive years, and jointly estimated both to quantify wildfire contributions to total PM2.5 exposure. This study developed a high-resolution machine learning framework to estimate daily 1-km concentrations of total and wildfire-related PM2.5 across the CONUS from 2018 to 2024. This framework incorporates chemical precursors and wildfire smoke density as predictors and relies on publicly accessible data sources enabling future updates. The model achieved high performance with cross-validated R2 of 0.72 and 0.89 for daily and annual estimates, respectively. Elevated total PM2.5 concentrations were observed along the west coast and in several metropolitan areas across the CONUS. Wildfire smoke contributed substantially to total PM2.5 concentrations during major wildfire years, accounting for approximately 35% of PM2.5 along the west coast in 2020, and over 25% in the eastern U.S. in 2023. Wildfire-related PM2.5 mortality accounted for 20% of PM2.5-attributable deaths along the west coast in 2020 (30 times that in 2019), and 24% in the northeastern U.S. in 2023 (14 times that in 2019). These findings highlight the growing role of wildfire smoke as a major driver of total PM2.5 exposure and associated health risks in both western and eastern U.S., underscoring the need for sustained nationwide public health interventions to reduce wildfire smoke exposure.\n\n\n\nO_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=73 SRC=\"FIGDIR/small/26367854v1_ufig1.gif\" ALT=\"Figure 1\">\nView larger version (32K):\norg.highwire.dtl.DTLVardef@9dc0a8org.highwire.dtl.DTLVardef@d36a6dorg.highwire.dtl.DTLVardef@1f020aforg.highwire.dtl.DTLVardef@1f1c748_HPS_FORMAT_FIGEXP  M_FIG Graphical Abstract\n\nC_FIG HighlightsO_LIDaily 1-km concentrations of total and wildfire PM2.5 were predicted for the CONUS.\nC_LIO_LIElevated PM2.5 was observed along the U.S. west coast and metropolitan areas.\nC_LIO_LIWildfire was a major driver of PM2.5 variability in both western and eastern U.S.\nC_LIO_LIWildfire contributed over 20% to PM2.5-related mortality in severe wildfire years.\nC_LI",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.11.26367854v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 406,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.11.26367854v1?rss=1"
    },
    {
      "id": "4f784a7a676348c282c2",
      "title": "Preprint: Uncertainty-aware longitudinal prediction of multiple adverse pregnancy outcomes",
      "content_text": "Risk of pregnancy complications is reassessed at each antenatal visit, but whether earlier predictions add information beyond the most recent one is unclear. Classifying every prediction as low or high risk can leave uncertainty unexpressed. Whether reliability per visit holds across visits is also unclear. This secondary analysis included 9289 nulliparous women from the nuMoM2b cohort (eight US centres, 2010-2013). Logistic regression models predicted gestational diabetes, pre-eclampsia…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "4f784a7a676348c282c2",
          "source": "web",
          "type": "change",
          "key": "#c3c986684396acb6c6bc",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Uncertainty-aware longitudinal prediction of multiple adverse pregnancy outcomes",
            "item_type": "record",
            "summary": "added: Preprint: Uncertainty-aware longitudinal prediction of multiple adverse pregnancy outcomes",
            "after": {
              "title": "Preprint: Uncertainty-aware longitudinal prediction of multiple adverse pregnancy outcomes",
              "authors": "Wu, Y.; Asvadi, S.; van der Ven, M.; Peri, E.; Xu, M.; van der Hout-van der Jagt, M. B.; OEH van Laar, J.; Chen, C.; Luo, Q.; Mischi, M.; Oei, S. G.; Long, X.",
              "author_corresponding": "Xi Long",
              "author_corresponding_institution": "Eindhoven University of Technology",
              "doi": "10.64898/2026.11.15.26368140",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "health informatics",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.15.26368140.source.xml",
              "abstract": "Risk of pregnancy complications is reassessed at each antenatal visit, but whether earlier predictions add information beyond the most recent one is unclear. Classifying every prediction as low or high risk can leave uncertainty unexpressed. Whether reliability per visit holds across visits is also unclear. This secondary analysis included 9289 nulliparous women from the nuMoM2b cohort (eight US centres, 2010-2013). Logistic regression models predicted gestational diabetes, pre-eclampsia, preterm birth, suspected fetal growth restriction and large for gestational age at 6-13, 16-21 and 22-29 weeks (Visits 3). Mondrian conformal prediction reported 'no' (low risk), 'yes' (high risk), or both (review). To test whether prediction history adds information beyond the Visit 3 prediction, we compared, among women classified as high risk at Visit 3, those first classified as high risk at Visit 2 or 3 (emerging high) with those classified as high risk at all three visits (persistent high), adjusting for Visit 3 predicted probability. The adjusted proportion with the outcome was higher in the emerging-high than the persistent-high group, by 6.1 percentage points for large for gestational age (95% CI -0.4 to 12.2) and 3.8 percentage points for suspected fetal growth restriction (-0.9 to 8.1). Other outcomes showed adjusted differences close to zero. With conformal prediction calibrated to a 90% level at each visit, the reported answers included the actual outcome in 89.6-90.6% of women at each visit (coverage). Coverage decreased when each woman's three visits were considered together (79.0-85.4%). For fetal growth outcomes, how a woman's predicted risk evolved during pregnancy may add information beyond her Visit 3 prediction. For repeated clinical use, the target coverage level should reflect the acceptable risk of incorrect low- or high-risk classifications over a woman's follow-up and the clinical decisions supported at each visit.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Risk of pregnancy complications is reassessed at each antenatal visit, but whether earlier predictions add information beyond the most recent one is unclear. Classifying every prediction as low or high risk can leave uncertainty unexpressed. Whether reliability per visit holds across visits is also unclear. This secondary analysis included 9289 nulliparous women from the nuMoM2b cohort (eight US centres, 2010-2013). Logistic regression models predicted gestational diabetes, pre-eclampsia, preterm birth, suspected fetal growth restriction and large for gestational age at 6-13, 16-21 and 22-29 weeks (Visits 3). Mondrian conformal prediction reported 'no' (low risk), 'yes' (high risk), or both (review). To test whether prediction history adds information beyond the Visit 3 prediction, we compared, among women classified as high risk at Visit 3, those first classified as high risk at Visit 2 or 3 (emerging high) with those classified as high risk at all three visits (persistent high), adjusting for Visit 3 predicted probability. The adjusted proportion with the outcome was higher in the emerging-high than the persistent-high group, by 6.1 percentage points for large for gestational age (95% CI -0.4 to 12.2) and 3.8 percentage points for suspected fetal growth restriction (-0.9 to 8.1). Other outcomes showed adjusted differences close to zero. With conformal prediction calibrated to a 90% level at each visit, the reported answers included the actual outcome in 89.6-90.6% of women at each visit (coverage). Coverage decreased when each woman's three visits were considered together (79.0-85.4%). For fetal growth outcomes, how a woman's predicted risk evolved during pregnancy may add information beyond her Visit 3 prediction. For repeated clinical use, the target coverage level should reflect the acceptable risk of incorrect low- or high-risk classifications over a woman's follow-up and the clinical decisions supported at each visit.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.15.26368140v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 204,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.15.26368140v1?rss=1"
    },
    {
      "id": "8ef8eec9838eed66180c",
      "title": "Preprint: Microcirculation Mirror: A zero-install browser workstation for hand microvascular anatomy and nailfold capillaroscopy",
      "content_text": "Background Hand microvasculature is conventionally presented through diagrams, cadaveric atlases and specialized optical instruments, while conventional clinical radiography cannot resolve individual capillary loops (5-15 m lumen) in vivo, which dominate cutaneous oxygen exchange. Methods We present Microcirculation Mirror, a zero-install browser workstation that registers layered hand anatomy to a live 21-landmark pose and couples it to a nailfold video capillaroscopy (NVC) simulator, a lumped…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "8ef8eec9838eed66180c",
          "source": "web",
          "type": "change",
          "key": "#d169fe68a94cff164c03",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Microcirculation Mirror: A zero-install browser workstation for hand microvascular anatomy and nailfold capillaroscopy",
            "item_type": "record",
            "summary": "added: Preprint: Microcirculation Mirror: A zero-install browser workstation for hand microvascular anatomy and nailfold capillaroscopy",
            "after": {
              "title": "Preprint: Microcirculation Mirror: A zero-install browser workstation for hand microvascular anatomy and nailfold capillaroscopy",
              "authors": "Wang, Y.; He, J.; Liu, W.; Xu, X.; Li, B.; Li, Y.; Wang, B.; Liu, M.",
              "author_corresponding": "Mingming Liu",
              "author_corresponding_institution": "Chinese Academy of Medical Sciences & Peking Union Medical College",
              "doi": "10.64898/2026.11.15.26368085",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc",
              "category": "health informatics",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.15.26368085.source.xml",
              "abstract": "Background Hand microvasculature is conventionally presented through diagrams, cadaveric atlases and specialized optical instruments, while conventional clinical radiography cannot resolve individual capillary loops (5-15 m lumen) in vivo, which dominate cutaneous oxygen exchange. Methods We present Microcirculation Mirror, a zero-install browser workstation that registers layered hand anatomy to a live 21-landmark pose and couples it to a nailfold video capillaroscopy (NVC) simulator, a lumped microcirculatory model and an imaging-physics module. The single-file application runs offline on a laptop or, over local HTTPS, on a phone as an installable app. Results Its 3D atlas contains 136 named structures per hand in six systems from open Z-Anatomy/BodyParts3D meshes, plus a literature-parameterized capillary layer. The NVC module renders a 200x, 1.2-mm field with six deterministic patterns and quantified density, giant capillaries, avascular width fraction, hemorrhages, tortuosity and ramification. A lumped model reports nine estimates (SIM); a physics module shows that a 10-m capillary occupies 0.07 of a 150-m detector pixel; with iodinated contrast it retains {approx}0.016% effective contrast, about 60x below a 1% detection threshold; unenhanced blood is {approx}270x lower. The 2D stage renders in 2.9 ms per frame; system merging reduces atlas draw calls from 136 to 6. Conclusions The camera-overlay layers are templates, the atlas macro-anatomy is open mesh data, and the capillary layer is sampled. No patient data are used. The instrument is a product prototype, not a medical device, and provides a reproducible framework for making multi-scale microvascular reasoning visible.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background Hand microvasculature is conventionally presented through diagrams, cadaveric atlases and specialized optical instruments, while conventional clinical radiography cannot resolve individual capillary loops (5-15 m lumen) in vivo, which dominate cutaneous oxygen exchange. Methods We present Microcirculation Mirror, a zero-install browser workstation that registers layered hand anatomy to a live 21-landmark pose and couples it to a nailfold video capillaroscopy (NVC) simulator, a lumped microcirculatory model and an imaging-physics module. The single-file application runs offline on a laptop or, over local HTTPS, on a phone as an installable app. Results Its 3D atlas contains 136 named structures per hand in six systems from open Z-Anatomy/BodyParts3D meshes, plus a literature-parameterized capillary layer. The NVC module renders a 200x, 1.2-mm field with six deterministic patterns and quantified density, giant capillaries, avascular width fraction, hemorrhages, tortuosity and ramification. A lumped model reports nine estimates (SIM); a physics module shows that a 10-m capillary occupies 0.07 of a 150-m detector pixel; with iodinated contrast it retains {approx}0.016% effective contrast, about 60x below a 1% detection threshold; unenhanced blood is {approx}270x lower. The 2D stage renders in 2.9 ms per frame; system merging reduces atlas draw calls from 136 to 6. Conclusions The camera-overlay layers are templates, the atlas macro-anatomy is open mesh data, and the capillary layer is sampled. No patient data are used. The instrument is a product prototype, not a medical device, and provides a reproducible framework for making multi-scale microvascular reasoning visible.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.15.26368085v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 204,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.15.26368085v1?rss=1"
    },
    {
      "id": "3e7a5d2cc8565e45bacf",
      "title": "Preprint: Requirements of a knowledge support tool for self-harm in general practice: a mixed-methods study with patients, carers, and clinicians",
      "content_text": "Background General practice has a central role in care following self-harm. However, clinicians frequently report uncertainty about best practice and patients describe poor care. A knowledge support tool is an add-on to electronic health systems that may improve services by providing personalised care information. Aim To understand what general practice clinicians, patients and carers need from a novel knowledge support tool for self-harm. Design and Setting Mixed-methods, using quantitative…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "3e7a5d2cc8565e45bacf",
          "source": "web",
          "type": "change",
          "key": "#ca18bb9cfd4c8e98535d",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Requirements of a knowledge support tool for self-harm in general practice: a mixed-methods study with patients, carers, and clinicians",
            "item_type": "record",
            "summary": "added: Preprint: Requirements of a knowledge support tool for self-harm in general practice: a mixed-methods study with patients, carers, and clinicians",
            "after": {
              "title": "Preprint: Requirements of a knowledge support tool for self-harm in general practice: a mixed-methods study with patients, carers, and clinicians",
              "authors": "Cant, H.; Mughal, F.; Asmal, S.; Petersen, K.; Groves, J.; Gardiner, E.; Bower, P.; Webb, R. T.; Kapur, N.; Westhead, J.; Palin, V.; Pate, A.; van Staa, T.; Quinlivan, L.",
              "author_corresponding": "Harriet Cant",
              "author_corresponding_institution": "The University of Manchester",
              "doi": "10.64898/2026.11.14.26368111",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_no",
              "category": "health informatics",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.14.26368111.source.xml",
              "abstract": "Background General practice has a central role in care following self-harm. However, clinicians frequently report uncertainty about best practice and patients describe poor care. A knowledge support tool is an add-on to electronic health systems that may improve services by providing personalised care information. Aim To understand what general practice clinicians, patients and carers need from a novel knowledge support tool for self-harm. Design and Setting Mixed-methods, using quantitative ratings, focus groups and follow-on interviews with general practice clinicians and patients/carers with lived experience of self-harm. Method Clinicians were recruited through social media and professional networks, and patients/carers through a third-sector organisation. During four focus groups and follow-on interviews, we explored the utility of potential content and functionality of a knowledge support tool. Quantitative utility ratings were summarised descriptively and qualitative data were analysed thematically using the framework method. People with lived/living experience were involved throughout. Results 13 clinicians and 14 patients/carers participated. Requirements of the knowledge support tool were captured across three qualitative themes: facilitating person-centred care, accessibility and usability, and balancing competing priorities of general practice. Across these themes, patients' and carers' needs were centred on promoting compassionate relationships and patient agency. Clinicians shared these needs but balanced them with a need to manage patient expectations and practice defensively under limited resources. Conclusion Our findings inform the core design of a knowledge support tool and suggest that such a tool could support the assessment and management of self-harm in general practice.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background General practice has a central role in care following self-harm. However, clinicians frequently report uncertainty about best practice and patients describe poor care. A knowledge support tool is an add-on to electronic health systems that may improve services by providing personalised care information. Aim To understand what general practice clinicians, patients and carers need from a novel knowledge support tool for self-harm. Design and Setting Mixed-methods, using quantitative ratings, focus groups and follow-on interviews with general practice clinicians and patients/carers with lived experience of self-harm. Method Clinicians were recruited through social media and professional networks, and patients/carers through a third-sector organisation. During four focus groups and follow-on interviews, we explored the utility of potential content and functionality of a knowledge support tool. Quantitative utility ratings were summarised descriptively and qualitative data were analysed thematically using the framework method. People with lived/living experience were involved throughout. Results 13 clinicians and 14 patients/carers participated. Requirements of the knowledge support tool were captured across three qualitative themes: facilitating person-centred care, accessibility and usability, and balancing competing priorities of general practice. Across these themes, patients' and carers' needs were centred on promoting compassionate relationships and patient agency. Clinicians shared these needs but balanced them with a need to manage patient expectations and practice defensively under limited resources. Conclusion Our findings inform the core design of a knowledge support tool and suggest that such a tool could support the assessment and management of self-harm in general practice.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368111v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 204,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368111v1?rss=1"
    },
    {
      "id": "0c240072a84bfe260cfc",
      "title": "Preprint: Eye-to-Eye: Gaze detection as a proxy for medical doctor behaviour during virtual and in-person appointments",
      "content_text": "The gaze direction of the physician during consultations plays an important role in patient satisfaction, with several studies pointing to the positive correlation between the amount of time the physician spends looking at the patient and patient satisfaction. Additionally, the effects of the virtual consultation environment on the gaze behaviour of the doctor have yet to be studied. Therefore, this study aims to assess the impact of the virtual consultation environment by comparing the amount…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "0c240072a84bfe260cfc",
          "source": "web",
          "type": "change",
          "key": "#5ace823cf58bc59d8f4d",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Eye-to-Eye: Gaze detection as a proxy for medical doctor behaviour during virtual and in-person appointments",
            "item_type": "record",
            "summary": "added: Preprint: Eye-to-Eye: Gaze detection as a proxy for medical doctor behaviour during virtual and in-person appointments",
            "after": {
              "title": "Preprint: Eye-to-Eye: Gaze detection as a proxy for medical doctor behaviour during virtual and in-person appointments",
              "authors": "Antao, R.; Moreno, P.; Santos-Victor, J.; da Silva, N. A.; Santos, R.; Leite, F.; Ferreira, D.",
              "author_corresponding": "Plinio Moreno",
              "author_corresponding_institution": "Instituto Superior Tecnico - Universidade de Lisboa",
              "doi": "10.64898/2026.11.17.26368012",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_no",
              "category": "health informatics",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.17.26368012.source.xml",
              "abstract": "The gaze direction of the physician during consultations plays an important role in patient satisfaction, with several studies pointing to the positive correlation between the amount of time the physician spends looking at the patient and patient satisfaction. Additionally, the effects of the virtual consultation environment on the gaze behaviour of the doctor have yet to be studied. Therefore, this study aims to assess the impact of the virtual consultation environment by comparing the amount of total time the doctor spends looking at the patient between face-to-face and virtual consultations, as well as the average duration during the consultation and the gaze frequency. The study population consisted of 14 doctors divided between 4 medical specialties: Gynaecology/Obstetrics (4), Neurology (3), Endocrinology (3) and General and Familiar Medicine (4). A low-cost desktop that runs an appearance-based gaze estimation pipeline was implemented in the clinical setup. Each doctor recorded 20 face-to-face consultations and 20 virtual consultations, which were then processed by the pipeline to obtain the percentage of time the doctor spent looking at the patient during the consultation. Overall, we found that doctors look more at the patient in virtual consultations compared to face-to-face consultations, both in total time and average duration during the consultation. Within medical specialties, three out the four specialties involved presented clear tendencies to look more at the patient in virtual consultations when compared to face-to-face consultations.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "The gaze direction of the physician during consultations plays an important role in patient satisfaction, with several studies pointing to the positive correlation between the amount of time the physician spends looking at the patient and patient satisfaction. Additionally, the effects of the virtual consultation environment on the gaze behaviour of the doctor have yet to be studied. Therefore, this study aims to assess the impact of the virtual consultation environment by comparing the amount of total time the doctor spends looking at the patient between face-to-face and virtual consultations, as well as the average duration during the consultation and the gaze frequency. The study population consisted of 14 doctors divided between 4 medical specialties: Gynaecology/Obstetrics (4), Neurology (3), Endocrinology (3) and General and Familiar Medicine (4). A low-cost desktop that runs an appearance-based gaze estimation pipeline was implemented in the clinical setup. Each doctor recorded 20 face-to-face consultations and 20 virtual consultations, which were then processed by the pipeline to obtain the percentage of time the doctor spent looking at the patient during the consultation. Overall, we found that doctors look more at the patient in virtual consultations compared to face-to-face consultations, both in total time and average duration during the consultation. Within medical specialties, three out the four specialties involved presented clear tendencies to look more at the patient in virtual consultations when compared to face-to-face consultations.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.17.26368012v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 204,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.17.26368012v1?rss=1"
    },
    {
      "id": "9040e0c55f9c2cb0728f",
      "title": "Preprint: Evaluation of improvement training for cancer MDT members",
      "content_text": "Abstract Background: Multidisciplinary team (MDT) meetings are central to cancer care. National policy, including the 2026 National Cancer Plan for England, expects MDTs to improve how they work. Although validated tools assess MDT performance, little is known about training in their use. We evaluated structured MDT improvement training delivered across two UK Cancer Alliances. Methods: Three one day courses, delivered in 2019, combined teaching and simulation using MDT assessment tools…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "9040e0c55f9c2cb0728f",
          "source": "web",
          "type": "change",
          "key": "#ec5a80f7b0a8fe9a0450",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Evaluation of improvement training for cancer MDT members",
            "item_type": "record",
            "summary": "added: Preprint: Evaluation of improvement training for cancer MDT members",
            "after": {
              "title": "Preprint: Evaluation of improvement training for cancer MDT members",
              "authors": "Atiyah, A.; Lamb, B.; Soukup, T.",
              "author_corresponding": "Ben Lamb",
              "author_corresponding_institution": "Barts Health NHS Trust",
              "doi": "10.64898/2026.11.14.26367953",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "health systems and quality improvement",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.14.26367953.source.xml",
              "abstract": "Abstract Background: Multidisciplinary team (MDT) meetings are central to cancer care. National policy, including the 2026 National Cancer Plan for England, expects MDTs to improve how they work. Although validated tools assess MDT performance, little is known about training in their use. We evaluated structured MDT improvement training delivered across two UK Cancer Alliances. Methods: Three one day courses, delivered in 2019, combined teaching and simulation using MDT assessment tools, including the Metric for the Observation of Decision-making (MDT MODe). Participants completed a 14 item Likert-scale survey (1 = strongly disagree to 5 = strongly agree) and open ended questions. Responses were summarised descriptively; subgroup comparisons used chi squared tests with Bonferroni correction. Free text responses were analysed thematically by two coders. Results: Forty eight MDT members responded (26 doctors, 10 nurses, 10 administrative staff). Twelve of 14 items scored a median of 4 (agree); understanding the information scored a 4.5. Support for mandatory training was more modest (median 3.5). After Bonferroni correction, significant differences by grade remained for knowledge of the MDT metric (adjusted p = 0.001) and MDT MODe instrument (adjusted p < 0.001). Strengths included teaching (n = 14), utility of MDT MODe (n = 10) and networking (n = 9). Weaknesses included poor audio visual quality (n = 18) and difficulty identifying speakers (n = 8). Conclusions: Expert led, simulation-based MDT improvement training was well received across professional groups. Although delivered in 2019, it addresses skills central to national MDT reform. Future courses should improve audio visual quality and offer implementation support. Pre, post evaluation and longer-term follow-up are needed.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Abstract Background: Multidisciplinary team (MDT) meetings are central to cancer care. National policy, including the 2026 National Cancer Plan for England, expects MDTs to improve how they work. Although validated tools assess MDT performance, little is known about training in their use. We evaluated structured MDT improvement training delivered across two UK Cancer Alliances. Methods: Three one day courses, delivered in 2019, combined teaching and simulation using MDT assessment tools, including the Metric for the Observation of Decision-making (MDT MODe). Participants completed a 14 item Likert-scale survey (1 = strongly disagree to 5 = strongly agree) and open ended questions. Responses were summarised descriptively; subgroup comparisons used chi squared tests with Bonferroni correction. Free text responses were analysed thematically by two coders. Results: Forty eight MDT members responded (26 doctors, 10 nurses, 10 administrative staff). Twelve of 14 items scored a median of 4 (agree); understanding the information scored a 4.5. Support for mandatory training was more modest (median 3.5). After Bonferroni correction, significant differences by grade remained for knowledge of the MDT metric (adjusted p = 0.001) and MDT MODe instrument (adjusted p < 0.001). Strengths included teaching (n = 14), utility of MDT MODe (n = 10) and networking (n = 9). Weaknesses included poor audio visual quality (n = 18) and difficulty identifying speakers (n = 8). Conclusions: Expert led, simulation-based MDT improvement training was well received across professional groups. Although delivered in 2019, it addresses skills central to national MDT reform. Future courses should improve audio visual quality and offer implementation support. Pre, post evaluation and longer-term follow-up are needed.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26367953v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 204,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26367953v1?rss=1"
    },
    {
      "id": "4e7517e668f484d97196",
      "title": "Preprint: Uptake and outcomes of earlier viral load testing and longer visit intervals in the early HIV treatment period: retrospective cohort analysis of South Africas 2023 ART guidelines revision",
      "content_text": "Background: South Africas 2023 revised ART Guidelines moved the first scheduled viral load (VL) test from 6 to 3 months after antiretroviral therapy (ART) initiation and accelerated differentiated care eligibility from 7 to 4 months among virally suppressed clients. We assessed uptake of these changes and their association with virologic outcomes. Methods: We analysed routine electronic medical record data from 18 primary healthcare clinics in three South African districts among all adults…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "4e7517e668f484d97196",
          "source": "web",
          "type": "change",
          "key": "#a21e5b17bae3e3922164",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Uptake and outcomes of earlier viral load testing and longer visit intervals in the early HIV treatment period: retrospective cohort analysis of South Africas 2023 ART guidelines revision",
            "item_type": "record",
            "summary": "added: Preprint: Uptake and outcomes of earlier viral load testing and longer visit intervals in the early HIV treatment period: retrospective cohort analysis of South Africas 2023 ART guidelines revision",
            "after": {
              "title": "Preprint: Uptake and outcomes of earlier viral load testing and longer visit intervals in the early HIV treatment period: retrospective cohort analysis of South Africas 2023 ART guidelines revision",
              "authors": "Kachingwe, E.; Maskew, M.; Mutanda, N.; Benade, M.; Scott, N.; Morgan, A.; Sande, L.; Ntjikelane, V.; Malala, L.; Manganyane, M.; Rosen, S.",
              "author_corresponding": "Sydney Rosen",
              "author_corresponding_institution": "School of Public Health, Boston University, Boston, MA, USA",
              "doi": "10.64898/2026.11.15.26368143",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "hiv aids",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.15.26368143.source.xml",
              "abstract": "Background: South Africas 2023 revised ART Guidelines moved the first scheduled viral load (VL) test from 6 to 3 months after antiretroviral therapy (ART) initiation and accelerated differentiated care eligibility from 7 to 4 months among virally suppressed clients. We assessed uptake of these changes and their association with virologic outcomes. Methods: We analysed routine electronic medical record data from 18 primary healthcare clinics in three South African districts among all adults initiating or re-initiating ART (N=16,338; January 2022-March 2025). Interrupted time series analyses were used to assess uptake of 3-month VL testing and assignment to greater than or equal to 6-month visit intervals following guideline implementation in April 2023. Modified Poisson regression was used to compare relative risks (RRs) for viral suppression at the first and second routine VL tests among clients tested at 3 months (test window=56-111 days) and 6 months (112-<252 days). Results: At the first VL assessment, 27% of participants had VL tests at 3 months and 30% at 6 months; the rest had tests outside either window (19%) or no test documented (25%). Three-month VL testing rose immediately after guideline implementation, reaching 72-85% coverage by the end of the study period. Assignment to greater than or equal to 6month visit intervals among clients with 3-month viral suppression increased after implementation, reaching 48-71% across districts. A second VL result was documented for 62% of clients tested in the 3- or 6-month window. Viral suppression did not differ meaningfully between clients initially tested at 3 months (72%) and those initially tested at 6 months (72%). Among clients with a second scheduled VL result, 82% were virally suppressed. Assignment to greater than or equal to 6-month visit intervals was not associated with subsequent viral suppression (aRR 1.02, 95% CI 0.99-1.06). Results should be interpreted with caution due to missing VL data. Conclusion: South Africas 2023 guideline revision was associated with rapid increases in 3-month VL testing and assignment to longer visit intervals. Viral suppression at the first VL test was similar among clients tested at 3 and 6 months, and longer visit intervals were not associated with poorer outcomes. These findings support earlier differentiation of HIV care within routine service delivery. Incomplete uptake of recommended testing and visit intervals offers opportunities to strengthen implementation and warrants continued evaluation of longer-term outcomes.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background: South Africas 2023 revised ART Guidelines moved the first scheduled viral load (VL) test from 6 to 3 months after antiretroviral therapy (ART) initiation and accelerated differentiated care eligibility from 7 to 4 months among virally suppressed clients. We assessed uptake of these changes and their association with virologic outcomes. Methods: We analysed routine electronic medical record data from 18 primary healthcare clinics in three South African districts among all adults initiating or re-initiating ART (N=16,338; January 2022-March 2025). Interrupted time series analyses were used to assess uptake of 3-month VL testing and assignment to greater than or equal to 6-month visit intervals following guideline implementation in April 2023. Modified Poisson regression was used to compare relative risks (RRs) for viral suppression at the first and second routine VL tests among clients tested at 3 months (test window=56-111 days) and 6 months (112-<252 days). Results: At the first VL assessment, 27% of participants had VL tests at 3 months and 30% at 6 months; the rest had tests outside either window (19%) or no test documented (25%). Three-month VL testing rose immediately after guideline implementation, reaching 72-85% coverage by the end of the study period. Assignment to greater than or equal to 6month visit intervals among clients with 3-month viral suppression increased after implementation, reaching 48-71% across districts. A second VL result was documented for 62% of clients tested in the 3- or 6-month window. Viral suppression did not differ meaningfully between clients initially tested at 3 months (72%) and those initially tested at 6 months (72%). Among clients with a second scheduled VL result, 82% were virally suppressed. Assignment to greater than or equal to 6-month visit intervals was not associated with subsequent viral suppression (aRR 1.02, 95% CI 0.99-1.06). Results should be interpreted with caution due to missing VL data. Conclusion: South Africas 2023 guideline revision was associated with rapid increases in 3-month VL testing and assignment to longer visit intervals. Viral suppression at the first VL test was similar among clients tested at 3 and 6 months, and longer visit intervals were not associated with poorer outcomes. These findings support earlier differentiation of HIV care within routine service delivery. Incomplete uptake of recommended testing and visit intervals offers opportunities to strengthen implementation and warrants continued evaluation of longer-term outcomes.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.15.26368143v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 204,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.15.26368143v1?rss=1"
    },
    {
      "id": "7b71bf7f022aac324903",
      "title": "Preprint: Practical evaluation of AI models to forecast a respiratory seasonal epidemic in Canada",
      "content_text": "Public health organizations can benefit greatly from infectious disease epidemic forecasting to guide and support interventions and policies that reduce morbidity. However, accurate and reliable epidemic forecasting remains notoriously challenging and is an evolving field in which new scientific advances continue to support forecasting efforts. Computational models that underpin artificial intelligence (AI) models are promising developments that may improve seasonal epidemic forecasting. This…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "7b71bf7f022aac324903",
          "source": "web",
          "type": "change",
          "key": "#4b7d34b331775ff11ff8",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Practical evaluation of AI models to forecast a respiratory seasonal epidemic in Canada",
            "item_type": "record",
            "summary": "added: Preprint: Practical evaluation of AI models to forecast a respiratory seasonal epidemic in Canada",
            "after": {
              "title": "Preprint: Practical evaluation of AI models to forecast a respiratory seasonal epidemic in Canada",
              "authors": "Benteke, B. L.; Yusuf, W.; Cojocaru, M. G.; Champredon, D.",
              "author_corresponding": "Benjamin Longaou Benteke",
              "author_corresponding_institution": "University of Guelph",
              "doi": "10.64898/2026.11.14.26368122",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "infectious diseases",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.14.26368122.source.xml",
              "abstract": "Public health organizations can benefit greatly from infectious disease epidemic forecasting to guide and support interventions and policies that reduce morbidity. However, accurate and reliable epidemic forecasting remains notoriously challenging and is an evolving field in which new scientific advances continue to support forecasting efforts. Computational models that underpin artificial intelligence (AI) models are promising developments that may improve seasonal epidemic forecasting. This study aims to compare the performance of a selection of AI models previously identified as well adapted to epidemic forecasting, including machine learning (XGBoost), deep learning models (Long Short-Term Memory (LSTM), Gated Recurrent Unit (GRU), Transformer), time-series foundation model (Chronos), and a hybrid model: physics-informed neural networks (PINNs), against statistical models (Autoregressive Integrated Moving Average (ARIMA), Prophet) and a compartmental epidemiological model (CEM) in seasonal epidemic forecasting across Canada. The study uses weekly positivity-rate incidence of seasonal influenza A across eight Canadian provinces during the 2025/2026 season as a test case. Each model generated short-term (up to 5 weeks ahead) forecasts independently for each province from October 11, 2025, to March 28, 2026. We evaluated performance using mean absolute error (MAE) for each province. Our results show that AI models, specifically GRU, Transformer, and Chronos models, achieve lower MAE than CEM in four of eight provinces (Alberta, British Columbia, Prince Edward Island, and Saskatchewan). Meanwhile, CEM and ARIMA outperform all AI models in three provinces (Ontario, Quebec, Manitoba) and one province (Nova Scotia), respectively. Furthermore, data pooling strategies that leverage multi-province data for the target virus or multi-virus data within individual provinces greatly improve deep learning models, and Chronos performs well under zero-shot forecasting in British Columbia. In contrast, Prophet always has the highest MAE, and PINN is worse than CEMs. Overall, AI models performed comparably to, or slightly better than, CEMs. However, these modest gains may not offset their lack of interpretability, high computational costs, and reliance on the specialized expertise required for implementation. We therefore conclude that AI models are best as a complement, rather than a replacement, to CEMs, which remain crucial for interpretability and informing decision-making.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Public health organizations can benefit greatly from infectious disease epidemic forecasting to guide and support interventions and policies that reduce morbidity. However, accurate and reliable epidemic forecasting remains notoriously challenging and is an evolving field in which new scientific advances continue to support forecasting efforts. Computational models that underpin artificial intelligence (AI) models are promising developments that may improve seasonal epidemic forecasting. This study aims to compare the performance of a selection of AI models previously identified as well adapted to epidemic forecasting, including machine learning (XGBoost), deep learning models (Long Short-Term Memory (LSTM), Gated Recurrent Unit (GRU), Transformer), time-series foundation model (Chronos), and a hybrid model: physics-informed neural networks (PINNs), against statistical models (Autoregressive Integrated Moving Average (ARIMA), Prophet) and a compartmental epidemiological model (CEM) in seasonal epidemic forecasting across Canada. The study uses weekly positivity-rate incidence of seasonal influenza A across eight Canadian provinces during the 2025/2026 season as a test case. Each model generated short-term (up to 5 weeks ahead) forecasts independently for each province from October 11, 2025, to March 28, 2026. We evaluated performance using mean absolute error (MAE) for each province. Our results show that AI models, specifically GRU, Transformer, and Chronos models, achieve lower MAE than CEM in four of eight provinces (Alberta, British Columbia, Prince Edward Island, and Saskatchewan). Meanwhile, CEM and ARIMA outperform all AI models in three provinces (Ontario, Quebec, Manitoba) and one province (Nova Scotia), respectively. Furthermore, data pooling strategies that leverage multi-province data for the target virus or multi-virus data within individual provinces greatly improve deep learning models, and Chronos performs well under zero-shot forecasting in British Columbia. In contrast, Prophet always has the highest MAE, and PINN is worse than CEMs. Overall, AI models performed comparably to, or slightly better than, CEMs. However, these modest gains may not offset their lack of interpretability, high computational costs, and reliance on the specialized expertise required for implementation. We therefore conclude that AI models are best as a complement, rather than a replacement, to CEMs, which remain crucial for interpretability and informing decision-making.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368122v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 204,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368122v1?rss=1"
    },
    {
      "id": "8ea4b82ae27b480072b0",
      "title": "Preprint: A rapid and sensitive Loop-Mediated Isothermal Amplification (LAMP) assay for detection of mecA antibiotic resistance gene in clinical and food bacterial isolates",
      "content_text": "An advanced LAMP assay targeting the mecA gene in methicillin-resistant Staphylococcus aureus (MRSA) was developed and validated using clinical and foodborne S. aureus isolates. Reference strains, including both methicillin-sensitive and methicillin-resistant S. aureus, were used to evaluate and optimize assay performance. With the newly designed ID16 LAMP primer set, the detection limit for mecA was 15 fg/L of total genomic DNA, equivalent to 5 copies/L, and the assay turnaround time was only…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "8ea4b82ae27b480072b0",
          "source": "web",
          "type": "change",
          "key": "#19708dd4edc581fba9e6",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: A rapid and sensitive Loop-Mediated Isothermal Amplification (LAMP) assay for detection of mecA antibiotic resistance gene in clinical and food bacterial isolates",
            "item_type": "record",
            "summary": "added: Preprint: A rapid and sensitive Loop-Mediated Isothermal Amplification (LAMP) assay for detection of mecA antibiotic resistance gene in clinical and food bacterial isolates",
            "after": {
              "title": "Preprint: A rapid and sensitive Loop-Mediated Isothermal Amplification (LAMP) assay for detection of mecA antibiotic resistance gene in clinical and food bacterial isolates",
              "authors": "Baldenweck, L.; Djisalov, M.; Pinamonti, D.; manzano, M.; Gadjanski, I.; Vidic, J.",
              "author_corresponding": "Jasmina Vidic",
              "author_corresponding_institution": "INRAE",
              "doi": "10.64898/2026.11.13.26367169",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "infectious diseases",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.13.26367169.source.xml",
              "abstract": "An advanced LAMP assay targeting the mecA gene in methicillin-resistant Staphylococcus aureus (MRSA) was developed and validated using clinical and foodborne S. aureus isolates. Reference strains, including both methicillin-sensitive and methicillin-resistant S. aureus, were used to evaluate and optimize assay performance. With the newly designed ID16 LAMP primer set, the detection limit for mecA was 15 fg/L of total genomic DNA, equivalent to 5 copies/L, and the assay turnaround time was only 25 min. All mecA-positive isolates identified by conventional qPCR were successfully detected by the LAMP assay. Overall, the developed LAMP method provides a rapid, highly specific, and sensitive alternative for mecA detection.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "An advanced LAMP assay targeting the mecA gene in methicillin-resistant Staphylococcus aureus (MRSA) was developed and validated using clinical and foodborne S. aureus isolates. Reference strains, including both methicillin-sensitive and methicillin-resistant S. aureus, were used to evaluate and optimize assay performance. With the newly designed ID16 LAMP primer set, the detection limit for mecA was 15 fg/L of total genomic DNA, equivalent to 5 copies/L, and the assay turnaround time was only 25 min. All mecA-positive isolates identified by conventional qPCR were successfully detected by the LAMP assay. Overall, the developed LAMP method provides a rapid, highly specific, and sensitive alternative for mecA detection.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26367169v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 204,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26367169v1?rss=1"
    },
    {
      "id": "70323a2560ceebc82489",
      "title": "Preprint: Deep learning of point-of-care lung ultrasound and clinical data for pulmonary tuberculosis triage in Uganda",
      "content_text": "Rationale: Point of care lung ultrasound is portable and radiation free and could extend tuberculosis screening to settings without chest radiography, but no standardized criteria exist for interpreting it for tuberculosis. Objectives: To develop and internally evaluate deep learning models that classify pulmonary tuberculosis from lung ultrasound images, alone and combined with routine clinical variables, and to derive an abbreviated scanning protocol. Methods: In a prospective study in…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "70323a2560ceebc82489",
          "source": "web",
          "type": "change",
          "key": "#31c3387c15618a6711b4",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Deep learning of point-of-care lung ultrasound and clinical data for pulmonary tuberculosis triage in Uganda",
            "item_type": "record",
            "summary": "added: Preprint: Deep learning of point-of-care lung ultrasound and clinical data for pulmonary tuberculosis triage in Uganda",
            "after": {
              "title": "Preprint: Deep learning of point-of-care lung ultrasound and clinical data for pulmonary tuberculosis triage in Uganda",
              "authors": "Sharma, A.; Nakiyingi, L.; Janeva, E. J.; Guevarra, K.; Nate, W.; Nabawanuka, E.; Shankman, R.; Dhamdhere, R.; Astorga, G.; Joloba, M. L.; Ellner, J.; Madabhushi, A.; Xie, Y. L.",
              "author_corresponding": "Akanksha Sharma",
              "author_corresponding_institution": "Emory University",
              "doi": "10.64898/2026.11.14.26368125",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "infectious diseases",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.14.26368125.source.xml",
              "abstract": "Rationale: Point of care lung ultrasound is portable and radiation free and could extend tuberculosis screening to settings without chest radiography, but no standardized criteria exist for interpreting it for tuberculosis. Objectives: To develop and internally evaluate deep learning models that classify pulmonary tuberculosis from lung ultrasound images, alone and combined with routine clinical variables, and to derive an abbreviated scanning protocol. Methods: In a prospective study in Kampala, Uganda (2023 to 2025), we enrolled people aged 13 years or older with microbiologically confirmed pulmonary tuberculosis, their household contacts, and symptomatic people with other respiratory conditions. One still frame from each of 12 lung ultrasound zones was analyzed with an attention-based multiple-instance learning network. We compared clinical-only (random forest), ultrasound only, and combined models and derived a 6 zone protocol from training set attention weights. Participants were allocated to training (n = 223), validation (n = 20), and held-out test (n = 73) sets. Results: Of 318 enrolled participants, 316 were analyzed (118 with and 198 without tuberculosis). In the test set, areas under the receiver operating characteristic curve were 0.88 (95% confidence interval, 0.80 to 0.95) for the clinical-only model; 0.93 (0.86 to 0.97) and 0.95 (0.89 to 0.99) for the 12 zone ultrasound-only and combined models; and 0.91 (0.83 to 0.97) and 0.93 (0.86 to 0.99) for the corresponding 6-zone models. At 90% sensitivity, specificity was 82.2% (34.9 to 97.8) for the 12-zone combined model and 91.1% (25.0 to 98.0) for the 6-zone combined model. Point estimates for all 12-zone models and the 6-zone combined model met the 2025 World Health Organization minimum accuracy targets for a high-sensitivity screening test ([&ge;]90% sensitivity, [&ge;]60% specificity). Conclusion: Lung ultrasound analyzed with attention-based deep learning and combined with clinical variables showed high internal discrimination for pulmonary tuberculosis, and a simplified 6-zone protocol retained most of this performance. External validation in intended-use screening populations is needed",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Rationale: Point of care lung ultrasound is portable and radiation free and could extend tuberculosis screening to settings without chest radiography, but no standardized criteria exist for interpreting it for tuberculosis. Objectives: To develop and internally evaluate deep learning models that classify pulmonary tuberculosis from lung ultrasound images, alone and combined with routine clinical variables, and to derive an abbreviated scanning protocol. Methods: In a prospective study in Kampala, Uganda (2023 to 2025), we enrolled people aged 13 years or older with microbiologically confirmed pulmonary tuberculosis, their household contacts, and symptomatic people with other respiratory conditions. One still frame from each of 12 lung ultrasound zones was analyzed with an attention-based multiple-instance learning network. We compared clinical-only (random forest), ultrasound only, and combined models and derived a 6 zone protocol from training set attention weights. Participants were allocated to training (n = 223), validation (n = 20), and held-out test (n = 73) sets. Results: Of 318 enrolled participants, 316 were analyzed (118 with and 198 without tuberculosis). In the test set, areas under the receiver operating characteristic curve were 0.88 (95% confidence interval, 0.80 to 0.95) for the clinical-only model; 0.93 (0.86 to 0.97) and 0.95 (0.89 to 0.99) for the 12 zone ultrasound-only and combined models; and 0.91 (0.83 to 0.97) and 0.93 (0.86 to 0.99) for the corresponding 6-zone models. At 90% sensitivity, specificity was 82.2% (34.9 to 97.8) for the 12-zone combined model and 91.1% (25.0 to 98.0) for the 6-zone combined model. Point estimates for all 12-zone models and the 6-zone combined model met the 2025 World Health Organization minimum accuracy targets for a high-sensitivity screening test ([&ge;]90% sensitivity, [&ge;]60% specificity). Conclusion: Lung ultrasound analyzed with attention-based deep learning and combined with clinical variables showed high internal discrimination for pulmonary tuberculosis, and a simplified 6-zone protocol retained most of this performance. External validation in intended-use screening populations is needed",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368125v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 204,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368125v1?rss=1"
    },
    {
      "id": "6f388fe0d8d9be0897d3",
      "title": "Preprint: Wavelet-derived indices of cardiac vagal and vasomotor oscillations as a new tool to better understand autonomic imbalance in post-COVID-19 dysautonomia",
      "content_text": "Background: When aiming to quantify autonomic imbalance, conventional heart rate variability (HRV) analysis generally reduces each posture to a single spectral value derived from interbeat intervals (IBI) alone. This analysis based only in IBI obscures transient events during blood pressure changes. We propose two wavelet-derived indices that quantify cardiac vagal and vasomotor sympathetic oscillations separately and over time. Since autonomic imbalance is directly related to baroreflex…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "6f388fe0d8d9be0897d3",
          "source": "web",
          "type": "change",
          "key": "#bf741831adf0a1a283c5",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Wavelet-derived indices of cardiac vagal and vasomotor oscillations as a new tool to better understand autonomic imbalance in post-COVID-19 dysautonomia",
            "item_type": "record",
            "summary": "added: Preprint: Wavelet-derived indices of cardiac vagal and vasomotor oscillations as a new tool to better understand autonomic imbalance in post-COVID-19 dysautonomia",
            "after": {
              "title": "Preprint: Wavelet-derived indices of cardiac vagal and vasomotor oscillations as a new tool to better understand autonomic imbalance in post-COVID-19 dysautonomia",
              "authors": "Romero Fragoso, I.; Sainz-Jimenez, A.; Reyes Cruz, T.; Chiquete, E.; Tamez-Torres, K.; Sifuentes-Osornio, J.; Fossion, R.; Estanol, B.; Aceves-Buendia, J. d. J.",
              "author_corresponding": "Jose de Jesus Aceves-Buendia",
              "author_corresponding_institution": "Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran",
              "doi": "10.64898/2026.11.14.26367993",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_no",
              "category": "cardiovascular medicine",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.14.26367993.source.xml",
              "abstract": "Background: When aiming to quantify autonomic imbalance, conventional heart rate variability (HRV) analysis generally reduces each posture to a single spectral value derived from interbeat intervals (IBI) alone. This analysis based only in IBI obscures transient events during blood pressure changes. We propose two wavelet-derived indices that quantify cardiac vagal and vasomotor sympathetic oscillations separately and over time. Since autonomic imbalance is directly related to baroreflex sensitivity (BRS), we evaluated them against an estimate of baroreflex sensitivity in post-COVID-19 patients. Methods: In this study, 121 participants (32 healthy controls and 89 patients with persistent post-COVID-19 autonomic symptoms) underwent an active standing test with continuous finger blood pressure. The continuous wavelet transform with generalized Morse wavelets yielded time-varying high-frequency power of IBI and low-frequency power of systolic blood pressure (SBP). Two new indices were proposed: Index I combined the magnitude and variability of HF IBI power (aimed to quantify parasympathetic activity), and the index J combined LF SBP power with the rate of its transient elevations (bursts), which aims to quantify sympathetic vasomotor activity; J/I was their ratio. Indices were computed for supine and orthostatic periods and compared with conventional HRV and BRS measurements. Results: Index I correlated strongly with HF power of IBI and was lower in all patient subgroups than in controls, Index J had only a weak relation with LF power of IBI. On standing, J increased most in the subgroups with the worst baroreflex function. Orthostatic J/I was higher than in controls in all three subgroups, while LF/HF showed no differences. J/I was inversely correlated with BRS, most strongly when standing, and more strongly than LF/HF also. Adding J to I raised the cross-validated variance explained in orthostatic BRS substantially. In one example patient, a window during symptoms showed vasomotor oscillations that were hidden in the posture average. Conclusions: Wavelet-derived indices from routine beat-to-beat recordings separate cardiac vagal modulation from sympathetic vasomotor oscillations and their transients. J/I correlates with BRS impairment more closely than LF/HF, providing a potential alternative estimate of autonomic balance, and its time-resolved visual output allows analysis of clinically relevant windows within a posture. The new proposed variables allowed an evaluation of autonomic imbalance that could be applied to different pathologies. Keywords: continuous wavelet transform; heart rate variability; blood pressure variability; baroreflex sensitivity; Mayer waves; dysautonomia; long COVID; active standing test; autonomic imbalance.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background: When aiming to quantify autonomic imbalance, conventional heart rate variability (HRV) analysis generally reduces each posture to a single spectral value derived from interbeat intervals (IBI) alone. This analysis based only in IBI obscures transient events during blood pressure changes. We propose two wavelet-derived indices that quantify cardiac vagal and vasomotor sympathetic oscillations separately and over time. Since autonomic imbalance is directly related to baroreflex sensitivity (BRS), we evaluated them against an estimate of baroreflex sensitivity in post-COVID-19 patients. Methods: In this study, 121 participants (32 healthy controls and 89 patients with persistent post-COVID-19 autonomic symptoms) underwent an active standing test with continuous finger blood pressure. The continuous wavelet transform with generalized Morse wavelets yielded time-varying high-frequency power of IBI and low-frequency power of systolic blood pressure (SBP). Two new indices were proposed: Index I combined the magnitude and variability of HF IBI power (aimed to quantify parasympathetic activity), and the index J combined LF SBP power with the rate of its transient elevations (bursts), which aims to quantify sympathetic vasomotor activity; J/I was their ratio. Indices were computed for supine and orthostatic periods and compared with conventional HRV and BRS measurements. Results: Index I correlated strongly with HF power of IBI and was lower in all patient subgroups than in controls, Index J had only a weak relation with LF power of IBI. On standing, J increased most in the subgroups with the worst baroreflex function. Orthostatic J/I was higher than in controls in all three subgroups, while LF/HF showed no differences. J/I was inversely correlated with BRS, most strongly when standing, and more strongly than LF/HF also. Adding J to I raised the cross-validated variance explained in orthostatic BRS substantially. In one example patient, a window during symptoms showed vasomotor oscillations that were hidden in the posture average. Conclusions: Wavelet-derived indices from routine beat-to-beat recordings separate cardiac vagal modulation from sympathetic vasomotor oscillations and their transients. J/I correlates with BRS impairment more closely than LF/HF, providing a potential alternative estimate of autonomic balance, and its time-resolved visual output allows analysis of clinically relevant windows within a posture. The new proposed variables allowed an evaluation of autonomic imbalance that could be applied to different pathologies. Keywords: continuous wavelet transform; heart rate variability; blood pressure variability; baroreflex sensitivity; Mayer waves; dysautonomia; long COVID; active standing test; autonomic imbalance.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26367993v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 204,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26367993v1?rss=1"
    },
    {
      "id": "17a845ad39c8049b70c3",
      "title": "Preprint: Prenatal care and clinical characteristics of adolescent pregnancies",
      "content_text": "Background: Descriptions of adolescent pregnancy can identify priorities for prenatal care and postpartum follow-up. This study characterized prenatal care and clinical outcomes documented in adolescent pregnancy records.\n\nMethodsWe conducted a retrospective, descriptive, observational cross-sectional review of records covering 2020-2024 at a single family medicine outpatient service. All eligible records were included. Prenatal care and clinical characteristics were summarized using…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "17a845ad39c8049b70c3",
          "source": "web",
          "type": "change",
          "key": "#e121126705fab10bafdf",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Prenatal care and clinical characteristics of adolescent pregnancies",
            "item_type": "record",
            "summary": "added: Preprint: Prenatal care and clinical characteristics of adolescent pregnancies",
            "after": {
              "title": "Preprint: Prenatal care and clinical characteristics of adolescent pregnancies",
              "authors": "Melendez Loredo, A. V.; Salgado, R. C.; Calva, L. R.",
              "author_corresponding": "Angela Victoria Melendez Loredo Sr.",
              "author_corresponding_institution": "Instituto Mexicano del Seguro Social",
              "doi": "10.64898/2026.11.12.26367235",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "obstetrics and gynecology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.12.26367235.source.xml",
              "abstract": "BackgroundDescriptions of adolescent pregnancy can identify priorities for prenatal care and postpartum follow-up. This study characterized prenatal care and clinical outcomes documented in adolescent pregnancy records.\n\nMethodsWe conducted a retrospective, descriptive, observational cross-sectional review of records covering 2020-2024 at a single family medicine outpatient service. All eligible records were included. Prenatal care and clinical characteristics were summarized using frequencies and percentages. Reporting was restricted to aggregate results to reduce the risk of participant identification.\n\nResultsThirty-nine records were analyzed. The first prenatal visit occurred in the second trimester in 53.85%. Overweight or obesity was recorded in 71.8%. Urinary tract infection occurred in 66.67% and gestational hypertension in 28.21%. No preterm births or obstetric hemorrhages were recorded. Vaginal delivery accounted for 51.28% and cesarean delivery for 48.72%. Postpartum contraceptive method was unspecified in 64.10% of records.\n\nConclusionsThis small, single-center study identified frequent urinary tract infections, a high recorded proportion of overweight or obesity, prenatal entry commonly after the first trimester, and incomplete postpartum contraceptive documentation. These findings identify local priorities for care and record quality; they do not establish causal relationships or population prevalence.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background: Descriptions of adolescent pregnancy can identify priorities for prenatal care and postpartum follow-up. This study characterized prenatal care and clinical outcomes documented in adolescent pregnancy records.\n\nMethodsWe conducted a retrospective, descriptive, observational cross-sectional review of records covering 2020-2024 at a single family medicine outpatient service. All eligible records were included. Prenatal care and clinical characteristics were summarized using frequencies and percentages. Reporting was restricted to aggregate results to reduce the risk of participant identification.\n\nResultsThirty-nine records were analyzed. The first prenatal visit occurred in the second trimester in 53.85%. Overweight or obesity was recorded in 71.8%. Urinary tract infection occurred in 66.67% and gestational hypertension in 28.21%. No preterm births or obstetric hemorrhages were recorded. Vaginal delivery accounted for 51.28% and cesarean delivery for 48.72%. Postpartum contraceptive method was unspecified in 64.10% of records.\n\nConclusionsThis small, single-center study identified frequent urinary tract infections, a high recorded proportion of overweight or obesity, prenatal entry commonly after the first trimester, and incomplete postpartum contraceptive documentation. These findings identify local priorities for care and record quality; they do not establish causal relationships or population prevalence.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.12.26367235v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 204,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.12.26367235v1?rss=1"
    },
    {
      "id": "92f5d724d698e89d80eb",
      "title": "Preprint: CRISPR-Cas3-Based Detection of Cryptosporidium and Pepper Mild Mottle Virus in Environmental Waters Using a Test-Strip Readout",
      "content_text": "Test-strip-based CRISPR diagnostics could enable decentralized nucleic acid monitoring, but their application to environmental waters has been constrained by insufficient sensitivity and complex environmental matrices. Here, we developed a highly sensitive and specific assay combining reverse transcription-nested recombinase polymerase amplification (RT-nRPA) with Cas3-Operated Nucleic Acid detectioN (CONAN) for test-strip-based detection of Cryptosporidium 18S rRNA and pepper mild mottle virus…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "92f5d724d698e89d80eb",
          "source": "web",
          "type": "change",
          "key": "#69cc3e614d25a08fdd4f",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: CRISPR-Cas3-Based Detection of Cryptosporidium and Pepper Mild Mottle Virus in Environmental Waters Using a Test-Strip Readout",
            "item_type": "record",
            "summary": "added: Preprint: CRISPR-Cas3-Based Detection of Cryptosporidium and Pepper Mild Mottle Virus in Environmental Waters Using a Test-Strip Readout",
            "after": {
              "title": "Preprint: CRISPR-Cas3-Based Detection of Cryptosporidium and Pepper Mild Mottle Virus in Environmental Waters Using a Test-Strip Readout",
              "authors": "Torii, S.; Hirano, R.; Angga, M. S.; Takeshita, K.; Yoshimi, K.; Kitajima, M.; Mashimo, T.; Oguma, K.",
              "author_corresponding": "Shotaro Torii",
              "author_corresponding_institution": "The University of Tokyo",
              "doi": "10.64898/2026.11.13.26368066",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "occupational and environmental health",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.13.26368066.source.xml",
              "abstract": "Test-strip-based CRISPR diagnostics could enable decentralized nucleic acid monitoring, but their application to environmental waters has been constrained by insufficient sensitivity and complex environmental matrices. Here, we developed a highly sensitive and specific assay combining reverse transcription-nested recombinase polymerase amplification (RT-nRPA) with Cas3-Operated Nucleic Acid detectioN (CONAN) for test-strip-based detection of Cryptosporidium 18S rRNA and pepper mild mottle virus (PMMoV). Introducing a second, nRPA step reduced the 50% limit of detection (LOD50) to 2.0 copies/reaction for Cryptosporidium and 1.5 copies/reaction for PMMoV. In 17 river water and six wastewater extracts, CONAN was positive for all nRPA products containing the Cryptosporidium sequence and negative for all products lacking the target. Cas12a-based DETECTR was negative for four Cryptosporidium-containing nRPA products, whereas LAMP and qPCR frequently cross-reacted with non-target environmental eukaryotic sequences. Consequently, nRPA-CONAN can overcome sensitivity and specificity constraints and offer a practical route toward instrument-light nucleic acid monitoring in environmental waters.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Test-strip-based CRISPR diagnostics could enable decentralized nucleic acid monitoring, but their application to environmental waters has been constrained by insufficient sensitivity and complex environmental matrices. Here, we developed a highly sensitive and specific assay combining reverse transcription-nested recombinase polymerase amplification (RT-nRPA) with Cas3-Operated Nucleic Acid detectioN (CONAN) for test-strip-based detection of Cryptosporidium 18S rRNA and pepper mild mottle virus (PMMoV). Introducing a second, nRPA step reduced the 50% limit of detection (LOD50) to 2.0 copies/reaction for Cryptosporidium and 1.5 copies/reaction for PMMoV. In 17 river water and six wastewater extracts, CONAN was positive for all nRPA products containing the Cryptosporidium sequence and negative for all products lacking the target. Cas12a-based DETECTR was negative for four Cryptosporidium-containing nRPA products, whereas LAMP and qPCR frequently cross-reacted with non-target environmental eukaryotic sequences. Consequently, nRPA-CONAN can overcome sensitivity and specificity constraints and offer a practical route toward instrument-light nucleic acid monitoring in environmental waters.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368066v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 204,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368066v1?rss=1"
    },
    {
      "id": "6385966dfa687e0240e2",
      "title": "Preprint: Hierarchical Graph Learning with Multimodal Distillation for Breast Cancer Survival Prediction",
      "content_text": "Imaging mass cytometry (IMC) and DNA methylation can provide complementary information for breast cancer prognosis, yet these measurements may be unavailable for new patients. In this paper, we propose HEAL-Surv, a teacher-student framework that uses both modalities during training to predict five-year net disease-specific survival (DSS) from clinical variables and molecular profiles at inference. An additive Cox teacher integrates all four modalities, using a hierarchical IMC graph encoder to…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "6385966dfa687e0240e2",
          "source": "web",
          "type": "change",
          "key": "#a6a29a204fd9839ccc30",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Hierarchical Graph Learning with Multimodal Distillation for Breast Cancer Survival Prediction",
            "item_type": "record",
            "summary": "added: Preprint: Hierarchical Graph Learning with Multimodal Distillation for Breast Cancer Survival Prediction",
            "after": {
              "title": "Preprint: Hierarchical Graph Learning with Multimodal Distillation for Breast Cancer Survival Prediction",
              "authors": "Tran, B. M.; Nguyen, V. A.; Dang, Q. A.; Nguyen Ngoc, M. H.; Tran, H. N.; Tran, D. H.",
              "author_corresponding": "Dang Hung Tran",
              "author_corresponding_institution": "Hanoi University of Industry",
              "doi": "10.64898/2026.11.14.26368121",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_no",
              "category": "oncology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.14.26368121.source.xml",
              "abstract": "Imaging mass cytometry (IMC) and DNA methylation can provide complementary information for breast cancer prognosis, yet these measurements may be unavailable for new patients. In this paper, we propose HEAL-Surv, a teacher-student framework that uses both modalities during training to predict five-year net disease-specific survival (DSS) from clinical variables and molecular profiles at inference. An additive Cox teacher integrates all four modalities, using a hierarchical IMC graph encoder to capture local cell relationships and coarser tissue organisation. The student learns from observed outcomes and cross-fitted teacher survival curves, giving more weight to targets that agree across random initialisations. In five-fold cross-validation on 423 METABRIC patients, the full teacher achieved a mean five-year Uno's concordance of 0.723. Removing any modality reduced mean concordance and increased mean Brier-based errors. Relative to the matched student trained on observed outcomes alone, distillation increased mean five-year Uno's concordance from 0.658 to 0.704, with higher integrated and five-year Brier scores. In a separate external evaluation, an IMC-clinical variant trained on METABRIC achieved a five-year Uno's concordance of 0.660 on 265 Basel patients without refitting. These findings support multimodal supervision for improving risk discrimination with fewer inference inputs, while external validation of the student remains necessary.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Imaging mass cytometry (IMC) and DNA methylation can provide complementary information for breast cancer prognosis, yet these measurements may be unavailable for new patients. In this paper, we propose HEAL-Surv, a teacher-student framework that uses both modalities during training to predict five-year net disease-specific survival (DSS) from clinical variables and molecular profiles at inference. An additive Cox teacher integrates all four modalities, using a hierarchical IMC graph encoder to capture local cell relationships and coarser tissue organisation. The student learns from observed outcomes and cross-fitted teacher survival curves, giving more weight to targets that agree across random initialisations. In five-fold cross-validation on 423 METABRIC patients, the full teacher achieved a mean five-year Uno's concordance of 0.723. Removing any modality reduced mean concordance and increased mean Brier-based errors. Relative to the matched student trained on observed outcomes alone, distillation increased mean five-year Uno's concordance from 0.658 to 0.704, with higher integrated and five-year Brier scores. In a separate external evaluation, an IMC-clinical variant trained on METABRIC achieved a five-year Uno's concordance of 0.660 on 265 Basel patients without refitting. These findings support multimodal supervision for improving risk discrimination with fewer inference inputs, while external validation of the student remains necessary.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368121v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 204,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368121v1?rss=1"
    },
    {
      "id": "c3d20f16c305a31aae1b",
      "title": "Preprint: Phase I Clinical Trial of Allogeneic Cytomegalovirus-specific T Cells in Combination with Pembrolizumab for Recurrent Glioblastoma",
      "content_text": "Purpose: Glioblastoma (GBM) remains refractory to immunotherapy due to its immunosuppressive microenvironment. Tumour-infiltrating cytomegalovirus (CMV)-specific T cells express elevated programmed cell death protein-1 (PD-1), suggesting checkpoint-mediated dysfunction may limit T-cell therapy. We evaluated the safety and immunological activity of allogeneic CMV-specific T-cell therapy (CYT-101) combined with pembrolizumab. Patients and Methods: In this phase I 3+3 dose-escalation study…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "c3d20f16c305a31aae1b",
          "source": "web",
          "type": "change",
          "key": "#86dcb37b0238116e999a",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Phase I Clinical Trial of Allogeneic Cytomegalovirus-specific T Cells in Combination with Pembrolizumab for Recurrent Glioblastoma",
            "item_type": "record",
            "summary": "added: Preprint: Phase I Clinical Trial of Allogeneic Cytomegalovirus-specific T Cells in Combination with Pembrolizumab for Recurrent Glioblastoma",
            "after": {
              "title": "Preprint: Phase I Clinical Trial of Allogeneic Cytomegalovirus-specific T Cells in Combination with Pembrolizumab for Recurrent Glioblastoma",
              "authors": "Walker, D.; Martins, P.; Khaledi, P.; Alexander, H.; Stirling, A.; Neller, M. A.; Kelly, J.; Biggs, V.; Reddiex, H.; Panikkar, A.; Beagley, L.; Flynn, S.; Raju, J.; Voogt, M.; Solomon, M.; Smith, C.; Khanna, R.",
              "author_corresponding": "Rajiv Khanna",
              "author_corresponding_institution": "Queensland Immunology Research Centre and QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Frazer Institute, University of Queensland",
              "doi": "10.64898/2026.11.17.26367100",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc",
              "category": "oncology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.17.26367100.source.xml",
              "abstract": "Purpose: Glioblastoma (GBM) remains refractory to immunotherapy due to its immunosuppressive microenvironment. Tumour-infiltrating cytomegalovirus (CMV)-specific T cells express elevated programmed cell death protein-1 (PD-1), suggesting checkpoint-mediated dysfunction may limit T-cell therapy. We evaluated the safety and immunological activity of allogeneic CMV-specific T-cell therapy (CYT-101) combined with pembrolizumab. Patients and Methods: In this phase I 3+3 dose-escalation study, recurrent GBM patients received four weekly infusions of CYT-101 followed by pembrolizumab. The primary endpoint was safety. Secondary endpoints included progression-free survival at 6 months (PFS-6), overall survival at 6 months (OS-6), and immune correlates of response. Results: CYT-101 T-cell therapy demonstrated polyfunctional activity, broad HLA restriction, potent cytolytic function, and diverse T-cell receptor repertoires. Nine patients received study treatment. No dose-limiting toxicities were observed, and the maximum tolerated dose was not reached. Only six adverse events were considered treatment-related, and no treatment-related serious adverse events, graft-versus-host disease, cytokine release syndrome, or neurotoxicity occurred. OS-6 and PFS-6 were 55% and 11%, respectively, with a median overall survival of 9.1 months. No objective clinical responses were seen. Of the nine treated participants, one had stable disease, five had progressive disease, and three were unevaluable by modified RANO criteria. Immune profiling revealed enhanced global CD4+ and CD8+ T-cell function following CYT-101 therapy, while donor-derived CYT-101 clonotypes were detected in six of nine participants, with significant T-cell repertoire remodelling. Conclusions: Allogeneic CMV-specific T-cell therapy combined with pembrolizumab was safe in recurrent GBM, supporting further evaluation of this strategy to overcome immune dysfunction in GBM.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Purpose: Glioblastoma (GBM) remains refractory to immunotherapy due to its immunosuppressive microenvironment. Tumour-infiltrating cytomegalovirus (CMV)-specific T cells express elevated programmed cell death protein-1 (PD-1), suggesting checkpoint-mediated dysfunction may limit T-cell therapy. We evaluated the safety and immunological activity of allogeneic CMV-specific T-cell therapy (CYT-101) combined with pembrolizumab. Patients and Methods: In this phase I 3+3 dose-escalation study, recurrent GBM patients received four weekly infusions of CYT-101 followed by pembrolizumab. The primary endpoint was safety. Secondary endpoints included progression-free survival at 6 months (PFS-6), overall survival at 6 months (OS-6), and immune correlates of response. Results: CYT-101 T-cell therapy demonstrated polyfunctional activity, broad HLA restriction, potent cytolytic function, and diverse T-cell receptor repertoires. Nine patients received study treatment. No dose-limiting toxicities were observed, and the maximum tolerated dose was not reached. Only six adverse events were considered treatment-related, and no treatment-related serious adverse events, graft-versus-host disease, cytokine release syndrome, or neurotoxicity occurred. OS-6 and PFS-6 were 55% and 11%, respectively, with a median overall survival of 9.1 months. No objective clinical responses were seen. Of the nine treated participants, one had stable disease, five had progressive disease, and three were unevaluable by modified RANO criteria. Immune profiling revealed enhanced global CD4+ and CD8+ T-cell function following CYT-101 therapy, while donor-derived CYT-101 clonotypes were detected in six of nine participants, with significant T-cell repertoire remodelling. Conclusions: Allogeneic CMV-specific T-cell therapy combined with pembrolizumab was safe in recurrent GBM, supporting further evaluation of this strategy to overcome immune dysfunction in GBM.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.17.26367100v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 204,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.17.26367100v1?rss=1"
    },
    {
      "id": "2354546aea5cd30efc75",
      "title": "Preprint: CONSORTiUM-IO: A Phase 1 Study Evaluating VE800 Plus Nivolumab in Treatment of Select Refractory or Metastatic Cancers",
      "content_text": "Microbiome modulation can augment responses to immunotherapy in advanced cancer. Early studies of anti-PD-1 therapies in combination with fecal microbiota transplantation (FMT) reported efficacy in immunotherapy-naive and -refractory settings. However, FMTs are variable in composition, difficult to scale, and risk the transfer of emerging pathogens. VE800 is a consortium of 11 strains of commensal bacteria derived from healthy donors and grown from clonal cell banks. VE800 increased anti-PD-1…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "2354546aea5cd30efc75",
          "source": "web",
          "type": "change",
          "key": "#665d12869e0b1a771397",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: CONSORTiUM-IO: A Phase 1 Study Evaluating VE800 Plus Nivolumab in Treatment of Select Refractory or Metastatic Cancers",
            "item_type": "record",
            "summary": "added: Preprint: CONSORTiUM-IO: A Phase 1 Study Evaluating VE800 Plus Nivolumab in Treatment of Select Refractory or Metastatic Cancers",
            "after": {
              "title": "Preprint: CONSORTiUM-IO: A Phase 1 Study Evaluating VE800 Plus Nivolumab in Treatment of Select Refractory or Metastatic Cancers",
              "authors": "Lyon De Ana, C.; Menon, R.; Bhattarai, S. K.; Prince, A. L.; Buresh, S.; Darrah, E.; Norman, J. M.; Szabady, R. L.; Bobilev, D.; Roberts, B.; Wang, J. S.; Bucci, V.; Faith, J. J.; Silber, J. L.; Honda, K.; Olle, B.; Davar, D.",
              "author_corresponding": "Jeremiah J Faith",
              "author_corresponding_institution": "Icahn School of Medicine at Mount Sinai",
              "doi": "10.64898/2026.11.13.26368051",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_no",
              "category": "oncology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.13.26368051.source.xml",
              "abstract": "Microbiome modulation can augment responses to immunotherapy in advanced cancer. Early studies of anti-PD-1 therapies in combination with fecal microbiota transplantation (FMT) reported efficacy in immunotherapy-naive and -refractory settings. However, FMTs are variable in composition, difficult to scale, and risk the transfer of emerging pathogens. VE800 is a consortium of 11 strains of commensal bacteria derived from healthy donors and grown from clonal cell banks. VE800 increased anti-PD-1 efficacy in preclinical models of cancer. CONSORTiUM-IO was a first-in-human, open-label phase 1 study that evaluated safety and efficacy of VE800 with nivolumab in advanced PD-1-refractory melanoma, PD-1-naive gastric/gastroesophageal junction (G/GEJ) adenocarcinoma and PD-1-naive microsatellite-stable colorectal cancer (MSS CRC). VE800 plus nivolumab was well tolerated but offered no improvement over historic response rates. Exploratory analyses in patients with melanoma revealed that VE800 strain engraftment was associated with greater progression-free survival (PFS) and increased immune activation peripherally.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Microbiome modulation can augment responses to immunotherapy in advanced cancer. Early studies of anti-PD-1 therapies in combination with fecal microbiota transplantation (FMT) reported efficacy in immunotherapy-naive and -refractory settings. However, FMTs are variable in composition, difficult to scale, and risk the transfer of emerging pathogens. VE800 is a consortium of 11 strains of commensal bacteria derived from healthy donors and grown from clonal cell banks. VE800 increased anti-PD-1 efficacy in preclinical models of cancer. CONSORTiUM-IO was a first-in-human, open-label phase 1 study that evaluated safety and efficacy of VE800 with nivolumab in advanced PD-1-refractory melanoma, PD-1-naive gastric/gastroesophageal junction (G/GEJ) adenocarcinoma and PD-1-naive microsatellite-stable colorectal cancer (MSS CRC). VE800 plus nivolumab was well tolerated but offered no improvement over historic response rates. Exploratory analyses in patients with melanoma revealed that VE800 strain engraftment was associated with greater progression-free survival (PFS) and increased immune activation peripherally.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368051v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 204,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368051v1?rss=1"
    },
    {
      "id": "e68935735f5af19a9bcb",
      "title": "Preprint: Integrated Genomic and Transcriptomic Profiling Reveals Distinct Biological Programs and Therapeutic Opportunities in Cancer of Unknown Primary",
      "content_text": "Background: Cancer of unknown primary (CUP) is a metastatic, heterogeneous malignancy accounting for 2-5% of cancer diagnoses globally. Failure to identify the primary site precludes tumor-type-specific therapy and, together with an aggressive clinical course, contributes to poor survival. The biological mechanisms driving these behaviors remain poorly understood. A deeper understanding of CUP biology is therefore essential to improve diagnostic precision and therapeutic strategies. To address…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "e68935735f5af19a9bcb",
          "source": "web",
          "type": "change",
          "key": "#b61293c0cc7d376333d0",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Integrated Genomic and Transcriptomic Profiling Reveals Distinct Biological Programs and Therapeutic Opportunities in Cancer of Unknown Primary",
            "item_type": "record",
            "summary": "added: Preprint: Integrated Genomic and Transcriptomic Profiling Reveals Distinct Biological Programs and Therapeutic Opportunities in Cancer of Unknown Primary",
            "after": {
              "title": "Preprint: Integrated Genomic and Transcriptomic Profiling Reveals Distinct Biological Programs and Therapeutic Opportunities in Cancer of Unknown Primary",
              "authors": "Wang, W.; Olsman, R.; Grashof, D. G. B.; Scheffers, L.; Leenders, M.; Robbrecht, D. G. J.; Snaebjornsson, P.; Katsikis, P. D.; van de Wouw, Y. A. J.; van de Werken, H. J. G.",
              "author_corresponding": "Harmen J.G. van de Werken",
              "author_corresponding_institution": "Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands",
              "doi": "10.64898/2026.11.14.26368097",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "oncology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.14.26368097.source.xml",
              "abstract": "Background: Cancer of unknown primary (CUP) is a metastatic, heterogeneous malignancy accounting for 2-5% of cancer diagnoses globally. Failure to identify the primary site precludes tumor-type-specific therapy and, together with an aggressive clinical course, contributes to poor survival. The biological mechanisms driving these behaviors remain poorly understood. A deeper understanding of CUP biology is therefore essential to improve diagnostic precision and therapeutic strategies. To address this knowledge gap, we comprehensively characterized the multi-omics landscape of CUP and identified biological and potentially therapeutic targets beyond tissue-of-origin (ToO) assignment. Methods: Whole-genome sequencing (WGS) data from 283 CUP patients were analyzed for ToO predictions, mutational signatures, driver alterations, genetic immune escape (GIE), and clinically actionable alterations. Matched RNA-sequencing (RNA-seq) data from 79 cases were used to characterize functional gene expression signatures and define transcriptomic subtypes. Clinical, WGS, and RNA-seq data were integrated via weighted gene co-expression network analysis (WGCNA). Results: High-confidence ToO predictions (likelihood >80%) were obtained for 58% of CUPs, most commonly predicting lung, gastrointestinal, and biliary tract origins. Mutational signatures clustering revealed four subgroups dominated by tobacco smoking, defective DNA mismatch repair (dMMR), UV exposure, and APOBEC activity, while a fifth group, comprising most tumors (n=169; 60%), showed mixed mutational processes. The cohort also frequently exhibited mutations in established cancer driver genes, including TP53, CDKN2A, KRAS, and epigenetic modifiers ARID1A, SMARCA4, and ARID2. GIE alterations occurred in 35% of tumors, mostly involving HLA-I genes. Transcriptomic profiling defined five subtypes with different degrees of immune infiltration, fibrosis, and tumor proliferation. These subtypes were not significantly associated with clinical or genomic features, indicating that the tumor microenvironment (TME) represents another layer of CUP heterogeneity. WGCNA further linked proliferative programs to cell-cycle, DNA-replication, and neuroendocrine features. WGS data identified potentially targetable alterations in 64% of the CUP patients. Conclusions: CUP comprises biologically heterogeneous tumors with diverse predicted origins, mutational histories, and TME subtypes. Transcriptomic profiling and integrated genomics suggest that immune escape and rapid proliferation contribute to the clinical aggressive behavior. Together, these findings provide a molecular framework for understanding CUP heterogeneity and support therapeutic stratification by both ToO predictions and tumor-specific molecular alterations.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background: Cancer of unknown primary (CUP) is a metastatic, heterogeneous malignancy accounting for 2-5% of cancer diagnoses globally. Failure to identify the primary site precludes tumor-type-specific therapy and, together with an aggressive clinical course, contributes to poor survival. The biological mechanisms driving these behaviors remain poorly understood. A deeper understanding of CUP biology is therefore essential to improve diagnostic precision and therapeutic strategies. To address this knowledge gap, we comprehensively characterized the multi-omics landscape of CUP and identified biological and potentially therapeutic targets beyond tissue-of-origin (ToO) assignment. Methods: Whole-genome sequencing (WGS) data from 283 CUP patients were analyzed for ToO predictions, mutational signatures, driver alterations, genetic immune escape (GIE), and clinically actionable alterations. Matched RNA-sequencing (RNA-seq) data from 79 cases were used to characterize functional gene expression signatures and define transcriptomic subtypes. Clinical, WGS, and RNA-seq data were integrated via weighted gene co-expression network analysis (WGCNA). Results: High-confidence ToO predictions (likelihood >80%) were obtained for 58% of CUPs, most commonly predicting lung, gastrointestinal, and biliary tract origins. Mutational signatures clustering revealed four subgroups dominated by tobacco smoking, defective DNA mismatch repair (dMMR), UV exposure, and APOBEC activity, while a fifth group, comprising most tumors (n=169; 60%), showed mixed mutational processes. The cohort also frequently exhibited mutations in established cancer driver genes, including TP53, CDKN2A, KRAS, and epigenetic modifiers ARID1A, SMARCA4, and ARID2. GIE alterations occurred in 35% of tumors, mostly involving HLA-I genes. Transcriptomic profiling defined five subtypes with different degrees of immune infiltration, fibrosis, and tumor proliferation. These subtypes were not significantly associated with clinical or genomic features, indicating that the tumor microenvironment (TME) represents another layer of CUP heterogeneity. WGCNA further linked proliferative programs to cell-cycle, DNA-replication, and neuroendocrine features. WGS data identified potentially targetable alterations in 64% of the CUP patients. Conclusions: CUP comprises biologically heterogeneous tumors with diverse predicted origins, mutational histories, and TME subtypes. Transcriptomic profiling and integrated genomics suggest that immune escape and rapid proliferation contribute to the clinical aggressive behavior. Together, these findings provide a molecular framework for understanding CUP heterogeneity and support therapeutic stratification by both ToO predictions and tumor-specific molecular alterations.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368097v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 204,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368097v1?rss=1"
    },
    {
      "id": "836d76bfe02c6ef30d40",
      "title": "Preprint: Feasibility and Psychological Outcomes of a Clinical Meditation Intervention for Patients with Cancer: A Mixed-Methods Pilot Study",
      "content_text": "Background: Psychological care is an important component of cancer care, addressing psychological distress and supporting patients as they cope with illness. Meditation-based approaches, including mindfulness-based interventions (MBIs), have been incorporated into supportive cancer care internationally. Clinical Meditation (Rinsho Meiso-ho), a meditation method developed in Japan, integrates traditional Buddhist meditation with a contemporary medical care perspective. However, its feasibility…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "836d76bfe02c6ef30d40",
          "source": "web",
          "type": "change",
          "key": "#c34b666149f7ea0c3068",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Feasibility and Psychological Outcomes of a Clinical Meditation Intervention for Patients with Cancer: A Mixed-Methods Pilot Study",
            "item_type": "record",
            "summary": "added: Preprint: Feasibility and Psychological Outcomes of a Clinical Meditation Intervention for Patients with Cancer: A Mixed-Methods Pilot Study",
            "after": {
              "title": "Preprint: Feasibility and Psychological Outcomes of a Clinical Meditation Intervention for Patients with Cancer: A Mixed-Methods Pilot Study",
              "authors": "Niida, A.; Koshiyama, T.; Baba, K.; Fujisawa, G.; Iwane, N.; Ohshita, D.; Shida, D.; Boku, N.",
              "author_corresponding": "Atsushi Niida",
              "author_corresponding_institution": "Laboratory of Molecular Medicine, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan",
              "doi": "10.64898/2026.11.11.26367801",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc",
              "category": "oncology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.11.26367801.source.xml",
              "abstract": "BackgroundPsychological care is an important component of cancer care, addressing psychological distress and supporting patients as they cope with illness. Meditation-based approaches, including mindfulness-based interventions (MBIs), have been incorporated into supportive cancer care internationally. Clinical Meditation (Rinsho Meiso-ho), a meditation method developed in Japan, integrates traditional Buddhist meditation with a contemporary medical care perspective. However, its feasibility and psychological outcomes in patients with cancer have not been sufficiently studied.\n\nObjectiveThis study aimed to evaluate the feasibility of a Clinical Meditation intervention and to explore psychological outcomes and participants experiences among patients with cancer who were receiving or scheduled to receive pharmacotherapy at the time of recruitment.\n\nMethodsThis single-arm pilot study used a convergent mixed-methods design to evaluate an 8-week program consisting of a 4-week structured phase (1 face-to-face session and 3 brief online group sessions, with prescribed home practice) and a 4-week self-directed phase (1 individual online session, with voluntary home practice). Feasibility was assessed descriptively using retention, attendance, practice frequency, and poststudy feedback. Anxiety, depression, insomnia, fatigue, spiritual well-being (SWB), and posttraumatic growth (PTG) were assessed at baseline, 4 weeks, and 8 weeks. Changes were examined using Friedman tests and exact Wilcoxon signed-rank tests, with adjustment for multiple comparisons. Free-text responses were analyzed thematically and integrated with questionnaire findings at the participant level.\n\nResultsEleven patients were enrolled; 9 (81.8%) completed the 4-week assessment and 8 (72.7%) completed the 8-week assessment. Median practice frequency declined from 5-6 days per week during the structured first month to 3-4 days per week during the self-directed second month (P=.031). Quantitative analyses included 9 participants, of whom 8 completed all 3 assessments; qualitative analyses included 8 participants. SWB and PTG showed significant overall changes (adjusted P=.02 and P=.04, respectively). SWB was higher than baseline at 4 weeks (adjusted P=.012), but the difference was not significant at 8 weeks. PTG was higher than baseline at both 4 and 8 weeks (both adjusted P=.047). No significant changes were observed in anxiety, depression, insomnia, or fatigue. Five themes were identified, encompassing experiences such as relaxation, greater distance from rumination, and meditation as a source of support. Participants accounts generally aligned with increases in SWB and PTG scores, although perceived benefits did not always correspond to changes in all questionnaire measures.\n\nConclusionsThis mixed-methods pilot study suggests that Clinical Meditation may be feasible and acceptable for patients with cancer, although sustaining meditation practice remains challenging. Exploratory increases in SWB and PTG warrant further investigation. Larger controlled studies, comparisons with established MBIs, and deeper qualitative research are needed to evaluate outcomes and clarify the distinctive features of Clinical Meditation.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background: Psychological care is an important component of cancer care, addressing psychological distress and supporting patients as they cope with illness. Meditation-based approaches, including mindfulness-based interventions (MBIs), have been incorporated into supportive cancer care internationally. Clinical Meditation (Rinsho Meiso-ho), a meditation method developed in Japan, integrates traditional Buddhist meditation with a contemporary medical care perspective. However, its feasibility and psychological outcomes in patients with cancer have not been sufficiently studied.\n\nObjectiveThis study aimed to evaluate the feasibility of a Clinical Meditation intervention and to explore psychological outcomes and participants experiences among patients with cancer who were receiving or scheduled to receive pharmacotherapy at the time of recruitment.\n\nMethodsThis single-arm pilot study used a convergent mixed-methods design to evaluate an 8-week program consisting of a 4-week structured phase (1 face-to-face session and 3 brief online group sessions, with prescribed home practice) and a 4-week self-directed phase (1 individual online session, with voluntary home practice). Feasibility was assessed descriptively using retention, attendance, practice frequency, and poststudy feedback. Anxiety, depression, insomnia, fatigue, spiritual well-being (SWB), and posttraumatic growth (PTG) were assessed at baseline, 4 weeks, and 8 weeks. Changes were examined using Friedman tests and exact Wilcoxon signed-rank tests, with adjustment for multiple comparisons. Free-text responses were analyzed thematically and integrated with questionnaire findings at the participant level.\n\nResultsEleven patients were enrolled; 9 (81.8%) completed the 4-week assessment and 8 (72.7%) completed the 8-week assessment. Median practice frequency declined from 5-6 days per week during the structured first month to 3-4 days per week during the self-directed second month (P=.031). Quantitative analyses included 9 participants, of whom 8 completed all 3 assessments; qualitative analyses included 8 participants. SWB and PTG showed significant overall changes (adjusted P=.02 and P=.04, respectively). SWB was higher than baseline at 4 weeks (adjusted P=.012), but the difference was not significant at 8 weeks. PTG was higher than baseline at both 4 and 8 weeks (both adjusted P=.047). No significant changes were observed in anxiety, depression, insomnia, or fatigue. Five themes were identified, encompassing experiences such as relaxation, greater distance from rumination, and meditation as a source of support. Participants accounts generally aligned with increases in SWB and PTG scores, although perceived benefits did not always correspond to changes in all questionnaire measures.\n\nConclusionsThis mixed-methods pilot study suggests that Clinical Meditation may be feasible and acceptable for patients with cancer, although sustaining meditation practice remains challenging. Exploratory increases in SWB and PTG warrant further investigation. Larger controlled studies, comparisons with established MBIs, and deeper qualitative research are needed to evaluate outcomes and clarify the distinctive features of Clinical Meditation.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.11.26367801v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 204,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.11.26367801v1?rss=1"
    },
    {
      "id": "f93814a0068e32647931",
      "title": "Preprint: Updated outcome of patients with lung only osteosarcoma recurrence following surgical resection enrolled in phase 2 clinical trials: A report from the Children's Oncology Group",
      "content_text": "Objective: Osteosarcoma is a rare primary bone cancer of adolescents and young adults without significant improvement in treatments or outcomes in several decades. Resection is standard of care for recurrent disease. Patients with lung only osteosarcoma recurrence following surgical resection (LOOR-FSR) may present the most meaningful opportunity for impactful intervention but alternative trial endpoints to objective response are needed. Here we update benchmarks for LOOR-FSR with contemporary…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "f93814a0068e32647931",
          "source": "web",
          "type": "change",
          "key": "#23ddb5fd378fc829ec5c",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Updated outcome of patients with lung only osteosarcoma recurrence following surgical resection enrolled in phase 2 clinical trials: A report from the Children's Oncology Group",
            "item_type": "record",
            "summary": "added: Preprint: Updated outcome of patients with lung only osteosarcoma recurrence following surgical resection enrolled in phase 2 clinical trials: A report from the Children's Oncology Group",
            "after": {
              "title": "Preprint: Updated outcome of patients with lung only osteosarcoma recurrence following surgical resection enrolled in phase 2 clinical trials: A report from the Children's Oncology Group",
              "authors": "Chou, A. J.; DelRocco, N.; Krailo, M.; Buxton, A.; Hingorani, P.; Weigel, B. J.; Fox, E.; Lagmay, J. P.; Gorlick, R.; Roberts, R.; Dubois, S. G.; Reed, D.; Janeway, K. A.",
              "author_corresponding": "Katherine A Janeway",
              "author_corresponding_institution": "Dana-Farber / Boston Childrens Cancer and Blood Disorders Center",
              "doi": "10.64898/2026.11.13.26368045",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_no",
              "category": "oncology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.13.26368045.source.xml",
              "abstract": "Objective: Osteosarcoma is a rare primary bone cancer of adolescents and young adults without significant improvement in treatments or outcomes in several decades. Resection is standard of care for recurrent disease. Patients with lung only osteosarcoma recurrence following surgical resection (LOOR-FSR) may present the most meaningful opportunity for impactful intervention but alternative trial endpoints to objective response are needed. Here we update benchmarks for LOOR-FSR with contemporary clinical trial data. Patients/Methods: This study included patients with pathologically confirmed LOOR-FSR enrolled on three Childrens Oncology Group phase 2 single arm trials. Benchmark endpoints assessed in this patient population were event-free survival (EFS) and overall survival (OS). In addition, we evaluated the impact of demographics and baseline clinical factors on outcome. Results: Ninety-nine patients met criteria for inclusion in this analysis. Median EFS and OS were 4.8 (95% CI: 3.5, 6.3) and 26.2 (23.3, 56.8) months respectively. Twelve-month EFS was 22% (15-31%) and ranged from 14% to 29% across the 3 trials, a difference that did not achieve statistical significance. The risk of EFS event was higher for those whose first recurrence occurred within two years of diagnosis (p=0.009). Other demographic and clinical factors did not statistically impact risk of event though estimated EFS for males was lower than for females. Conclusion: Despite almost doubling the number of patients in this historical control cohort, wide variance in outcomes led to confidence intervals unchanged from previously published work. Until the most significant factors contributing to variability of outcomes in this patient population are quantified, single arm trials of new approaches will only be able to identify large effect sizes. Smaller effect sizes will require randomization.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Objective: Osteosarcoma is a rare primary bone cancer of adolescents and young adults without significant improvement in treatments or outcomes in several decades. Resection is standard of care for recurrent disease. Patients with lung only osteosarcoma recurrence following surgical resection (LOOR-FSR) may present the most meaningful opportunity for impactful intervention but alternative trial endpoints to objective response are needed. Here we update benchmarks for LOOR-FSR with contemporary clinical trial data. Patients/Methods: This study included patients with pathologically confirmed LOOR-FSR enrolled on three Childrens Oncology Group phase 2 single arm trials. Benchmark endpoints assessed in this patient population were event-free survival (EFS) and overall survival (OS). In addition, we evaluated the impact of demographics and baseline clinical factors on outcome. Results: Ninety-nine patients met criteria for inclusion in this analysis. Median EFS and OS were 4.8 (95% CI: 3.5, 6.3) and 26.2 (23.3, 56.8) months respectively. Twelve-month EFS was 22% (15-31%) and ranged from 14% to 29% across the 3 trials, a difference that did not achieve statistical significance. The risk of EFS event was higher for those whose first recurrence occurred within two years of diagnosis (p=0.009). Other demographic and clinical factors did not statistically impact risk of event though estimated EFS for males was lower than for females. Conclusion: Despite almost doubling the number of patients in this historical control cohort, wide variance in outcomes led to confidence intervals unchanged from previously published work. Until the most significant factors contributing to variability of outcomes in this patient population are quantified, single arm trials of new approaches will only be able to identify large effect sizes. Smaller effect sizes will require randomization.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368045v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 204,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368045v1?rss=1"
    },
    {
      "id": "8137387fe4d74467e573",
      "title": "Preprint: Safety of Bio-Interventional Uveoscleral Outflow Enhancement: Twelve-Month Post-Operative Results from 395 Eyes in the CREST Study",
      "content_text": "Purpose: To characterize 12-month ocular safety of bio-interventional uveoscleral outflow enhancement in open-angle glaucoma (OAG).\n\nDesignProspective, multicenter real-world evidence study (CREST; NCT05506423).\n\nParticipantsAdults with OAG treated by bio-interventional uveoscleral outflow enhancement with acellular scleral allograft spacers (AlloFlo, Iantrek, Inc.), standalone or with phacoemulsification, reaching 12 months of follow-up.\n\nMethodsAdverse events were captured prospectively at…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "8137387fe4d74467e573",
          "source": "web",
          "type": "change",
          "key": "#254a186aed51918aa030",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Safety of Bio-Interventional Uveoscleral Outflow Enhancement: Twelve-Month Post-Operative Results from 395 Eyes in the CREST Study",
            "item_type": "record",
            "summary": "added: Preprint: Safety of Bio-Interventional Uveoscleral Outflow Enhancement: Twelve-Month Post-Operative Results from 395 Eyes in the CREST Study",
            "after": {
              "title": "Preprint: Safety of Bio-Interventional Uveoscleral Outflow Enhancement: Twelve-Month Post-Operative Results from 395 Eyes in the CREST Study",
              "authors": "Rhee, D.; Lewis, J.; De Francesco, T.; Nelson, K.; Ianchulev, T.; Sarkisian, S. R.",
              "author_corresponding": "Tsontcho Ianchulev",
              "author_corresponding_institution": "New York Eye and Ear of Mount Sinai",
              "doi": "10.64898/2026.11.12.26367928",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "ophthalmology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.12.26367928.source.xml",
              "abstract": "PurposeTo characterize 12-month ocular safety of bio-interventional uveoscleral outflow enhancement in open-angle glaucoma (OAG).\n\nDesignProspective, multicenter real-world evidence study (CREST; NCT05506423).\n\nParticipantsAdults with OAG treated by bio-interventional uveoscleral outflow enhancement with acellular scleral allograft spacers (AlloFlo, Iantrek, Inc.), standalone or with phacoemulsification, reaching 12 months of follow-up.\n\nMethodsAdverse events were captured prospectively at each protocol-specified visit against pre-defined definitions; data were analyzed at the eye level.\n\nMain Outcome MeasuresPre-specified ocular safety endpoints: adverse events, clinically significant hypotony, sustained intraocular pressure (IOP) elevation [&ge;] 10 mmHg beyond 30 days, allograft migration, corneal endothelial decompensation, secondary incisional glaucoma surgery, and endothelial cell density.\n\nResultsOf 395 eyes (mean age 72.8 years; 52% female), 267 were combined with phacoemulsification (Cohort 1) and 128 standalone (Cohort 2). Medicated IOP decreased from 19.1 to 14.5 mmHg (p < 0.001) and medications from 1.9 to 1.2, with 42% medication-free. Sustained IOP elevation occurred in 34 eyes (8.6%), BCVA loss [&ge;] 2 lines in 15 (3.8%), hyphema > 2 mm in 6 (1.5%) and hypotony in 1 (0.3%). Two allograft spacers entered the anterior chamber in one eye and were successfully repositioned intraoperatively. Serious events occurred in 12 eyes (3.0%). In the N=91 eyes with paired specular microscopy data, endothelial cell density changed -6.5% (-8.7%, -4.4%). There were no reports of endothelial decompensation, endophthalmitis, or sympathetic ophthalmia.\n\nConclusionsThrough 12 months no endothelial decompensation, endophthalmitis or sympathetic ophthalmia occurred, and most events were self-limiting or medically managed. Endothelial cell loss tracked concurrent cataract surgery rather than the allograft, though that subgroup is small. Follow-up remains shorter than the interval over which an earlier supraciliary microstent diverged from controls.\n\nTrial RegistrationClinicalTrials.gov (NCT05506423.)",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Purpose: To characterize 12-month ocular safety of bio-interventional uveoscleral outflow enhancement in open-angle glaucoma (OAG).\n\nDesignProspective, multicenter real-world evidence study (CREST; NCT05506423).\n\nParticipantsAdults with OAG treated by bio-interventional uveoscleral outflow enhancement with acellular scleral allograft spacers (AlloFlo, Iantrek, Inc.), standalone or with phacoemulsification, reaching 12 months of follow-up.\n\nMethodsAdverse events were captured prospectively at each protocol-specified visit against pre-defined definitions; data were analyzed at the eye level.\n\nMain Outcome MeasuresPre-specified ocular safety endpoints: adverse events, clinically significant hypotony, sustained intraocular pressure (IOP) elevation [&ge;] 10 mmHg beyond 30 days, allograft migration, corneal endothelial decompensation, secondary incisional glaucoma surgery, and endothelial cell density.\n\nResultsOf 395 eyes (mean age 72.8 years; 52% female), 267 were combined with phacoemulsification (Cohort 1) and 128 standalone (Cohort 2). Medicated IOP decreased from 19.1 to 14.5 mmHg (p < 0.001) and medications from 1.9 to 1.2, with 42% medication-free. Sustained IOP elevation occurred in 34 eyes (8.6%), BCVA loss [&ge;] 2 lines in 15 (3.8%), hyphema > 2 mm in 6 (1.5%) and hypotony in 1 (0.3%). Two allograft spacers entered the anterior chamber in one eye and were successfully repositioned intraoperatively. Serious events occurred in 12 eyes (3.0%). In the N=91 eyes with paired specular microscopy data, endothelial cell density changed -6.5% (-8.7%, -4.4%). There were no reports of endothelial decompensation, endophthalmitis, or sympathetic ophthalmia.\n\nConclusionsThrough 12 months no endothelial decompensation, endophthalmitis or sympathetic ophthalmia occurred, and most events were self-limiting or medically managed. Endothelial cell loss tracked concurrent cataract surgery rather than the allograft, though that subgroup is small. Follow-up remains shorter than the interval over which an earlier supraciliary microstent diverged from controls.\n\nTrial RegistrationClinicalTrials.gov (NCT05506423.)",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.12.26367928v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 204,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.12.26367928v1?rss=1"
    },
    {
      "id": "5cb0b77d05bffe234541",
      "title": "Preprint: Uveoscleral Outflow Enhancement as a Complementary Bio-intervention after Failed Prior Trabecular Outflow Treatment: 12-Month Outcomes of Allograft-reinforced Cyclodialysis in Open Angle Glaucoma",
      "content_text": "Abstract and KeywordsO_ST_ABSBackgroundC_ST_ABSEyes with open-angle glaucoma uncontrolled after a trabecular outflow procedure have limited options before progressing to bleb-forming surgery. The uveoscleral pathway is distinct, relatively pressure-independent, and conjunctiva-sparing. We report 12-month outcomes of standalone allograft-reinforced cyclodialysis in eyes with IOP that remained uncontrolled after prior trabecular outflow intervention.\n\nMethodsAnalysis of a multicentre registry…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "5cb0b77d05bffe234541",
          "source": "web",
          "type": "change",
          "key": "#b92c89534c20696e5927",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Uveoscleral Outflow Enhancement as a Complementary Bio-intervention after Failed Prior Trabecular Outflow Treatment: 12-Month Outcomes of Allograft-reinforced Cyclodialysis in Open Angle Glaucoma",
            "item_type": "record",
            "summary": "added: Preprint: Uveoscleral Outflow Enhancement as a Complementary Bio-intervention after Failed Prior Trabecular Outflow Treatment: 12-Month Outcomes of Allograft-reinforced Cyclodialysis in Open Angle Glaucoma",
            "after": {
              "title": "Preprint: Uveoscleral Outflow Enhancement as a Complementary Bio-intervention after Failed Prior Trabecular Outflow Treatment: 12-Month Outcomes of Allograft-reinforced Cyclodialysis in Open Angle Glaucoma",
              "authors": "Gazzard, G.; Jayaram, H.; Garg, R.; Ianchulev, T.; Stamper, R.; Tsai, J.; Singh, I. P.",
              "author_corresponding": "Tsontcho Ianchulev",
              "author_corresponding_institution": "New York Eye and Ear of Mount Sinai",
              "doi": "10.64898/2026.11.12.26367933",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "ophthalmology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.12.26367933.source.xml",
              "abstract": "Abstract and KeywordsO_ST_ABSBackgroundC_ST_ABSEyes with open-angle glaucoma uncontrolled after a trabecular outflow procedure have limited options before progressing to bleb-forming surgery. The uveoscleral pathway is distinct, relatively pressure-independent, and conjunctiva-sparing. We report 12-month outcomes of standalone allograft-reinforced cyclodialysis in eyes with IOP that remained uncontrolled after prior trabecular outflow intervention.\n\nMethodsAnalysis of a multicentre registry (CREST; NCT05506423). Eligible eyes had at least one prior trabecular outflow procedure, no prior bleb-forming surgery, and underwent uveoscleral outflow bio-intervention with at least 12 months of follow-up. IOP reported as mean with 95% CI, medication as mean {+/-} SD.\n\nResultsForty-seven eyes were eligible; 91.5% completed 12 months. Consistent with moderate-to-advanced glaucoma, baseline IOP was 22.5 mmHg (20.1, 24.9) on 3.0 (1.3) IOP-lowering medications, with visual field mean deviation -11.7 dB (8.1). 95.7% were pseudophakic. In the per-protocol efficacy analysis, IOP fell 6.1 mmHg (3.7, 8.6), a 25.0% reduction (15.5%, 34.5%; p < 0.001), with no increase in medication. At 12 months, the Kaplan-Meier estimate of freedom from incisional reoperation was 78.2% (61.8%, 88.2%). There were no vision-threatening, clinically significant adverse events associated with the procedure such as persistent hypotony, maculopathy or other complications.\n\nConclusionsIn eyes with inadequately controlled IOP following prior trabecular intervention, standalone allograft-reinforced cyclodialysis was associated with clinically meaningful IOP reduction without an increase in medication burden or permanent vision loss.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Abstract and KeywordsO_ST_ABSBackgroundC_ST_ABSEyes with open-angle glaucoma uncontrolled after a trabecular outflow procedure have limited options before progressing to bleb-forming surgery. The uveoscleral pathway is distinct, relatively pressure-independent, and conjunctiva-sparing. We report 12-month outcomes of standalone allograft-reinforced cyclodialysis in eyes with IOP that remained uncontrolled after prior trabecular outflow intervention.\n\nMethodsAnalysis of a multicentre registry (CREST; NCT05506423). Eligible eyes had at least one prior trabecular outflow procedure, no prior bleb-forming surgery, and underwent uveoscleral outflow bio-intervention with at least 12 months of follow-up. IOP reported as mean with 95% CI, medication as mean {+/-} SD.\n\nResultsForty-seven eyes were eligible; 91.5% completed 12 months. Consistent with moderate-to-advanced glaucoma, baseline IOP was 22.5 mmHg (20.1, 24.9) on 3.0 (1.3) IOP-lowering medications, with visual field mean deviation -11.7 dB (8.1). 95.7% were pseudophakic. In the per-protocol efficacy analysis, IOP fell 6.1 mmHg (3.7, 8.6), a 25.0% reduction (15.5%, 34.5%; p < 0.001), with no increase in medication. At 12 months, the Kaplan-Meier estimate of freedom from incisional reoperation was 78.2% (61.8%, 88.2%). There were no vision-threatening, clinically significant adverse events associated with the procedure such as persistent hypotony, maculopathy or other complications.\n\nConclusionsIn eyes with inadequately controlled IOP following prior trabecular intervention, standalone allograft-reinforced cyclodialysis was associated with clinically meaningful IOP reduction without an increase in medication burden or permanent vision loss.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.12.26367933v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 204,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.12.26367933v1?rss=1"
    },
    {
      "id": "42586ab6ea95057e2899",
      "title": "Preprint: Role of Intravenous Tranexamic Acid in Immediate Breast Reconstruction with an Extended Latissimus Dorsi Flap: A Retrospective Cohort Study",
      "content_text": "Background: The purpose of this study was to assess the impact of intravenous tranexamic acid (TXA) on postoperative drainage, laboratory parameters, and complications in patients undergoing immediate extended latissimus dorsi (ELD) flap breast reconstruction. Methods: This retrospective cohort study included 82 patients who underwent immediate ELD flap breast reconstruction between January 2019 and May 2026. The TXA group (n = 42) received 1 g of intravenous TXA at the start of surgery after…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "42586ab6ea95057e2899",
          "source": "web",
          "type": "change",
          "key": "#2edfe3753393d6aef505",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Role of Intravenous Tranexamic Acid in Immediate Breast Reconstruction with an Extended Latissimus Dorsi Flap: A Retrospective Cohort Study",
            "item_type": "record",
            "summary": "added: Preprint: Role of Intravenous Tranexamic Acid in Immediate Breast Reconstruction with an Extended Latissimus Dorsi Flap: A Retrospective Cohort Study",
            "after": {
              "title": "Preprint: Role of Intravenous Tranexamic Acid in Immediate Breast Reconstruction with an Extended Latissimus Dorsi Flap: A Retrospective Cohort Study",
              "authors": "li, z.; ni, j.; wang, s.",
              "author_corresponding": "jian ni",
              "author_corresponding_institution": "Nanjing Drum Tower Hospital",
              "doi": "10.64898/2026.11.14.26368090",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_no",
              "category": "orthopedics",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.14.26368090.source.xml",
              "abstract": "Background: The purpose of this study was to assess the impact of intravenous tranexamic acid (TXA) on postoperative drainage, laboratory parameters, and complications in patients undergoing immediate extended latissimus dorsi (ELD) flap breast reconstruction. Methods: This retrospective cohort study included 82 patients who underwent immediate ELD flap breast reconstruction between January 2019 and May 2026. The TXA group (n = 42) received 1 g of intravenous TXA at the start of surgery after its routine adoption in July 2021; the control group (n = 40) underwent surgery before this date without TXA. Drainage, perioperative hemoglobin, hematocrit, and CRP levels, and postoperative complications were assessed using multivariable linear regression, with Cox regression as a complementary time-to-event analysis. Results: After adjustment for potential confounders, TXA use was associated with a shorter drain duration ({beta} = -1.85 days, 95% CI -3.09 to -0.61; p = 0.004) and lower total drainage volume ({beta} = -131.5 mL, 95% CI -247.2 to -15.8; p = 0.027). The adjusted Cox model also showed previous drain removal in the TXA group (HR = 2.59, 95% CI: 1.50-4.46; p < 0.001). Hematoma was found in 0 patients in the TXA group and 6 patients in the control group (p = 0.011); this result is to be regarded as descriptive and hypothesis-generating. Conclusion: This study provides some evidence that intravenous TXA reduces postoperative drainage and hematoma rates after immediate ELD flap breast reconstruction; however, prospective randomized studies are necessary to validate its safety profile and define its exact role.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background: The purpose of this study was to assess the impact of intravenous tranexamic acid (TXA) on postoperative drainage, laboratory parameters, and complications in patients undergoing immediate extended latissimus dorsi (ELD) flap breast reconstruction. Methods: This retrospective cohort study included 82 patients who underwent immediate ELD flap breast reconstruction between January 2019 and May 2026. The TXA group (n = 42) received 1 g of intravenous TXA at the start of surgery after its routine adoption in July 2021; the control group (n = 40) underwent surgery before this date without TXA. Drainage, perioperative hemoglobin, hematocrit, and CRP levels, and postoperative complications were assessed using multivariable linear regression, with Cox regression as a complementary time-to-event analysis. Results: After adjustment for potential confounders, TXA use was associated with a shorter drain duration ({beta} = -1.85 days, 95% CI -3.09 to -0.61; p = 0.004) and lower total drainage volume ({beta} = -131.5 mL, 95% CI -247.2 to -15.8; p = 0.027). The adjusted Cox model also showed previous drain removal in the TXA group (HR = 2.59, 95% CI: 1.50-4.46; p < 0.001). Hematoma was found in 0 patients in the TXA group and 6 patients in the control group (p = 0.011); this result is to be regarded as descriptive and hypothesis-generating. Conclusion: This study provides some evidence that intravenous TXA reduces postoperative drainage and hematoma rates after immediate ELD flap breast reconstruction; however, prospective randomized studies are necessary to validate its safety profile and define its exact role.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368090v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 204,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368090v1?rss=1"
    },
    {
      "id": "0201375243c216e655f8",
      "title": "Preprint: Impaired cortical gap-mediated inhibition in chronic tinnitus but with limited individual diagnostic accuracy",
      "content_text": "Tinnitus lacks an objective marker, limiting diagnosis and treatment evaluation. We tested whether gap-mediated inhibition of cortical sound-evoked responses provides one. In a prospective, multicentre case-control study at seven sites in the United States and Europe, adults with and without chronic tinnitus heard brief pulses preceded or not by a silent gap, embedded in broadband or narrowband carriers, during electroencephalography. The primary outcome was inhibition of the N100 response. Of…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "0201375243c216e655f8",
          "source": "web",
          "type": "change",
          "key": "#1e4238bc868526960e67",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Impaired cortical gap-mediated inhibition in chronic tinnitus but with limited individual diagnostic accuracy",
            "item_type": "record",
            "summary": "added: Preprint: Impaired cortical gap-mediated inhibition in chronic tinnitus but with limited individual diagnostic accuracy",
            "after": {
              "title": "Preprint: Impaired cortical gap-mediated inhibition in chronic tinnitus but with limited individual diagnostic accuracy",
              "authors": "Lu, H.; Shabestari, P. S.; Engelke, M.; Ajmera, S.; Arulchelvan, E.; Braun, C.; Fernandez del Campo, I. S.; Jain, N.; Kaniewska, E.; Kleinjung, T.; Korn, J.; Ost, J.; Ralston Ruesch, L.; Rambour, S.; Shields, N.; Staudinger, S.; Tödtli, B.; Wolpert, S. M.; Yasoda-Mohan, A.; Husain, F. T.; Campbell, J.; De Ridder, D.; Langguth, B.; Schlee, W.; Vanneste, S.; Neff, P. K. A.; Cederroth, C. R.",
              "author_corresponding": "Christopher R. Cederroth",
              "author_corresponding_institution": "Karolinska Institutet",
              "doi": "10.64898/2026.11.11.26367707",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_no",
              "category": "otolaryngology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.11.26367707.source.xml",
              "abstract": "Tinnitus lacks an objective marker, limiting diagnosis and treatment evaluation. We tested whether gap-mediated inhibition of cortical sound-evoked responses provides one. In a prospective, multicentre case-control study at seven sites in the United States and Europe, adults with and without chronic tinnitus heard brief pulses preceded or not by a silent gap, embedded in broadband or narrowband carriers, during electroencephalography. The primary outcome was inhibition of the N100 response. Of 584 eligible participants, 455 yielded high-quality recordings with complete covariate data (232 cases, 223 controls; mean age 45.4 years, 52% women) that entered the adjusted analyses. Inhibition was strongest for broadband noise whereas narrowband carriers gave limited dynamic range. Participants with tinnitus showed reduced broadband gap-mediated inhibition ({beta} = -19.27%, d = -0.413, cluster-corrected p = 0.002), scaling with tinnitus severity (covariate-adjusted {surd}THI model: partial R2 = 0.049, p = 0.0015). In contrast, discrimination of individuals was limited (AUC 0.612, 95% CI 0.560-0.663). Cortical gap inhibition is a reproducible group-level effect rather than an individual diagnostic test.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Tinnitus lacks an objective marker, limiting diagnosis and treatment evaluation. We tested whether gap-mediated inhibition of cortical sound-evoked responses provides one. In a prospective, multicentre case-control study at seven sites in the United States and Europe, adults with and without chronic tinnitus heard brief pulses preceded or not by a silent gap, embedded in broadband or narrowband carriers, during electroencephalography. The primary outcome was inhibition of the N100 response. Of 584 eligible participants, 455 yielded high-quality recordings with complete covariate data (232 cases, 223 controls; mean age 45.4 years, 52% women) that entered the adjusted analyses. Inhibition was strongest for broadband noise whereas narrowband carriers gave limited dynamic range. Participants with tinnitus showed reduced broadband gap-mediated inhibition ({beta} = -19.27%, d = -0.413, cluster-corrected p = 0.002), scaling with tinnitus severity (covariate-adjusted {surd}THI model: partial R2 = 0.049, p = 0.0015). In contrast, discrimination of individuals was limited (AUC 0.612, 95% CI 0.560-0.663). Cortical gap inhibition is a reproducible group-level effect rather than an individual diagnostic test.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.11.26367707v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 204,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.11.26367707v1?rss=1"
    },
    {
      "id": "0a4b5aeaafc45cb22473",
      "title": "Preprint: Data-driven modeling of trigeminal nerve shape reveals pain-associated morphology in trigeminal neuralgia",
      "content_text": "Although the leading theory for the cause of trigeminal neuralgia (TN) is neurovascular compression, compression alone does not fully explain which nerves are painful. Recent work has demonstrated that pain in TN is associated with morphological changes of the trigeminal nerve, which may be a result of specific forms of compression or other disease processes. These changes have so far been quantified by hand-crafted geometric measurements, which can miss higher-order characteristics of the…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "0a4b5aeaafc45cb22473",
          "source": "web",
          "type": "change",
          "key": "#09b62dc034b1dee1694f",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Data-driven modeling of trigeminal nerve shape reveals pain-associated morphology in trigeminal neuralgia",
            "item_type": "record",
            "summary": "added: Preprint: Data-driven modeling of trigeminal nerve shape reveals pain-associated morphology in trigeminal neuralgia",
            "after": {
              "title": "Preprint: Data-driven modeling of trigeminal nerve shape reveals pain-associated morphology in trigeminal neuralgia",
              "authors": "Xie, M. E.; Liang, H.; Wang, X.; Yedavalli, V.; Jackson, C.; Lim, M.; Huang, J.; Bettegowda, C.; Liu, P.; Xu, R.",
              "author_corresponding": "Risheng Xu",
              "author_corresponding_institution": "Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD",
              "doi": "10.64898/2026.11.11.26367487",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "pain medicine",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.11.26367487.source.xml",
              "abstract": "Although the leading theory for the cause of trigeminal neuralgia (TN) is neurovascular compression, compression alone does not fully explain which nerves are painful. Recent work has demonstrated that pain in TN is associated with morphological changes of the trigeminal nerve, which may be a result of specific forms of compression or other disease processes. These changes have so far been quantified by hand-crafted geometric measurements, which can miss higher-order characteristics of the anatomy that are difficult to visualize. In this study, we use a cohort of 479 patients with TN who underwent microvascular decompression and had high-resolution pre-operative MRI scans to determine whether data-driven 3D shape features of the trigeminal nerve capture pain-associated morphology better than predefined metrics. We find that a predictive model using our shape features can distinguish nerves implicated in pain from those without pain in a held-out test cohort with an area under the receiver operating characteristic curve (AUROC) of 0.719, compared with 0.626 for a model using existing hand-crafted measurements (p=0.005). Our study identifies candidate nerve morphology biomarkers of TN pain through data-driven shape analysis and demonstrates that these higher-order features relate better to symptoms of TN than conventional shape metrics.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Although the leading theory for the cause of trigeminal neuralgia (TN) is neurovascular compression, compression alone does not fully explain which nerves are painful. Recent work has demonstrated that pain in TN is associated with morphological changes of the trigeminal nerve, which may be a result of specific forms of compression or other disease processes. These changes have so far been quantified by hand-crafted geometric measurements, which can miss higher-order characteristics of the anatomy that are difficult to visualize. In this study, we use a cohort of 479 patients with TN who underwent microvascular decompression and had high-resolution pre-operative MRI scans to determine whether data-driven 3D shape features of the trigeminal nerve capture pain-associated morphology better than predefined metrics. We find that a predictive model using our shape features can distinguish nerves implicated in pain from those without pain in a held-out test cohort with an area under the receiver operating characteristic curve (AUROC) of 0.719, compared with 0.626 for a model using existing hand-crafted measurements (p=0.005). Our study identifies candidate nerve morphology biomarkers of TN pain through data-driven shape analysis and demonstrates that these higher-order features relate better to symptoms of TN than conventional shape metrics.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.11.26367487v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/90",
            "content_type": "application/json",
            "elapsed_ms": 204,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.11.26367487v1?rss=1"
    },
    {
      "id": "38d67562e173a2dd4b32",
      "title": "Preprint: Exploring perceptions and attitudes toward pain in surgical trauma patients in a public hospital in Guatemala: a qualitative study",
      "content_text": "Pain is nearly universal following traumatic injuries. However, pain perception, expression, and coping may be shaped by biological, psychological, social, and cultural factors that remain poorly characterized among underrepresented populations. This study explored experiences, attitudes, and expectations toward pain among hospitalized trauma patients at a public hospital in Guatemala.\n\nWe conducted a qualitative study using semi-structured interviews with consenting adults admitted to the…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "38d67562e173a2dd4b32",
          "source": "web",
          "type": "change",
          "key": "#49e546514b8e3f7332fc",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Exploring perceptions and attitudes toward pain in surgical trauma patients in a public hospital in Guatemala: a qualitative study",
            "item_type": "record",
            "summary": "added: Preprint: Exploring perceptions and attitudes toward pain in surgical trauma patients in a public hospital in Guatemala: a qualitative study",
            "after": {
              "title": "Preprint: Exploring perceptions and attitudes toward pain in surgical trauma patients in a public hospital in Guatemala: a qualitative study",
              "authors": "Mahalingam, V.; Turner, R.; Zacarias, K.; Ramirez, S.; Simmons, C. G.; Gamboa, J. E.",
              "author_corresponding": "Jakob  E Gamboa",
              "author_corresponding_institution": "University of Colorado School of Medicine",
              "doi": "10.64898/2026.11.11.26367874",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "pain medicine",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.11.26367874.source.xml",
              "abstract": "Pain is nearly universal following traumatic injuries. However, pain perception, expression, and coping may be shaped by biological, psychological, social, and cultural factors that remain poorly characterized among underrepresented populations. This study explored experiences, attitudes, and expectations toward pain among hospitalized trauma patients at a public hospital in Guatemala.\n\nWe conducted a qualitative study using semi-structured interviews with consenting adults admitted to the orthopedic trauma service at Hospital Nacional de Coatepeque in southwestern Guatemala from May to June 2025. Interviews explored pain experiences, coping strategies, interactions with healthcare providers, and expectations for pain management. Interviews were conducted in Spanish, audio-recorded, transcribed verbatim, translated into English by bilingual researchers, and analyzed using inductive thematic analysis.\n\nFive interrelated themes were identified: 1) lived experience and trajectory of pain; 2) coping, adaptation, and psychological endurance; 3) spirituality, meaning-making, and moral framing of suffering; 4) pain management and interactions with the healthcare system; and 5) social context, responsibilities, and life disruptions. Participants described severe early pain accompanied by physical, emotional, and functional distress that generally improved over time. Psychological coping, faith, and family responsibilities were central to resilience and recovery. Notably, patients often reported acceptable or improving numerical pain scores despite narratives describing substantial physical, emotional, and functional suffering, suggesting that standardized pain scales may not fully capture lived experiences.\n\nTrauma patients in Guatemala described pain as a multidimensional experience shaped by physical, psychological, spiritual, and sociocultural factors. Despite severe pain, patients demonstrated resilience, often accepting pain as a temporary part of healing while prioritizing recovery and return to family responsibilities. The discordance between numerical pain scores and narratives of suffering underscores limitations of pain scores as standalone measures. These findings support culturally informed, patient-centered strategies that integrate pharmacologic treatment with attention to psychological, spiritual, and social dimensions of recovery.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Pain is nearly universal following traumatic injuries. However, pain perception, expression, and coping may be shaped by biological, psychological, social, and cultural factors that remain poorly characterized among underrepresented populations. This study explored experiences, attitudes, and expectations toward pain among hospitalized trauma patients at a public hospital in Guatemala.\n\nWe conducted a qualitative study using semi-structured interviews with consenting adults admitted to the orthopedic trauma service at Hospital Nacional de Coatepeque in southwestern Guatemala from May to June 2025. Interviews explored pain experiences, coping strategies, interactions with healthcare providers, and expectations for pain management. Interviews were conducted in Spanish, audio-recorded, transcribed verbatim, translated into English by bilingual researchers, and analyzed using inductive thematic analysis.\n\nFive interrelated themes were identified: 1) lived experience and trajectory of pain; 2) coping, adaptation, and psychological endurance; 3) spirituality, meaning-making, and moral framing of suffering; 4) pain management and interactions with the healthcare system; and 5) social context, responsibilities, and life disruptions. Participants described severe early pain accompanied by physical, emotional, and functional distress that generally improved over time. Psychological coping, faith, and family responsibilities were central to resilience and recovery. Notably, patients often reported acceptable or improving numerical pain scores despite narratives describing substantial physical, emotional, and functional suffering, suggesting that standardized pain scales may not fully capture lived experiences.\n\nTrauma patients in Guatemala described pain as a multidimensional experience shaped by physical, psychological, spiritual, and sociocultural factors. Despite severe pain, patients demonstrated resilience, often accepting pain as a temporary part of healing while prioritizing recovery and return to family responsibilities. The discordance between numerical pain scores and narratives of suffering underscores limitations of pain scores as standalone measures. These findings support culturally informed, patient-centered strategies that integrate pharmacologic treatment with attention to psychological, spiritual, and social dimensions of recovery.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.11.26367874v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
            "content_type": "application/json",
            "elapsed_ms": 187,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.11.26367874v1?rss=1"
    },
    {
      "id": "c47ed4c4bb2940f4d137",
      "title": "Preprint: Pain-indicated buprenorphine prescribing in the United States, 2017-2025: national trends, state policy approaches, and payer patterns in a longitudinal ecological study",
      "content_text": "Background: Buprenorphine offers an analgesic option for selected adults with chronic pain. National trends in pain-indicated buprenorphine prescribing, variation across state policy approaches, and consistency within multiple insurance payers have not been examined together. We described national and state prescribing trends, compared growth among states with documented policies, and examined whether state patterns persisted among Medicaid recipients.\n\nMethodsLongitudinal ecological analysis…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "c47ed4c4bb2940f4d137",
          "source": "web",
          "type": "change",
          "key": "#143cc8343ff80aaea470",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Pain-indicated buprenorphine prescribing in the United States, 2017-2025: national trends, state policy approaches, and payer patterns in a longitudinal ecological study",
            "item_type": "record",
            "summary": "added: Preprint: Pain-indicated buprenorphine prescribing in the United States, 2017-2025: national trends, state policy approaches, and payer patterns in a longitudinal ecological study",
            "after": {
              "title": "Preprint: Pain-indicated buprenorphine prescribing in the United States, 2017-2025: national trends, state policy approaches, and payer patterns in a longitudinal ecological study",
              "authors": "Adams, M. C. B.; Kline, D. M.; Yong, J. C.; McDonnell, C.; Hurley, R. W.",
              "author_corresponding": "Robert  W. Hurley",
              "author_corresponding_institution": "Wake Forest University School of Medicine",
              "doi": "10.64898/2026.11.12.26367897",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "pain medicine",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.12.26367897.source.xml",
              "abstract": "BackgroundBuprenorphine offers an analgesic option for selected adults with chronic pain. National trends in pain-indicated buprenorphine prescribing, variation across state policy approaches, and consistency within multiple insurance payers have not been examined together. We described national and state prescribing trends, compared growth among states with documented policies, and examined whether state patterns persisted among Medicaid recipients.\n\nMethodsLongitudinal ecological analysis of 2017-2025 prescription claims for 867,591 unique adults receiving transdermal or buccal buprenorphine across 888 three-digit ZIP code areas, with a systematic policy review of the 50 states and District of Columbia. Outcomes were annual recipients of pain-indicated formulations per 100,000 adults, observed and modeled with a hierarchical Bayesian model (95% credible intervals), state policy characteristics, and payer-restricted rates.\n\nResultsThe observed national rate increased from 53.59 to 78.04 recipients per 100,000 adults (45.6%; 4.81% annualized); model-derived average annual growth was 5.04% (95% credible interval, 2.88%-7.28%). The policy review identified distinct guidance, coverage, oversight, and educational approaches. Annualized growth was 25.43% in Minnesota, 13.50% in Colorado, 6.29% in North Carolina, 3.35% in Virginia, 2.99% in California, 0.63% in West Virginia, 0.50% in Oregon, and -2.96% in Mississippi.\n\nIdentifiable-Medicaid prescribing grew 3.10% annualized nationally versus 4.81% for all payers and increased in Colorado and Minnesota, but declined in Virginia and North Carolina, where plan coding and managed-care transitions limited Medicaid identification.\n\nConclusionsPrescribing increased nationally but varied substantially across states with different policy approaches, and Medicaid-restricted patterns did not consistently mirror all-payer trends. Policy content, timing, and payer reach warrant evaluation; however, these ecological comparisons do not establish causation.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background: Buprenorphine offers an analgesic option for selected adults with chronic pain. National trends in pain-indicated buprenorphine prescribing, variation across state policy approaches, and consistency within multiple insurance payers have not been examined together. We described national and state prescribing trends, compared growth among states with documented policies, and examined whether state patterns persisted among Medicaid recipients.\n\nMethodsLongitudinal ecological analysis of 2017-2025 prescription claims for 867,591 unique adults receiving transdermal or buccal buprenorphine across 888 three-digit ZIP code areas, with a systematic policy review of the 50 states and District of Columbia. Outcomes were annual recipients of pain-indicated formulations per 100,000 adults, observed and modeled with a hierarchical Bayesian model (95% credible intervals), state policy characteristics, and payer-restricted rates.\n\nResultsThe observed national rate increased from 53.59 to 78.04 recipients per 100,000 adults (45.6%; 4.81% annualized); model-derived average annual growth was 5.04% (95% credible interval, 2.88%-7.28%). The policy review identified distinct guidance, coverage, oversight, and educational approaches. Annualized growth was 25.43% in Minnesota, 13.50% in Colorado, 6.29% in North Carolina, 3.35% in Virginia, 2.99% in California, 0.63% in West Virginia, 0.50% in Oregon, and -2.96% in Mississippi.\n\nIdentifiable-Medicaid prescribing grew 3.10% annualized nationally versus 4.81% for all payers and increased in Colorado and Minnesota, but declined in Virginia and North Carolina, where plan coding and managed-care transitions limited Medicaid identification.\n\nConclusionsPrescribing increased nationally but varied substantially across states with different policy approaches, and Medicaid-restricted patterns did not consistently mirror all-payer trends. Policy content, timing, and payer reach warrant evaluation; however, these ecological comparisons do not establish causation.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.12.26367897v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
            "content_type": "application/json",
            "elapsed_ms": 187,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.12.26367897v1?rss=1"
    },
    {
      "id": "6b2939320a93bfafe183",
      "title": "Preprint: Human-Agentic AI Collaboration Workflow for Trend Analysis of ChatGPT Applications in Healthcare",
      "content_text": "Background: With the rapid advancement of artificial intelligence (AI), large language models (LLMs) such as ChatGPT have demonstrated strong potential to transform healthcare research and practice. However, LLMs are probabilistic and generate inherently variable outputs, which create risk and uncertainty in healthcare applications. Therefore, analyzing the current research landscape of ChatGPT applications is imperative to understand applied techniques and related concerns and to facilitate…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "6b2939320a93bfafe183",
          "source": "web",
          "type": "change",
          "key": "#87794f2340318cbe2656",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Human-Agentic AI Collaboration Workflow for Trend Analysis of ChatGPT Applications in Healthcare",
            "item_type": "record",
            "summary": "added: Preprint: Human-Agentic AI Collaboration Workflow for Trend Analysis of ChatGPT Applications in Healthcare",
            "after": {
              "title": "Preprint: Human-Agentic AI Collaboration Workflow for Trend Analysis of ChatGPT Applications in Healthcare",
              "authors": "Chou, P. J.; Lin, Y. H.; Li, E. Y.",
              "author_corresponding": "Po Ju Chou",
              "author_corresponding_institution": "National Chung Cheng University, Minhsiung, Chiayi 62130, Taiwan",
              "doi": "10.64898/2026.11.14.26368120",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "health informatics",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.14.26368120.source.xml",
              "abstract": "Background: With the rapid advancement of artificial intelligence (AI), large language models (LLMs) such as ChatGPT have demonstrated strong potential to transform healthcare research and practice. However, LLMs are probabilistic and generate inherently variable outputs, which create risk and uncertainty in healthcare applications. Therefore, analyzing the current research landscape of ChatGPT applications is imperative to understand applied techniques and related concerns and to facilitate their practical integration into healthcare information systems. Objective: Leveraging LLM-based agentic AI with domain experts to analyze trends in ChatGPT healthcare applications and to examine the collaborative and interpretative capacities of LLM agents in broader contexts beyond narrowly defined topics. Methods: The review used a systematic search of the PubMed and Web of Science databases, following PRISMA-ScR guidelines, and focused on ChatGPT applications, associated concerns, applied techniques, and usage factors. To support the review process, an adaptive, iterative LLM-based agentic AI with a human-in-the-loop mechanism was employed for automated metadata extraction, identification, classification, and knowledge synthesis. The extracted information was subsequently used for temporal and thematic analyses, citation network construction, and main-path analysis. Results: Across 192 papers, the review identified 511 ChatGPT application types, 690 concern items, and 368 influence usage factors distinct from traditional IT, achieving a metadata error rate of 1.04%. The human-agentic AI workflow enabled efficient synthesis of contextual information across studies, addressing the growing challenge of timely evidence integration in medical knowledge. The findings provide insights into the evolving trajectories of ChatGPT applications in healthcare and demonstrate the value of an expert-validated human-agentic AI workflow in supporting literature analysis and streamlining review processes. Conclusion: This review provides a comprehensive overview of emerging ChatGPT applications, associated concerns, applied techniques, and usage factors in healthcare. The study further provides meaningful insights into the operational mechanisms of agentic AI, demonstrating the potential of human-AI collaboration for medical informatics research.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background: With the rapid advancement of artificial intelligence (AI), large language models (LLMs) such as ChatGPT have demonstrated strong potential to transform healthcare research and practice. However, LLMs are probabilistic and generate inherently variable outputs, which create risk and uncertainty in healthcare applications. Therefore, analyzing the current research landscape of ChatGPT applications is imperative to understand applied techniques and related concerns and to facilitate their practical integration into healthcare information systems. Objective: Leveraging LLM-based agentic AI with domain experts to analyze trends in ChatGPT healthcare applications and to examine the collaborative and interpretative capacities of LLM agents in broader contexts beyond narrowly defined topics. Methods: The review used a systematic search of the PubMed and Web of Science databases, following PRISMA-ScR guidelines, and focused on ChatGPT applications, associated concerns, applied techniques, and usage factors. To support the review process, an adaptive, iterative LLM-based agentic AI with a human-in-the-loop mechanism was employed for automated metadata extraction, identification, classification, and knowledge synthesis. The extracted information was subsequently used for temporal and thematic analyses, citation network construction, and main-path analysis. Results: Across 192 papers, the review identified 511 ChatGPT application types, 690 concern items, and 368 influence usage factors distinct from traditional IT, achieving a metadata error rate of 1.04%. The human-agentic AI workflow enabled efficient synthesis of contextual information across studies, addressing the growing challenge of timely evidence integration in medical knowledge. The findings provide insights into the evolving trajectories of ChatGPT applications in healthcare and demonstrate the value of an expert-validated human-agentic AI workflow in supporting literature analysis and streamlining review processes. Conclusion: This review provides a comprehensive overview of emerging ChatGPT applications, associated concerns, applied techniques, and usage factors in healthcare. The study further provides meaningful insights into the operational mechanisms of agentic AI, demonstrating the potential of human-AI collaboration for medical informatics research.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368120v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
            "content_type": "application/json",
            "elapsed_ms": 187,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368120v1?rss=1"
    },
    {
      "id": "a8bfd9e1b943561197db",
      "title": "Preprint: Recording sampling rate as a negative-control exposure for detecting measurement-driven bias in heart-rate-variability-outcome associations: a quantitative bias analysis across ICU waveform databases",
      "content_text": "Importance. Heart-rate variability (HRV) is studied extensively as a prognostic marker in critical illness, yet the electrocardiographic sampling rate at which HRV is computed systematically distorts the resulting values. Whether the associations between HRV and clinical outcomes reported in the literature are partly a consequence of this distortion has not been examined directly. Objective. To evaluate whether between-database differences in native ECG sampling rate can be used as a…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "a8bfd9e1b943561197db",
          "source": "web",
          "type": "change",
          "key": "#abc7e0cdfff765ba46f7",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Recording sampling rate as a negative-control exposure for detecting measurement-driven bias in heart-rate-variability-outcome associations: a quantitative bias analysis across ICU waveform databases",
            "item_type": "record",
            "summary": "added: Preprint: Recording sampling rate as a negative-control exposure for detecting measurement-driven bias in heart-rate-variability-outcome associations: a quantitative bias analysis across ICU waveform databases",
            "after": {
              "title": "Preprint: Recording sampling rate as a negative-control exposure for detecting measurement-driven bias in heart-rate-variability-outcome associations: a quantitative bias analysis across ICU waveform databases",
              "authors": "Ye, H.; Zhang, Q.; Chen, S.; Li, P.; Wan, J.; Hao, Y.",
              "author_corresponding": "Yilong Hao",
              "author_corresponding_institution": "Department of Critical Care Medicine, Shanghai Pudong New Area People's Hospital, Shanghai Jiao Tong University School of Medicine, 490 South Chuanhuan Road, Pu",
              "doi": "10.64898/2026.11.15.26368154",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "health informatics",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.15.26368154.source.xml",
              "abstract": "Importance. Heart-rate variability (HRV) is studied extensively as a prognostic marker in critical illness, yet the electrocardiographic sampling rate at which HRV is computed systematically distorts the resulting values. Whether the associations between HRV and clinical outcomes reported in the literature are partly a consequence of this distortion has not been examined directly. Objective. To evaluate whether between-database differences in native ECG sampling rate can be used as a negative-control exposure to detect measurement-driven bias in HRV-outcome associations, and to quantify the sensitivity of a published association to an empirically measured distortion coefficient using quantitative bias analysis (QBA). Design. A methods investigation in three parts. Part I sets out the causal structure and states why a strict instrumental-variable (IV) design is inappropriate here. Part II derives a bias-correction factor under a multiplicative measurement-error model and propagates the empirical confidence interval of the distortion coefficient as a sensitivity band. Part III applies the procedure to an observed HRV-mortality association from a single ICU waveform database, and examines the separate bias arising from threshold-based categorisation. Setting and data sources. Two critical-care waveform databases with different native sampling rates (MIMIC-IV Waveform, approximately 250 Hz; MIMIC-III Waveform Matched p04, 125 Hz) and an independent 500-Hz reference cohort (PTB-XL) for mechanism validation. The outcome association was estimated in 1,445 ICU stays from MIMIC-III p04, of whom 141 died in hospital (9.8%). Exposures. Native ECG sampling rate as a negative-control exposure; SDNN, RMSSD and heart rate as the measured exposures whose associations with mortality are evaluated. Main outcomes and measures. In-hospital mortality. Distortion coefficients were obtained by end-to-end reprocessing of 7,293 original waveform segments with a fixed QRS detector. Corrected odds ratios were reported as QBA sensitivity bands rather than point-identified effects. Misclassification was quantified as the proportion of recordings below a 20 ms HRV threshold reclassified above it by coarse sampling. Results. End-to-end reprocessing gave an RMSSD distortion coefficient of 1.1575 (95% CI 1.0835-1.2492; 2,276 segments in 188 patients) for 250->62.5 Hz and 1.0588 (95% CI 1.0294-1.1033; 4,988 segments) for 125->62.5 Hz; high-frequency power was more affected than low-frequency power (1.2033 vs 1.0716). Under the multiplicative model, an observed crude RMSSD-mortality odds ratio of 1.802 corresponded to a corrected interval of 1.8335-1.915 across the coefficient's 95% CI. The correction was small relative to confounding: the same association fell to 1.116 after age adjustment. Coarse sampling reclassified 33.70% of low-HRV recordings in MIMIC-IV and 20.72% in MIMIC-III, a larger potential source of bias than the continuous-scale correction. The cross-database negative-control gradient was completed after linking both waveform cohorts to hospital outcomes: RMSSD inflation was reproducible (median x1.101 at 125->62.5 Hz in MIMIC-III and x1.270 at 250->62.5 Hz in MIMIC-IV), but the age-adjusted HRV-mortality risk ratio did not increase at lower rates (MIMIC-III 1.70->1.21; MIMIC-IV 1.31->1.29->1.20; all 95% CIs crossed 1). The falsification test was therefore negative in these cohorts, and we report it as such rather than as evidence that measurement bias is absent. Conclusions and Relevance. Sampling rate is a detectable and correctable source of bias in HRV-outcome research. Recording the sampling rate of each signal, stratifying effects by baseline variability, and reporting a QBA sensitivity band before dichotomising HRV would make published associations more interpretable. The object of inference here is the measurement-error method, not a new clinical biomarker; the proposed reporting steps require no additional data collection.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Importance. Heart-rate variability (HRV) is studied extensively as a prognostic marker in critical illness, yet the electrocardiographic sampling rate at which HRV is computed systematically distorts the resulting values. Whether the associations between HRV and clinical outcomes reported in the literature are partly a consequence of this distortion has not been examined directly. Objective. To evaluate whether between-database differences in native ECG sampling rate can be used as a negative-control exposure to detect measurement-driven bias in HRV-outcome associations, and to quantify the sensitivity of a published association to an empirically measured distortion coefficient using quantitative bias analysis (QBA). Design. A methods investigation in three parts. Part I sets out the causal structure and states why a strict instrumental-variable (IV) design is inappropriate here. Part II derives a bias-correction factor under a multiplicative measurement-error model and propagates the empirical confidence interval of the distortion coefficient as a sensitivity band. Part III applies the procedure to an observed HRV-mortality association from a single ICU waveform database, and examines the separate bias arising from threshold-based categorisation. Setting and data sources. Two critical-care waveform databases with different native sampling rates (MIMIC-IV Waveform, approximately 250 Hz; MIMIC-III Waveform Matched p04, 125 Hz) and an independent 500-Hz reference cohort (PTB-XL) for mechanism validation. The outcome association was estimated in 1,445 ICU stays from MIMIC-III p04, of whom 141 died in hospital (9.8%). Exposures. Native ECG sampling rate as a negative-control exposure; SDNN, RMSSD and heart rate as the measured exposures whose associations with mortality are evaluated. Main outcomes and measures. In-hospital mortality. Distortion coefficients were obtained by end-to-end reprocessing of 7,293 original waveform segments with a fixed QRS detector. Corrected odds ratios were reported as QBA sensitivity bands rather than point-identified effects. Misclassification was quantified as the proportion of recordings below a 20 ms HRV threshold reclassified above it by coarse sampling. Results. End-to-end reprocessing gave an RMSSD distortion coefficient of 1.1575 (95% CI 1.0835-1.2492; 2,276 segments in 188 patients) for 250->62.5 Hz and 1.0588 (95% CI 1.0294-1.1033; 4,988 segments) for 125->62.5 Hz; high-frequency power was more affected than low-frequency power (1.2033 vs 1.0716). Under the multiplicative model, an observed crude RMSSD-mortality odds ratio of 1.802 corresponded to a corrected interval of 1.8335-1.915 across the coefficient's 95% CI. The correction was small relative to confounding: the same association fell to 1.116 after age adjustment. Coarse sampling reclassified 33.70% of low-HRV recordings in MIMIC-IV and 20.72% in MIMIC-III, a larger potential source of bias than the continuous-scale correction. The cross-database negative-control gradient was completed after linking both waveform cohorts to hospital outcomes: RMSSD inflation was reproducible (median x1.101 at 125->62.5 Hz in MIMIC-III and x1.270 at 250->62.5 Hz in MIMIC-IV), but the age-adjusted HRV-mortality risk ratio did not increase at lower rates (MIMIC-III 1.70->1.21; MIMIC-IV 1.31->1.29->1.20; all 95% CIs crossed 1). The falsification test was therefore negative in these cohorts, and we report it as such rather than as evidence that measurement bias is absent. Conclusions and Relevance. Sampling rate is a detectable and correctable source of bias in HRV-outcome research. Recording the sampling rate of each signal, stratifying effects by baseline variability, and reporting a QBA sensitivity band before dichotomising HRV would make published associations more interpretable. The object of inference here is the measurement-error method, not a new clinical biomarker; the proposed reporting steps require no additional data collection.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.15.26368154v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
            "content_type": "application/json",
            "elapsed_ms": 187,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.15.26368154v1?rss=1"
    },
    {
      "id": "4bba53785baff5bb7b32",
      "title": "Preprint: Evaluation of System One Models on Biomedical Texts",
      "content_text": "Objective To compare the performance and cost of System One models (SOMs) with general-purpose large language models (LLMs) on biomedical tasks and evaluate confidence-based routing. Materials and Methods We evaluated three SOMs and three LLMs across seven datasets and eight endpoints covering question answering, error detection, structured extraction, and clinical-note assessment. Outcomes included task-specific performance, recorded inference cost and latency, and confidence calibration…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "4bba53785baff5bb7b32",
          "source": "web",
          "type": "change",
          "key": "#23d8272fa8eb8831939a",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Evaluation of System One Models on Biomedical Texts",
            "item_type": "record",
            "summary": "added: Preprint: Evaluation of System One Models on Biomedical Texts",
            "after": {
              "title": "Preprint: Evaluation of System One Models on Biomedical Texts",
              "authors": "Chen, A. F.; Yang, A.; Guth, D. R.; Berl, F. M.; Guth, S. C.; Yuan, W.",
              "author_corresponding": "William Yuan",
              "author_corresponding_institution": "NYU Grossman School of Medicine",
              "doi": "10.64898/2026.11.15.26368126",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "health informatics",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.15.26368126.source.xml",
              "abstract": "Objective To compare the performance and cost of System One models (SOMs) with general-purpose large language models (LLMs) on biomedical tasks and evaluate confidence-based routing. Materials and Methods We evaluated three SOMs and three LLMs across seven datasets and eight endpoints covering question answering, error detection, structured extraction, and clinical-note assessment. Outcomes included task-specific performance, recorded inference cost and latency, and confidence calibration. Calibration data determined routing schemes and confidence thresholds to evaluate test predictions, with cost-matched random referral as a comparator. Results Claude Opus 5.5 had the highest primary performance on all eight endpoints. The strongest SOM, Jev, had competitive performance with the evaluated LLMs and cost less than 1% of Opus on most datasets. Three selected SOM-to-LLM routes reduced costs by 30.0%-71.7% relative to the receiving LLM, with modest reductions in performance. On one benchmark, SOM-to-SOM routing achieved 91.1% accuracy, compared with 82.3% and 82.2% for the individual models. Discussion SOMs offered favorable performance-cost tradeoffs for most tasks. The magnitude of the advantages depended on task structure and prompting requirements. Confidence-based routing between SOMs and LLMs can leverage complementary model strengths and offers additional flexibility in performance-cost tradeoffs. The price advantages offered by SOMs can facilitate experimentation and development of workflows. This warrants further evaluation on closed datasets. Conclusion For biomedical tasks with predefined choices, SOMs represent a competitive stand-alone or first-stage approach.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Objective To compare the performance and cost of System One models (SOMs) with general-purpose large language models (LLMs) on biomedical tasks and evaluate confidence-based routing. Materials and Methods We evaluated three SOMs and three LLMs across seven datasets and eight endpoints covering question answering, error detection, structured extraction, and clinical-note assessment. Outcomes included task-specific performance, recorded inference cost and latency, and confidence calibration. Calibration data determined routing schemes and confidence thresholds to evaluate test predictions, with cost-matched random referral as a comparator. Results Claude Opus 5.5 had the highest primary performance on all eight endpoints. The strongest SOM, Jev, had competitive performance with the evaluated LLMs and cost less than 1% of Opus on most datasets. Three selected SOM-to-LLM routes reduced costs by 30.0%-71.7% relative to the receiving LLM, with modest reductions in performance. On one benchmark, SOM-to-SOM routing achieved 91.1% accuracy, compared with 82.3% and 82.2% for the individual models. Discussion SOMs offered favorable performance-cost tradeoffs for most tasks. The magnitude of the advantages depended on task structure and prompting requirements. Confidence-based routing between SOMs and LLMs can leverage complementary model strengths and offers additional flexibility in performance-cost tradeoffs. The price advantages offered by SOMs can facilitate experimentation and development of workflows. This warrants further evaluation on closed datasets. Conclusion For biomedical tasks with predefined choices, SOMs represent a competitive stand-alone or first-stage approach.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.15.26368126v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
            "content_type": "application/json",
            "elapsed_ms": 187,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.15.26368126v1?rss=1"
    },
    {
      "id": "9617c9f20157b814c370",
      "title": "Preprint: Changes in Medicaid GLP-1 Prescription Dispensing After 4 States Ended Weight-Management Coverage",
      "content_text": "On January 1, 2026, California, New Hampshire, Pennsylvania, and South Carolina ended Medicaid coverage of GLP-1s indicated for weight management. In 2025 Q4 these four states accounted for 60.5% of Medicaid weight-management GLP-1 prescriptions nationally (661,478 of 1,094,191). We used State Drug Utilization Data from 2024 Q1 through 2026 Q1 to describe dispensing in the first quarter after withdrawal, classifying products by FDA-approved indication. In the withdrawing states…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "9617c9f20157b814c370",
          "source": "web",
          "type": "change",
          "key": "#d81eda09b1770122a73a",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Changes in Medicaid GLP-1 Prescription Dispensing After 4 States Ended Weight-Management Coverage",
            "item_type": "record",
            "summary": "added: Preprint: Changes in Medicaid GLP-1 Prescription Dispensing After 4 States Ended Weight-Management Coverage",
            "after": {
              "title": "Preprint: Changes in Medicaid GLP-1 Prescription Dispensing After 4 States Ended Weight-Management Coverage",
              "authors": "Lo, W.-L.; Conti, R. M.; Nguyen, T.; Gupta, S.; Wing, C.; Simon, K.",
              "author_corresponding": "Kosali Simon",
              "author_corresponding_institution": "Indiana University",
              "doi": "10.64898/2026.11.15.26368150",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "health policy",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.15.26368150.source.xml",
              "abstract": "On January 1, 2026, California, New Hampshire, Pennsylvania, and South Carolina ended Medicaid coverage of GLP-1s indicated for weight management. In 2025 Q4 these four states accounted for 60.5% of Medicaid weight-management GLP-1 prescriptions nationally (661,478 of 1,094,191). We used State Drug Utilization Data from 2024 Q1 through 2026 Q1 to describe dispensing in the first quarter after withdrawal, classifying products by FDA-approved indication. In the withdrawing states, weight-management GLP-1 prescriptions were 1.06 per 100 enrollee-months in 2025 Q3, 1.08 in 2025 Q4, and 0.16 in 2026 Q1, a decline of 85%, while in six states that kept coverage the same figures were 0.90, 0.97, and 0.82. The difference-in-differences estimate was -0.67 (95% CI, -1.21 to -0.18). Gross reimbursement in the withdrawing states fell by $1,079 per 100 enrollee-months from 2025 Q3 to 2026 Q1. Dispensing of GLP-1s labeled for other indications did not rise: the estimate against 33 never-covering states was -0.03 (95% CI, -0.29 to 0.23), so increases larger than 0.23 per 100 enrollee-months, about one quarter of the weight-management decline, can be ruled out. Substitution toward diabetes-labeled products was at most limited in the first quarter after coverage ended.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "On January 1, 2026, California, New Hampshire, Pennsylvania, and South Carolina ended Medicaid coverage of GLP-1s indicated for weight management. In 2025 Q4 these four states accounted for 60.5% of Medicaid weight-management GLP-1 prescriptions nationally (661,478 of 1,094,191). We used State Drug Utilization Data from 2024 Q1 through 2026 Q1 to describe dispensing in the first quarter after withdrawal, classifying products by FDA-approved indication. In the withdrawing states, weight-management GLP-1 prescriptions were 1.06 per 100 enrollee-months in 2025 Q3, 1.08 in 2025 Q4, and 0.16 in 2026 Q1, a decline of 85%, while in six states that kept coverage the same figures were 0.90, 0.97, and 0.82. The difference-in-differences estimate was -0.67 (95% CI, -1.21 to -0.18). Gross reimbursement in the withdrawing states fell by $1,079 per 100 enrollee-months from 2025 Q3 to 2026 Q1. Dispensing of GLP-1s labeled for other indications did not rise: the estimate against 33 never-covering states was -0.03 (95% CI, -0.29 to 0.23), so increases larger than 0.23 per 100 enrollee-months, about one quarter of the weight-management decline, can be ruled out. Substitution toward diabetes-labeled products was at most limited in the first quarter after coverage ended.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.15.26368150v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
            "content_type": "application/json",
            "elapsed_ms": 187,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.15.26368150v1?rss=1"
    },
    {
      "id": "7d152c2e405b3a5fae46",
      "title": "Preprint: Whole-genome sequencing enables improved AML diagnostics and refines assessment of TP53 allelic state and complex karyotype",
      "content_text": "Accurate genetic characterization is central to modern acute myeloid leukemia (AML) diagnostics, yet current standard-of-care (SoC) testing relies on multiple complementary assays. We compared paired tumor-normal whole-genome sequencing (WGS) with SoC diagnostics in a population-based cohort of 109 adult AML patients, assessing variant detection, disease classification according to ICC 2022 and WHO 2022, and risk stratification according to ELN 2022. WGS showed high concordance with SoC across…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "7d152c2e405b3a5fae46",
          "source": "web",
          "type": "change",
          "key": "#015140284819defad025",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Whole-genome sequencing enables improved AML diagnostics and refines assessment of TP53 allelic state and complex karyotype",
            "item_type": "record",
            "summary": "added: Preprint: Whole-genome sequencing enables improved AML diagnostics and refines assessment of TP53 allelic state and complex karyotype",
            "after": {
              "title": "Preprint: Whole-genome sequencing enables improved AML diagnostics and refines assessment of TP53 allelic state and complex karyotype",
              "authors": "Stanek, P.; Orsmark-Pietras, C.; Henningsson, R.; Rissler, M.; Landberg, N.; Agerstam, H.; Staffas, A.; Fogelstrand, L.; Palmqvist, L.; Barbany, G.; Knulst, M.; Juliusson, G.; Lazarevic, V.; Wirta, V.; Cavelier, L.; Rosenquist, R.; Lilljebjörn, H.; Fioretos, T.",
              "author_corresponding": "Petr Stanek",
              "author_corresponding_institution": "Lund University",
              "doi": "10.64898/2026.11.13.26368028",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_no",
              "category": "hematology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.13.26368028.source.xml",
              "abstract": "Accurate genetic characterization is central to modern acute myeloid leukemia (AML) diagnostics, yet current standard-of-care (SoC) testing relies on multiple complementary assays. We compared paired tumor-normal whole-genome sequencing (WGS) with SoC diagnostics in a population-based cohort of 109 adult AML patients, assessing variant detection, disease classification according to ICC 2022 and WHO 2022, and risk stratification according to ELN 2022. WGS showed high concordance with SoC across variant classes. When considering all reported SoC variants together with high-confidence WGS variants as true positives, WGS showed equal to higher sensitivity than SoC for single-nucleotide variants and small insertions/deletions (97% vs 92%), structural variants (SVs; 100% vs 87%), and copy-number alterations (CNAs; 88.5% both). WGS identified clinically important lesions missed by SoC in 16 cases (15%), including FLT3-ITDs and KMT2A, NUP98 and MECOM rearrangements. Classification and risk assignments were 95-96% concordant, with WGS-driven reclassifications in 4-5% of cases, primarily through detection of cryptic SVs and myelodysplasia-related lesions. Integrated analysis of genomic alterations, including copy-neutral loss-of-heterozygosity, refined TP53 allelic state assessment and demonstrated increased genomic complexity in AML with biallelic TP53 alterations. We developed a supervised machine-learning model for complex karyotype (CK) probability, based on WGS-derived copy-number and SV burden, enabling automated identification of CK cases from WGS data. Collectively, these results support paired tumor-normal WGS as a single comprehensive assay well suited for AML diagnostics according to current classification and risk-stratification systems, while refining assessment of TP53 allelic state and karyotypic complexity.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Accurate genetic characterization is central to modern acute myeloid leukemia (AML) diagnostics, yet current standard-of-care (SoC) testing relies on multiple complementary assays. We compared paired tumor-normal whole-genome sequencing (WGS) with SoC diagnostics in a population-based cohort of 109 adult AML patients, assessing variant detection, disease classification according to ICC 2022 and WHO 2022, and risk stratification according to ELN 2022. WGS showed high concordance with SoC across variant classes. When considering all reported SoC variants together with high-confidence WGS variants as true positives, WGS showed equal to higher sensitivity than SoC for single-nucleotide variants and small insertions/deletions (97% vs 92%), structural variants (SVs; 100% vs 87%), and copy-number alterations (CNAs; 88.5% both). WGS identified clinically important lesions missed by SoC in 16 cases (15%), including FLT3-ITDs and KMT2A, NUP98 and MECOM rearrangements. Classification and risk assignments were 95-96% concordant, with WGS-driven reclassifications in 4-5% of cases, primarily through detection of cryptic SVs and myelodysplasia-related lesions. Integrated analysis of genomic alterations, including copy-neutral loss-of-heterozygosity, refined TP53 allelic state assessment and demonstrated increased genomic complexity in AML with biallelic TP53 alterations. We developed a supervised machine-learning model for complex karyotype (CK) probability, based on WGS-derived copy-number and SV burden, enabling automated identification of CK cases from WGS data. Collectively, these results support paired tumor-normal WGS as a single comprehensive assay well suited for AML diagnostics according to current classification and risk-stratification systems, while refining assessment of TP53 allelic state and karyotypic complexity.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368028v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
            "content_type": "application/json",
            "elapsed_ms": 187,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368028v1?rss=1"
    },
    {
      "id": "ea606617ab1582ef7674",
      "title": "Preprint: No evidence of an association between graft-versus-host disease and BK polyomavirus viral proteins LTAg and VP1",
      "content_text": "Introduction: This is an immunohistochemical (IHC) pilot study of adult patients who underwent allogeneic stem cell transplantation (alloSCT) for hematological disease and had BKPyV reactivation (BKPyV viruria) as well as graft-versus-host-disease (GvHD) to investigate, if there is an association between these two diseases. Methods: The study was prospectively registered at the German Clinical Trials Register (https://drks.de/search/en/trial/DRKS00039127/details). The full protocol is available…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "ea606617ab1582ef7674",
          "source": "web",
          "type": "change",
          "key": "#5afd1f8d98089268090c",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: No evidence of an association between graft-versus-host disease and BK polyomavirus viral proteins LTAg and VP1",
            "item_type": "record",
            "summary": "added: Preprint: No evidence of an association between graft-versus-host disease and BK polyomavirus viral proteins LTAg and VP1",
            "after": {
              "title": "Preprint: No evidence of an association between graft-versus-host disease and BK polyomavirus viral proteins LTAg and VP1",
              "authors": "Asadikomeleh, S.; Neumann, T.; Krueger, W.; Ribback, S.; Schneidewind, L.",
              "author_corresponding": "Laila Schneidewind",
              "author_corresponding_institution": "University of Greifswald",
              "doi": "10.64898/2026.11.17.26368216",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_no",
              "category": "infectious diseases",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.17.26368216.source.xml",
              "abstract": "Introduction: This is an immunohistochemical (IHC) pilot study of adult patients who underwent allogeneic stem cell transplantation (alloSCT) for hematological disease and had BKPyV reactivation (BKPyV viruria) as well as graft-versus-host-disease (GvHD) to investigate, if there is an association between these two diseases. Methods: The study was prospectively registered at the German Clinical Trials Register (https://drks.de/search/en/trial/DRKS00039127/details). The full protocol is available with this link. Results: Seven (58.3%) of the identified patients were treated in our prospective clinical trial regarding urological complications in alloSCT. All of them had BKPyV viruria during inpatient treatment for the transplantation and developed acute GvHD of the skin. Five (41.7%) of the patients were recruited in our prospective study of long-term survivors (more than five years) of alloSCT. All of them had BKPyV viruria as well as chronic GvHD of the skin at time of their examination. Acute myeloid leukemia was the most frequent underlying indication for alloSCT (n=7; 58.3%), followed by Non-Hodgkin-Lymphoma (NHL; n=2; 16,7%). Interestingly, IHC was negative for LTAg as well as VP1 in all patients. Therefore, it must also be stated that both virus proteins were negative in IHC for acute as well as chronic GvHD of the skin. Consequently, no further molecular investigations were realized. Conclusion: There is no evidence for an association between the viral proteins LTAg and VP1 of BKPyV and skin GvHD in immunohistochemistry. Due to the pilot character of our investigation, the results should be interpreted with great caution.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Introduction: This is an immunohistochemical (IHC) pilot study of adult patients who underwent allogeneic stem cell transplantation (alloSCT) for hematological disease and had BKPyV reactivation (BKPyV viruria) as well as graft-versus-host-disease (GvHD) to investigate, if there is an association between these two diseases. Methods: The study was prospectively registered at the German Clinical Trials Register (https://drks.de/search/en/trial/DRKS00039127/details). The full protocol is available with this link. Results: Seven (58.3%) of the identified patients were treated in our prospective clinical trial regarding urological complications in alloSCT. All of them had BKPyV viruria during inpatient treatment for the transplantation and developed acute GvHD of the skin. Five (41.7%) of the patients were recruited in our prospective study of long-term survivors (more than five years) of alloSCT. All of them had BKPyV viruria as well as chronic GvHD of the skin at time of their examination. Acute myeloid leukemia was the most frequent underlying indication for alloSCT (n=7; 58.3%), followed by Non-Hodgkin-Lymphoma (NHL; n=2; 16,7%). Interestingly, IHC was negative for LTAg as well as VP1 in all patients. Therefore, it must also be stated that both virus proteins were negative in IHC for acute as well as chronic GvHD of the skin. Consequently, no further molecular investigations were realized. Conclusion: There is no evidence for an association between the viral proteins LTAg and VP1 of BKPyV and skin GvHD in immunohistochemistry. Due to the pilot character of our investigation, the results should be interpreted with great caution.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.17.26368216v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
            "content_type": "application/json",
            "elapsed_ms": 187,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.17.26368216v1?rss=1"
    },
    {
      "id": "a42a5f7caf5080d6661d",
      "title": "Preprint: Improving respiratory virus forecasts by capturing the effects of school holidays, public holidays and seasonal changes in transmission",
      "content_text": "Respiratory viruses impose a substantial burden of morbidity and mortality globally, and models that forecast this burden are widely used to support public health decision-making. However, the public health utility of these forecasts can be limited by poor predictive accuracy. In this work, we show how capturing the effects of school holidays, public holidays and seasonal changes in transmission can improve respiratory virus forecasting performance. We construct a Bayesian renewal model where…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "a42a5f7caf5080d6661d",
          "source": "web",
          "type": "change",
          "key": "#75a540ee34757d6f1d80",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Improving respiratory virus forecasts by capturing the effects of school holidays, public holidays and seasonal changes in transmission",
            "item_type": "record",
            "summary": "added: Preprint: Improving respiratory virus forecasts by capturing the effects of school holidays, public holidays and seasonal changes in transmission",
            "after": {
              "title": "Preprint: Improving respiratory virus forecasts by capturing the effects of school holidays, public holidays and seasonal changes in transmission",
              "authors": "Tobin, R. J.; Eales, O.; Plank, M. J.; Morris, D. J.; McCaw, J. M.; Shearer, F. M.",
              "author_corresponding": "Freya M Shearer",
              "author_corresponding_institution": "The University of Melbourne",
              "doi": "10.64898/2026.11.15.26367964",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc",
              "category": "infectious diseases",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.15.26367964.source.xml",
              "abstract": "Respiratory viruses impose a substantial burden of morbidity and mortality globally, and models that forecast this burden are widely used to support public health decision-making. However, the public health utility of these forecasts can be limited by poor predictive accuracy. In this work, we show how capturing the effects of school holidays, public holidays and seasonal changes in transmission can improve respiratory virus forecasting performance. We construct a Bayesian renewal model where the effective reproduction number R(t) is composed of log-additive components including school and public holiday effects and an annually-periodic Gaussian process. The model also allows for the relative rate of reporting to vary with school and public holidays. We use this model to forecast respiratory syncytial virus (RSV), influenza and SARS-CoV-2 case incidence across a 28-day horizon over five jurisdictions in Australia. Applied to the 2025 winter season, our forecasts outperform a random-walk baseline forecast across all settings. We find that the inclusion of holiday and seasonal transmission effects improved forecasting performance across the three pathogens. We show that the school holidays are associated with population-wide reductions in R(t) on the order of 5-15% but are generally not associated with changes in reporting. Collectively, our results provide support for the inclusion of holiday and seasonal effects in future respiratory virus forecasting models.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Respiratory viruses impose a substantial burden of morbidity and mortality globally, and models that forecast this burden are widely used to support public health decision-making. However, the public health utility of these forecasts can be limited by poor predictive accuracy. In this work, we show how capturing the effects of school holidays, public holidays and seasonal changes in transmission can improve respiratory virus forecasting performance. We construct a Bayesian renewal model where the effective reproduction number R(t) is composed of log-additive components including school and public holiday effects and an annually-periodic Gaussian process. The model also allows for the relative rate of reporting to vary with school and public holidays. We use this model to forecast respiratory syncytial virus (RSV), influenza and SARS-CoV-2 case incidence across a 28-day horizon over five jurisdictions in Australia. Applied to the 2025 winter season, our forecasts outperform a random-walk baseline forecast across all settings. We find that the inclusion of holiday and seasonal transmission effects improved forecasting performance across the three pathogens. We show that the school holidays are associated with population-wide reductions in R(t) on the order of 5-15% but are generally not associated with changes in reporting. Collectively, our results provide support for the inclusion of holiday and seasonal effects in future respiratory virus forecasting models.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.15.26367964v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
            "content_type": "application/json",
            "elapsed_ms": 187,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.15.26367964v1?rss=1"
    },
    {
      "id": "7da0f2ad3093673851bd",
      "title": "Preprint: Early potassium response to mineralocorticoid receptor antagonist therapy and cardiovascular outcomes in primary aldosteronism: a landmark cohort study",
      "content_text": "Background Mineralocorticoid receptor antagonists (MRAs) are standard therapy for primary aldosteronism (PA). Serum potassium is measured in nearly every treated patient, but the long-term prognostic value of potassium attained early after initiation is undefined. Methods In the TriNetX Research Network, we identified adults with PA newly initiating spironolactone or eplerenone in 2000-2025, without prior adrenalectomy (n=4,169; 180-day landmark design). Achieved potassium (last value on days…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "7da0f2ad3093673851bd",
          "source": "web",
          "type": "change",
          "key": "#26c3be62fe367fc8aada",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Early potassium response to mineralocorticoid receptor antagonist therapy and cardiovascular outcomes in primary aldosteronism: a landmark cohort study",
            "item_type": "record",
            "summary": "added: Preprint: Early potassium response to mineralocorticoid receptor antagonist therapy and cardiovascular outcomes in primary aldosteronism: a landmark cohort study",
            "after": {
              "title": "Preprint: Early potassium response to mineralocorticoid receptor antagonist therapy and cardiovascular outcomes in primary aldosteronism: a landmark cohort study",
              "authors": "Chen, S.-H.; Huang, Y. H.; Lee, Y.-H.; Yang, S.-M.; Huang, C.-J.; Pang, Y.-K.; Chen, Y.-Y.; Cheng, H.-M.",
              "author_corresponding": "Hao-Min Cheng",
              "author_corresponding_institution": "Taipei Veterans General Hospital",
              "doi": "10.64898/2026.11.15.26368152",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "cardiovascular medicine",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.15.26368152.source.xml",
              "abstract": "Background Mineralocorticoid receptor antagonists (MRAs) are standard therapy for primary aldosteronism (PA). Serum potassium is measured in nearly every treated patient, but the long-term prognostic value of potassium attained early after initiation is undefined. Methods In the TriNetX Research Network, we identified adults with PA newly initiating spironolactone or eplerenone in 2000-2025, without prior adrenalectomy (n=4,169; 180-day landmark design). Achieved potassium (last value on days 14-180) was categorised as <4.0, 4.0-<4.5, 4.5-<5.0 and [&ge;]5.0 mmol/L, and its change from baseline in tertiles, using cause-specific Cox and Fine-Gray models. The primary outcome was a composite of myocardial infarction, stroke or death; incident heart failure was co-primary. Findings Over a median 3.0 years, 623 composite events occurred. Estimated risk was lowest at 4.5-<5.0 mmol/L (adjusted hazard ratio 0.65, 95% CI 0.52-0.83, versus <4.0 mmol/L), lower than the 4.0-<4.5 mmol/L band, and not different from [&ge;]5.0 mmol/L. A larger rise in potassium was associated with lower risk. A similar pattern was seen for incident heart failure (0.54, 0.36-0.80; 248 events). Potassium below the 3.6 mmol/L consensus threshold for hypokalaemia carried no significantly higher risk (1.22, 0.96-1.56). The change in potassium correlated weakly with the change in renin (rho = 0.15). Interpretation In MRA-treated PA, cardiovascular and heart-failure risk was lowest at an early achieved potassium of 4.5-<5.0 mmol/L, well above the 3.6 mmol/L accepted by consensus criteria as correction of hypokalaemia; correction alone may therefore be an insufficient treatment target. Whether titrating therapy towards this band improves outcomes requires prospective evaluation.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background Mineralocorticoid receptor antagonists (MRAs) are standard therapy for primary aldosteronism (PA). Serum potassium is measured in nearly every treated patient, but the long-term prognostic value of potassium attained early after initiation is undefined. Methods In the TriNetX Research Network, we identified adults with PA newly initiating spironolactone or eplerenone in 2000-2025, without prior adrenalectomy (n=4,169; 180-day landmark design). Achieved potassium (last value on days 14-180) was categorised as <4.0, 4.0-<4.5, 4.5-<5.0 and [&ge;]5.0 mmol/L, and its change from baseline in tertiles, using cause-specific Cox and Fine-Gray models. The primary outcome was a composite of myocardial infarction, stroke or death; incident heart failure was co-primary. Findings Over a median 3.0 years, 623 composite events occurred. Estimated risk was lowest at 4.5-<5.0 mmol/L (adjusted hazard ratio 0.65, 95% CI 0.52-0.83, versus <4.0 mmol/L), lower than the 4.0-<4.5 mmol/L band, and not different from [&ge;]5.0 mmol/L. A larger rise in potassium was associated with lower risk. A similar pattern was seen for incident heart failure (0.54, 0.36-0.80; 248 events). Potassium below the 3.6 mmol/L consensus threshold for hypokalaemia carried no significantly higher risk (1.22, 0.96-1.56). The change in potassium correlated weakly with the change in renin (rho = 0.15). Interpretation In MRA-treated PA, cardiovascular and heart-failure risk was lowest at an early achieved potassium of 4.5-<5.0 mmol/L, well above the 3.6 mmol/L accepted by consensus criteria as correction of hypokalaemia; correction alone may therefore be an insufficient treatment target. Whether titrating therapy towards this band improves outcomes requires prospective evaluation.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.15.26368152v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
            "content_type": "application/json",
            "elapsed_ms": 187,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.15.26368152v1?rss=1"
    },
    {
      "id": "4c757865e0afba8bf57e",
      "title": "Preprint: Multidrug-Resistant Tuberculosis Rates Among High-Risk Populations in Brazil: An Analysis from 2001 to 2021",
      "content_text": "Multidrug-Resistant Tuberculosis (MDR-TB) represents a global public health threat, with a rising prevalence, particularly among vulnerable populations. This cross-sectional study analyzed MDR-TB notifications in Brazil from 2001 to 2021, using data from DATASUS, and stratified by periods and risk groups (HIV-positive individuals, smokers, drug users, healthcare workers, incarcerated individuals, and people experiencing homelessness). Descriptive analyses and parametric statistical tests (ANOVA…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "4c757865e0afba8bf57e",
          "source": "web",
          "type": "change",
          "key": "#d4bc95b04dd14a718e9b",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Multidrug-Resistant Tuberculosis Rates Among High-Risk Populations in Brazil: An Analysis from 2001 to 2021",
            "item_type": "record",
            "summary": "added: Preprint: Multidrug-Resistant Tuberculosis Rates Among High-Risk Populations in Brazil: An Analysis from 2001 to 2021",
            "after": {
              "title": "Preprint: Multidrug-Resistant Tuberculosis Rates Among High-Risk Populations in Brazil: An Analysis from 2001 to 2021",
              "authors": "Dailton Guedes de Oliveira Moraes, C.; Granato, A. E. C.; Santos de Marins, I.; Pinto Alves Ferreira, P. O.; Pinto Alves Ferreira, V. A.; Ribeiro Junior, C. A.; Armenara Namorato, H.; Edimar da Costa Junior, J.; Pinto, F. A.",
              "author_corresponding": "Carlos Dailton Guedes de Oliveira Moraes",
              "author_corresponding_institution": "Academicos de Medicina da Faculdade de Ciencias Medicas de Sao Jose dos Campos - FCMSJC - Humanitas",
              "doi": "10.64898/2026.11.15.26368155",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc0_ng",
              "category": "epidemiology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.15.26368155.source.xml",
              "abstract": "Multidrug-Resistant Tuberculosis (MDR-TB) represents a global public health threat, with a rising prevalence, particularly among vulnerable populations. This cross-sectional study analyzed MDR-TB notifications in Brazil from 2001 to 2021, using data from DATASUS, and stratified by periods and risk groups (HIV-positive individuals, smokers, drug users, healthcare workers, incarcerated individuals, and people experiencing homelessness). Descriptive analyses and parametric statistical tests (ANOVA and Tukey, p less than 0.05) were applied. A significant increase in cases was observed across all groups, especially between 2017 and 2021, with growth ranging from 294% to 574% depending on the population. Factors such as treatment abandonment, coinfection, social vulnerability, and occupational exposure were key determinants for MDR-TB dissemination. The findings indicate that current public health policies are insufficient, highlighting the urgent need for targeted prevention strategies, therapeutic follow-up, and control measures for high-risk populations.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Multidrug-Resistant Tuberculosis (MDR-TB) represents a global public health threat, with a rising prevalence, particularly among vulnerable populations. This cross-sectional study analyzed MDR-TB notifications in Brazil from 2001 to 2021, using data from DATASUS, and stratified by periods and risk groups (HIV-positive individuals, smokers, drug users, healthcare workers, incarcerated individuals, and people experiencing homelessness). Descriptive analyses and parametric statistical tests (ANOVA and Tukey, p less than 0.05) were applied. A significant increase in cases was observed across all groups, especially between 2017 and 2021, with growth ranging from 294% to 574% depending on the population. Factors such as treatment abandonment, coinfection, social vulnerability, and occupational exposure were key determinants for MDR-TB dissemination. The findings indicate that current public health policies are insufficient, highlighting the urgent need for targeted prevention strategies, therapeutic follow-up, and control measures for high-risk populations.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.15.26368155v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
            "content_type": "application/json",
            "elapsed_ms": 187,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.15.26368155v1?rss=1"
    },
    {
      "id": "12cf9d85624dd6d4f47f",
      "title": "Preprint: Patient, carer and clinical stakeholder views on using artificial intelligence and machine learning for the histopathological diagnosis of duodenal biopsies",
      "content_text": "Objective: Biopsies are examined under the microscope by a pathologist, giving a diagnosis, which guides treatment and predicts prognosis. A shortage of pathologists and increasing workload leads to diagnostic delays, while for duodenal (small intestinal) biopsies, variable diagnostic concordance between pathologists limits accuracy. These challenges have motivated us to develop an artificial intelligence (AI)-mediated approach for the automated diagnosis of up to 80% of duodenal biopsies…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "12cf9d85624dd6d4f47f",
          "source": "web",
          "type": "change",
          "key": "#6ae67b1263375fdd8a5f",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Patient, carer and clinical stakeholder views on using artificial intelligence and machine learning for the histopathological diagnosis of duodenal biopsies",
            "item_type": "record",
            "summary": "added: Preprint: Patient, carer and clinical stakeholder views on using artificial intelligence and machine learning for the histopathological diagnosis of duodenal biopsies",
            "after": {
              "title": "Preprint: Patient, carer and clinical stakeholder views on using artificial intelligence and machine learning for the histopathological diagnosis of duodenal biopsies",
              "authors": "Baby, J. G.; Jaeckle, F.; Williams, J.; Shepherd, K.; Urwin, H.; Soilleux, E. J.",
              "author_corresponding": "Elizabeth J Soilleux",
              "author_corresponding_institution": "University of Cambridge",
              "doi": "10.64898/2026.11.16.26368196",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "gastroenterology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.16.26368196.source.xml",
              "abstract": "Objective: Biopsies are examined under the microscope by a pathologist, giving a diagnosis, which guides treatment and predicts prognosis. A shortage of pathologists and increasing workload leads to diagnostic delays, while for duodenal (small intestinal) biopsies, variable diagnostic concordance between pathologists limits accuracy. These challenges have motivated us to develop an artificial intelligence (AI)-mediated approach for the automated diagnosis of up to 80% of duodenal biopsies (i.e., most cases of the two most frequent diagnoses: coeliac disease and normal). We set out to understand patient, carer and stakeholder views regarding the adoption of such technology. Methods and Analysis: We conducted mixed-methods stakeholder engagement (February 2024 to June 2026). We ran a national online patients and carers questionnaire (n=231 respondents) and four UK focus-group workshops, one of which additionally captured Likert-scale attitudes1 immediately before and after a structured educational session (n=34 matched pairs). Healthcare professionals completed an online questionnaire (n=37) and took part in a structured workshop. Quantitative data were summarised descriptively; free-text and workshop data were analysed thematically and triangulated across all sources. Results: Most patients and carers supported AI-reliant diagnosis (68.4%) and would strongly trust systems with formal regulatory approval (66.7%). Most wanted to be informed if AI was used (73.6%), but only 52.4% felt explicit permission was necessary. Qualitative themes centred on clear and available evidence of accuracy, human oversight, transparent communication and clear terminology, with the term machine learning being preferred to artificial intelligence. Agreement (agree or strongly agree combined) with statements relating to trust, acceptance and perceived benefit of AI was significantly higher after a structured educational session (38.2% to 67.6%, 85.3% to 97.1%, and 52.9% to 97.1% respectively; all p<0.003). Healthcare professionals favoured an AI assistant model over full automation, citing the need for validation, explainability, data governance and workflow integration. Patients also preferred some level of human oversight. Conclusion: Patients and healthcare professionals are cautiously supportive of AI-assisted diagnosis of duodenal biopsies, conditional upon demonstration of accuracy, appropriate human oversight and transparent communication. Attitudes towards AI-assisted diagnosis were more favourable after structured explanation.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Objective: Biopsies are examined under the microscope by a pathologist, giving a diagnosis, which guides treatment and predicts prognosis. A shortage of pathologists and increasing workload leads to diagnostic delays, while for duodenal (small intestinal) biopsies, variable diagnostic concordance between pathologists limits accuracy. These challenges have motivated us to develop an artificial intelligence (AI)-mediated approach for the automated diagnosis of up to 80% of duodenal biopsies (i.e., most cases of the two most frequent diagnoses: coeliac disease and normal). We set out to understand patient, carer and stakeholder views regarding the adoption of such technology. Methods and Analysis: We conducted mixed-methods stakeholder engagement (February 2024 to June 2026). We ran a national online patients and carers questionnaire (n=231 respondents) and four UK focus-group workshops, one of which additionally captured Likert-scale attitudes1 immediately before and after a structured educational session (n=34 matched pairs). Healthcare professionals completed an online questionnaire (n=37) and took part in a structured workshop. Quantitative data were summarised descriptively; free-text and workshop data were analysed thematically and triangulated across all sources. Results: Most patients and carers supported AI-reliant diagnosis (68.4%) and would strongly trust systems with formal regulatory approval (66.7%). Most wanted to be informed if AI was used (73.6%), but only 52.4% felt explicit permission was necessary. Qualitative themes centred on clear and available evidence of accuracy, human oversight, transparent communication and clear terminology, with the term machine learning being preferred to artificial intelligence. Agreement (agree or strongly agree combined) with statements relating to trust, acceptance and perceived benefit of AI was significantly higher after a structured educational session (38.2% to 67.6%, 85.3% to 97.1%, and 52.9% to 97.1% respectively; all p<0.003). Healthcare professionals favoured an AI assistant model over full automation, citing the need for validation, explainability, data governance and workflow integration. Patients also preferred some level of human oversight. Conclusion: Patients and healthcare professionals are cautiously supportive of AI-assisted diagnosis of duodenal biopsies, conditional upon demonstration of accuracy, appropriate human oversight and transparent communication. Attitudes towards AI-assisted diagnosis were more favourable after structured explanation.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.16.26368196v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
            "content_type": "application/json",
            "elapsed_ms": 187,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.16.26368196v1?rss=1"
    },
    {
      "id": "8ea8f02d8ed06abc4a97",
      "title": "Preprint: The genetic architecture of wisdom and its relationship with health, personality, and cognition",
      "content_text": "Wisdom is a personality trait composed of self-reflection, pro-social behaviors, emotional regulation, acceptance of divergent perspectives, decisiveness, social advising, and spirituality. Greater levels of wisdom are linked to better overall health, well-being, happiness, life satisfaction, and resilience. However, the underlying genetic architecture of wisdom remains unexplored. We assessed wisdom using responses to the SD-WISE-7 in 153,384 23andMe research-consented participants and…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "8ea8f02d8ed06abc4a97",
          "source": "web",
          "type": "change",
          "key": "#e4f6b56d5ca239827efa",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: The genetic architecture of wisdom and its relationship with health, personality, and cognition",
            "item_type": "record",
            "summary": "added: Preprint: The genetic architecture of wisdom and its relationship with health, personality, and cognition",
            "after": {
              "title": "Preprint: The genetic architecture of wisdom and its relationship with health, personality, and cognition",
              "authors": "Malatesta, F.; Thorpe, H.; Gonzalez, J.; Meredith, J. J.; Vilar-Ribo, L.; Courchesne-Krak, N.; Gustavson, D.; 23andMe Research Team,  ; Tran, V.; Saini, S.; Rios, E. M.; Palmer, A.; Sanchez-Roige, S.",
              "author_corresponding": "Sandra Sanchez-Roige",
              "author_corresponding_institution": "Department of Psychiatry; Institute for Genomic Medicine, University of California San Diego, La Jolla, CA, USA",
              "doi": "10.64898/2026.11.10.26367758",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc",
              "category": "psychiatry and clinical psychology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.10.26367758.source.xml",
              "abstract": "Wisdom is a personality trait composed of self-reflection, pro-social behaviors, emotional regulation, acceptance of divergent perspectives, decisiveness, social advising, and spirituality. Greater levels of wisdom are linked to better overall health, well-being, happiness, life satisfaction, and resilience. However, the underlying genetic architecture of wisdom remains unexplored. We assessed wisdom using responses to the SD-WISE-7 in 153,384 23andMe research-consented participants and conducted a multi-ancestry GWAS. We identified one genome-wide significant locus (rs2325631, p=1.41E-08) near MANEA on chromosome 6. Wisdom was heritable (h2SNP=0.03{+/-}4.50E-03) and genetically correlated with numerous traits, including greater subjective well-being, openness, and risk tolerance, and lower neuroticism and loneliness. Crucially, wisdom was genetically distinct from intelligence and the cognitive component of educational attainment. Wisdom polygenic scores were associated with psychosocial outcomes, but not cognitive performance in All of Us. This study advances our understanding of wisdom as a heritable trait that could guide interventions to improve human health.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Wisdom is a personality trait composed of self-reflection, pro-social behaviors, emotional regulation, acceptance of divergent perspectives, decisiveness, social advising, and spirituality. Greater levels of wisdom are linked to better overall health, well-being, happiness, life satisfaction, and resilience. However, the underlying genetic architecture of wisdom remains unexplored. We assessed wisdom using responses to the SD-WISE-7 in 153,384 23andMe research-consented participants and conducted a multi-ancestry GWAS. We identified one genome-wide significant locus (rs2325631, p=1.41E-08) near MANEA on chromosome 6. Wisdom was heritable (h2SNP=0.03{+/-}4.50E-03) and genetically correlated with numerous traits, including greater subjective well-being, openness, and risk tolerance, and lower neuroticism and loneliness. Crucially, wisdom was genetically distinct from intelligence and the cognitive component of educational attainment. Wisdom polygenic scores were associated with psychosocial outcomes, but not cognitive performance in All of Us. This study advances our understanding of wisdom as a heritable trait that could guide interventions to improve human health.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.10.26367758v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
            "content_type": "application/json",
            "elapsed_ms": 187,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.10.26367758v1?rss=1"
    },
    {
      "id": "c0c916b1e9e65cb6cf8b",
      "title": "Preprint: Cervicovaginal metabolites mediate the relationship between vaginal microbiota and risk for Chlamydia trachomatis infection",
      "content_text": "Background: Chlamydia trachomatis (CT) remains the most prevalent bacterial sexually transmitted infection and a cause of adverse reproductive outcomes. Epidemiologic studies describe bacterial vaginosis (BV) as a major risk factor for CT infection. Emerging data suggest that BV-associated bacteria and their metabolites contribute to CT susceptibility. Here, we measured the role of specific bacteria in incident CT and evaluated a hypothesized causal role between the vaginal microbiota, its…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "c0c916b1e9e65cb6cf8b",
          "source": "web",
          "type": "change",
          "key": "#3f443e319b8d299ab2ea",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Cervicovaginal metabolites mediate the relationship between vaginal microbiota and risk for Chlamydia trachomatis infection",
            "item_type": "record",
            "summary": "added: Preprint: Cervicovaginal metabolites mediate the relationship between vaginal microbiota and risk for Chlamydia trachomatis infection",
            "after": {
              "title": "Preprint: Cervicovaginal metabolites mediate the relationship between vaginal microbiota and risk for Chlamydia trachomatis infection",
              "authors": "Dabee, S.; Tsamir-Rimon, M.; Akingba, O.; Kinuthia, J.; MacDonald, J. W.; Bammler, T. K.; Raftery, D.; Hybiske, K.; Tapia, K.; Jaoko, W.; Borenstein, E.; Balkus, J. E.; McClelland, R. S.; Jaspan, H. B.",
              "author_corresponding": "Heather B Jaspan",
              "author_corresponding_institution": "Seattle Childrens Research Institute, Seattle, WA, USA",
              "doi": "10.64898/2026.11.16.26368223",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "sexual and reproductive health",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.16.26368223.source.xml",
              "abstract": "Background: Chlamydia trachomatis (CT) remains the most prevalent bacterial sexually transmitted infection and a cause of adverse reproductive outcomes. Epidemiologic studies describe bacterial vaginosis (BV) as a major risk factor for CT infection. Emerging data suggest that BV-associated bacteria and their metabolites contribute to CT susceptibility. Here, we measured the role of specific bacteria in incident CT and evaluated a hypothesized causal role between the vaginal microbiota, its metabolites, and CT risk. Methods: We conducted a nested case-control study of Kenyan women who engage in transactional sex from the Mombasa Cohort who acquired CT versus those who did not, and compared their vaginal microbiome and metabolome at the visit preceding CT acquisition. We determined CT infection and total bacterial load using qPCRs. 16S rRNA sequencing was used to characterize the genital microbiome, and BV status was determined using Nugent-Hillier and Amsel scoring criteria. Metabolites were measured using targeted liquid chromatography-mass spectrometry from a subset of women. Findings: Women with BV, high vaginal microbial diversity, and community state types III and IV were significantly more likely to have CT at their next visit. CT infection itself did not alter vaginal microbial diversity. More specifically, both concentrations and relative abundances of Lactobacillus crispatus and several BV-associated bacteria (Sneathia sanguinegens, Umbribacter vaginalis, Prevotella amnii, Hoylesella/Prevotella timonensis, and Ureaplasma urealyticum) were predictive of CT outcomes. Vaginal metabolites differed between cases and controls pre-CT, including Tyramine, reduced and oxidized Glutathione, and sucrose. In a mediation analysis, the vaginal metabolome significantly mediated the relationship between the microbiome and CT infection. Interpretation: We show for the first time that the association between BV and CT risk is mediated by differences in the metabolome. Identification of the mechanisms underlying increased CT risk with BV can inform interventions to reduce infections in high-risk women. Funding: US NIH (R01AI13214401-A1)",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background: Chlamydia trachomatis (CT) remains the most prevalent bacterial sexually transmitted infection and a cause of adverse reproductive outcomes. Epidemiologic studies describe bacterial vaginosis (BV) as a major risk factor for CT infection. Emerging data suggest that BV-associated bacteria and their metabolites contribute to CT susceptibility. Here, we measured the role of specific bacteria in incident CT and evaluated a hypothesized causal role between the vaginal microbiota, its metabolites, and CT risk. Methods: We conducted a nested case-control study of Kenyan women who engage in transactional sex from the Mombasa Cohort who acquired CT versus those who did not, and compared their vaginal microbiome and metabolome at the visit preceding CT acquisition. We determined CT infection and total bacterial load using qPCRs. 16S rRNA sequencing was used to characterize the genital microbiome, and BV status was determined using Nugent-Hillier and Amsel scoring criteria. Metabolites were measured using targeted liquid chromatography-mass spectrometry from a subset of women. Findings: Women with BV, high vaginal microbial diversity, and community state types III and IV were significantly more likely to have CT at their next visit. CT infection itself did not alter vaginal microbial diversity. More specifically, both concentrations and relative abundances of Lactobacillus crispatus and several BV-associated bacteria (Sneathia sanguinegens, Umbribacter vaginalis, Prevotella amnii, Hoylesella/Prevotella timonensis, and Ureaplasma urealyticum) were predictive of CT outcomes. Vaginal metabolites differed between cases and controls pre-CT, including Tyramine, reduced and oxidized Glutathione, and sucrose. In a mediation analysis, the vaginal metabolome significantly mediated the relationship between the microbiome and CT infection. Interpretation: We show for the first time that the association between BV and CT risk is mediated by differences in the metabolome. Identification of the mechanisms underlying increased CT risk with BV can inform interventions to reduce infections in high-risk women. Funding: US NIH (R01AI13214401-A1)",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.16.26368223v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
            "content_type": "application/json",
            "elapsed_ms": 187,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.16.26368223v1?rss=1"
    },
    {
      "id": "95258fc6398127906209",
      "title": "Preprint: Frequency and antibiotic susceptibility of urinary Klebsiella in Lahore",
      "content_text": "Urinary tract infections are commonly caused by bacteria whose antibiotic susceptibility varies between clinical settings. We studied urinary isolates from 95 patients with suspected infection at Lahore General Hospital, Pakistan, between July and December 2023. Urine culture showed significant bacterial growth in 63 specimens (66.3%). Escherichia coli accounted for 30 isolates, followed by 18 Klebsiella isolates, comprising 16 Klebsiella pneumoniae and two Klebsiella oxytoca. Klebsiella was…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "95258fc6398127906209",
          "source": "web",
          "type": "change",
          "key": "#34012bf13c473ae64064",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
          "timestamp": null,
          "observed_at": "2026-11-18T00:48:17Z",
          "data": {
            "change": "added",
            "label": "Preprint: Frequency and antibiotic susceptibility of urinary Klebsiella in Lahore",
            "item_type": "record",
            "summary": "added: Preprint: Frequency and antibiotic susceptibility of urinary Klebsiella in Lahore",
            "after": {
              "title": "Preprint: Frequency and antibiotic susceptibility of urinary Klebsiella in Lahore",
              "authors": "Kalsoom, Z.; Khan, M. M.; Rashid, S. R.",
              "author_corresponding": "Muhammad Mohsin Khan",
              "author_corresponding_institution": "Institute of Microbiology, University of Agriculture Faisalabad, Faisalabad, Pakistan",
              "doi": "10.64898/2026.11.15.26368163",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "infectious diseases",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.15.26368163.source.xml",
              "abstract": "Urinary tract infections are commonly caused by bacteria whose antibiotic susceptibility varies between clinical settings. We studied urinary isolates from 95 patients with suspected infection at Lahore General Hospital, Pakistan, between July and December 2023. Urine culture showed significant bacterial growth in 63 specimens (66.3%). Escherichia coli accounted for 30 isolates, followed by 18 Klebsiella isolates, comprising 16 Klebsiella pneumoniae and two Klebsiella oxytoca. Klebsiella was recovered from 12 female and six male patients, and the largest number of Klebsiella isolates occurred in patients aged 21-30 years. The aggregate susceptibility results, recorded for 18 isolates per antibiotic, showed the highest susceptibility to imipenem and meropenem (17/18 each), followed by nitrofurantoin (16/18). Resistance to several cephalosporins, fluoroquinolones and aminoglycosides was frequent. These findings describe the bacterial distribution and reported susceptibility patterns in a small hospital sample. Larger studies with verified species-specific susceptibility data are needed before these findings can guide local treatment policy.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Urinary tract infections are commonly caused by bacteria whose antibiotic susceptibility varies between clinical settings. We studied urinary isolates from 95 patients with suspected infection at Lahore General Hospital, Pakistan, between July and December 2023. Urine culture showed significant bacterial growth in 63 specimens (66.3%). Escherichia coli accounted for 30 isolates, followed by 18 Klebsiella isolates, comprising 16 Klebsiella pneumoniae and two Klebsiella oxytoca. Klebsiella was recovered from 12 female and six male patients, and the largest number of Klebsiella isolates occurred in patients aged 21-30 years. The aggregate susceptibility results, recorded for 18 isolates per antibiotic, showed the highest susceptibility to imipenem and meropenem (17/18 each), followed by nitrofurantoin (16/18). Resistance to several cephalosporins, fluoroquinolones and aminoglycosides was frequent. These findings describe the bacterial distribution and reported susceptibility patterns in a small hospital sample. Larger studies with verified species-specific susceptibility data are needed before these findings can guide local treatment policy.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.15.26368163v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-16/2026-11-18/120",
            "content_type": "application/json",
            "elapsed_ms": 187,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.15.26368163v1?rss=1"
    },
    {
      "id": "e5f1918798a13b9f7cd7",
      "title": "Preprint: Public Acceptability of Self-Payment for Community Pharmacists' Services: A National Online Survey",
      "content_text": "Background The traditional business model for sustaining United States (U.S.) community pharmacies has relied on income generated by product sales. A fee-for-service model could help alleviate insufficient profit by monetizing conventionally free pharmacy services if patients are willing to pay out-of-pocket. Objectives This study evaluated public acceptability of out-of-pocket payment for community pharmacist-provided services, variation in payment acceptability across services, and assessed…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "e5f1918798a13b9f7cd7",
          "source": "web",
          "type": "change",
          "key": "#3797b9351ba0a13fc703",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
          "timestamp": null,
          "observed_at": "2026-11-17T19:58:46Z",
          "data": {
            "change": "added",
            "label": "Preprint: Public Acceptability of Self-Payment for Community Pharmacists' Services: A National Online Survey",
            "item_type": "record",
            "summary": "added: Preprint: Public Acceptability of Self-Payment for Community Pharmacists' Services: A National Online Survey",
            "after": {
              "title": "Preprint: Public Acceptability of Self-Payment for Community Pharmacists' Services: A National Online Survey",
              "authors": "Pesaturo, K.; Pezzuto, J.-H.; Mattison, M.; Pezzuto, J. M.",
              "author_corresponding": "Kimberly Pesaturo",
              "author_corresponding_institution": "Western New England University",
              "doi": "10.64898/2026.11.15.26368139",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "health economics",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.15.26368139.source.xml",
              "abstract": "Background The traditional business model for sustaining United States (U.S.) community pharmacies has relied on income generated by product sales. A fee-for-service model could help alleviate insufficient profit by monetizing conventionally free pharmacy services if patients are willing to pay out-of-pocket. Objectives This study evaluated public acceptability of out-of-pocket payment for community pharmacist-provided services, variation in payment acceptability across services, and assessed whether payment acceptability differed by respondent characteristics and trust constructs. Methods This study represents a cross-sectional online survey of U.S. adults conducted during spring 2026 using a non-probability sampling approach. Primary outcomes were binary stated payment-acceptability judgments for a variety of pharmacist and health services. The survey used a between-subjects randomized payment-framing design, where participants were assigned to either a stated-price condition or an any-payment condition. Secondary outcomes included trust designations and participant demographic characteristics. Results A total of 1069 respondents completed the survey. A $20 fee was viewed more favorably than a general \"any amount of money\" fee. In the $20 stated-price condition, agreement was highest for osteoporosis screening (75.8%) and travel-related vaccines (69.0%), and lowest for antibiotic use consultation (23.9%) and wound care (32.1%). Older respondents and Hispanic respondents were less likely to view payment as acceptable, whereas men and respondents with greater pharmacist trust were more likely to view payment as acceptable. Conclusion Although patients historically have received many community pharmacy services at no cost, this study demonstrates that the concept of self-payment ifor certain services is considered acceptable, especially for services not typically provided.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background The traditional business model for sustaining United States (U.S.) community pharmacies has relied on income generated by product sales. A fee-for-service model could help alleviate insufficient profit by monetizing conventionally free pharmacy services if patients are willing to pay out-of-pocket. Objectives This study evaluated public acceptability of out-of-pocket payment for community pharmacist-provided services, variation in payment acceptability across services, and assessed whether payment acceptability differed by respondent characteristics and trust constructs. Methods This study represents a cross-sectional online survey of U.S. adults conducted during spring 2026 using a non-probability sampling approach. Primary outcomes were binary stated payment-acceptability judgments for a variety of pharmacist and health services. The survey used a between-subjects randomized payment-framing design, where participants were assigned to either a stated-price condition or an any-payment condition. Secondary outcomes included trust designations and participant demographic characteristics. Results A total of 1069 respondents completed the survey. A $20 fee was viewed more favorably than a general \"any amount of money\" fee. In the $20 stated-price condition, agreement was highest for osteoporosis screening (75.8%) and travel-related vaccines (69.0%), and lowest for antibiotic use consultation (23.9%) and wound care (32.1%). Older respondents and Hispanic respondents were less likely to view payment as acceptable, whereas men and respondents with greater pharmacist trust were more likely to view payment as acceptable. Conclusion Although patients historically have received many community pharmacy services at no cost, this study demonstrates that the concept of self-payment ifor certain services is considered acceptable, especially for services not typically provided.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.15.26368139v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
            "content_type": "application/json",
            "elapsed_ms": 586,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.15.26368139v1?rss=1"
    },
    {
      "id": "78dbb2257e909b8db7fd",
      "title": "Preprint: B-cell involvement supports anti-CD20 therapy in paediatric rheumatic heart disease: Proof of concept and initial safety",
      "content_text": "Rheumatic heart disease (RHD) remains a major cause of cardiovascular morbidity and mortality, particularly in low- and middle-income countries, yet no therapy targets its underlying autoimmune mechanisms. We combined transcriptomic analyses of rheumatic mitral valves tissues with a translational approach. Using a panel of 750 mRNAs, we found a marked upregulation of B-cell-related pathways, including CD20-associated and multiple immunoglobulin genes, supporting a pathogenic role of B cells in…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "78dbb2257e909b8db7fd",
          "source": "web",
          "type": "change",
          "key": "#5aa3450e85c3b0282d34",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
          "timestamp": null,
          "observed_at": "2026-11-17T18:39:20Z",
          "data": {
            "change": "added",
            "label": "Preprint: B-cell involvement supports anti-CD20 therapy in paediatric rheumatic heart disease: Proof of concept and initial safety",
            "item_type": "record",
            "summary": "added: Preprint: B-cell involvement supports anti-CD20 therapy in paediatric rheumatic heart disease: Proof of concept and initial safety",
            "after": {
              "title": "Preprint: B-cell involvement supports anti-CD20 therapy in paediatric rheumatic heart disease: Proof of concept and initial safety",
              "authors": "Jouven, X.; Kaya Samba, M.; Ismael, H.; Farchati, H.; Loupy, A.; Hermine, O.; Antignac, M.; Bruneval, P.; Fridman, W. H.; Ait Oufella, H.; Sy, L.; Tine, E.; Sarr, N. A.; Fall, A. L.; Menant, E.; Diop, I. B.",
              "author_corresponding": "Xavier Jouven",
              "author_corresponding_institution": "Universite Paris-Cite, Inserm, PARCC, F-75015 Paris, France",
              "doi": "10.64898/2026.11.17.26367998",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "cardiovascular medicine",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.17.26367998.source.xml",
              "abstract": "Rheumatic heart disease (RHD) remains a major cause of cardiovascular morbidity and mortality, particularly in low- and middle-income countries, yet no therapy targets its underlying autoimmune mechanisms. We combined transcriptomic analyses of rheumatic mitral valves tissues with a translational approach. Using a panel of 750 mRNAs, we found a marked upregulation of B-cell-related pathways, including CD20-associated and multiple immunoglobulin genes, supporting a pathogenic role of B cells in RHD. We therefore evaluated an anti-CD20 B-cell depleting monoclonal antibody (Rituximab), in a feasibility study in children with RHD, in Dakar, Senegal. Treatment was well tolerated, and in the following RCT first year preliminary safety analysis asked by the ethical committee, children who received rituximab showed a decrease in anti-streptolysin O titers and clinical improvement compared to controls. This proof-of-concept reveals B cells as a therapeutic target and suggests that an anti-CD20 agent may represent a potential disease-modifying therapy for RHD.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Rheumatic heart disease (RHD) remains a major cause of cardiovascular morbidity and mortality, particularly in low- and middle-income countries, yet no therapy targets its underlying autoimmune mechanisms. We combined transcriptomic analyses of rheumatic mitral valves tissues with a translational approach. Using a panel of 750 mRNAs, we found a marked upregulation of B-cell-related pathways, including CD20-associated and multiple immunoglobulin genes, supporting a pathogenic role of B cells in RHD. We therefore evaluated an anti-CD20 B-cell depleting monoclonal antibody (Rituximab), in a feasibility study in children with RHD, in Dakar, Senegal. Treatment was well tolerated, and in the following RCT first year preliminary safety analysis asked by the ethical committee, children who received rituximab showed a decrease in anti-streptolysin O titers and clinical improvement compared to controls. This proof-of-concept reveals B cells as a therapeutic target and suggests that an anti-CD20 agent may represent a potential disease-modifying therapy for RHD.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.17.26367998v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
            "content_type": "application/json",
            "elapsed_ms": 713,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.17.26367998v1?rss=1"
    },
    {
      "id": "d37388a11d92e023c393",
      "title": "Preprint: Cardiorespiratory Limits Exist in HFpEF Independent of Age and BMI",
      "content_text": "Background: Heart-failure with preserved ejection fraction (HFpEF) is a clinical syndrome marked by exercise intolerance associated with impairments in cardiac and respiratory performance. HFpEF is associated with age and weight; however, it remains unclear whether cardiorespiratory limitations exist independent of these comorbidities. Hypothesis: Independent of age and BMI, there are cardiorespiratory limitations inherent to the HFpEF syndrome that have yet to be fully elicited. Methods: A…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "d37388a11d92e023c393",
          "source": "web",
          "type": "change",
          "key": "#5510ac322c175f9bb882",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
          "timestamp": null,
          "observed_at": "2026-11-17T18:39:20Z",
          "data": {
            "change": "added",
            "label": "Preprint: Cardiorespiratory Limits Exist in HFpEF Independent of Age and BMI",
            "item_type": "record",
            "summary": "added: Preprint: Cardiorespiratory Limits Exist in HFpEF Independent of Age and BMI",
            "after": {
              "title": "Preprint: Cardiorespiratory Limits Exist in HFpEF Independent of Age and BMI",
              "authors": "LaGalbo, S.; Gowda, M.; Hess, T.; Tipnis, P.; Raza, F.; Saleh, D.",
              "author_corresponding": "Serafino LaGalbo",
              "author_corresponding_institution": "University of Wisconsin Hospitals and Clinics",
              "doi": "10.64898/2026.11.14.26368115",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_no",
              "category": "cardiovascular medicine",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.14.26368115.source.xml",
              "abstract": "Background: Heart-failure with preserved ejection fraction (HFpEF) is a clinical syndrome marked by exercise intolerance associated with impairments in cardiac and respiratory performance. HFpEF is associated with age and weight; however, it remains unclear whether cardiorespiratory limitations exist independent of these comorbidities. Hypothesis: Independent of age and BMI, there are cardiorespiratory limitations inherent to the HFpEF syndrome that have yet to be fully elicited. Methods: A patient cohort with a clinical diagnosis of HFpEF (HFpEF; N = 38) and counterparts without identifiable cardiopulmonary disease (control; N = 21) underwent phenotyping with echocardiography and cardiopulmonary exercise testing with invasive hemodynamic monitoring. Results: Study cohorts were similar in age, BMI and height (p=NS for all metrics). Body-surface area (BSA) (2.1 m2 v 1.9 m2, p < 0.05), atrial fibrillation prevalence (50 v 14%, p < 0.05), and average E/e (11.5 v 9.5, p < 0.05) were elevated within the HFpEF cohort. Peak VO2 (14.1 v 19.1 mL/Kg/min, p < 0.001) was also diminished among those with HFpEF. Resting (17.1 v 11.4mmHg, p < 0.001) and exercise wedge pressures (29.3 v 16.7mmHg, p < 0.001) were elevated whereas stroke volume (93.3 v 110.4 mL, p < 0.05) and cardiac output (Direct Fick; 8.0 v 9.8, p < 0.05) during exercise were diminished in HFpEF patients. FVC, FVC%, FEV1 and FEV1% were also significantly diminished in the HFpEF cohort. Conclusions: Cardiorespiratory limitations exist as a feature of the HFpEF syndrome, independent of age and BMI. BSA remained associated with HFpEF in keeping with adiposity as a feature of pathophysiology.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background: Heart-failure with preserved ejection fraction (HFpEF) is a clinical syndrome marked by exercise intolerance associated with impairments in cardiac and respiratory performance. HFpEF is associated with age and weight; however, it remains unclear whether cardiorespiratory limitations exist independent of these comorbidities. Hypothesis: Independent of age and BMI, there are cardiorespiratory limitations inherent to the HFpEF syndrome that have yet to be fully elicited. Methods: A patient cohort with a clinical diagnosis of HFpEF (HFpEF; N = 38) and counterparts without identifiable cardiopulmonary disease (control; N = 21) underwent phenotyping with echocardiography and cardiopulmonary exercise testing with invasive hemodynamic monitoring. Results: Study cohorts were similar in age, BMI and height (p=NS for all metrics). Body-surface area (BSA) (2.1 m2 v 1.9 m2, p < 0.05), atrial fibrillation prevalence (50 v 14%, p < 0.05), and average E/e (11.5 v 9.5, p < 0.05) were elevated within the HFpEF cohort. Peak VO2 (14.1 v 19.1 mL/Kg/min, p < 0.001) was also diminished among those with HFpEF. Resting (17.1 v 11.4mmHg, p < 0.001) and exercise wedge pressures (29.3 v 16.7mmHg, p < 0.001) were elevated whereas stroke volume (93.3 v 110.4 mL, p < 0.05) and cardiac output (Direct Fick; 8.0 v 9.8, p < 0.05) during exercise were diminished in HFpEF patients. FVC, FVC%, FEV1 and FEV1% were also significantly diminished in the HFpEF cohort. Conclusions: Cardiorespiratory limitations exist as a feature of the HFpEF syndrome, independent of age and BMI. BSA remained associated with HFpEF in keeping with adiposity as a feature of pathophysiology.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368115v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
            "content_type": "application/json",
            "elapsed_ms": 713,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368115v1?rss=1"
    },
    {
      "id": "ee4335e71825053871e0",
      "title": "Preprint: Charted times of bedside pain assessments are slot labels: prevalence across hospitals, consequences for estimating analgesic onset, and when hourly charting is an adequate approximation",
      "content_text": "Objective. Temporal and causal analyses of electronic health records (EHRs) treat the charted time of an observation as the time it was made. We quantified how often bedside pain and sedation assessments are charted to a time slot, how this affects estimates of analgesic onset, and when hourly charting is an adequate approximation. Methods. We used intensive care unit (ICU) data from one academic center (MIMIC-IV) and 78 hospitals (eICU-CRD). Slot labeling was identified from charted minutes…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "ee4335e71825053871e0",
          "source": "web",
          "type": "change",
          "key": "#2e8546db61e8c1fac364",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
          "timestamp": null,
          "observed_at": "2026-11-17T18:39:20Z",
          "data": {
            "change": "added",
            "label": "Preprint: Charted times of bedside pain assessments are slot labels: prevalence across hospitals, consequences for estimating analgesic onset, and when hourly charting is an adequate approximation",
            "item_type": "record",
            "summary": "added: Preprint: Charted times of bedside pain assessments are slot labels: prevalence across hospitals, consequences for estimating analgesic onset, and when hourly charting is an adequate approximation",
            "after": {
              "title": "Preprint: Charted times of bedside pain assessments are slot labels: prevalence across hospitals, consequences for estimating analgesic onset, and when hourly charting is an adequate approximation",
              "authors": "Lee, Y.; Moe, K.",
              "author_corresponding": "Yangming Lee",
              "author_corresponding_institution": "RIT",
              "doi": "10.64898/2026.11.14.26368116",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "emergency medicine",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.14.26368116.source.xml",
              "abstract": "Objective. Temporal and causal analyses of electronic health records (EHRs) treat the charted time of an observation as the time it was made. We quantified how often bedside pain and sedation assessments are charted to a time slot, how this affects estimates of analgesic onset, and when hourly charting is an adequate approximation. Methods. We used intensive care unit (ICU) data from one academic center (MIMIC-IV) and 78 hospitals (eICU-CRD). Slot labeling was identified from charted minutes and from the delay between charted and entry times. In MIMIC-IV, opioid administration times served as anchors, and faster onset of intravenous (IV) than oral opioids as a pharmacologic benchmark. We compared onset estimated from charted times with onset from exactly timed records, bounded true assessment times under alternative charting mechanisms, and used simulation to relate bias to the ratio of slot width to response time constant ({Delta}/k). Results. In MIMIC-IV, 68% of pain and 76% of sedation scores were charted on the hour and entered a median of 41-44 minutes later. Of the first reassessments after a dose, 32-34% of on-hour records carried a time before the dose, against 12-14% of off-hour records. Across eICU hospitals, the on-hour share ranged from 15% to 92% (10th-90th percentile). By charted time, oral opioids appeared nearly as fast as IV (pain change at 15-30 minutes, -1.76 vs -2.11 points); exactly timed records showed -0.80 vs -2.00. Slower oral onset held under every charting mechanism compatible with the data, but its magnitude was not identified (ratio of time constants 1.2-11.6). In simulation, analysis by charted time was adequate up to {Delta}/k {approx} 2 when rounding was to the nearest slot, but only up to {Delta}/k {approx} 0.1 when rounding had a direction. Conclusion. Charted times of bedside assessments are often slot labels, and charting practice is hospital-specific. For ICU analgesic onset, neither condition for an adequate approximation can be assumed, and EHR data alone cannot recover the size of the effect.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Objective. Temporal and causal analyses of electronic health records (EHRs) treat the charted time of an observation as the time it was made. We quantified how often bedside pain and sedation assessments are charted to a time slot, how this affects estimates of analgesic onset, and when hourly charting is an adequate approximation. Methods. We used intensive care unit (ICU) data from one academic center (MIMIC-IV) and 78 hospitals (eICU-CRD). Slot labeling was identified from charted minutes and from the delay between charted and entry times. In MIMIC-IV, opioid administration times served as anchors, and faster onset of intravenous (IV) than oral opioids as a pharmacologic benchmark. We compared onset estimated from charted times with onset from exactly timed records, bounded true assessment times under alternative charting mechanisms, and used simulation to relate bias to the ratio of slot width to response time constant ({Delta}/k). Results. In MIMIC-IV, 68% of pain and 76% of sedation scores were charted on the hour and entered a median of 41-44 minutes later. Of the first reassessments after a dose, 32-34% of on-hour records carried a time before the dose, against 12-14% of off-hour records. Across eICU hospitals, the on-hour share ranged from 15% to 92% (10th-90th percentile). By charted time, oral opioids appeared nearly as fast as IV (pain change at 15-30 minutes, -1.76 vs -2.11 points); exactly timed records showed -0.80 vs -2.00. Slower oral onset held under every charting mechanism compatible with the data, but its magnitude was not identified (ratio of time constants 1.2-11.6). In simulation, analysis by charted time was adequate up to {Delta}/k {approx} 2 when rounding was to the nearest slot, but only up to {Delta}/k {approx} 0.1 when rounding had a direction. Conclusion. Charted times of bedside assessments are often slot labels, and charting practice is hospital-specific. For ICU analgesic onset, neither condition for an adequate approximation can be assumed, and EHR data alone cannot recover the size of the effect.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368116v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
            "content_type": "application/json",
            "elapsed_ms": 713,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368116v1?rss=1"
    },
    {
      "id": "75df88b030cf7cdb02b2",
      "title": "Preprint: Accurate Prediction of Hepatic Disease Severity in MASLD Using a Learned Phenotype",
      "content_text": "Background & Aims: Most prognostic models for metabolic dysfunction-associated steatotic liver disease (MASLD) target prespecified hepatic endpoints, potentially limiting attainable accuracy. We developed and externally validated a model that learns the future hepatic phenotype most reliably predictable from baseline clinical characteristics. Methods: We analyzed 332 HALO-MASLD participants (456 follow-up observations). Sparse Canonical Outcome REgression (SCORE) learned a weighted phenotype…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "75df88b030cf7cdb02b2",
          "source": "web",
          "type": "change",
          "key": "#1dbd94a1b8d7f277e0ad",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
          "timestamp": null,
          "observed_at": "2026-11-17T18:39:20Z",
          "data": {
            "change": "added",
            "label": "Preprint: Accurate Prediction of Hepatic Disease Severity in MASLD Using a Learned Phenotype",
            "item_type": "record",
            "summary": "added: Preprint: Accurate Prediction of Hepatic Disease Severity in MASLD Using a Learned Phenotype",
            "after": {
              "title": "Preprint: Accurate Prediction of Hepatic Disease Severity in MASLD Using a Learned Phenotype",
              "authors": "Strobl, E. V.; Miedel, M.; Taylor, D. L.; Behari, J.",
              "author_corresponding": "Eric V Strobl",
              "author_corresponding_institution": "University of Pittsburgh",
              "doi": "10.64898/2026.11.14.26368091",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "gastroenterology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.14.26368091.source.xml",
              "abstract": "Background & Aims: Most prognostic models for metabolic dysfunction-associated steatotic liver disease (MASLD) target prespecified hepatic endpoints, potentially limiting attainable accuracy. We developed and externally validated a model that learns the future hepatic phenotype most reliably predictable from baseline clinical characteristics. Methods: We analyzed 332 HALO-MASLD participants (456 follow-up observations). Sparse Canonical Outcome REgression (SCORE) learned a weighted phenotype from eight hepatic measures, coupled with broken adaptive ridge regression using 99 baseline predictor columns. Participant-level nested five-fold cross-validation compared prediction of the learned phenotype with future liver stiffness measurement (LSM), controlled attenuation parameter (CAP), and FIB-4 benchmarks. Models were externally validated without refitting in the independent NIDDK NAFLD Adult Database 2 cohort (520 participants, 732 follow-up observations). Biological validity and bootstrap stability were also assessed. Results: The learned phenotype emphasized lower platelet count and higher bilirubin, alkaline phosphatase, and LSM. In HALO, predictive correlation was r=0.860 (95% CI [0.824, 0.896]) and predictive R^2=0.671, versus r=0.763 for LSM and r=0.469 for CAP predicted from all baseline variables. All six prespecified comparisons remained significant after Holm correction (p_Holm < 0.05). The phenotype correlated with MRE stiffness (rho = 0.694) and biopsy fibrosis stage (rho = 0.567), and was higher with imaging evidence of portal hypertension (p < 0.001). Bootstrap relearning yielded mean phenotype correlation 0.947. In NIDDK, predictive correlation was r = 0.836 (95% CI [0.805, 0.863]; predictive R^2 = 0.680), and associations with fibrosis and portal hypertension replicated. Conclusions: Learning the prediction target produced a sparse, clinically interpretable hepatic phenotype more accurately predicted than conventional longitudinal MASLD endpoints in both cohorts. The resulting LIFT-MASLD model is available at https://liftmasld.github.io.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background & Aims: Most prognostic models for metabolic dysfunction-associated steatotic liver disease (MASLD) target prespecified hepatic endpoints, potentially limiting attainable accuracy. We developed and externally validated a model that learns the future hepatic phenotype most reliably predictable from baseline clinical characteristics. Methods: We analyzed 332 HALO-MASLD participants (456 follow-up observations). Sparse Canonical Outcome REgression (SCORE) learned a weighted phenotype from eight hepatic measures, coupled with broken adaptive ridge regression using 99 baseline predictor columns. Participant-level nested five-fold cross-validation compared prediction of the learned phenotype with future liver stiffness measurement (LSM), controlled attenuation parameter (CAP), and FIB-4 benchmarks. Models were externally validated without refitting in the independent NIDDK NAFLD Adult Database 2 cohort (520 participants, 732 follow-up observations). Biological validity and bootstrap stability were also assessed. Results: The learned phenotype emphasized lower platelet count and higher bilirubin, alkaline phosphatase, and LSM. In HALO, predictive correlation was r=0.860 (95% CI [0.824, 0.896]) and predictive R^2=0.671, versus r=0.763 for LSM and r=0.469 for CAP predicted from all baseline variables. All six prespecified comparisons remained significant after Holm correction (p_Holm < 0.05). The phenotype correlated with MRE stiffness (rho = 0.694) and biopsy fibrosis stage (rho = 0.567), and was higher with imaging evidence of portal hypertension (p < 0.001). Bootstrap relearning yielded mean phenotype correlation 0.947. In NIDDK, predictive correlation was r = 0.836 (95% CI [0.805, 0.863]; predictive R^2 = 0.680), and associations with fibrosis and portal hypertension replicated. Conclusions: Learning the prediction target produced a sparse, clinically interpretable hepatic phenotype more accurately predicted than conventional longitudinal MASLD endpoints in both cohorts. The resulting LIFT-MASLD model is available at https://liftmasld.github.io.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368091v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
            "content_type": "application/json",
            "elapsed_ms": 713,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368091v1?rss=1"
    },
    {
      "id": "2742b80771226d2ab68d",
      "title": "Preprint: MorphoStain: Physics-Guided Latent Diffusion and Morphological Distillation for Multiplex Stain Decomposition in Alzheimer's Neuropathology",
      "content_text": "Multiplex immunohistochemistry (mIHC) enables simultaneous biomarker profiling, yet unmixing co-localized targets with identical spectra, such as dual-DAB marking of Tau and Amyloid-beta in Alzheimer's pathology, remains mathematically ill-posed. We propose MorphoStain, an unsupervised, physics-guided framework for morphological stain decomposition with epistemic uncertainty quantification. MorphoStain models stain separation via a conditional Latent Diffusion Teacher operating on a…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "2742b80771226d2ab68d",
          "source": "web",
          "type": "change",
          "key": "#764a04c8eee2b70ebfa6",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
          "timestamp": null,
          "observed_at": "2026-11-17T18:39:20Z",
          "data": {
            "change": "added",
            "label": "Preprint: MorphoStain: Physics-Guided Latent Diffusion and Morphological Distillation for Multiplex Stain Decomposition in Alzheimer's Neuropathology",
            "item_type": "record",
            "summary": "added: Preprint: MorphoStain: Physics-Guided Latent Diffusion and Morphological Distillation for Multiplex Stain Decomposition in Alzheimer's Neuropathology",
            "after": {
              "title": "Preprint: MorphoStain: Physics-Guided Latent Diffusion and Morphological Distillation for Multiplex Stain Decomposition in Alzheimer's Neuropathology",
              "authors": "Saraei, M.; Zand, M.; Rahmani, S.",
              "author_corresponding": "Mohammadreza Saraei",
              "author_corresponding_institution": "The University of Arizona",
              "doi": "10.64898/2026.11.15.26368147",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "pathology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.15.26368147.source.xml",
              "abstract": "Multiplex immunohistochemistry (mIHC) enables simultaneous biomarker profiling, yet unmixing co-localized targets with identical spectra, such as dual-DAB marking of Tau and Amyloid-beta in Alzheimer's pathology, remains mathematically ill-posed. We propose MorphoStain, an unsupervised, physics-guided framework for morphological stain decomposition with epistemic uncertainty quantification. MorphoStain models stain separation via a conditional Latent Diffusion Teacher operating on a Beer-Lambert optical-density manifold, guided by pathology foundation models. To enable real-time clinical throughput, the teacher is distilled into a FastStudentU-Net (0.12M parameters, > 1,400x compression), while a Symmetric Morphological Routing Module dynamically disentangles identical chromogen overlap. Evaluated on 9,908 held-out patches from the SEA-AD cohort, MorphoStain achieves 40.56 dB PSNR and 0.9961 SSIM at 140.1 FPS, showing statistically significant gains over InverseAE (Cohen's d = 3.52) and NMF (Cohen's d = 7.02), with p < 0.001 for both comparisons.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Multiplex immunohistochemistry (mIHC) enables simultaneous biomarker profiling, yet unmixing co-localized targets with identical spectra, such as dual-DAB marking of Tau and Amyloid-beta in Alzheimer's pathology, remains mathematically ill-posed. We propose MorphoStain, an unsupervised, physics-guided framework for morphological stain decomposition with epistemic uncertainty quantification. MorphoStain models stain separation via a conditional Latent Diffusion Teacher operating on a Beer-Lambert optical-density manifold, guided by pathology foundation models. To enable real-time clinical throughput, the teacher is distilled into a FastStudentU-Net (0.12M parameters, > 1,400x compression), while a Symmetric Morphological Routing Module dynamically disentangles identical chromogen overlap. Evaluated on 9,908 held-out patches from the SEA-AD cohort, MorphoStain achieves 40.56 dB PSNR and 0.9961 SSIM at 140.1 FPS, showing statistically significant gains over InverseAE (Cohen's d = 3.52) and NMF (Cohen's d = 7.02), with p < 0.001 for both comparisons.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.15.26368147v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
            "content_type": "application/json",
            "elapsed_ms": 713,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.15.26368147v1?rss=1"
    },
    {
      "id": "f5851bb432f1c33ce986",
      "title": "Preprint: ZNF683-positive tissue-resident memory T cells organize treatment-refractory niches with targetable circuits in inclusion body myositis",
      "content_text": "Inclusion body myositis (IBM) is a progressive autoimmune myositis refractory to conventional immunosuppression, yet mechanisms sustaining chronic inflammation remain unresolved. Integrating comparative single-nucleus RNA sequencing, spatial transcriptomics, and orthogonal validation across autoimmune myositis, we identified ZNF683+IL7R+ cytotoxic tissue-resident memory T (TRM) cells with natural killer cell-like features enriched in IBM. Trajectory analysis positioned an early-disease ZBTB16+…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "f5851bb432f1c33ce986",
          "source": "web",
          "type": "change",
          "key": "#c9db5c211d3ea82cb11a",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
          "timestamp": null,
          "observed_at": "2026-11-17T18:39:20Z",
          "data": {
            "change": "added",
            "label": "Preprint: ZNF683-positive tissue-resident memory T cells organize treatment-refractory niches with targetable circuits in inclusion body myositis",
            "item_type": "record",
            "summary": "added: Preprint: ZNF683-positive tissue-resident memory T cells organize treatment-refractory niches with targetable circuits in inclusion body myositis",
            "after": {
              "title": "Preprint: ZNF683-positive tissue-resident memory T cells organize treatment-refractory niches with targetable circuits in inclusion body myositis",
              "authors": "De Los Reyes, F. V. A.; Hayashi, S.; Kato, M.; Tanboon, J.; Noguchi, S.; Nishino, I.",
              "author_corresponding": "Shinichiro Hayashi",
              "author_corresponding_institution": "Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry; Kodaira, Tokyo, Japan",
              "doi": "10.64898/2026.11.16.26367991",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_no",
              "category": "pathology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.16.26367991.source.xml",
              "abstract": "Inclusion body myositis (IBM) is a progressive autoimmune myositis refractory to conventional immunosuppression, yet mechanisms sustaining chronic inflammation remain unresolved. Integrating comparative single-nucleus RNA sequencing, spatial transcriptomics, and orthogonal validation across autoimmune myositis, we identified ZNF683+IL7R+ cytotoxic tissue-resident memory T (TRM) cells with natural killer cell-like features enriched in IBM. Trajectory analysis positioned an early-disease ZBTB16+ cytotoxic T cell state upstream of ZNF683+IL7R+TRM. ZNF683 overexpression induced memory and natural killer cell-like transcriptional programs while attenuating glucocorticoid-response signatures, linking this program to treatment refractoriness. Ligand-receptor modeling nominated candidate targetable circuits involving IL-15-IL15RA, XCL1-XCR1, and HMGB1/CXCL12-CXCR4. Spatial transcriptomics localized ZNF683+TRM to stress-associated IBM niches. These findings define a disease-specific TRM-centered circuit linked to treatment refractoriness and candidate therapeutic vulnerabilities in IBM.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Inclusion body myositis (IBM) is a progressive autoimmune myositis refractory to conventional immunosuppression, yet mechanisms sustaining chronic inflammation remain unresolved. Integrating comparative single-nucleus RNA sequencing, spatial transcriptomics, and orthogonal validation across autoimmune myositis, we identified ZNF683+IL7R+ cytotoxic tissue-resident memory T (TRM) cells with natural killer cell-like features enriched in IBM. Trajectory analysis positioned an early-disease ZBTB16+ cytotoxic T cell state upstream of ZNF683+IL7R+TRM. ZNF683 overexpression induced memory and natural killer cell-like transcriptional programs while attenuating glucocorticoid-response signatures, linking this program to treatment refractoriness. Ligand-receptor modeling nominated candidate targetable circuits involving IL-15-IL15RA, XCL1-XCR1, and HMGB1/CXCL12-CXCR4. Spatial transcriptomics localized ZNF683+TRM to stress-associated IBM niches. These findings define a disease-specific TRM-centered circuit linked to treatment refractoriness and candidate therapeutic vulnerabilities in IBM.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.16.26367991v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
            "content_type": "application/json",
            "elapsed_ms": 713,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.16.26367991v1?rss=1"
    },
    {
      "id": "07686f4553c43c35b1ca",
      "title": "Preprint: MR-based normative volumetric analyses reveal genotype-dependent brain anomalies in FGFR-related craniosynostoses",
      "content_text": "Craniostenosis, a cranial malformation due to premature suture fusion, includes rare FGFR related conditions such as Crouzon (CS), Muenke (MS), and Apert (AS) syndromes. These mutations affect skull but also brain development and are associated with variable neurodevelopmental outcomes. This brain impairment is still poorly described and understood, prompting for neuroimaging anatomical studies. We thus investigated regional brain growth and volumetric scaling in patients with these three…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "07686f4553c43c35b1ca",
          "source": "web",
          "type": "change",
          "key": "#fefd3e4dc3166ed839ee",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
          "timestamp": null,
          "observed_at": "2026-11-17T18:39:20Z",
          "data": {
            "change": "added",
            "label": "Preprint: MR-based normative volumetric analyses reveal genotype-dependent brain anomalies in FGFR-related craniosynostoses",
            "item_type": "record",
            "summary": "added: Preprint: MR-based normative volumetric analyses reveal genotype-dependent brain anomalies in FGFR-related craniosynostoses",
            "after": {
              "title": "Preprint: MR-based normative volumetric analyses reveal genotype-dependent brain anomalies in FGFR-related craniosynostoses",
              "authors": "Delassus, O.; Sadoine, J.; Paternoster, G.; Chollet, L.; Ndambidi Yungi, B.; Beaufort, Q.; Taverne, M.; Boddaert, N.; Mangin, J.-F.; Khonsari, R. H.; Germanaud, D.",
              "author_corresponding": "David Germanaud",
              "author_corresponding_institution": "Universite Paris-Saclay, CEA, Joliot Institute, NeuroSpin, UNIACT",
              "doi": "10.64898/2026.11.14.26367821",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "pediatrics",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.14.26367821.source.xml",
              "abstract": "Craniostenosis, a cranial malformation due to premature suture fusion, includes rare FGFR related conditions such as Crouzon (CS), Muenke (MS), and Apert (AS) syndromes. These mutations affect skull but also brain development and are associated with variable neurodevelopmental outcomes. This brain impairment is still poorly described and understood, prompting for neuroimaging anatomical studies. We thus investigated regional brain growth and volumetric scaling in patients with these three syndromes and non-syndromic non FGFR related craniostenoses, using a normative modelling framework. We analyzed a rare set of brain MRI from 65 patients close to first cranial surgery time (30 CS among which 23 pre-surgery, 4 AS, 6 MS, 23 non syndromic) and 130 typically developing controls. Millimetric 3D T1 weighted images were segmented into 6 cortical and 3 subcortical regions (AssemblyNet, Morphologist). After harmonization (ComBat), normative growth curves (Turner model) and static scaling curves (power law model, effect of brain size regardless of age) were derived in controls. Patient deviations were assessed using permutation tests on mean normalized distance to typical model and abnormality rates (10th/90th percentiles). Patients with CS showed typical brain volumes for age except for enlarged ventricles, but slightly overscaled frontal volumes for brain size. Non-syndromic patients showed very similar volume distribution for age and brain size than CS ones. Patients with AS displayed increased total brain, temporal, cerebellar and central volumes for age, with overscaled temporal and cerebellar regions but underscaled frontal volumes for brain size. Patients with MS showed a similar, though milder, pattern: increased temporal volume for age, with temporal overscaling but frontal underscaling for frain size. Our findings reveal genotype dependent brain anomalies in FGFR related craniosynostoses, with a convergent pattern of temporal frontal disproportions in AS and MS, associated with very specific mutations in the FGFR2 and 3 genes respectively, contrasting with a much more typical brain organization in more heterogeneous CS and non syndromic patients. Beyond the pathophysiological meaning of these results, which call for a larger similar study covering as wide a range of patient variability as possible, our work highlights the relevance of normative modelling approach for characterizing rare craniofacial disorders using clinical MRI datasets.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Craniostenosis, a cranial malformation due to premature suture fusion, includes rare FGFR related conditions such as Crouzon (CS), Muenke (MS), and Apert (AS) syndromes. These mutations affect skull but also brain development and are associated with variable neurodevelopmental outcomes. This brain impairment is still poorly described and understood, prompting for neuroimaging anatomical studies. We thus investigated regional brain growth and volumetric scaling in patients with these three syndromes and non-syndromic non FGFR related craniostenoses, using a normative modelling framework. We analyzed a rare set of brain MRI from 65 patients close to first cranial surgery time (30 CS among which 23 pre-surgery, 4 AS, 6 MS, 23 non syndromic) and 130 typically developing controls. Millimetric 3D T1 weighted images were segmented into 6 cortical and 3 subcortical regions (AssemblyNet, Morphologist). After harmonization (ComBat), normative growth curves (Turner model) and static scaling curves (power law model, effect of brain size regardless of age) were derived in controls. Patient deviations were assessed using permutation tests on mean normalized distance to typical model and abnormality rates (10th/90th percentiles). Patients with CS showed typical brain volumes for age except for enlarged ventricles, but slightly overscaled frontal volumes for brain size. Non-syndromic patients showed very similar volume distribution for age and brain size than CS ones. Patients with AS displayed increased total brain, temporal, cerebellar and central volumes for age, with overscaled temporal and cerebellar regions but underscaled frontal volumes for brain size. Patients with MS showed a similar, though milder, pattern: increased temporal volume for age, with temporal overscaling but frontal underscaling for frain size. Our findings reveal genotype dependent brain anomalies in FGFR related craniosynostoses, with a convergent pattern of temporal frontal disproportions in AS and MS, associated with very specific mutations in the FGFR2 and 3 genes respectively, contrasting with a much more typical brain organization in more heterogeneous CS and non syndromic patients. Beyond the pathophysiological meaning of these results, which call for a larger similar study covering as wide a range of patient variability as possible, our work highlights the relevance of normative modelling approach for characterizing rare craniofacial disorders using clinical MRI datasets.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26367821v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
            "content_type": "application/json",
            "elapsed_ms": 713,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26367821v1?rss=1"
    },
    {
      "id": "8cb0df1b841f5db10e43",
      "title": "Preprint: Sex and Gender Reporting and Female Participation Relative to Disease Burden in ClinicalTrials.gov",
      "content_text": "Importance: Assessing representation by sex assigned at birth and gender identity requires reporting of both in trials. If disclosure of full gender and sex participation from clinicaltrials.gov is limited, it poses challenges in characterization and understanding of those participant experiences. Objective: To determine how often ClinicalTrials.gov trials published trials report sex and gender, which characteristics are associated with reporting, and how participants' female share compares…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "8cb0df1b841f5db10e43",
          "source": "web",
          "type": "change",
          "key": "#e14e11bf2e1e6e13d65d",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
          "timestamp": null,
          "observed_at": "2026-11-17T18:39:20Z",
          "data": {
            "change": "added",
            "label": "Preprint: Sex and Gender Reporting and Female Participation Relative to Disease Burden in ClinicalTrials.gov",
            "item_type": "record",
            "summary": "added: Preprint: Sex and Gender Reporting and Female Participation Relative to Disease Burden in ClinicalTrials.gov",
            "after": {
              "title": "Preprint: Sex and Gender Reporting and Female Participation Relative to Disease Burden in ClinicalTrials.gov",
              "authors": "Green, M. D.; Aziz, M.; Sullenger, R. D.; Yoo, B. J.; O'Brien, E. C.; Navar, A. M.; Duroseau, B.; Thorpe, R. J.; Brantner, C. L.",
              "author_corresponding": "Michael D. Green",
              "author_corresponding_institution": "Johns Hopkins Bloomberg School of Public Health",
              "doi": "10.64898/2026.11.14.26368113",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc",
              "category": "public and global health",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.14.26368113.source.xml",
              "abstract": "Importance: Assessing representation by sex assigned at birth and gender identity requires reporting of both in trials. If disclosure of full gender and sex participation from clinicaltrials.gov is limited, it poses challenges in characterization and understanding of those participant experiences. Objective: To determine how often ClinicalTrials.gov trials published trials report sex and gender, which characteristics are associated with reporting, and how participants' female share compares with that of the general public. Design, Setting, and Participants: Cross-sectional study of interventional trials registered to ClinicalTrials.gov, with or without US sites, with primary completion on or after September 27, 2008, and results first posted from January 1, 2009, through April 30, 2026. Exposures: Funder type, phase, US sites, enrollment, primary completion year, number of countries, and therapeutic area. Main Outcomes and Measures: Reporting of sex and gender, and the female participation-to-prevalence ratio (PPR; trial female share divided by the number of people with the condition). Results: Among 58,007 trials (median enrollment, 72 [IQR, 31 to 206]; 42,644 [74%] with US sites), 553 (0.95%) reported gender and 57,683 (99.44%) reported sex. Gender reporting was more common with National Institutes of Health (NIH) funding (odds ratio [OR], 9.05; 95% CI, 6.65 to 12.6), US sites (OR, 4.21; 95% CI, 2.96 to 6.22), and larger enrollment. Across 10 conditions (15,552 mixed-sex trials), median PPR ranged from 0.68 (95% CI, 0.64 to 0.71) for chronic obstructive pulmonary disease to 1.05 (95% CI, 1.01 to 1.09) for obesity and had a relatively lower female share in 8. Among the 10 conditions most prevalent in our cohort, 6,917 of 16,097 trial condition combinations (43.0%) reached a PPR of at least 0.90; odds of reaching it were higher for NIH-funded (OR, 1.22; 95% CI, 1.11 to 1.34) and lower for government-funded trials (OR, 0.26; 95% CI, 0.20 to 0.33) as compared to industry-funded trials. Conclusions and Relevance: In ClinicalTrials.gov, sex reporting is nearly universal, whereas gender reporting is concentrated among NIH-funded, US-based, and larger trials. Female trial enrollment fell below the female share of people with the condition for most conditions, emphasizing the benefit of condition-specific benchmarks in clinical trials.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Importance: Assessing representation by sex assigned at birth and gender identity requires reporting of both in trials. If disclosure of full gender and sex participation from clinicaltrials.gov is limited, it poses challenges in characterization and understanding of those participant experiences. Objective: To determine how often ClinicalTrials.gov trials published trials report sex and gender, which characteristics are associated with reporting, and how participants' female share compares with that of the general public. Design, Setting, and Participants: Cross-sectional study of interventional trials registered to ClinicalTrials.gov, with or without US sites, with primary completion on or after September 27, 2008, and results first posted from January 1, 2009, through April 30, 2026. Exposures: Funder type, phase, US sites, enrollment, primary completion year, number of countries, and therapeutic area. Main Outcomes and Measures: Reporting of sex and gender, and the female participation-to-prevalence ratio (PPR; trial female share divided by the number of people with the condition). Results: Among 58,007 trials (median enrollment, 72 [IQR, 31 to 206]; 42,644 [74%] with US sites), 553 (0.95%) reported gender and 57,683 (99.44%) reported sex. Gender reporting was more common with National Institutes of Health (NIH) funding (odds ratio [OR], 9.05; 95% CI, 6.65 to 12.6), US sites (OR, 4.21; 95% CI, 2.96 to 6.22), and larger enrollment. Across 10 conditions (15,552 mixed-sex trials), median PPR ranged from 0.68 (95% CI, 0.64 to 0.71) for chronic obstructive pulmonary disease to 1.05 (95% CI, 1.01 to 1.09) for obesity and had a relatively lower female share in 8. Among the 10 conditions most prevalent in our cohort, 6,917 of 16,097 trial condition combinations (43.0%) reached a PPR of at least 0.90; odds of reaching it were higher for NIH-funded (OR, 1.22; 95% CI, 1.11 to 1.34) and lower for government-funded trials (OR, 0.26; 95% CI, 0.20 to 0.33) as compared to industry-funded trials. Conclusions and Relevance: In ClinicalTrials.gov, sex reporting is nearly universal, whereas gender reporting is concentrated among NIH-funded, US-based, and larger trials. Female trial enrollment fell below the female share of people with the condition for most conditions, emphasizing the benefit of condition-specific benchmarks in clinical trials.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368113v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
            "content_type": "application/json",
            "elapsed_ms": 713,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368113v1?rss=1"
    },
    {
      "id": "737fc3b7da95bfc920d8",
      "title": "Preprint: Cell-free telomeric DNA and integrity indices in axial spondyloarthritis: associations with somatic and mental burden: a case-control study.",
      "content_text": "Objectives: Depression and anxiety in axial spondyloarthritis (axSpA) are associated with higher disease activity. This study examined whether circulating cell-free nuclear DNA (cf-nDNA), mitochondrial DNA (cf-mtDNA), relative telomere length (T/S ratio), and DNA integrity index (DII) are associated with mental burden and disease characteristics in axSpA. Methods: Plasma cf-nDNA, cf-mtDNA, T/S ratio, and ALU-247/ALU-115 ratio (DII) were analysed in 79 patients with axSpA and 88 age- and…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "737fc3b7da95bfc920d8",
          "source": "web",
          "type": "change",
          "key": "#82a2761d4037700dc7f9",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
          "timestamp": null,
          "observed_at": "2026-11-17T18:39:20Z",
          "data": {
            "change": "added",
            "label": "Preprint: Cell-free telomeric DNA and integrity indices in axial spondyloarthritis: associations with somatic and mental burden: a case-control study.",
            "item_type": "record",
            "summary": "added: Preprint: Cell-free telomeric DNA and integrity indices in axial spondyloarthritis: associations with somatic and mental burden: a case-control study.",
            "after": {
              "title": "Preprint: Cell-free telomeric DNA and integrity indices in axial spondyloarthritis: associations with somatic and mental burden: a case-control study.",
              "authors": "Husakova, M.; Banerjee, B.; Skubica, P.; Pavelka, K.; Kucharikova, K.; Kotrs, J.; Senolt, L.; Olejarova, M.; Mohr, P.; Dankova, P.",
              "author_corresponding": "Marketa Husakova",
              "author_corresponding_institution": "First Faculty of Medicine, Charles University and Rheumatology Institute, Na Slupi 4, Prague, Czech Republic",
              "doi": "10.64898/2026.11.15.26368092",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_no",
              "category": "rheumatology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.15.26368092.source.xml",
              "abstract": "Objectives: Depression and anxiety in axial spondyloarthritis (axSpA) are associated with higher disease activity. This study examined whether circulating cell-free nuclear DNA (cf-nDNA), mitochondrial DNA (cf-mtDNA), relative telomere length (T/S ratio), and DNA integrity index (DII) are associated with mental burden and disease characteristics in axSpA. Methods: Plasma cf-nDNA, cf-mtDNA, T/S ratio, and ALU-247/ALU-115 ratio (DII) were analysed in 79 patients with axSpA and 88 age- and sex-matched healthy controls (HCs). Mental burden was assessed using the Mini-International Neuropsychiatric Interview (M.I.N.I.), Beck Depression Inventory-II, and Beck Anxiety Inventory. Clinical measures included the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP), and radiographic disease pattern. Results: Sex differences were observed in disease phenotype and hip involvement. Affective or anxiety disorders were more frequent in axSpA vs. HC (26.6% vs. 2.3%, p<0.001); depressive symptoms were also more frequent (20.2% vs. 2.27%, p<0.001) and higher in active vs. inactive disease (30.0% vs. 3.45%, p<0.001). Compared with HCs, patients had higher cf-mtDNA and lower DII (both p<0.01), with a trend towards lower T/S ratio. Females had higher T/S ratio and DII than males, and higher cf-mtDNA overall. Lower T/S ratio was associated with affective disorders, while only CRP independently predicted depressive symptom severity. Conclusions: Altered cfDNA profiles, particularly increased cf-mtDNA and reduced DII, are associated with axSpA, disease activity and mental burden, supporting their potential as biomarkers of disease-related processes.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Objectives: Depression and anxiety in axial spondyloarthritis (axSpA) are associated with higher disease activity. This study examined whether circulating cell-free nuclear DNA (cf-nDNA), mitochondrial DNA (cf-mtDNA), relative telomere length (T/S ratio), and DNA integrity index (DII) are associated with mental burden and disease characteristics in axSpA. Methods: Plasma cf-nDNA, cf-mtDNA, T/S ratio, and ALU-247/ALU-115 ratio (DII) were analysed in 79 patients with axSpA and 88 age- and sex-matched healthy controls (HCs). Mental burden was assessed using the Mini-International Neuropsychiatric Interview (M.I.N.I.), Beck Depression Inventory-II, and Beck Anxiety Inventory. Clinical measures included the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP), and radiographic disease pattern. Results: Sex differences were observed in disease phenotype and hip involvement. Affective or anxiety disorders were more frequent in axSpA vs. HC (26.6% vs. 2.3%, p<0.001); depressive symptoms were also more frequent (20.2% vs. 2.27%, p<0.001) and higher in active vs. inactive disease (30.0% vs. 3.45%, p<0.001). Compared with HCs, patients had higher cf-mtDNA and lower DII (both p<0.01), with a trend towards lower T/S ratio. Females had higher T/S ratio and DII than males, and higher cf-mtDNA overall. Lower T/S ratio was associated with affective disorders, while only CRP independently predicted depressive symptom severity. Conclusions: Altered cfDNA profiles, particularly increased cf-mtDNA and reduced DII, are associated with axSpA, disease activity and mental burden, supporting their potential as biomarkers of disease-related processes.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.15.26368092v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
            "content_type": "application/json",
            "elapsed_ms": 713,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.15.26368092v1?rss=1"
    },
    {
      "id": "436e83a4b70f5c832f99",
      "title": "Preprint: White Matter Pathway-Specific Effects of Subthalamic Deep Brain Stimulation on Vergence Motor Strategy and Binocular Stability",
      "content_text": "Objective: Clear vision across viewing distances requires the eyes to achieve binocular alignment and hold it steady. Alignment can be established through smooth dysconjugate eye movement, vergence, alone or in conjunction with rapid saccades. The circuits governing movement strategy and subsequent gaze holding remain less understood. Methods: We used subthalamic nucleus (STN) deep brain stimulation (DBS) to probe these components in 23 participants with Parkinson disease (PD), comparing…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "436e83a4b70f5c832f99",
          "source": "web",
          "type": "change",
          "key": "#a89de828a220a2f4ee64",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
          "timestamp": null,
          "observed_at": "2026-11-17T18:39:20Z",
          "data": {
            "change": "added",
            "label": "Preprint: White Matter Pathway-Specific Effects of Subthalamic Deep Brain Stimulation on Vergence Motor Strategy and Binocular Stability",
            "item_type": "record",
            "summary": "added: Preprint: White Matter Pathway-Specific Effects of Subthalamic Deep Brain Stimulation on Vergence Motor Strategy and Binocular Stability",
            "after": {
              "title": "Preprint: White Matter Pathway-Specific Effects of Subthalamic Deep Brain Stimulation on Vergence Motor Strategy and Binocular Stability",
              "authors": "Quagraine, I.; Guha, A.; Kilbane, C.; Ghasia, F. F.; Shaikh, A. G.",
              "author_corresponding": "Aasef G Shaikh",
              "author_corresponding_institution": "Case Western Reserve University",
              "doi": "10.64898/2026.11.14.26368127",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "neurology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.14.26368127.source.xml",
              "abstract": "Objective: Clear vision across viewing distances requires the eyes to achieve binocular alignment and hold it steady. Alignment can be established through smooth dysconjugate eye movement, vergence, alone or in conjunction with rapid saccades. The circuits governing movement strategy and subsequent gaze holding remain less understood. Methods: We used subthalamic nucleus (STN) deep brain stimulation (DBS) to probe these components in 23 participants with Parkinson disease (PD), comparing binocular eye movements with stimulation on and off and relating behavioral changes to modeled stimulation anatomy. Results: Combined saccade vergence responses predominated in both stimulation states, but individual strategy changes were associated with stimulation location. Greater field of Forel coverage was associated with reduced saccade assisted divergence, and stimulation anatomy helped predict individual changes in this movement strategy. Greater right associative STN coverage correlated with shorter convergence latency. The clearest group effect emerged after movement ended; DBS reduced gaze-holding variance by 37.0% after convergence and 29.4% after divergence, an overall reduction of 33.3% (95% confidence interval, 13.7 to 49.3%; p=0.008). Participants with improved gaze holding had numerically greater modeled exposure to Forel and cerebellothalamic pathways. Conclusions: These findings suggest distinct contributions of associative STN to initiation, consistent with go/no-go control, and Forel pathways to movement strategy. Improved gaze holding raises the novel possibility that stimulation engaging Forel and cerebellar outflow pathways enhances vergence neural integration. Significance: Binocular eye movements reveal how basal ganglia and cerebellar pathways establish movement strategy and sustain alignment, guiding targeted stimulation studies in PD.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Objective: Clear vision across viewing distances requires the eyes to achieve binocular alignment and hold it steady. Alignment can be established through smooth dysconjugate eye movement, vergence, alone or in conjunction with rapid saccades. The circuits governing movement strategy and subsequent gaze holding remain less understood. Methods: We used subthalamic nucleus (STN) deep brain stimulation (DBS) to probe these components in 23 participants with Parkinson disease (PD), comparing binocular eye movements with stimulation on and off and relating behavioral changes to modeled stimulation anatomy. Results: Combined saccade vergence responses predominated in both stimulation states, but individual strategy changes were associated with stimulation location. Greater field of Forel coverage was associated with reduced saccade assisted divergence, and stimulation anatomy helped predict individual changes in this movement strategy. Greater right associative STN coverage correlated with shorter convergence latency. The clearest group effect emerged after movement ended; DBS reduced gaze-holding variance by 37.0% after convergence and 29.4% after divergence, an overall reduction of 33.3% (95% confidence interval, 13.7 to 49.3%; p=0.008). Participants with improved gaze holding had numerically greater modeled exposure to Forel and cerebellothalamic pathways. Conclusions: These findings suggest distinct contributions of associative STN to initiation, consistent with go/no-go control, and Forel pathways to movement strategy. Improved gaze holding raises the novel possibility that stimulation engaging Forel and cerebellar outflow pathways enhances vergence neural integration. Significance: Binocular eye movements reveal how basal ganglia and cerebellar pathways establish movement strategy and sustain alignment, guiding targeted stimulation studies in PD.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368127v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
            "content_type": "application/json",
            "elapsed_ms": 713,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368127v1?rss=1"
    },
    {
      "id": "34a06946471f46e8add9",
      "title": "Preprint: Plasma Proteomic Identifies GDF15 as a Candidate Lithium Treatment Response Biomarker in Mild Cognitive Impairment: A Secondary Analysis of the LATTICE Randomized Clinical Trial",
      "content_text": "Lithium (Li) demonstrates neuroprotective effects relevant to Alzheimer disease (AD). However, its molecular mechanisms remain insufficiently characterized. This study analyzed plasma proteomic profiles from the Li as a Treatment to Prevent Impairment of Cognition in Elders (LATTICE) randomized clinical trial to identify markers associated with amyloid beta pathology, disease progression, and response to Li treatment. In the LATTICE trial, 80 older adults with mild cognitive impairment (MCI)…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "34a06946471f46e8add9",
          "source": "web",
          "type": "change",
          "key": "#bdeaca5b5419101502b6",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
          "timestamp": null,
          "observed_at": "2026-11-17T18:39:20Z",
          "data": {
            "change": "added",
            "label": "Preprint: Plasma Proteomic Identifies GDF15 as a Candidate Lithium Treatment Response Biomarker in Mild Cognitive Impairment: A Secondary Analysis of the LATTICE Randomized Clinical Trial",
            "item_type": "record",
            "summary": "added: Preprint: Plasma Proteomic Identifies GDF15 as a Candidate Lithium Treatment Response Biomarker in Mild Cognitive Impairment: A Secondary Analysis of the LATTICE Randomized Clinical Trial",
            "after": {
              "title": "Preprint: Plasma Proteomic Identifies GDF15 as a Candidate Lithium Treatment Response Biomarker in Mild Cognitive Impairment: A Secondary Analysis of the LATTICE Randomized Clinical Trial",
              "authors": "Sehrawat, A.; Shi, R.; Farinas, M. F.; Emanuel, J. E.; Zeng, X.; Lopresti, B. J.; Royse, S. K.; Weinstein, A. M.; Butters, M. A.; Lee, L.; Gildengers, A. G.; Karikari, T. K.",
              "author_corresponding": "Anuradha Sehrawat",
              "author_corresponding_institution": "University of Pittsburgh",
              "doi": "10.64898/2026.11.14.26368038",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_no",
              "category": "neurology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.14.26368038.source.xml",
              "abstract": "Lithium (Li) demonstrates neuroprotective effects relevant to Alzheimer disease (AD). However, its molecular mechanisms remain insufficiently characterized. This study analyzed plasma proteomic profiles from the Li as a Treatment to Prevent Impairment of Cognition in Elders (LATTICE) randomized clinical trial to identify markers associated with amyloid beta pathology, disease progression, and response to Li treatment. In the LATTICE trial, 80 older adults with mild cognitive impairment (MCI) were randomly assigned to receive either low-dose Li carbonate or placebo for two years. Longitudinal plasma samples were analyzed using the NULISAseq CNS Disease Panel 120 proteomic panel. Baseline protein levels were compared according to randomized treatment assignment, amyloid beta PET status, and MCI subtype. Analyses included longitudinal changes in protein levels associated with treatment and time, associations between baseline protein levels and subsequent cognitive, functional, and neuroimaging trajectories, and the influence of baseline protein levels on Li treatment effects. Among the 80 participants, 62 had amnestic MCI and 21 were positive on amyloid beta PET. Baseline proteomic differences were more strongly associated with amyloid beta PET status than with randomized treatment assignment. Plasma p-tau217 concentrations were elevated in individuals who were positive on amyloid beta PET and remained significant after false discovery rate correction. Over time, CALB2 and TREM2 exhibited nominal treatment-by-time interactions in the full cohort, while in the amnestic MCI subgroup, CALB2, TREM2, and amyloid beta 40 demonstrated nominal effects. None persisted after multiple-testing correction. GDF15 showed the most consistent associations with CDR Sum of Boxes trajectories and treatment-effect modification that remained significant after false discovery rate correction in the amnestic MCI subgroup, whereas p-tau217 was most consistently associated with hippocampal volume trajectories. Other protein-outcome associations were exploratory. Plasma proteomics identified distinct molecular patterns associated with amyloid beta pathology and the MCI phenotype, along with exploratory evidence of Li-associated protein changes. Plasma GDF15 and p-tau217 emerged as potential markers of clinical progression and treatment-response heterogeneity, warranting validation in larger, adequately powered trials.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Lithium (Li) demonstrates neuroprotective effects relevant to Alzheimer disease (AD). However, its molecular mechanisms remain insufficiently characterized. This study analyzed plasma proteomic profiles from the Li as a Treatment to Prevent Impairment of Cognition in Elders (LATTICE) randomized clinical trial to identify markers associated with amyloid beta pathology, disease progression, and response to Li treatment. In the LATTICE trial, 80 older adults with mild cognitive impairment (MCI) were randomly assigned to receive either low-dose Li carbonate or placebo for two years. Longitudinal plasma samples were analyzed using the NULISAseq CNS Disease Panel 120 proteomic panel. Baseline protein levels were compared according to randomized treatment assignment, amyloid beta PET status, and MCI subtype. Analyses included longitudinal changes in protein levels associated with treatment and time, associations between baseline protein levels and subsequent cognitive, functional, and neuroimaging trajectories, and the influence of baseline protein levels on Li treatment effects. Among the 80 participants, 62 had amnestic MCI and 21 were positive on amyloid beta PET. Baseline proteomic differences were more strongly associated with amyloid beta PET status than with randomized treatment assignment. Plasma p-tau217 concentrations were elevated in individuals who were positive on amyloid beta PET and remained significant after false discovery rate correction. Over time, CALB2 and TREM2 exhibited nominal treatment-by-time interactions in the full cohort, while in the amnestic MCI subgroup, CALB2, TREM2, and amyloid beta 40 demonstrated nominal effects. None persisted after multiple-testing correction. GDF15 showed the most consistent associations with CDR Sum of Boxes trajectories and treatment-effect modification that remained significant after false discovery rate correction in the amnestic MCI subgroup, whereas p-tau217 was most consistently associated with hippocampal volume trajectories. Other protein-outcome associations were exploratory. Plasma proteomics identified distinct molecular patterns associated with amyloid beta pathology and the MCI phenotype, along with exploratory evidence of Li-associated protein changes. Plasma GDF15 and p-tau217 emerged as potential markers of clinical progression and treatment-response heterogeneity, warranting validation in larger, adequately powered trials.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368038v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
            "content_type": "application/json",
            "elapsed_ms": 713,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368038v1?rss=1"
    },
    {
      "id": "0bc5e14ce9c457994678",
      "title": "Preprint: Normative Modeling of Structural and Diffusion MRI for Epilepsy Diagnosis and Classification",
      "content_text": "Background and Objectives: Normative modeling expresses an individual's brain measures as deviations from a large healthy reference and has been advanced as a route to precision imaging biomarkers in epilepsy, where structural abnormality is distributed rather than confined to the presumed focus. Whether this framework can inform clinical classification from clinically acquired T1-weighted and diffusion MRI is untested. We asked whether normative deviations discriminate between (1) epilepsy and…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "0bc5e14ce9c457994678",
          "source": "web",
          "type": "change",
          "key": "#2206afdbdd00e0c03e01",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
          "timestamp": null,
          "observed_at": "2026-11-17T18:39:20Z",
          "data": {
            "change": "added",
            "label": "Preprint: Normative Modeling of Structural and Diffusion MRI for Epilepsy Diagnosis and Classification",
            "item_type": "record",
            "summary": "added: Preprint: Normative Modeling of Structural and Diffusion MRI for Epilepsy Diagnosis and Classification",
            "after": {
              "title": "Preprint: Normative Modeling of Structural and Diffusion MRI for Epilepsy Diagnosis and Classification",
              "authors": "Zhou, D. J.; Jaskir, M.; Hutchinson, R.; Eisenberg, E. S.; Gal, J.; Imtiaz, T. J.; Goldblum, Z.; Vadali, C.; Lucas, A.; Josyula, M.; Gugger, J. J.; Conrad, E. C.; Das, S.; Stein, J. M.; Davis, K. A.; Sinha, N.",
              "author_corresponding": "Nishant Sinha",
              "author_corresponding_institution": "University of Pennsylvania",
              "doi": "10.64898/2026.11.14.26368080",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "neurology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.14.26368080.source.xml",
              "abstract": "Background and Objectives: Normative modeling expresses an individual's brain measures as deviations from a large healthy reference and has been advanced as a route to precision imaging biomarkers in epilepsy, where structural abnormality is distributed rather than confined to the presumed focus. Whether this framework can inform clinical classification from clinically acquired T1-weighted and diffusion MRI is untested. We asked whether normative deviations discriminate between (1) epilepsy and functional seizures; (2) focal and generalized epilepsy; and (3) drug-resistant and drug-responsive epilepsy. Methods: We retrospectively studied patients with epilepsy or functional seizures without comorbid epilepsy who underwent 3-Tesla epilepsy-protocol MRI at the University of Pennsylvania. Morphometric deviation scores (cortical thickness, subcortical volume) were derived from CentileBrain (n>37,000 healthy references). White matter fractional anisotropy and mean diffusivity profiles were referenced to harmonized Human Connectome Project cohorts. Lobar composites, hemispheric asymmetry indices, and whole-tract means were compared with rank-sum tests; discrimination was summarized as area under the ROC curve (AUC) with bootstrap confidence intervals and Benjamini-Hochberg correction. Whole-brain deviation burden was examined as a secondary analysis. Minimum detectable effects were estimated by Monte Carlo simulation at 80% power (=0.05). Results: We included 273 patients with epilepsy (203 focal, 37 generalized, 33 unclassified; 97 drug-resistant, 176 drug-responsive) and 32 with functional seizures. In the primary analyses, no regional or tract-level normative measure distinguished epilepsy from functional seizures, focal from generalized epilepsy, or drug-resistant from drug-responsive epilepsy; AUCs did not exceed 0.62, with upper confidence limits up to 0.72. In the secondary analysis, whole-brain morphometric deviation burden was modestly higher in epilepsy than in functional seizures (AUC 0.66, 95% CI 0.57-0.74) but did not separate the within-epilepsy comparisons. The study could detect AUC [&ge;]0.65 for epilepsy versus functional seizures, [&ge;]0.64 for focal versus generalized, and [&ge;]0.60 for drug-resistant versus drug-responsive epilepsy. Discussion: Univariate normative deviation summaries from clinical MRI do not currently distinguish these groups well enough to guide care. Whole-brain deviation burden, the only summary measure that differed after correction, was detectable at the group level but insufficient for individual-level classification. Progress may require network-targeted analysis of patient-specific deviations and multimodal integration.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background and Objectives: Normative modeling expresses an individual's brain measures as deviations from a large healthy reference and has been advanced as a route to precision imaging biomarkers in epilepsy, where structural abnormality is distributed rather than confined to the presumed focus. Whether this framework can inform clinical classification from clinically acquired T1-weighted and diffusion MRI is untested. We asked whether normative deviations discriminate between (1) epilepsy and functional seizures; (2) focal and generalized epilepsy; and (3) drug-resistant and drug-responsive epilepsy. Methods: We retrospectively studied patients with epilepsy or functional seizures without comorbid epilepsy who underwent 3-Tesla epilepsy-protocol MRI at the University of Pennsylvania. Morphometric deviation scores (cortical thickness, subcortical volume) were derived from CentileBrain (n>37,000 healthy references). White matter fractional anisotropy and mean diffusivity profiles were referenced to harmonized Human Connectome Project cohorts. Lobar composites, hemispheric asymmetry indices, and whole-tract means were compared with rank-sum tests; discrimination was summarized as area under the ROC curve (AUC) with bootstrap confidence intervals and Benjamini-Hochberg correction. Whole-brain deviation burden was examined as a secondary analysis. Minimum detectable effects were estimated by Monte Carlo simulation at 80% power (=0.05). Results: We included 273 patients with epilepsy (203 focal, 37 generalized, 33 unclassified; 97 drug-resistant, 176 drug-responsive) and 32 with functional seizures. In the primary analyses, no regional or tract-level normative measure distinguished epilepsy from functional seizures, focal from generalized epilepsy, or drug-resistant from drug-responsive epilepsy; AUCs did not exceed 0.62, with upper confidence limits up to 0.72. In the secondary analysis, whole-brain morphometric deviation burden was modestly higher in epilepsy than in functional seizures (AUC 0.66, 95% CI 0.57-0.74) but did not separate the within-epilepsy comparisons. The study could detect AUC [&ge;]0.65 for epilepsy versus functional seizures, [&ge;]0.64 for focal versus generalized, and [&ge;]0.60 for drug-resistant versus drug-responsive epilepsy. Discussion: Univariate normative deviation summaries from clinical MRI do not currently distinguish these groups well enough to guide care. Whole-brain deviation burden, the only summary measure that differed after correction, was detectable at the group level but insufficient for individual-level classification. Progress may require network-targeted analysis of patient-specific deviations and multimodal integration.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368080v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
            "content_type": "application/json",
            "elapsed_ms": 713,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368080v1?rss=1"
    },
    {
      "id": "9496955859873af83bdd",
      "title": "Preprint: Changes in Resting-State Functional Network Specialization in Progressive Supranuclear Palsy",
      "content_text": "Progressive supranuclear palsy (PSP) is a neurodegenerative tauopathy characterized by heterogeneous clinical presentations and disruption of distributed neural networks. Resting-state functional MRI (rs-fMRI) provides a systems-level approach to examine intrinsic brain connectivity and may offer insights into disease-related network dysfunction. In this study, we compared rs-fMRI connectivity measures between individuals with PSP and healthy controls and explored differences across PSP…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "9496955859873af83bdd",
          "source": "web",
          "type": "change",
          "key": "#59bf9abdb999117fb3c2",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
          "timestamp": null,
          "observed_at": "2026-11-17T18:39:20Z",
          "data": {
            "change": "added",
            "label": "Preprint: Changes in Resting-State Functional Network Specialization in Progressive Supranuclear Palsy",
            "item_type": "record",
            "summary": "added: Preprint: Changes in Resting-State Functional Network Specialization in Progressive Supranuclear Palsy",
            "after": {
              "title": "Preprint: Changes in Resting-State Functional Network Specialization in Progressive Supranuclear Palsy",
              "authors": "Vazquez, J.; Soldan, A.; Albert, M.; Lu, H.; Pantelyat, A.",
              "author_corresponding": "Alexander Pantelyat",
              "author_corresponding_institution": "Johns Hopkins University School of Medicine",
              "doi": "10.64898/2026.11.14.26367857",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_no",
              "category": "neurology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.14.26367857.source.xml",
              "abstract": "Progressive supranuclear palsy (PSP) is a neurodegenerative tauopathy characterized by heterogeneous clinical presentations and disruption of distributed neural networks. Resting-state functional MRI (rs-fMRI) provides a systems-level approach to examine intrinsic brain connectivity and may offer insights into disease-related network dysfunction. In this study, we compared rs-fMRI connectivity measures between individuals with PSP and healthy controls and explored differences across PSP clinical variants. 23 participants with probable or possible PSP and 23 age- and sex-matched healthy controls underwent structural and functional MRI. Graph theory metrics and functional connectivity measures across seven canonical resting-state networks were analyzed. Clinical severity was assessed using the PSP Rating Scale (PSPRS) and cognitive measures including the Montreal Cognitive Assessment (MoCA) and frontal assessment battery (FAB). Compared with controls, participants with PSP demonstrated significantly reduced global network modularity and segregation, indicating decreased functional network specialization. Functional connectivity was significantly reduced in multiple large-scale networks, including frontoparietal control, default mode, dorsal attention, somatomotor, and visual networks. No significant differences in graph theory metrics or network connectivity were observed between PSP clinical variants. These findings suggest that PSP is associated with widespread disruption of intrinsic functional networks, reflected by reduced modular organization and network segregation across several canonical resting-state systems while preserving local nodal clustering and global efficiency. Network-level alterations appear broadly similar across clinical variants, supporting the concept that PSP represents a distributed network disorder.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Progressive supranuclear palsy (PSP) is a neurodegenerative tauopathy characterized by heterogeneous clinical presentations and disruption of distributed neural networks. Resting-state functional MRI (rs-fMRI) provides a systems-level approach to examine intrinsic brain connectivity and may offer insights into disease-related network dysfunction. In this study, we compared rs-fMRI connectivity measures between individuals with PSP and healthy controls and explored differences across PSP clinical variants. 23 participants with probable or possible PSP and 23 age- and sex-matched healthy controls underwent structural and functional MRI. Graph theory metrics and functional connectivity measures across seven canonical resting-state networks were analyzed. Clinical severity was assessed using the PSP Rating Scale (PSPRS) and cognitive measures including the Montreal Cognitive Assessment (MoCA) and frontal assessment battery (FAB). Compared with controls, participants with PSP demonstrated significantly reduced global network modularity and segregation, indicating decreased functional network specialization. Functional connectivity was significantly reduced in multiple large-scale networks, including frontoparietal control, default mode, dorsal attention, somatomotor, and visual networks. No significant differences in graph theory metrics or network connectivity were observed between PSP clinical variants. These findings suggest that PSP is associated with widespread disruption of intrinsic functional networks, reflected by reduced modular organization and network segregation across several canonical resting-state systems while preserving local nodal clustering and global efficiency. Network-level alterations appear broadly similar across clinical variants, supporting the concept that PSP represents a distributed network disorder.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26367857v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
            "content_type": "application/json",
            "elapsed_ms": 713,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26367857v1?rss=1"
    },
    {
      "id": "c04d27d421d5dff19da7",
      "title": "Preprint: Hidden Dependencies in Endometriosis Microarray Classifiers: Sample Reuse, Outcome-Informed Batch Correction, and Diagnostic Reassessment",
      "content_text": "Distinct Gene Expression Omnibus (GEO) accessions do not necessarily represent independent transcriptomic samples. We investigated exact array reuse, access to test diagnoses during batch correction, and cohort and acquisition-date confounding in endometriosis classifiers. We compared decompressed CEL files using SHA-256, reconstructed a matrisome elastic-net workflow, changed test labels supplied to ComBat, and conducted 3,582 constrained training-label refits. We also evaluated the effect of…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "c04d27d421d5dff19da7",
          "source": "web",
          "type": "change",
          "key": "#95450befa9f7e52edf01",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
          "timestamp": null,
          "observed_at": "2026-11-17T18:39:20Z",
          "data": {
            "change": "added",
            "label": "Preprint: Hidden Dependencies in Endometriosis Microarray Classifiers: Sample Reuse, Outcome-Informed Batch Correction, and Diagnostic Reassessment",
            "item_type": "record",
            "summary": "added: Preprint: Hidden Dependencies in Endometriosis Microarray Classifiers: Sample Reuse, Outcome-Informed Batch Correction, and Diagnostic Reassessment",
            "after": {
              "title": "Preprint: Hidden Dependencies in Endometriosis Microarray Classifiers: Sample Reuse, Outcome-Informed Batch Correction, and Diagnostic Reassessment",
              "authors": "Krikun, E.; Alkhateeb, A.",
              "author_corresponding": "Elena Krikun",
              "author_corresponding_institution": "Lakehead University",
              "doi": "10.64898/2026.11.15.26368137",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "obstetrics and gynecology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.15.26368137.source.xml",
              "abstract": "Distinct Gene Expression Omnibus (GEO) accessions do not necessarily represent independent transcriptomic samples. We investigated exact array reuse, access to test diagnoses during batch correction, and cohort and acquisition-date confounding in endometriosis classifiers. We compared decompressed CEL files using SHA-256, reconstructed a matrisome elastic-net workflow, changed test labels supplied to ComBat, and conducted 3,582 constrained training-label refits. We also evaluated the effect of removing matching training copies in a five-gene Huang-inspired random forest and performed a 324-probe nested internal benchmark within GSE51981. Of 37 test CEL files, 26 (70.3%) were identical to training arrays; all had been scanned in 2004-2005. Changing a test diagnosis supplied to ComBat moved the fixed classifier score toward the supplied label in all 37 interventions. In a deduplicated, batch-constrained comparison, median nominal balanced accuracy was 0.881 when ComBat received true test outcomes and 0.549 without them; the outcome-informed arm performed better in 1,193 of 1,194 matched refit comparisons. In the separate Huang-inspired reconstruction, removing each target's matching training copy lowered pooled AUC from 1.000 to 0.323 (conditional 95% interval 0.105-0.571). Exploratory nested AUC was 0.733 for endometriosis versus other gynecological conditions, and date-held-out AUC in 2009 was 0.698. For endometriosis versus healthy controls, a date-only out-of-fold model achieved AUC 0.935, compared with 0.893 for the molecular model. Together, these findings show how exact array reuse, outcome-informed preprocessing, and acquisition-date structure can compromise the interpretation of nominally independent validation. They describe reconstructions and exploratory internal analyses, not corrected performance estimates for the published classifiers.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Distinct Gene Expression Omnibus (GEO) accessions do not necessarily represent independent transcriptomic samples. We investigated exact array reuse, access to test diagnoses during batch correction, and cohort and acquisition-date confounding in endometriosis classifiers. We compared decompressed CEL files using SHA-256, reconstructed a matrisome elastic-net workflow, changed test labels supplied to ComBat, and conducted 3,582 constrained training-label refits. We also evaluated the effect of removing matching training copies in a five-gene Huang-inspired random forest and performed a 324-probe nested internal benchmark within GSE51981. Of 37 test CEL files, 26 (70.3%) were identical to training arrays; all had been scanned in 2004-2005. Changing a test diagnosis supplied to ComBat moved the fixed classifier score toward the supplied label in all 37 interventions. In a deduplicated, batch-constrained comparison, median nominal balanced accuracy was 0.881 when ComBat received true test outcomes and 0.549 without them; the outcome-informed arm performed better in 1,193 of 1,194 matched refit comparisons. In the separate Huang-inspired reconstruction, removing each target's matching training copy lowered pooled AUC from 1.000 to 0.323 (conditional 95% interval 0.105-0.571). Exploratory nested AUC was 0.733 for endometriosis versus other gynecological conditions, and date-held-out AUC in 2009 was 0.698. For endometriosis versus healthy controls, a date-only out-of-fold model achieved AUC 0.935, compared with 0.893 for the molecular model. Together, these findings show how exact array reuse, outcome-informed preprocessing, and acquisition-date structure can compromise the interpretation of nominally independent validation. They describe reconstructions and exploratory internal analyses, not corrected performance estimates for the published classifiers.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.15.26368137v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
            "content_type": "application/json",
            "elapsed_ms": 713,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.15.26368137v1?rss=1"
    },
    {
      "id": "cf6922c716c814251488",
      "title": "Preprint: Research Involvement and Partnership Outcomes Among Patient-Centered Outcomes Research Partners",
      "content_text": "Importance: Meaningful patient and community involvement is increasingly emphasized in health research. Still, little is known about how such research involvement relates to the quality of patient and community partnerships. Objective: To examine the associations of patient and community involvement in research with partnership outcomes. The associations of patient involvement in specific research phases (e.g., grant writing, recruitment, and data collection) with these metrics were examined as…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "cf6922c716c814251488",
          "source": "web",
          "type": "change",
          "key": "#64362c8c735a902c96ae",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
          "timestamp": null,
          "observed_at": "2026-11-17T17:42:02Z",
          "data": {
            "change": "added",
            "label": "Preprint: Research Involvement and Partnership Outcomes Among Patient-Centered Outcomes Research Partners",
            "item_type": "record",
            "summary": "added: Preprint: Research Involvement and Partnership Outcomes Among Patient-Centered Outcomes Research Partners",
            "after": {
              "title": "Preprint: Research Involvement and Partnership Outcomes Among Patient-Centered Outcomes Research Partners",
              "authors": "Tapiavala, V. N.; Bather, J.; Ricci-De Lucca, E.; Murnane, E. L.; Goodman, M. S.; Fortuna, K. L.",
              "author_corresponding": "Karen L Fortuna",
              "author_corresponding_institution": "Patient Innovation Lab, Department of Community and Family Medicine, Geisel School of Medicine, Lebanon, NH, USA.",
              "doi": "10.64898/2026.11.14.26368107",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "health systems and quality improvement",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.14.26368107.source.xml",
              "abstract": "Importance: Meaningful patient and community involvement is increasingly emphasized in health research. Still, little is known about how such research involvement relates to the quality of patient and community partnerships. Objective: To examine the associations of patient and community involvement in research with partnership outcomes. The associations of patient involvement in specific research phases (e.g., grant writing, recruitment, and data collection) with these metrics were examined as a secondary objective. Design: This cross-sectional observational study used baseline data from a national cohort study across the United States collected from September to December 2024. Setting: This national study was conducted online with recruitment occurring over multiple channels. Participants: Participants included patient and community research partners aged 18 years and older and were recruited in a convenience sample. Exposures: The extent to which participants have contributed to prior research studies were calculated by adding binary indicators representing their involvement in phases of the research process. These indicators were examined individually as secondary exposures. Main Outcome(s) and Measure(s): Primary outcomes included partnership quality and research engagement, with trust in medical researchers and partnership recommendation as secondary and tertiary outcomes. Multivariable linear and modified Poisson regressions were utilized to estimate regression coefficients and adjusted prevalence ratios (aPRs). Results: Among 330 participants (mean age = 36.5 years, SD = 9.7), 56.1% were male, and 37.3% and 31.8% were White or Black, respectively. Involvement in patient-centered outcomes research was associated with partnership quality ({beta}, 0.86; 95% CI, 0.30-1.42, P=0.003), research engagement ({beta}, 0.04; 95% CI, 0.01-0.06, P=0.006), trust in medical researchers ({beta}, 0.69; 95% CI, 0.31-1.07, P<0.001), and greater willingness to recommend becoming a research partner (aPR, 1.09; 95% CI, 1.05-1.14, P<0.001). Conclusions and Relevance: Patient-centered outcomes research may provide patient and community research partners with a sense of shared ownership, improving partnership quality. While the causal links require further investigation, these associations may be driven by inclusion in recruitment, grant writing, data collection, and shared governance.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Importance: Meaningful patient and community involvement is increasingly emphasized in health research. Still, little is known about how such research involvement relates to the quality of patient and community partnerships. Objective: To examine the associations of patient and community involvement in research with partnership outcomes. The associations of patient involvement in specific research phases (e.g., grant writing, recruitment, and data collection) with these metrics were examined as a secondary objective. Design: This cross-sectional observational study used baseline data from a national cohort study across the United States collected from September to December 2024. Setting: This national study was conducted online with recruitment occurring over multiple channels. Participants: Participants included patient and community research partners aged 18 years and older and were recruited in a convenience sample. Exposures: The extent to which participants have contributed to prior research studies were calculated by adding binary indicators representing their involvement in phases of the research process. These indicators were examined individually as secondary exposures. Main Outcome(s) and Measure(s): Primary outcomes included partnership quality and research engagement, with trust in medical researchers and partnership recommendation as secondary and tertiary outcomes. Multivariable linear and modified Poisson regressions were utilized to estimate regression coefficients and adjusted prevalence ratios (aPRs). Results: Among 330 participants (mean age = 36.5 years, SD = 9.7), 56.1% were male, and 37.3% and 31.8% were White or Black, respectively. Involvement in patient-centered outcomes research was associated with partnership quality ({beta}, 0.86; 95% CI, 0.30-1.42, P=0.003), research engagement ({beta}, 0.04; 95% CI, 0.01-0.06, P=0.006), trust in medical researchers ({beta}, 0.69; 95% CI, 0.31-1.07, P<0.001), and greater willingness to recommend becoming a research partner (aPR, 1.09; 95% CI, 1.05-1.14, P<0.001). Conclusions and Relevance: Patient-centered outcomes research may provide patient and community research partners with a sense of shared ownership, improving partnership quality. While the causal links require further investigation, these associations may be driven by inclusion in recruitment, grant writing, data collection, and shared governance.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368107v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
            "content_type": "application/json",
            "elapsed_ms": 190,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368107v1?rss=1"
    },
    {
      "id": "50f2823bde31faa20941",
      "title": "Preprint: Rising Tuberculosis Presentations in Ontario, Canada Are Not Explained by Community SARS-CoV-2 Activity: A Population-Based Time-Series Study",
      "content_text": "Background: Tuberculosis (TB) notifications have increased in several high-income countries since 2020. Proposed explanations include pandemic related disruption of treatment for latent tuberculosis, changes in population composition, and immune dysfunction following SARS CoV 2 infection. We assessed whether TB presentations increased during the pandemic era and then tested whether community SARS CoV 2 activity was followed by increased mycobacterial disease. Methods: We conducted a…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "50f2823bde31faa20941",
          "source": "web",
          "type": "change",
          "key": "#d6de709edf97489313d4",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
          "timestamp": null,
          "observed_at": "2026-11-17T17:42:02Z",
          "data": {
            "change": "added",
            "label": "Preprint: Rising Tuberculosis Presentations in Ontario, Canada Are Not Explained by Community SARS-CoV-2 Activity: A Population-Based Time-Series Study",
            "item_type": "record",
            "summary": "added: Preprint: Rising Tuberculosis Presentations in Ontario, Canada Are Not Explained by Community SARS-CoV-2 Activity: A Population-Based Time-Series Study",
            "after": {
              "title": "Preprint: Rising Tuberculosis Presentations in Ontario, Canada Are Not Explained by Community SARS-CoV-2 Activity: A Population-Based Time-Series Study",
              "authors": "Wilson, N. J.; Tuite, A.; Lee, C. E.; Berkowitz, R. J.; Wiebe, B.; Hall, J.; Boushy, D.; Fisman, D.",
              "author_corresponding": "David Fisman",
              "author_corresponding_institution": "University of Toronto",
              "doi": "10.64898/2026.11.14.26367737",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "infectious diseases",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.14.26367737.source.xml",
              "abstract": "Background: Tuberculosis (TB) notifications have increased in several high-income countries since 2020. Proposed explanations include pandemic related disruption of treatment for latent tuberculosis, changes in population composition, and immune dysfunction following SARS CoV 2 infection. We assessed whether TB presentations increased during the pandemic era and then tested whether community SARS CoV 2 activity was followed by increased mycobacterial disease. Methods: We conducted a population-based ecological time-series study of first TB- and nontuberculous mycobacterial (NTM)-coded hospital, emergency-department and ambulatory clinic presentations in the Greater Toronto/Hamilton Area Plus (GTHA+), Ontario (2024 population approximately 11.2 million), from April 2011 through March 2024. NTM served as a comparator because it shares diagnostic pathways with TB but differs epidemiologically. Negative binomial projection and full-series models estimated pandemic-era changes under three alternative trend assumptions. Distributed lag non linear models estimated cumulative rate ratios for standardized community viral activity over 0 to 12 weeks; sensitivity analyses extended the maximum lag to 26 and 52 weeks. Influenza and respiratory syncytial virus (RSV) were prespecified comparators; data for five additional viral exposures were obtained after the primary analysis was completed and analysed as exploratory comparisons. Results: We identified 3,985 first TB-coded and 5,214 first NTM-coded acute-care presentations. Across six models, estimated pandemic-era TB increases ranged from 3% to 22%. No model suggested an increased in NTM. SARS-CoV-2 activity was not positively associated with TB (cumulative rate ratio per 1-SD increase over 0 to 12 weeks 0.909, 95% CI 0.822 to 1.006) or NTM (0.953, 0.868 to 1.047). No positive associations were identified in subgroup analyses or with maximum lags of 26 or 52 weeks. Influenza was not associated with either outcome. RSV was associated with TB and NTM; only the RSV/NTM association met the Bonferroni threshold among the prespecified comparisons, and no exploratory associations met the experiment wide threshold. Conclusions: We identified a modest pandemic era increase in TB-coded acute-care presentations in Ontario, Canada, although its estimated size depended on assumptions about underlying trends. NTM-coded presentations did not increase. Community SARS-CoV-2 activity was not positively associated with subsequent TB or NTM presentations at lags of up to one year and did not provide a temporal explanation for the population-level TB increase. Individual-level effects cannot be excluded.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background: Tuberculosis (TB) notifications have increased in several high-income countries since 2020. Proposed explanations include pandemic related disruption of treatment for latent tuberculosis, changes in population composition, and immune dysfunction following SARS CoV 2 infection. We assessed whether TB presentations increased during the pandemic era and then tested whether community SARS CoV 2 activity was followed by increased mycobacterial disease. Methods: We conducted a population-based ecological time-series study of first TB- and nontuberculous mycobacterial (NTM)-coded hospital, emergency-department and ambulatory clinic presentations in the Greater Toronto/Hamilton Area Plus (GTHA+), Ontario (2024 population approximately 11.2 million), from April 2011 through March 2024. NTM served as a comparator because it shares diagnostic pathways with TB but differs epidemiologically. Negative binomial projection and full-series models estimated pandemic-era changes under three alternative trend assumptions. Distributed lag non linear models estimated cumulative rate ratios for standardized community viral activity over 0 to 12 weeks; sensitivity analyses extended the maximum lag to 26 and 52 weeks. Influenza and respiratory syncytial virus (RSV) were prespecified comparators; data for five additional viral exposures were obtained after the primary analysis was completed and analysed as exploratory comparisons. Results: We identified 3,985 first TB-coded and 5,214 first NTM-coded acute-care presentations. Across six models, estimated pandemic-era TB increases ranged from 3% to 22%. No model suggested an increased in NTM. SARS-CoV-2 activity was not positively associated with TB (cumulative rate ratio per 1-SD increase over 0 to 12 weeks 0.909, 95% CI 0.822 to 1.006) or NTM (0.953, 0.868 to 1.047). No positive associations were identified in subgroup analyses or with maximum lags of 26 or 52 weeks. Influenza was not associated with either outcome. RSV was associated with TB and NTM; only the RSV/NTM association met the Bonferroni threshold among the prespecified comparisons, and no exploratory associations met the experiment wide threshold. Conclusions: We identified a modest pandemic era increase in TB-coded acute-care presentations in Ontario, Canada, although its estimated size depended on assumptions about underlying trends. NTM-coded presentations did not increase. Community SARS-CoV-2 activity was not positively associated with subsequent TB or NTM presentations at lags of up to one year and did not provide a temporal explanation for the population-level TB increase. Individual-level effects cannot be excluded.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26367737v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
            "content_type": "application/json",
            "elapsed_ms": 190,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26367737v1?rss=1"
    },
    {
      "id": "22a737384f33fd8f2d41",
      "title": "Preprint: Old lineages, new threat: the re-emergence of pneumococcal serotype 14 in adults in Catalonia, Spain (2023-2025).",
      "content_text": "Introduction: The introduction of pneumococcal conjugate vaccines resulted in a decline in invasive pneumococcal disease (IPD). Nevertheless, recent studies report a re-emergence of vaccine-included serotypes. Aim: To describe the recent re-emergence of serotype 14 IPD among adults in Catalonia and to investigate the factors underlying its resurgence. Methods: We analysed two collections of adult IPD isolates: a historical series from Hospital Universitari de Bellvitge (1996-2025) and a…",
      "date_published": "2026-11-17T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "22a737384f33fd8f2d41",
          "source": "web",
          "type": "change",
          "key": "#06f52a4173fbc6e13cef",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
          "timestamp": null,
          "observed_at": "2026-11-17T17:42:02Z",
          "data": {
            "change": "added",
            "label": "Preprint: Old lineages, new threat: the re-emergence of pneumococcal serotype 14 in adults in Catalonia, Spain (2023-2025).",
            "item_type": "record",
            "summary": "added: Preprint: Old lineages, new threat: the re-emergence of pneumococcal serotype 14 in adults in Catalonia, Spain (2023-2025).",
            "after": {
              "title": "Preprint: Old lineages, new threat: the re-emergence of pneumococcal serotype 14 in adults in Catalonia, Spain (2023-2025).",
              "authors": "Gonzalez-Diaz, A.; Broner, S.; Calvo-Silveria, S.; Grau, I.; Quesada, M. D.; Belles, A.; del Corral, E.; Pico-Plana, E.; Clapes, E.; Vinado, B.; Berbel, D.; Llopis, M. A.; Dominguez, M. A.; Marti, S.; Camara, J.; Ciruela, P.; Ardanuy, C.",
              "author_corresponding": "Aida Gonzalez-Diaz",
              "author_corresponding_institution": "Microbiology Department, Hospital Universitari de Bellvitge, IDIBELL, Hospitalet de Llobregat, Spain;Research Network for Respiratory Diseases (CIBERES), ISCIII",
              "doi": "10.64898/2026.11.16.26367621",
              "date": "2026-11-17",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "infectious diseases",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/17/2026.11.16.26367621.source.xml",
              "abstract": "Introduction: The introduction of pneumococcal conjugate vaccines resulted in a decline in invasive pneumococcal disease (IPD). Nevertheless, recent studies report a re-emergence of vaccine-included serotypes. Aim: To describe the recent re-emergence of serotype 14 IPD among adults in Catalonia and to investigate the factors underlying its resurgence. Methods: We analysed two collections of adult IPD isolates: a historical series from Hospital Universitari de Bellvitge (1996-2025) and a multicentre series from seven tertiary hospitals in Catalonia (2023-2025). Isolates were serotyped (Quellung) and genotyped by PFGE/MLST (1996-2022) or Illumina sequencing (2023-2025). Clinical data were retrospectively collected. Results: The historical series showed that, after peaking in 2009, serotype 14 frequency gradually declined, with only -4 cases reported annually between 2016 and 2020. However, the number of serotype 14 isolates increased again in 2025, reaching 11.0% of all isolates at HUB and 10.8% across Catalonia. Genomic data showed that this increase involved multiple previously circulating lineages (GPSC6, GPSC18, GPSC16 and GPSC39), with no dominant clone. Analysis of the capsular locus revealed substantial genetic diversity, with no association between capsular variants and either lineage or year of isolation. A substantial proportion of patients (56.3%) had multiple comorbidities and only 18.8% were appropriately vaccinated. Discussion: The re-emergence of serotype 14 was not associated with a novel lineage or capsular variant. Instead, it may reflect a combination of post-pandemic transmission changes, higher-valency paediatric vaccines, and natural fluctuations in serotype circulation. These findings highlight the limits of herd protection and underscore the need to strengthen adult vaccination, particularly among at-risk populations.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Introduction: The introduction of pneumococcal conjugate vaccines resulted in a decline in invasive pneumococcal disease (IPD). Nevertheless, recent studies report a re-emergence of vaccine-included serotypes. Aim: To describe the recent re-emergence of serotype 14 IPD among adults in Catalonia and to investigate the factors underlying its resurgence. Methods: We analysed two collections of adult IPD isolates: a historical series from Hospital Universitari de Bellvitge (1996-2025) and a multicentre series from seven tertiary hospitals in Catalonia (2023-2025). Isolates were serotyped (Quellung) and genotyped by PFGE/MLST (1996-2022) or Illumina sequencing (2023-2025). Clinical data were retrospectively collected. Results: The historical series showed that, after peaking in 2009, serotype 14 frequency gradually declined, with only -4 cases reported annually between 2016 and 2020. However, the number of serotype 14 isolates increased again in 2025, reaching 11.0% of all isolates at HUB and 10.8% across Catalonia. Genomic data showed that this increase involved multiple previously circulating lineages (GPSC6, GPSC18, GPSC16 and GPSC39), with no dominant clone. Analysis of the capsular locus revealed substantial genetic diversity, with no association between capsular variants and either lineage or year of isolation. A substantial proportion of patients (56.3%) had multiple comorbidities and only 18.8% were appropriately vaccinated. Discussion: The re-emergence of serotype 14 was not associated with a novel lineage or capsular variant. Instead, it may reflect a combination of post-pandemic transmission changes, higher-valency paediatric vaccines, and natural fluctuations in serotype circulation. These findings highlight the limits of herd protection and underscore the need to strengthen adult vaccination, particularly among at-risk populations.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.16.26367621v1?rss=1",
              "published_at": "2026-11-17T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
            "content_type": "application/json",
            "elapsed_ms": 190,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.16.26367621v1?rss=1"
    },
    {
      "id": "1af17955976a6effdf14",
      "title": "Preprint: Medicaid and the Type of Post-Acute Care Among Working-Age Survivors of Intensive Care: A Two-Setting Comparison of a Massachusetts Academic Medical Center and Texas Hospitalizations With ICU or Coronary Care Charges",
      "content_text": "Insurance-related differences in post-acute care after critical illness have mostly been studied within single conditions or settings. We described differences between Medicaid and private insurance in discharge destination and length of stay among working-age adults in two non-equivalent settings: 20,511 patients whose first hospitalization included an ICU stay at one Massachusetts academic medical center (2008 to 2022), and 603,512 Texas hospitalizations with ICU or coronary care unit…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "1af17955976a6effdf14",
          "source": "web",
          "type": "change",
          "key": "#2e048bf7b827fb1399b0",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
          "timestamp": null,
          "observed_at": "2026-11-17T08:00:04Z",
          "data": {
            "change": "added",
            "label": "Preprint: Medicaid and the Type of Post-Acute Care Among Working-Age Survivors of Intensive Care: A Two-Setting Comparison of a Massachusetts Academic Medical Center and Texas Hospitalizations With ICU or Coronary Care Charges",
            "item_type": "record",
            "summary": "added: Preprint: Medicaid and the Type of Post-Acute Care Among Working-Age Survivors of Intensive Care: A Two-Setting Comparison of a Massachusetts Academic Medical Center and Texas Hospitalizations With ICU or Coronary Care Charges",
            "after": {
              "title": "Preprint: Medicaid and the Type of Post-Acute Care Among Working-Age Survivors of Intensive Care: A Two-Setting Comparison of a Massachusetts Academic Medical Center and Texas Hospitalizations With ICU or Coronary Care Charges",
              "authors": "Uddin, M. N.",
              "author_corresponding": "Mohammad Nasir Uddin",
              "author_corresponding_institution": "Westcliff University",
              "doi": "10.64898/2026.11.13.26368054",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "health policy",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.13.26368054.source.xml",
              "abstract": "Insurance-related differences in post-acute care after critical illness have mostly been studied within single conditions or settings. We described differences between Medicaid and private insurance in discharge destination and length of stay among working-age adults in two non-equivalent settings: 20,511 patients whose first hospitalization included an ICU stay at one Massachusetts academic medical center (2008 to 2022), and 603,512 Texas hospitalizations with ICU or coronary care unit accommodation charges in 325 acute care hospitals (2017 to 2019). Adjusted for admission-time characteristics, Medicaid was associated in both settings with more skilled nursing facility discharge (5.2 and 4.3 percentage points), less inpatient rehabilitation (-2.0 and -2.6 points), and longer stays. Long-term acute care and total facility use differed in direction. Destination differences persisted with further adjustment and in a common 2017 to 2019 period; length-of-stay differences narrowed. Texas Medicaid rules limiting adult freestanding rehabilitation and inpatient days are consistent with, but cannot establish, a role for benefit design.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Insurance-related differences in post-acute care after critical illness have mostly been studied within single conditions or settings. We described differences between Medicaid and private insurance in discharge destination and length of stay among working-age adults in two non-equivalent settings: 20,511 patients whose first hospitalization included an ICU stay at one Massachusetts academic medical center (2008 to 2022), and 603,512 Texas hospitalizations with ICU or coronary care unit accommodation charges in 325 acute care hospitals (2017 to 2019). Adjusted for admission-time characteristics, Medicaid was associated in both settings with more skilled nursing facility discharge (5.2 and 4.3 percentage points), less inpatient rehabilitation (-2.0 and -2.6 points), and longer stays. Long-term acute care and total facility use differed in direction. Destination differences persisted with further adjustment and in a common 2017 to 2019 period; length-of-stay differences narrowed. Texas Medicaid rules limiting adult freestanding rehabilitation and inpatient days are consistent with, but cannot establish, a role for benefit design.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368054v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
            "content_type": "application/json",
            "elapsed_ms": 709,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368054v1?rss=1"
    },
    {
      "id": "f79a89f8fd8ebc35a2d3",
      "title": "Preprint: Mobile money vendors as a community channel for adolescent condom provision and sexual health information in Uganda: a type-II hybrid effectiveness-implementation study",
      "content_text": "Purpose: Unmarried adolescents in Uganda have limited access to sexual and reproductive health (SRH) services, and conventional programs have struggled to reach them sustainably. Mobile money vendors (MMVs) are ubiquitous in young people's daily lives. We assessed the feasibility of an MMV-based intervention to provide condoms and SRH information to adolescents. Methods: In this type-II hybrid effectiveness-implementation study in Eastern Uganda, 30 MMVs provided oral and printed information…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "f79a89f8fd8ebc35a2d3",
          "source": "web",
          "type": "change",
          "key": "#b3f21d604dc4d7ad30e3",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
          "timestamp": null,
          "observed_at": "2026-11-17T05:04:43Z",
          "data": {
            "change": "added",
            "label": "Preprint: Mobile money vendors as a community channel for adolescent condom provision and sexual health information in Uganda: a type-II hybrid effectiveness-implementation study",
            "item_type": "record",
            "summary": "added: Preprint: Mobile money vendors as a community channel for adolescent condom provision and sexual health information in Uganda: a type-II hybrid effectiveness-implementation study",
            "after": {
              "title": "Preprint: Mobile money vendors as a community channel for adolescent condom provision and sexual health information in Uganda: a type-II hybrid effectiveness-implementation study",
              "authors": "Komasawa, M.; Sato, M.; Honda, S.; Kitakule, P.; Waiswa, P.",
              "author_corresponding": "Makiko Komasawa",
              "author_corresponding_institution": "Nagasaki University School of Tropical Medicine and Global Health",
              "doi": "10.64898/2026.11.15.26367221",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_no",
              "category": "sexual and reproductive health",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.15.26367221.source.xml",
              "abstract": "Purpose: Unmarried adolescents in Uganda have limited access to sexual and reproductive health (SRH) services, and conventional programs have struggled to reach them sustainably. Mobile money vendors (MMVs) are ubiquitous in young people's daily lives. We assessed the feasibility of an MMV-based intervention to provide condoms and SRH information to adolescents. Methods: In this type-II hybrid effectiveness-implementation study in Eastern Uganda, 30 MMVs provided oral and printed information, free condoms, and referrals for four months in 2024. Feasibility was assessed using the Bowen framework, drawing on service logs, baseline and endline surveys of adolescents aged 15-19 years (n = 1,204), three focus group discussions with MMVs, eight key informant interviews, a post-intervention MMV survey, and supervision reports. Results: MMVs recorded 104,849 adolescent customer visits; oral information was provided at 54,365 visits and condoms at 21,056 visits. Condom use in the intervention arm increased from 67.3% to 77.7% (p = 0.04), and the proportion obtaining condoms from MMVs rose from 0% to 64.6%. Adolescents valued the service's convenience and confidentiality. Initial resistance from some community adults largely diminished, although referrals remained few (210 cases). All MMV shops completed the intervention without disrupting business, and customer numbers and sales rose 1.64- and 1.50-fold. Suggested adaptations included vendor identification and services for girls, integration with public health systems for scalability. Conclusions: The MMV-based approach was feasible and reached hard-to-access unmarried adolescents with condoms and SRH information. For scale-up, improvements for adaptation and large-scale evaluation are necessary.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Purpose: Unmarried adolescents in Uganda have limited access to sexual and reproductive health (SRH) services, and conventional programs have struggled to reach them sustainably. Mobile money vendors (MMVs) are ubiquitous in young people's daily lives. We assessed the feasibility of an MMV-based intervention to provide condoms and SRH information to adolescents. Methods: In this type-II hybrid effectiveness-implementation study in Eastern Uganda, 30 MMVs provided oral and printed information, free condoms, and referrals for four months in 2024. Feasibility was assessed using the Bowen framework, drawing on service logs, baseline and endline surveys of adolescents aged 15-19 years (n = 1,204), three focus group discussions with MMVs, eight key informant interviews, a post-intervention MMV survey, and supervision reports. Results: MMVs recorded 104,849 adolescent customer visits; oral information was provided at 54,365 visits and condoms at 21,056 visits. Condom use in the intervention arm increased from 67.3% to 77.7% (p = 0.04), and the proportion obtaining condoms from MMVs rose from 0% to 64.6%. Adolescents valued the service's convenience and confidentiality. Initial resistance from some community adults largely diminished, although referrals remained few (210 cases). All MMV shops completed the intervention without disrupting business, and customer numbers and sales rose 1.64- and 1.50-fold. Suggested adaptations included vendor identification and services for girls, integration with public health systems for scalability. Conclusions: The MMV-based approach was feasible and reached hard-to-access unmarried adolescents with condoms and SRH information. For scale-up, improvements for adaptation and large-scale evaluation are necessary.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.15.26367221v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
            "content_type": "application/json",
            "elapsed_ms": 311,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.15.26367221v1?rss=1"
    },
    {
      "id": "57ae4154015500b4b3b4",
      "title": "Preprint: Wastewater metagenomic sequencing quantitatively tracks transmission dynamics for human pathogenic viruses",
      "content_text": "Wastewater metagenomic sequencing theoretically characterizes all nucleic acids in a sample, but whether sequencing reads reflect transmission dynamics of circulating viruses in the contributing community is unknown. We evaluated if wastewater metagenomic sequencing data can be used to reconstruct transmission dynamics of endemic, routinely circulating viruses. Using deep, untargeted wastewater metagenomic sequencing data from four locations in the United States, we generated quantitative…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "57ae4154015500b4b3b4",
          "source": "web",
          "type": "change",
          "key": "#deadcd29f4d2ff4c6cfa",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
          "timestamp": null,
          "observed_at": "2026-11-17T04:06:43Z",
          "data": {
            "change": "added",
            "label": "Preprint: Wastewater metagenomic sequencing quantitatively tracks transmission dynamics for human pathogenic viruses",
            "item_type": "record",
            "summary": "added: Preprint: Wastewater metagenomic sequencing quantitatively tracks transmission dynamics for human pathogenic viruses",
            "after": {
              "title": "Preprint: Wastewater metagenomic sequencing quantitatively tracks transmission dynamics for human pathogenic viruses",
              "authors": "Chan, E. M. G.; Justen, L.; Zulli, A.; McLaren, M. R.; Linfield, R. Y.; Moskatel, L. S.; Whittaker, C.",
              "author_corresponding": "Charles Whittaker",
              "author_corresponding_institution": "Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA",
              "doi": "10.64898/2026.11.13.26368067",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "public and global health",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.13.26368067.source.xml",
              "abstract": "Wastewater metagenomic sequencing theoretically characterizes all nucleic acids in a sample, but whether sequencing reads reflect transmission dynamics of circulating viruses in the contributing community is unknown. We evaluated if wastewater metagenomic sequencing data can be used to reconstruct transmission dynamics of endemic, routinely circulating viruses. Using deep, untargeted wastewater metagenomic sequencing data from four locations in the United States, we generated quantitative estimates of transmission dynamics (time-varying growth rate and effective reproduction number) within a Bayesian framework for widely monitored viruses. Across locations and viruses, estimates were statistically concordant with those derived from clinical surveillance and polymerase chain reaction (PCR)-based wastewater monitoring data. Furthermore, we estimated growth rate from wastewater metagenomic sequencing data for numerous viruses not otherwise widely monitored, demonstrating the data expands the targets that can feasibly be monitored in parallel. Wastewater metagenomic sequencing can support both novel pathogen detection and routine surveillance of endemic pathogens.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Wastewater metagenomic sequencing theoretically characterizes all nucleic acids in a sample, but whether sequencing reads reflect transmission dynamics of circulating viruses in the contributing community is unknown. We evaluated if wastewater metagenomic sequencing data can be used to reconstruct transmission dynamics of endemic, routinely circulating viruses. Using deep, untargeted wastewater metagenomic sequencing data from four locations in the United States, we generated quantitative estimates of transmission dynamics (time-varying growth rate and effective reproduction number) within a Bayesian framework for widely monitored viruses. Across locations and viruses, estimates were statistically concordant with those derived from clinical surveillance and polymerase chain reaction (PCR)-based wastewater monitoring data. Furthermore, we estimated growth rate from wastewater metagenomic sequencing data for numerous viruses not otherwise widely monitored, demonstrating the data expands the targets that can feasibly be monitored in parallel. Wastewater metagenomic sequencing can support both novel pathogen detection and routine surveillance of endemic pathogens.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368067v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
            "content_type": "application/json",
            "elapsed_ms": 265,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368067v1?rss=1"
    },
    {
      "id": "219dd94d9f113a59d7ac",
      "title": "Preprint: Physical calibration and signal periodic updates to synchronize IMUs for 5-day continuous knee flexion tracking",
      "content_text": "Wearable inertial measurement unit (IMU) sensors provide a promising method to assess real-world human motion kinematics. However, multi-day multi-IMU tracking is difficult due to the desynchronization driven by inaccurate IMU clocks. In this study, 15 volunteers wore IMUs continuously on their thighs and shanks for 5 weekdays (Mon-Fri), which included 3 repeated in-lab motion capture sessions. We synchronized thigh and shank IMUs using two methods. The first was physical calibration, where we…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "219dd94d9f113a59d7ac",
          "source": "web",
          "type": "change",
          "key": "#a9fc7020e766532f6b1f",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
          "timestamp": null,
          "observed_at": "2026-11-17T04:06:43Z",
          "data": {
            "change": "added",
            "label": "Preprint: Physical calibration and signal periodic updates to synchronize IMUs for 5-day continuous knee flexion tracking",
            "item_type": "record",
            "summary": "added: Preprint: Physical calibration and signal periodic updates to synchronize IMUs for 5-day continuous knee flexion tracking",
            "after": {
              "title": "Preprint: Physical calibration and signal periodic updates to synchronize IMUs for 5-day continuous knee flexion tracking",
              "authors": "Song, K.; Baxter, J. R.",
              "author_corresponding": "Josh R Baxter",
              "author_corresponding_institution": "University of Pennsylvania",
              "doi": "10.64898/2026.11.14.26368098",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "rehabilitation medicine and physical therapy",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.14.26368098.source.xml",
              "abstract": "Wearable inertial measurement unit (IMU) sensors provide a promising method to assess real-world human motion kinematics. However, multi-day multi-IMU tracking is difficult due to the desynchronization driven by inaccurate IMU clocks. In this study, 15 volunteers wore IMUs continuously on their thighs and shanks for 5 weekdays (Mon-Fri), which included 3 repeated in-lab motion capture sessions. We synchronized thigh and shank IMUs using two methods. The first was physical calibration, where we maneuvered the IMUs in a rigid holder to produce sync signals pre-donning (Mon) and post-doffing (Fri), then linearly resampled data from one IMU to match the other via cross-correlation. The second was signal-based periodic updates, where we shifted IMU clocks hourly based on the timewise alignment of preprocessed body-worn acceleration signals. After syncing, we used sensor-to-segment alignment and accelerometer-gyroscope fusion to estimate knee flexion and compared results to camera-based motion capture. Physical calibration alone removed clock offset in most cases, where IMU-estimated knee flexion generally matched motion capture (correlation [&ge;]0.944; root-mean-square difference RMSD [&le;]6.9 degrees). But in some participants, residual mid-week desynchronization (~0.2s) resulted in misestimated knee flexion (Wed: RMSD up to ~19 degrees). After applying signal-based updates or combining it with physical calibration, IMU matched motion capture on all 3 days (Mon: r [&ge;]0.975, RMSD [&le;]6.1 degrees; Wed: r [&ge;]0.971, RMSD [&le;]6.2 degrees, Fri: r [&ge;]0.977; RMSD [&le;]5.9 degrees). Our multi-modal synchronization enables week-long knee flexion tracking and lays a foundation for advanced syncing tools, for improving the feasibility of wearable multi-IMU systems to continuously monitor real-world knee kinematics in clinical studies.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Wearable inertial measurement unit (IMU) sensors provide a promising method to assess real-world human motion kinematics. However, multi-day multi-IMU tracking is difficult due to the desynchronization driven by inaccurate IMU clocks. In this study, 15 volunteers wore IMUs continuously on their thighs and shanks for 5 weekdays (Mon-Fri), which included 3 repeated in-lab motion capture sessions. We synchronized thigh and shank IMUs using two methods. The first was physical calibration, where we maneuvered the IMUs in a rigid holder to produce sync signals pre-donning (Mon) and post-doffing (Fri), then linearly resampled data from one IMU to match the other via cross-correlation. The second was signal-based periodic updates, where we shifted IMU clocks hourly based on the timewise alignment of preprocessed body-worn acceleration signals. After syncing, we used sensor-to-segment alignment and accelerometer-gyroscope fusion to estimate knee flexion and compared results to camera-based motion capture. Physical calibration alone removed clock offset in most cases, where IMU-estimated knee flexion generally matched motion capture (correlation [&ge;]0.944; root-mean-square difference RMSD [&le;]6.9 degrees). But in some participants, residual mid-week desynchronization (~0.2s) resulted in misestimated knee flexion (Wed: RMSD up to ~19 degrees). After applying signal-based updates or combining it with physical calibration, IMU matched motion capture on all 3 days (Mon: r [&ge;]0.975, RMSD [&le;]6.1 degrees; Wed: r [&ge;]0.971, RMSD [&le;]6.2 degrees, Fri: r [&ge;]0.977; RMSD [&le;]5.9 degrees). Our multi-modal synchronization enables week-long knee flexion tracking and lays a foundation for advanced syncing tools, for improving the feasibility of wearable multi-IMU systems to continuously monitor real-world knee kinematics in clinical studies.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368098v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
            "content_type": "application/json",
            "elapsed_ms": 265,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368098v1?rss=1"
    },
    {
      "id": "ee52bc165e360e060a87",
      "title": "Preprint: Barriers and facilitators to cervical precancer treatment adherence among women in Harare, Zimbabwe: A qualitative study",
      "content_text": "Adherence to recommended treatment after a positive cervical screening result remains suboptimal in Zimbabwe. This study explored how women interpreted a cervical precancer diagnosis and how emotional, interpersonal, economic, and health-system factors shaped treatment decisions. We conducted semi-structured in-depth interviews with 25 purposively selected women aged 25-50 years who had screened positive by visual inspection with acetic acid and were recommended for ablative or excisional…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "ee52bc165e360e060a87",
          "source": "web",
          "type": "change",
          "key": "#197c03ae32b57acf2f15",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
          "timestamp": null,
          "observed_at": "2026-11-17T04:06:43Z",
          "data": {
            "change": "added",
            "label": "Preprint: Barriers and facilitators to cervical precancer treatment adherence among women in Harare, Zimbabwe: A qualitative study",
            "item_type": "record",
            "summary": "added: Preprint: Barriers and facilitators to cervical precancer treatment adherence among women in Harare, Zimbabwe: A qualitative study",
            "after": {
              "title": "Preprint: Barriers and facilitators to cervical precancer treatment adherence among women in Harare, Zimbabwe: A qualitative study",
              "authors": "Mutibura, B.; Murewanhema, G.; Chirenje, Z. M.; Mhungu, N.; Guzha, B. T.",
              "author_corresponding": "Belinda Mutibura",
              "author_corresponding_institution": "University Of Zimbabwe",
              "doi": "10.64898/2026.11.13.26368072",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "sexual and reproductive health",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.13.26368072.source.xml",
              "abstract": "Adherence to recommended treatment after a positive cervical screening result remains suboptimal in Zimbabwe. This study explored how women interpreted a cervical precancer diagnosis and how emotional, interpersonal, economic, and health-system factors shaped treatment decisions. We conducted semi-structured in-depth interviews with 25 purposively selected women aged 25-50 years who had screened positive by visual inspection with acetic acid and were recommended for ablative or excisional treatment at two high-volume clinics in Harare. The qualitative component drew on the Health Belief Model and a phenomenological orientation to lived experience. Data were examined using combined deductive and inductive thematic analysis. Three interrelated themes were identified. First, women initially interpreted precancer through fear, shock, and uncertainty; misconceptions that precancer meant invasive cancer, infertility, or imminent death could delay action, whereas clear counselling reframed the diagnosis as treatable. Second, multilevel conditions shaped adherence. Supportive health workers, partner or family encouragement, prior awareness, and connection to HIV services facilitated treatment, while indirect costs, transport, fragmented referral pathways, scheduled excisional services, inconsistent communication, partner opposition, and sexual coercion impeded care. Third, Health Belief Model constructs operated in both directions: perceived severity motivated action when paired with credible benefits and self-efficacy, but produced avoidance when amplified by misinformation and weak support. Improving treatment completion will require standardised counselling, reliable navigation and follow-up, more accessible excisional services, and interventions that address partner dynamics and indirect costs. Screening scale-up should be matched by timely treatment capacity so that women with positive results complete the prevention pathway.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Adherence to recommended treatment after a positive cervical screening result remains suboptimal in Zimbabwe. This study explored how women interpreted a cervical precancer diagnosis and how emotional, interpersonal, economic, and health-system factors shaped treatment decisions. We conducted semi-structured in-depth interviews with 25 purposively selected women aged 25-50 years who had screened positive by visual inspection with acetic acid and were recommended for ablative or excisional treatment at two high-volume clinics in Harare. The qualitative component drew on the Health Belief Model and a phenomenological orientation to lived experience. Data were examined using combined deductive and inductive thematic analysis. Three interrelated themes were identified. First, women initially interpreted precancer through fear, shock, and uncertainty; misconceptions that precancer meant invasive cancer, infertility, or imminent death could delay action, whereas clear counselling reframed the diagnosis as treatable. Second, multilevel conditions shaped adherence. Supportive health workers, partner or family encouragement, prior awareness, and connection to HIV services facilitated treatment, while indirect costs, transport, fragmented referral pathways, scheduled excisional services, inconsistent communication, partner opposition, and sexual coercion impeded care. Third, Health Belief Model constructs operated in both directions: perceived severity motivated action when paired with credible benefits and self-efficacy, but produced avoidance when amplified by misinformation and weak support. Improving treatment completion will require standardised counselling, reliable navigation and follow-up, more accessible excisional services, and interventions that address partner dynamics and indirect costs. Screening scale-up should be matched by timely treatment capacity so that women with positive results complete the prevention pathway.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368072v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
            "content_type": "application/json",
            "elapsed_ms": 265,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368072v1?rss=1"
    },
    {
      "id": "2a21a3b5b9c99cb1a360",
      "title": "Preprint: Documented Human Implementation of NIH SBIR/STTR-Funded Neurosurgical Technologies: A Retrospective Cohort Study",
      "content_text": "Background: Federal small business awards from the National Institutes of Health fund neurosurgical devices and procedural technologies, but how often the specific funded capability reaches human use is unknown. We determined how often these technologies had documented human implementation and in which settings. Methods: We assembled a retrospective public-source cohort of technologies supported by Small Business Innovation Research and Small Business Technology Transfer awards from fiscal…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "2a21a3b5b9c99cb1a360",
          "source": "web",
          "type": "change",
          "key": "#c327fbc072a732fcc4c0",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
          "timestamp": null,
          "observed_at": "2026-11-17T04:06:43Z",
          "data": {
            "change": "added",
            "label": "Preprint: Documented Human Implementation of NIH SBIR/STTR-Funded Neurosurgical Technologies: A Retrospective Cohort Study",
            "item_type": "record",
            "summary": "added: Preprint: Documented Human Implementation of NIH SBIR/STTR-Funded Neurosurgical Technologies: A Retrospective Cohort Study",
            "after": {
              "title": "Preprint: Documented Human Implementation of NIH SBIR/STTR-Funded Neurosurgical Technologies: A Retrospective Cohort Study",
              "authors": "Bachu, A.; Rajesh, R.; Ciecierska, S.-S.; Ahn, Y. J.; Germanwala, A. V.",
              "author_corresponding": "Abhinav Bachu",
              "author_corresponding_institution": "Department of Neurological Surgery, Loyola University Chicago Stritch School of Medicine, 2160 S. First Avenue, Maywood, IL 60153, United States",
              "doi": "10.64898/2026.11.13.26368058",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "surgery",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.13.26368058.source.xml",
              "abstract": "Background: Federal small business awards from the National Institutes of Health fund neurosurgical devices and procedural technologies, but how often the specific funded capability reaches human use is unknown. We determined how often these technologies had documented human implementation and in which settings. Methods: We assembled a retrospective public-source cohort of technologies supported by Small Business Innovation Research and Small Business Technology Transfer awards from fiscal years 2005-2020 by keyword filtering and funded-purpose review. Confirmation required living-human use of the funded capability or a supported direct extension after a qualifying same-technology award, with public evidence by October 8, 2026. Exploratory comparisons examined program, observed phase, award era, and cumulative support. A 500-family random sample assessed screening omissions. Results: The cohort comprised 209 technologies, 221 award families, and 453 applications receiving $206,825,343. Human implementation was documented for 31/209 technologies (14.8%; Wilson 95% confidence interval, 10.7%-20.3%); evidence was not located for 156 and was indeterminate for 22. Confirmed settings were neurosurgical-scope care (26), other clinical care (2), mixed surgical cohorts (1), and nonclinical human evaluation (2). Confirmation was more frequent with observed Phase II support than Phase I only (21/98 vs 10/111; difference, 12.4 percentage points; company-component bootstrap 95% confidence interval, 2.8-22.4). None of four conventional tests met a Holm-adjusted .05 threshold. Screening scenarios estimated 40-76 omitted families. Conclusion: Approximately one in seven included technologies had documented human implementation. Linking individual awards to implemented capabilities provides an empirical benchmark for early neurosurgical translation and a practical foundation for tracking subsequent clinical evaluation.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background: Federal small business awards from the National Institutes of Health fund neurosurgical devices and procedural technologies, but how often the specific funded capability reaches human use is unknown. We determined how often these technologies had documented human implementation and in which settings. Methods: We assembled a retrospective public-source cohort of technologies supported by Small Business Innovation Research and Small Business Technology Transfer awards from fiscal years 2005-2020 by keyword filtering and funded-purpose review. Confirmation required living-human use of the funded capability or a supported direct extension after a qualifying same-technology award, with public evidence by October 8, 2026. Exploratory comparisons examined program, observed phase, award era, and cumulative support. A 500-family random sample assessed screening omissions. Results: The cohort comprised 209 technologies, 221 award families, and 453 applications receiving $206,825,343. Human implementation was documented for 31/209 technologies (14.8%; Wilson 95% confidence interval, 10.7%-20.3%); evidence was not located for 156 and was indeterminate for 22. Confirmed settings were neurosurgical-scope care (26), other clinical care (2), mixed surgical cohorts (1), and nonclinical human evaluation (2). Confirmation was more frequent with observed Phase II support than Phase I only (21/98 vs 10/111; difference, 12.4 percentage points; company-component bootstrap 95% confidence interval, 2.8-22.4). None of four conventional tests met a Holm-adjusted .05 threshold. Screening scenarios estimated 40-76 omitted families. Conclusion: Approximately one in seven included technologies had documented human implementation. Linking individual awards to implemented capabilities provides an empirical benchmark for early neurosurgical translation and a practical foundation for tracking subsequent clinical evaluation.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368058v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
            "content_type": "application/json",
            "elapsed_ms": 265,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368058v1?rss=1"
    },
    {
      "id": "1d83600c077f0c42a8f6",
      "title": "Preprint: Prompt Injection Can Alter Large Language Model Scores and Feedback on Medical Student Essays: A Four-Model Stress Test",
      "content_text": "Background: Large language models (LLMs) can support health professions educational assessment by scoring narrative text. However, educator-authored scoring instructions and student text enter the same language-processing context. Prompt injection exploits this boundary by embedding LLM-directed instructions (\"attacks\") within to-be-assessed text. The scope of this problem across different LLM configurations, attack conditions, and attacker objectives remains incompletely characterized. This…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "1d83600c077f0c42a8f6",
          "source": "web",
          "type": "change",
          "key": "#da77c3dba98e5d8fe5a6",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
          "timestamp": null,
          "observed_at": "2026-11-17T04:06:43Z",
          "data": {
            "change": "added",
            "label": "Preprint: Prompt Injection Can Alter Large Language Model Scores and Feedback on Medical Student Essays: A Four-Model Stress Test",
            "item_type": "record",
            "summary": "added: Preprint: Prompt Injection Can Alter Large Language Model Scores and Feedback on Medical Student Essays: A Four-Model Stress Test",
            "after": {
              "title": "Preprint: Prompt Injection Can Alter Large Language Model Scores and Feedback on Medical Student Essays: A Four-Model Stress Test",
              "authors": "Cook, D. A.",
              "author_corresponding": "David A Cook",
              "author_corresponding_institution": "Mayo Clinic College of Medicine and Science",
              "doi": "10.64898/2026.11.14.26368103",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "medical education",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.14.26368103.source.xml",
              "abstract": "Background: Large language models (LLMs) can support health professions educational assessment by scoring narrative text. However, educator-authored scoring instructions and student text enter the same language-processing context. Prompt injection exploits this boundary by embedding LLM-directed instructions (\"attacks\") within to-be-assessed text. The scope of this problem across different LLM configurations, attack conditions, and attacker objectives remains incompletely characterized. This study explores: How susceptible is LLM scoring to various prompt injection attacks embedded in reflection essays? Methods: This adversarial stress test examined LLM-based scoring of 4 fabricated medical student reflection essays across 8 prompt injection conditions and 4 LLM configurations. We selected 4 essays used in a previous study representing human reference scores 1 to 4 (maximum 6). In October 2026, we used GPT-4.1-mini, GPT-4.1, GPT-5.2, and GPT-6-Luna to score each essay 15 times without modification (\"clean\") and 5 times for each prompt injection attack. Six \"score-targeting attacks\" sought the maximum score of 6; 2 \"feedback-targeting attacks\" sought unauthorized change to narrative feedback, testing whether injections can control the scorer apart from the score itself. The primary outcome was attack success. Results: For clean replications, exact agreement with the human reference standard was 45/60 (75%) for GPT-4.1-mini and >98% for other LLMs. Across all score-targeting attacks and LLMs, 140/480 (29.2%) attained the target score of 6. Analyzed by LLM, 62/120 (51.7%) were successful for GPT-4.1-mini; 51 (42.5%) for GPT-4.1, 25 (20.8%) for GPT-5.2, and 2 (1.7%) for GPT-6-Luna. Analyzed by attack condition, score-targeting success ranged 6% to 56%. Among feedback-targeting attacks, 157/160 achieved success (98.1%), with [&ge;]95% success for each LLM. Conclusions: Prompt injection is an unresolved threat to LLM-based scoring and feedback. Although score-targeting attacks were often resisted, feedback-targeting attacks were nearly always successful. No LLM was uniformly resistant, and resistance to one attack provided little assurance about another.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background: Large language models (LLMs) can support health professions educational assessment by scoring narrative text. However, educator-authored scoring instructions and student text enter the same language-processing context. Prompt injection exploits this boundary by embedding LLM-directed instructions (\"attacks\") within to-be-assessed text. The scope of this problem across different LLM configurations, attack conditions, and attacker objectives remains incompletely characterized. This study explores: How susceptible is LLM scoring to various prompt injection attacks embedded in reflection essays? Methods: This adversarial stress test examined LLM-based scoring of 4 fabricated medical student reflection essays across 8 prompt injection conditions and 4 LLM configurations. We selected 4 essays used in a previous study representing human reference scores 1 to 4 (maximum 6). In October 2026, we used GPT-4.1-mini, GPT-4.1, GPT-5.2, and GPT-6-Luna to score each essay 15 times without modification (\"clean\") and 5 times for each prompt injection attack. Six \"score-targeting attacks\" sought the maximum score of 6; 2 \"feedback-targeting attacks\" sought unauthorized change to narrative feedback, testing whether injections can control the scorer apart from the score itself. The primary outcome was attack success. Results: For clean replications, exact agreement with the human reference standard was 45/60 (75%) for GPT-4.1-mini and >98% for other LLMs. Across all score-targeting attacks and LLMs, 140/480 (29.2%) attained the target score of 6. Analyzed by LLM, 62/120 (51.7%) were successful for GPT-4.1-mini; 51 (42.5%) for GPT-4.1, 25 (20.8%) for GPT-5.2, and 2 (1.7%) for GPT-6-Luna. Analyzed by attack condition, score-targeting success ranged 6% to 56%. Among feedback-targeting attacks, 157/160 achieved success (98.1%), with [&ge;]95% success for each LLM. Conclusions: Prompt injection is an unresolved threat to LLM-based scoring and feedback. Although score-targeting attacks were often resisted, feedback-targeting attacks were nearly always successful. No LLM was uniformly resistant, and resistance to one attack provided little assurance about another.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368103v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
            "content_type": "application/json",
            "elapsed_ms": 265,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368103v1?rss=1"
    },
    {
      "id": "519243a6727cd6e93a9f",
      "title": "Preprint: Greater medial temporal lobe atrophy is associated with less severe cardiac sympathetic denervation in dementia with Lewy bodies",
      "content_text": "Background: Cardiac sympathetic denervation varies in dementia with Lewy bodies (DLB). Our previous neuropathological study demonstrated an association between greater Alzheimer's disease (AD) pathology and milder cardiac sympathetic denervation in DLB. We investigated whether medial temporal lobe atrophy (MTA), a potential marker of concomitant AD pathology, correlates with cardiac sympathetic denervation assessed by 123I-metaiodobenzylguanidine (MIBG) cardiac scintigraphy in probable DLB…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "519243a6727cd6e93a9f",
          "source": "web",
          "type": "change",
          "key": "#fe06f9e24c05a2ab2c6e",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
          "timestamp": null,
          "observed_at": "2026-11-17T04:06:43Z",
          "data": {
            "change": "added",
            "label": "Preprint: Greater medial temporal lobe atrophy is associated with less severe cardiac sympathetic denervation in dementia with Lewy bodies",
            "item_type": "record",
            "summary": "added: Preprint: Greater medial temporal lobe atrophy is associated with less severe cardiac sympathetic denervation in dementia with Lewy bodies",
            "after": {
              "title": "Preprint: Greater medial temporal lobe atrophy is associated with less severe cardiac sympathetic denervation in dementia with Lewy bodies",
              "authors": "Takahashi, M.; Kitsuka, N.; Maruoka, H.; Abe, K.; Orimo, S.; Inaba, A.",
              "author_corresponding": "Makoto Takahashi",
              "author_corresponding_institution": "Division of Neurology and Gerontoroly, Department of Internal Medicine, Iwate Medical University",
              "doi": "10.64898/2026.11.13.26367891",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "neurology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.13.26367891.source.xml",
              "abstract": "Background: Cardiac sympathetic denervation varies in dementia with Lewy bodies (DLB). Our previous neuropathological study demonstrated an association between greater Alzheimer's disease (AD) pathology and milder cardiac sympathetic denervation in DLB. We investigated whether medial temporal lobe atrophy (MTA), a potential marker of concomitant AD pathology, correlates with cardiac sympathetic denervation assessed by 123I-metaiodobenzylguanidine (MIBG) cardiac scintigraphy in probable DLB. Methods: In this retrospective cross-sectional study, we analyzed 162 patients with probable DLB. MTA was assessed by Voxel-based Specific Regional Analysis System for Alzheimer's Disease (VSRAD) Z-scores, and cardiac MIBG uptake by early and delayed heart-to-mediastinum (H/M) ratios. Associations were examined using Spearman and partial Spearman correlations adjusted for age at diagnosis, sex, and disease duration. Sensitivity analyses excluded patients with MIBG-dependent classification, diabetes mellitus or cardiac disease. Results: VSRAD Z-scores correlated positively with early ({rho} = 0.173, P = 0.028) and delayed H/M ratios ({rho} = 0.225, P = 0.004). After adjustment, the association was no longer significant for the early H/M ratio ({rho} = 0.133, P = 0.094), whereas it remained significant for the delayed H/M ratio ({rho} = 0.196, P = 0.013). The adjusted delayed H/M association persisted after excluding 18 patients with MIBG-dependent classification ({rho} = 0.211, P = 0.012) and 40 with diabetes or cardiac disease ({rho} = 0.231, P = 0.011). Conclusions: Greater MTA was associated with relatively preserved cardiac MIBG uptake in probable DLB, particularly on delayed imaging. Consistent with our neuropathological observations, these findings suggest that concomitant AD pathology may contribute to variability in cardiac sympathetic denervation.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background: Cardiac sympathetic denervation varies in dementia with Lewy bodies (DLB). Our previous neuropathological study demonstrated an association between greater Alzheimer's disease (AD) pathology and milder cardiac sympathetic denervation in DLB. We investigated whether medial temporal lobe atrophy (MTA), a potential marker of concomitant AD pathology, correlates with cardiac sympathetic denervation assessed by 123I-metaiodobenzylguanidine (MIBG) cardiac scintigraphy in probable DLB. Methods: In this retrospective cross-sectional study, we analyzed 162 patients with probable DLB. MTA was assessed by Voxel-based Specific Regional Analysis System for Alzheimer's Disease (VSRAD) Z-scores, and cardiac MIBG uptake by early and delayed heart-to-mediastinum (H/M) ratios. Associations were examined using Spearman and partial Spearman correlations adjusted for age at diagnosis, sex, and disease duration. Sensitivity analyses excluded patients with MIBG-dependent classification, diabetes mellitus or cardiac disease. Results: VSRAD Z-scores correlated positively with early ({rho} = 0.173, P = 0.028) and delayed H/M ratios ({rho} = 0.225, P = 0.004). After adjustment, the association was no longer significant for the early H/M ratio ({rho} = 0.133, P = 0.094), whereas it remained significant for the delayed H/M ratio ({rho} = 0.196, P = 0.013). The adjusted delayed H/M association persisted after excluding 18 patients with MIBG-dependent classification ({rho} = 0.211, P = 0.012) and 40 with diabetes or cardiac disease ({rho} = 0.231, P = 0.011). Conclusions: Greater MTA was associated with relatively preserved cardiac MIBG uptake in probable DLB, particularly on delayed imaging. Consistent with our neuropathological observations, these findings suggest that concomitant AD pathology may contribute to variability in cardiac sympathetic denervation.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26367891v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
            "content_type": "application/json",
            "elapsed_ms": 265,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26367891v1?rss=1"
    },
    {
      "id": "11c431301055b6294ec2",
      "title": "Preprint: Cortical surface area is an independent predictor of incident dementia",
      "content_text": "Cortical surface area (cSA) is associated with intelligence and cognition, yet structural MRI studies of neurodegeneration in Alzheimers disease and related dementias (ADRD) have emphasized quantification of cortical thickness (cTH) and volume, with very limited evaluation of cSA. We examined whether cSA of AD-relevant brain regions provide diagnostic, prognostic, and biological information beyond cTH and volume across 5,430 participants (3,124 cognitively unimpaired; 1,634 mild cognitive…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "11c431301055b6294ec2",
          "source": "web",
          "type": "change",
          "key": "#797756fa7e3c2e9a96b6",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
          "timestamp": null,
          "observed_at": "2026-11-17T04:06:43Z",
          "data": {
            "change": "added",
            "label": "Preprint: Cortical surface area is an independent predictor of incident dementia",
            "item_type": "record",
            "summary": "added: Preprint: Cortical surface area is an independent predictor of incident dementia",
            "after": {
              "title": "Preprint: Cortical surface area is an independent predictor of incident dementia",
              "authors": "Wiskoski, H. E.; Zahra, S.; French, S. R.; Arias, J. C.; Waughman, X.; Do, L.; Escareno, C.; Vidana, P.; Mushtaq, R.; Johnson, K.; Altbach, M. I.; Reiman, E. M.; Elahi, F. M.; Vitali, F.; Bedrick, E.; Trouard, T. P.; Alexander, G. E.; Weinkauf, C. C.",
              "author_corresponding": "Craig C Weinkauf",
              "author_corresponding_institution": "Department of Surgery, Department of Biomedical Engineering, Department of Neuroscience, University of Arizona",
              "doi": "10.64898/2026.11.13.26367749",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "neurology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.13.26367749.source.xml",
              "abstract": "Cortical surface area (cSA) is associated with intelligence and cognition, yet structural MRI studies of neurodegeneration in Alzheimers disease and related dementias (ADRD) have emphasized quantification of cortical thickness (cTH) and volume, with very limited evaluation of cSA. We examined whether cSA of AD-relevant brain regions provide diagnostic, prognostic, and biological information beyond cTH and volume across 5,430 participants (3,124 cognitively unimpaired; 1,634 mild cognitive impairment [MCI]; 672 ADRD) from three aging and dementia cohorts: the National Alzheimers Coordinating Center, Alzheimers Disease Neuroimaging Initiative, and Carotids and Minds study. In cross-sectional analyses, cSA and cTH showed weak correlation, and lower cSA was independently associated with greater odds of MCI and ADRD after adjustment for cTH and covariates. Participants with both low cSA and low cTH had greater risk of MCI and ADRD compared to low cSA, cTH, or volume alone. In longitudinal models, baseline cSA predicted incident ADRD independent from cTH, and combined cSA/cTH models outperformed cSA, cTH, or volume alone for predicting incident ADRD over a mean follow-up of 4.3 years. Complementing these findings, proteomics analyses revealed distinct signatures associated with cSA compared to cTH. Overall, these findings support cSA as a clinically informative and biologically distinct dimension of AD-related cortical vulnerability.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Cortical surface area (cSA) is associated with intelligence and cognition, yet structural MRI studies of neurodegeneration in Alzheimers disease and related dementias (ADRD) have emphasized quantification of cortical thickness (cTH) and volume, with very limited evaluation of cSA. We examined whether cSA of AD-relevant brain regions provide diagnostic, prognostic, and biological information beyond cTH and volume across 5,430 participants (3,124 cognitively unimpaired; 1,634 mild cognitive impairment [MCI]; 672 ADRD) from three aging and dementia cohorts: the National Alzheimers Coordinating Center, Alzheimers Disease Neuroimaging Initiative, and Carotids and Minds study. In cross-sectional analyses, cSA and cTH showed weak correlation, and lower cSA was independently associated with greater odds of MCI and ADRD after adjustment for cTH and covariates. Participants with both low cSA and low cTH had greater risk of MCI and ADRD compared to low cSA, cTH, or volume alone. In longitudinal models, baseline cSA predicted incident ADRD independent from cTH, and combined cSA/cTH models outperformed cSA, cTH, or volume alone for predicting incident ADRD over a mean follow-up of 4.3 years. Complementing these findings, proteomics analyses revealed distinct signatures associated with cSA compared to cTH. Overall, these findings support cSA as a clinically informative and biologically distinct dimension of AD-related cortical vulnerability.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26367749v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
            "content_type": "application/json",
            "elapsed_ms": 265,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26367749v1?rss=1"
    },
    {
      "id": "70285449ce528881a6d5",
      "title": "Preprint: Circulating Apolipoprotein Profiles and Their Associations with Mild Cognitive and Behavioral Impairment in Older Adults: A Cross-Sectional Study",
      "content_text": "Background Mild cognitive impairment (MCI) and mild behavioral impairment (MBI) are overlapping prodromal states associated with dementia risk. Circulating apolipoproteins (Apos) may be linked to cognitive and behavioral changes, but their relationships remain unclear. Objective Examine plasma concentrations of multiple Apos in prodromal dementia. Methods This cross-sectional study included 148 Thai participants aged 60-75 years: 56 cognitively normal controls, 47 with MCI without MBI, and 45…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "70285449ce528881a6d5",
          "source": "web",
          "type": "change",
          "key": "#6e7b89a8662aa5b1d512",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
          "timestamp": null,
          "observed_at": "2026-11-17T04:06:43Z",
          "data": {
            "change": "added",
            "label": "Preprint: Circulating Apolipoprotein Profiles and Their Associations with Mild Cognitive and Behavioral Impairment in Older Adults: A Cross-Sectional Study",
            "item_type": "record",
            "summary": "added: Preprint: Circulating Apolipoprotein Profiles and Their Associations with Mild Cognitive and Behavioral Impairment in Older Adults: A Cross-Sectional Study",
            "after": {
              "title": "Preprint: Circulating Apolipoprotein Profiles and Their Associations with Mild Cognitive and Behavioral Impairment in Older Adults: A Cross-Sectional Study",
              "authors": "Amrapala, A.; Hemrungrojn, S.; Nupairoj, N.; Solmi, M.; Tunvirachaisakul, C.; Maes, M.",
              "author_corresponding": "Michael Maes",
              "author_corresponding_institution": "University of Electronic Science and Technology of China",
              "doi": "10.64898/2026.11.14.26368084",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "neurology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.14.26368084.source.xml",
              "abstract": "Background Mild cognitive impairment (MCI) and mild behavioral impairment (MBI) are overlapping prodromal states associated with dementia risk. Circulating apolipoproteins (Apos) may be linked to cognitive and behavioral changes, but their relationships remain unclear. Objective Examine plasma concentrations of multiple Apos in prodromal dementia. Methods This cross-sectional study included 148 Thai participants aged 60-75 years: 56 cognitively normal controls, 47 with MCI without MBI, and 45 with MBI with or without MCI. We measured ApoA1, ApoA2, ApoB, ApoC1, ApoC3, ApoD, ApoE, ApoH, and ApoJ, five lipids, and APOE genotype, and computed an atherogenic Apo composite (ApoB-ApoC1-ApoC3). Primary analyses used multivariable linear regression of quantitative cognitive and behavioral outcomes. Group comparisons were secondary and served to contextualize the dimensional regression findings. Results Across Montreal Cognitive Assessment (MoCA) models, 20.7-28.2% of variance was explained by combinations of ApoH, ApoC3, APOE {varepsilon}4 carrier status, age, and male sex (inverse associations), and free cholesterol and education (positive associations). The atherogenic composite was inversely associated with MoCA total, memory index, and delayed recall scores, and with Consortium to Establish a Registry for Alzheimer's Disease (CERAD) verbal fluency and word list recall. No significant predictors emerged for Neuropsychiatric Inventory (NPI) scores or NPI caregiver distress. All nine Apos differed significantly between groups, with levels highest in MCI, intermediate in MBI, and lowest in controls. Conclusions Circulating Apo profiles differed across controls, MCI, and MBI groups and were more consistently associated with cognitive than behavioral outcomes. ApoH and the atherogenic Apo composite warrant further investigation as candidate biomarkers of early cognitive dysfunction.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background Mild cognitive impairment (MCI) and mild behavioral impairment (MBI) are overlapping prodromal states associated with dementia risk. Circulating apolipoproteins (Apos) may be linked to cognitive and behavioral changes, but their relationships remain unclear. Objective Examine plasma concentrations of multiple Apos in prodromal dementia. Methods This cross-sectional study included 148 Thai participants aged 60-75 years: 56 cognitively normal controls, 47 with MCI without MBI, and 45 with MBI with or without MCI. We measured ApoA1, ApoA2, ApoB, ApoC1, ApoC3, ApoD, ApoE, ApoH, and ApoJ, five lipids, and APOE genotype, and computed an atherogenic Apo composite (ApoB-ApoC1-ApoC3). Primary analyses used multivariable linear regression of quantitative cognitive and behavioral outcomes. Group comparisons were secondary and served to contextualize the dimensional regression findings. Results Across Montreal Cognitive Assessment (MoCA) models, 20.7-28.2% of variance was explained by combinations of ApoH, ApoC3, APOE {varepsilon}4 carrier status, age, and male sex (inverse associations), and free cholesterol and education (positive associations). The atherogenic composite was inversely associated with MoCA total, memory index, and delayed recall scores, and with Consortium to Establish a Registry for Alzheimer's Disease (CERAD) verbal fluency and word list recall. No significant predictors emerged for Neuropsychiatric Inventory (NPI) scores or NPI caregiver distress. All nine Apos differed significantly between groups, with levels highest in MCI, intermediate in MBI, and lowest in controls. Conclusions Circulating Apo profiles differed across controls, MCI, and MBI groups and were more consistently associated with cognitive than behavioral outcomes. ApoH and the atherogenic Apo composite warrant further investigation as candidate biomarkers of early cognitive dysfunction.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368084v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
            "content_type": "application/json",
            "elapsed_ms": 265,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368084v1?rss=1"
    },
    {
      "id": "3999d2c21759ad9ba961",
      "title": "Preprint: Usual dietary fibre intake in Australia: A comparison of the 2011-12 and 2023 National Nutrition and Physical Activity Surveys",
      "content_text": "Background & Aims: Dietary fibre is an essential macronutrient for human health. Whether fibre intake has changed in Australia over the last decade remains unknown. This study estimated usual fibre intake among Australian children and adults in 2023 and compared it with 2011-12. Methods: We used data from the 2011-12 (n=12,153) and 2023 (n=11,198) National Nutrition and Physical Activity Surveys with repeat 24-hour recalls. Usual intake was estimated with the National Cancer Institute method…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "3999d2c21759ad9ba961",
          "source": "web",
          "type": "change",
          "key": "#655cf1da9e1a74d70214",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
          "timestamp": null,
          "observed_at": "2026-11-17T04:06:43Z",
          "data": {
            "change": "added",
            "label": "Preprint: Usual dietary fibre intake in Australia: A comparison of the 2011-12 and 2023 National Nutrition and Physical Activity Surveys",
            "item_type": "record",
            "summary": "added: Preprint: Usual dietary fibre intake in Australia: A comparison of the 2011-12 and 2023 National Nutrition and Physical Activity Surveys",
            "after": {
              "title": "Preprint: Usual dietary fibre intake in Australia: A comparison of the 2011-12 and 2023 National Nutrition and Physical Activity Surveys",
              "authors": "Lu, J.; Leech, R.; Snelson, M.; Marques, F.",
              "author_corresponding": "Francine Marques",
              "author_corresponding_institution": "Monash University",
              "doi": "10.64898/2026.11.14.26368081",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_no",
              "category": "nutrition",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.14.26368081.source.xml",
              "abstract": "Background & Aims: Dietary fibre is an essential macronutrient for human health. Whether fibre intake has changed in Australia over the last decade remains unknown. This study estimated usual fibre intake among Australian children and adults in 2023 and compared it with 2011-12. Methods: We used data from the 2011-12 (n=12,153) and 2023 (n=11,198) National Nutrition and Physical Activity Surveys with repeat 24-hour recalls. Usual intake was estimated with the National Cancer Institute method and compared with the Adequate Intake (AI) and the Suggested Dietary Target (SDT) levels. Fibre density (g/1,000 kcal) was modelled jointly with energy. Results: Mean usual fibre intake in adults decreased by 2.1 g/day (95% confidence interval 1.6-2.6), from 22.9 to 20.8 g/day. The proportion meeting the AI fell from 24.6% to 17.2%, and SDT from 11.4% to 7.5%. Declines occurred in both sexes and were largest among adults aged 51 years and over. Fibre density fell by 3.2% to 10.7 g/1,000 kcal. Intake in children was stable (19.7 and 20.0 g/day), but only 21.8% of adolescents aged 14-18 years met the AI. In 2023, intake was significantly lower in adults from the most disadvantaged areas and in those with hypertension or obesity. Conclusions: Usual fibre intake among Australian adults declined over the last decade, reflecting both lower energy intake and less fibre-rich food choices. Strategies to improve the availability, affordability, and uptake of fibre-rich foods are needed, particularly for adolescents, older adults, and socioeconomically disadvantaged groups.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background & Aims: Dietary fibre is an essential macronutrient for human health. Whether fibre intake has changed in Australia over the last decade remains unknown. This study estimated usual fibre intake among Australian children and adults in 2023 and compared it with 2011-12. Methods: We used data from the 2011-12 (n=12,153) and 2023 (n=11,198) National Nutrition and Physical Activity Surveys with repeat 24-hour recalls. Usual intake was estimated with the National Cancer Institute method and compared with the Adequate Intake (AI) and the Suggested Dietary Target (SDT) levels. Fibre density (g/1,000 kcal) was modelled jointly with energy. Results: Mean usual fibre intake in adults decreased by 2.1 g/day (95% confidence interval 1.6-2.6), from 22.9 to 20.8 g/day. The proportion meeting the AI fell from 24.6% to 17.2%, and SDT from 11.4% to 7.5%. Declines occurred in both sexes and were largest among adults aged 51 years and over. Fibre density fell by 3.2% to 10.7 g/1,000 kcal. Intake in children was stable (19.7 and 20.0 g/day), but only 21.8% of adolescents aged 14-18 years met the AI. In 2023, intake was significantly lower in adults from the most disadvantaged areas and in those with hypertension or obesity. Conclusions: Usual fibre intake among Australian adults declined over the last decade, reflecting both lower energy intake and less fibre-rich food choices. Strategies to improve the availability, affordability, and uptake of fibre-rich foods are needed, particularly for adolescents, older adults, and socioeconomically disadvantaged groups.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368081v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
            "content_type": "application/json",
            "elapsed_ms": 265,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368081v1?rss=1"
    },
    {
      "id": "b13949ce7dfb4c38ad1e",
      "title": "Preprint: Beyond prescription: Determinants of low-dose aspirin adoption and uptake across the pre-eclampsia prevention pathway in Nepal - a qualitative study guided by the COM-B model",
      "content_text": "Despite strong evidence supporting low-dose aspirin (LDA) for preventing pre-eclampsia among women at risk, implementation remains suboptimal globally. The prevention pathway encompasses early antenatal care engagement, screening and risk identification, prescribing LDA, and medication uptake. This qualitative study explored barriers and facilitators to LDA adoption by providers (i.e., prescribing) and uptake among women in Nepal. A qualitative study was conducted with pregnant women…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "b13949ce7dfb4c38ad1e",
          "source": "web",
          "type": "change",
          "key": "#844704eac28fcaf66f18",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
          "timestamp": null,
          "observed_at": "2026-11-17T04:06:43Z",
          "data": {
            "change": "added",
            "label": "Preprint: Beyond prescription: Determinants of low-dose aspirin adoption and uptake across the pre-eclampsia prevention pathway in Nepal - a qualitative study guided by the COM-B model",
            "item_type": "record",
            "summary": "added: Preprint: Beyond prescription: Determinants of low-dose aspirin adoption and uptake across the pre-eclampsia prevention pathway in Nepal - a qualitative study guided by the COM-B model",
            "after": {
              "title": "Preprint: Beyond prescription: Determinants of low-dose aspirin adoption and uptake across the pre-eclampsia prevention pathway in Nepal - a qualitative study guided by the COM-B model",
              "authors": "Harrison, L.; Uprety, S.; Ojha, A.; Rai, T.; Paudel, P.; Dhungana, J.; Chandrasekaran, S.; Ramakrishnan, U.; Shrestha, A.; Rhodes, E. C.",
              "author_corresponding": "Leila Harrison",
              "author_corresponding_institution": "Emory University",
              "doi": "10.64898/2026.11.13.26368074",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "obstetrics and gynecology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.13.26368074.source.xml",
              "abstract": "Despite strong evidence supporting low-dose aspirin (LDA) for preventing pre-eclampsia among women at risk, implementation remains suboptimal globally. The prevention pathway encompasses early antenatal care engagement, screening and risk identification, prescribing LDA, and medication uptake. This qualitative study explored barriers and facilitators to LDA adoption by providers (i.e., prescribing) and uptake among women in Nepal. A qualitative study was conducted with pregnant women, healthcare providers, and maternal and child health stakeholders in Nepal. Data collection and analysis were guided by the Capability, Opportunity, Motivation, and Behavior (COM-B) model. Participants were purposively recruited from three tertiary hospitals and maternal health organizations. Semi-structured interviews explored experiences and perspectives related to antenatal care, such as pre-eclampsia risk screening, LDA prescribing, and uptake. Data were analyzed using rapid qualitative analysis and organized according to the COM-B components.   Seventy-three participants were interviewed, including 36 pregnant women, both at risk and not at risk for pre-eclampsia; 29 healthcare providers, including consultant/senior obstetricians, mid-level doctors, and nurses or midwives; and 8 maternal and child health stakeholders representing government, multi-lateral, non-governmental, professional, and academic institutions. LDA adoption and uptake were affected by interdependent gaps across the prevention pathway. Delayed antenatal care engagement and inconsistent screening limited timely identification of women at risk, while gaps in national guidance and standardized prescribing protocols contributed to variable provider prescribing practices. Among women prescribed LDA, clear counselling on its purpose and safety and trust in providers supported uptake. LDA adoption and uptake depend on a functioning prevention pathway in which women engage with antenatal care early enough for timely risk assessment, those at risk are identified through screening, providers prescribe appropriately, and women are supported to use the medication. Strengthening this pathway requires coordinated attention to health-system and provider capacity as well as communication with women, rather than strategies focused narrowly on prescribing or medication use. These findings will inform the development of implementation strategies for Nepal and other low-resource settings seeking to integrate evidence-based preventive interventions into maternal healthcare systems.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Despite strong evidence supporting low-dose aspirin (LDA) for preventing pre-eclampsia among women at risk, implementation remains suboptimal globally. The prevention pathway encompasses early antenatal care engagement, screening and risk identification, prescribing LDA, and medication uptake. This qualitative study explored barriers and facilitators to LDA adoption by providers (i.e., prescribing) and uptake among women in Nepal. A qualitative study was conducted with pregnant women, healthcare providers, and maternal and child health stakeholders in Nepal. Data collection and analysis were guided by the Capability, Opportunity, Motivation, and Behavior (COM-B) model. Participants were purposively recruited from three tertiary hospitals and maternal health organizations. Semi-structured interviews explored experiences and perspectives related to antenatal care, such as pre-eclampsia risk screening, LDA prescribing, and uptake. Data were analyzed using rapid qualitative analysis and organized according to the COM-B components.   Seventy-three participants were interviewed, including 36 pregnant women, both at risk and not at risk for pre-eclampsia; 29 healthcare providers, including consultant/senior obstetricians, mid-level doctors, and nurses or midwives; and 8 maternal and child health stakeholders representing government, multi-lateral, non-governmental, professional, and academic institutions. LDA adoption and uptake were affected by interdependent gaps across the prevention pathway. Delayed antenatal care engagement and inconsistent screening limited timely identification of women at risk, while gaps in national guidance and standardized prescribing protocols contributed to variable provider prescribing practices. Among women prescribed LDA, clear counselling on its purpose and safety and trust in providers supported uptake. LDA adoption and uptake depend on a functioning prevention pathway in which women engage with antenatal care early enough for timely risk assessment, those at risk are identified through screening, providers prescribe appropriately, and women are supported to use the medication. Strengthening this pathway requires coordinated attention to health-system and provider capacity as well as communication with women, rather than strategies focused narrowly on prescribing or medication use. These findings will inform the development of implementation strategies for Nepal and other low-resource settings seeking to integrate evidence-based preventive interventions into maternal healthcare systems.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368074v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
            "content_type": "application/json",
            "elapsed_ms": 265,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368074v1?rss=1"
    },
    {
      "id": "eda516ecd53e3f00bcbf",
      "title": "Preprint: Exome-wide rare-variant associations vary across disease trajectories",
      "content_text": "Genetic studies of chronic disease typically collapse longitudinal clinical histories into binary case-control outcomes, obscuring disease timing and differences in genetic association patterns across disease transitions. Time-to-event analysis can preserve this information, but rare-variant analysis of post-diagnosis progression is challenged by sparse carrier-events and extensive censoring. We developed GATE-GENE, a scalable gene-based framework that maintains calibration under these…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "eda516ecd53e3f00bcbf",
          "source": "web",
          "type": "change",
          "key": "#4f56598f4b3ec83b6398",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
          "timestamp": null,
          "observed_at": "2026-11-17T04:06:43Z",
          "data": {
            "change": "added",
            "label": "Preprint: Exome-wide rare-variant associations vary across disease trajectories",
            "item_type": "record",
            "summary": "added: Preprint: Exome-wide rare-variant associations vary across disease trajectories",
            "after": {
              "title": "Preprint: Exome-wide rare-variant associations vary across disease trajectories",
              "authors": "Wang, Y.; Luo, W.; Hu, L.; Chen, T.; Lu, W.; Dowd, C.; Wen, C.; Bi, W.; Koyama, S.; Surakka, I.; Neale, B. M.; Daly, M.; Nataranjan, P.; Martin, A.; Zhou, W.",
              "author_corresponding": "Ying Wang",
              "author_corresponding_institution": "Massachusetts General Hospital; Broad Institute of MIT and Harvard; Ohio State University",
              "doi": "10.64898/2026.11.14.26368035",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_no",
              "category": "genetic and genomic medicine",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.14.26368035.source.xml",
              "abstract": "Genetic studies of chronic disease typically collapse longitudinal clinical histories into binary case-control outcomes, obscuring disease timing and differences in genetic association patterns across disease transitions. Time-to-event analysis can preserve this information, but rare-variant analysis of post-diagnosis progression is challenged by sparse carrier-events and extensive censoring. We developed GATE-GENE, a scalable gene-based framework that maintains calibration under these conditions. Across 300 onset phenotypes in UK Biobank (UKB), GATE-GENE identified 107 exome-wide significant germline associations involving 89 genes and 67 diseases. Across 95 multi-state trajectories comprising baseline (T0), an upstream disease state (T1) and a downstream disease state (T2), disease onset (T0[-&gt;]T1) and subsequent progression (T1[-&gt;]T2) showed limited detectable sharing of rare-variant association signals. Progression showed greater concordance of gene-level association signals with downstream phenotypes (T0[-&gt;]T2) when the analyses shared T2 events occurring after T1. Removing overlapping downstream events reduced the median correlation between gene-level association signals from 0.063 to 0.001, after accounting for background correlation. Null simulations reproduced the relationship between event overlap and concordance without genetic effects, whereas additional simulations showed that near-zero concordance could persist despite extensive underlying causal-gene sharing. This attenuation was reproduced across three ancestry groups in All of Us. Cross-biobank meta-analysis identified 12 additional exome-wide significant progression associations beyond three UKB discoveries, although clinical sensitivity analyses suggested that the strongest PKD1 signals largely reflected underlying cystic kidney disease. Together, these findings establish GATE-GENE for investigating rare-variant associations with disease timing and progression, while demonstrating how overlapping clinical events and limited carrier-event information complicate inference about genetic sharing across disease transitions.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Genetic studies of chronic disease typically collapse longitudinal clinical histories into binary case-control outcomes, obscuring disease timing and differences in genetic association patterns across disease transitions. Time-to-event analysis can preserve this information, but rare-variant analysis of post-diagnosis progression is challenged by sparse carrier-events and extensive censoring. We developed GATE-GENE, a scalable gene-based framework that maintains calibration under these conditions. Across 300 onset phenotypes in UK Biobank (UKB), GATE-GENE identified 107 exome-wide significant germline associations involving 89 genes and 67 diseases. Across 95 multi-state trajectories comprising baseline (T0), an upstream disease state (T1) and a downstream disease state (T2), disease onset (T0[-&gt;]T1) and subsequent progression (T1[-&gt;]T2) showed limited detectable sharing of rare-variant association signals. Progression showed greater concordance of gene-level association signals with downstream phenotypes (T0[-&gt;]T2) when the analyses shared T2 events occurring after T1. Removing overlapping downstream events reduced the median correlation between gene-level association signals from 0.063 to 0.001, after accounting for background correlation. Null simulations reproduced the relationship between event overlap and concordance without genetic effects, whereas additional simulations showed that near-zero concordance could persist despite extensive underlying causal-gene sharing. This attenuation was reproduced across three ancestry groups in All of Us. Cross-biobank meta-analysis identified 12 additional exome-wide significant progression associations beyond three UKB discoveries, although clinical sensitivity analyses suggested that the strongest PKD1 signals largely reflected underlying cystic kidney disease. Together, these findings establish GATE-GENE for investigating rare-variant associations with disease timing and progression, while demonstrating how overlapping clinical events and limited carrier-event information complicate inference about genetic sharing across disease transitions.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368035v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
            "content_type": "application/json",
            "elapsed_ms": 265,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368035v1?rss=1"
    },
    {
      "id": "dc0e000e70aa2ff0488b",
      "title": "Preprint: Private Equity Practice Connections and Medicare Professional Payments Among US Neurological Surgeons",
      "content_text": "Background: Medicare payment patterns among neurosurgeons with private equity connections remain poorly characterized. We compared annual professional payments by connection type. Methods: In this retrospective cross-sectional study, public Medicare provider summaries for 2013-2024 were linked to dated affiliation and investment records. The primary comparison included 69 practice or management-services organization-connected surgeons and 4,016 comparison surgeons. Connected surgeons…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "dc0e000e70aa2ff0488b",
          "source": "web",
          "type": "change",
          "key": "#f83a8c6bfb3179520652",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
          "timestamp": null,
          "observed_at": "2026-11-17T04:06:43Z",
          "data": {
            "change": "added",
            "label": "Preprint: Private Equity Practice Connections and Medicare Professional Payments Among US Neurological Surgeons",
            "item_type": "record",
            "summary": "added: Preprint: Private Equity Practice Connections and Medicare Professional Payments Among US Neurological Surgeons",
            "after": {
              "title": "Preprint: Private Equity Practice Connections and Medicare Professional Payments Among US Neurological Surgeons",
              "authors": "Bachu, A.; Rajesh, R.; Uram, Z.; Chinthala, A.; Germanwala, A. V.",
              "author_corresponding": "Abhinav Bachu",
              "author_corresponding_institution": "Department of Neurological Surgery, Loyola University Chicago Stritch School of Medicine, 2160 S. First Avenue, Maywood, IL 60153, United States",
              "doi": "10.64898/2026.11.13.26368057",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "health economics",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.13.26368057.source.xml",
              "abstract": "Background: Medicare payment patterns among neurosurgeons with private equity connections remain poorly characterized. We compared annual professional payments by connection type. Methods: In this retrospective cross-sectional study, public Medicare provider summaries for 2013-2024 were linked to dated affiliation and investment records. The primary comparison included 69 practice or management-services organization-connected surgeons and 4,016 comparison surgeons. Connected surgeons contributed index-year payments; comparison surgeons contributed averages over eligible years. Welch comparisons of log payments estimated geometric mean ratios. Supporting analyses examined dollar differences, state-year standardization, beneficiary age/risk balance, 35 hospital-operator surgeons, and longitudinal trajectories. Payments were expressed in 2024 US dollars. Results: The primary geometric mean ratio was 1.38 (95% confidence interval 1.11-1.72; P = .004). The arithmetic mean difference was +$31,250 (-$3,006 to +$65,506); the state-year standardized difference was +$32,204 (+$2,886 to +$65,372). Age/risk balancing attenuated the ratio to 1.25 (1.01-1.59). The hospital-operator ratio was 0.53 (0.35-0.81); the pooled ratio was 1.00 (0.81-1.25). Among 50 longitudinally eligible practice or management-services organization-connected surgeons, the differential annual change was +16.9% (-0.3% to +37.2%) on the log scale and -$15,727 (wild cluster bootstrap interval -$95,893 to +$35,191) in dollars. Excluding one high-billing surgeon reversed the dollar estimate. All intervals are 95% confidence intervals. Conclusion: Practice and management-services organization connections were associated with higher unadjusted payments; balancing attenuated the ratio to 1.25. Hospital-operator payments were lower. Longitudinal estimates were imprecise and do not establish acquisition effects.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background: Medicare payment patterns among neurosurgeons with private equity connections remain poorly characterized. We compared annual professional payments by connection type. Methods: In this retrospective cross-sectional study, public Medicare provider summaries for 2013-2024 were linked to dated affiliation and investment records. The primary comparison included 69 practice or management-services organization-connected surgeons and 4,016 comparison surgeons. Connected surgeons contributed index-year payments; comparison surgeons contributed averages over eligible years. Welch comparisons of log payments estimated geometric mean ratios. Supporting analyses examined dollar differences, state-year standardization, beneficiary age/risk balance, 35 hospital-operator surgeons, and longitudinal trajectories. Payments were expressed in 2024 US dollars. Results: The primary geometric mean ratio was 1.38 (95% confidence interval 1.11-1.72; P = .004). The arithmetic mean difference was +$31,250 (-$3,006 to +$65,506); the state-year standardized difference was +$32,204 (+$2,886 to +$65,372). Age/risk balancing attenuated the ratio to 1.25 (1.01-1.59). The hospital-operator ratio was 0.53 (0.35-0.81); the pooled ratio was 1.00 (0.81-1.25). Among 50 longitudinally eligible practice or management-services organization-connected surgeons, the differential annual change was +16.9% (-0.3% to +37.2%) on the log scale and -$15,727 (wild cluster bootstrap interval -$95,893 to +$35,191) in dollars. Excluding one high-billing surgeon reversed the dollar estimate. All intervals are 95% confidence intervals. Conclusion: Practice and management-services organization connections were associated with higher unadjusted payments; balancing attenuated the ratio to 1.25. Hospital-operator payments were lower. Longitudinal estimates were imprecise and do not establish acquisition effects.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368057v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
            "content_type": "application/json",
            "elapsed_ms": 265,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368057v1?rss=1"
    },
    {
      "id": "4b629b666bea3a1f6ef3",
      "title": "Preprint: Investigating the Lived Experiences, Needs, and Stories (LENS) of Shwachman-Diamond Syndrome Patients and Caregivers",
      "content_text": "Background: Shwachman-Diamond Syndrome is a rare genetic condition characterized by pancreatic insufficiency, skeletal differences, and hematologic manifestations. Previous research has focused on describing diagnosis and treatments of the disease. There is a gap in research highlighting SDS patient perspectives. This study aimed to elucidate the challenges of living with and seeking treatment for SDS based on the lived experiences of SDS patients and caregivers. Methods: We conducted…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "4b629b666bea3a1f6ef3",
          "source": "web",
          "type": "change",
          "key": "#3f310ffafca0a9562257",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
          "timestamp": null,
          "observed_at": "2026-11-17T04:06:44Z",
          "data": {
            "change": "added",
            "label": "Preprint: Investigating the Lived Experiences, Needs, and Stories (LENS) of Shwachman-Diamond Syndrome Patients and Caregivers",
            "item_type": "record",
            "summary": "added: Preprint: Investigating the Lived Experiences, Needs, and Stories (LENS) of Shwachman-Diamond Syndrome Patients and Caregivers",
            "after": {
              "title": "Preprint: Investigating the Lived Experiences, Needs, and Stories (LENS) of Shwachman-Diamond Syndrome Patients and Caregivers",
              "authors": "Lynch, G. K.; Hars, E. S.; Cirino, A. L.; Thompson, A. S.; Merker, V. L.",
              "author_corresponding": "Vanessa L Merker",
              "author_corresponding_institution": "Massachusetts General Hospital",
              "doi": "10.64898/2026.11.14.26368095",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "hematology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.14.26368095.source.xml",
              "abstract": "Background: Shwachman-Diamond Syndrome is a rare genetic condition characterized by pancreatic insufficiency, skeletal differences, and hematologic manifestations. Previous research has focused on describing diagnosis and treatments of the disease. There is a gap in research highlighting SDS patient perspectives. This study aimed to elucidate the challenges of living with and seeking treatment for SDS based on the lived experiences of SDS patients and caregivers. Methods: We conducted semi-structured interviews via Zoom or telephone calls with adults with SDS and caregivers of people with SDS. A semi-structured guide was developed by a multidisciplinary team and utilized for each interview. Interviews were transcribed verbatim and analyzed within the Dedoose platform. Three analysts performed inductive open coding of initial transcripts to collaboratively develop a codebook. The final codebook was applied to remaining transcripts by one analyst. Thematic analysis was performed to draw meaning from codes and identify common themes. Results: 20 participants consented and were interviewed for this study, including 11 caregivers of loved ones with SDS and 9 adults with SDS. Two larger themes were identified: 1) SDS Impact on Daily Life and 2) Navigating Healthcare as an SDS Patient or Caregiver. Symptoms and management of SDS affected a wide range of areas, including careers, education, recreational activities, and socialization. When navigating the healthcare system, many participants shared that they felt misunderstood by providers and needed to frequently advocate for themselves or their loved ones. Numerous participants faced issues with accessing specialists who were knowledgeable or willing to learn about SDS and expressed the need for increased patient resources to help navigate a new diagnosis. Conclusions: This study highlights the lived experiences of those impacted by SDS. Participants explained the impact of SDS symptoms and management on all aspects of daily life including career, socialization and extra-curricular activities. Additionally, people expressed that the development and distribution of SDS-specific resources are needed to improve both new patient and healthcare provider education. Increased awareness and education of the condition and the unique medical needs within clinical settings is necessary for expanding access to care.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background: Shwachman-Diamond Syndrome is a rare genetic condition characterized by pancreatic insufficiency, skeletal differences, and hematologic manifestations. Previous research has focused on describing diagnosis and treatments of the disease. There is a gap in research highlighting SDS patient perspectives. This study aimed to elucidate the challenges of living with and seeking treatment for SDS based on the lived experiences of SDS patients and caregivers. Methods: We conducted semi-structured interviews via Zoom or telephone calls with adults with SDS and caregivers of people with SDS. A semi-structured guide was developed by a multidisciplinary team and utilized for each interview. Interviews were transcribed verbatim and analyzed within the Dedoose platform. Three analysts performed inductive open coding of initial transcripts to collaboratively develop a codebook. The final codebook was applied to remaining transcripts by one analyst. Thematic analysis was performed to draw meaning from codes and identify common themes. Results: 20 participants consented and were interviewed for this study, including 11 caregivers of loved ones with SDS and 9 adults with SDS. Two larger themes were identified: 1) SDS Impact on Daily Life and 2) Navigating Healthcare as an SDS Patient or Caregiver. Symptoms and management of SDS affected a wide range of areas, including careers, education, recreational activities, and socialization. When navigating the healthcare system, many participants shared that they felt misunderstood by providers and needed to frequently advocate for themselves or their loved ones. Numerous participants faced issues with accessing specialists who were knowledgeable or willing to learn about SDS and expressed the need for increased patient resources to help navigate a new diagnosis. Conclusions: This study highlights the lived experiences of those impacted by SDS. Participants explained the impact of SDS symptoms and management on all aspects of daily life including career, socialization and extra-curricular activities. Additionally, people expressed that the development and distribution of SDS-specific resources are needed to improve both new patient and healthcare provider education. Increased awareness and education of the condition and the unique medical needs within clinical settings is necessary for expanding access to care.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368095v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
            "content_type": "application/json",
            "elapsed_ms": 255,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368095v1?rss=1"
    },
    {
      "id": "b914957c0c32b9b81329",
      "title": "Preprint: Efficacy of an early first dose of whole-cell pertussis vaccine in infants for the prevention of IgE-mediated food allergy: A randomised controlled trial",
      "content_text": "Background Evidence from mechanistic and observational studies suggests that replacing the first acellular pertussis (aP) vaccine dose in early infancy with a whole-cell pertussis (wP)-containing vaccine may reduce the risk of developing IgE-mediated food allergy during childhood. Objective We aimed to determine if a dose of wP at approximately 6 weeks old, in lieu of aP vaccine, could reduce the incidence of food allergy in infants. Methods In this multicentre, randomised, participant and…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "b914957c0c32b9b81329",
          "source": "web",
          "type": "change",
          "key": "#265b757dae3dac6e653a",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
          "timestamp": null,
          "observed_at": "2026-11-17T04:06:44Z",
          "data": {
            "change": "added",
            "label": "Preprint: Efficacy of an early first dose of whole-cell pertussis vaccine in infants for the prevention of IgE-mediated food allergy: A randomised controlled trial",
            "item_type": "record",
            "summary": "added: Preprint: Efficacy of an early first dose of whole-cell pertussis vaccine in infants for the prevention of IgE-mediated food allergy: A randomised controlled trial",
            "after": {
              "title": "Preprint: Efficacy of an early first dose of whole-cell pertussis vaccine in infants for the prevention of IgE-mediated food allergy: A randomised controlled trial",
              "authors": "Perez Chacon, G.; Totterdell, J.; Estcourt, M. J.; Perrett, K. P.; Campbell, D. E.; Marsh, J. A.; Wood, N.; Bartlett, A. W.; Williams, P. C. M.; O'Sullivan, M. D.; Waddington, C. S.; Messina, N. L.; Wainstein, B.; Hsu, P.; McAlister, S.; Jones, M. A.; Hughes, C.; Wadia, U.; McIntyre, P. B.; Curtis, N.; Gold, M.; Holt, P. G.; Richmond, P. C.; Snelling, T.",
              "author_corresponding": "Tom Snelling",
              "author_corresponding_institution": "Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.",
              "doi": "10.64898/2026.11.13.26367163",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "allergy and immunology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.13.26367163.source.xml",
              "abstract": "Background Evidence from mechanistic and observational studies suggests that replacing the first acellular pertussis (aP) vaccine dose in early infancy with a whole-cell pertussis (wP)-containing vaccine may reduce the risk of developing IgE-mediated food allergy during childhood. Objective We aimed to determine if a dose of wP at approximately 6 weeks old, in lieu of aP vaccine, could reduce the incidence of food allergy in infants. Methods In this multicentre, randomised, participant and outcome assessor-blinded, parallel, two-stage, Bayesian adaptive trial we assigned Australian infants to one of two pertussis vaccination schedules. These consisted of either a standard homologous priming with a hexavalent combination aP vaccine (diphtheria, tetanus, aP, hepatitis B, inactivated poliovirus types 1, 2, and 3, and Haemophilus influenzae type b; DTaP-HepB-IPV-Hib) at approximately 6 weeks, 4 months and 6 months old ( aP-only&rsquo schedule), or a first dose of a WHO-prequalified pentavalent wP combination vaccine (DTwP-HepB-Hib; Pentabio, PT Bio Farma Indonesia) at approximately 6 weeks old, followed by hexavalent aP combination vaccine at approximately 4 months and 6 months old ( mixed wP/aP&rsquo schedule). The primary outcome was physician-confirmed food allergy by age 12 months requiring both evidence of sensitisation and compatible symptoms in response to either incidental or medically supervised oral food challenge. The initial target sample size was 3,000 enrolments to provide approximately 85% power to detect a policy-relevant 3 percentage point reduction in the risk of the primary outcome. Results A total of 972 infants were enrolled, 486 in each study arm. Of these, 26 of 486 (5.3%) assigned to the aP-only group and 31 of 486 (6.4%) assigned to the mixed wP/aP schedule met the primary endpoint definition. The posterior median difference (95% credible interval) in food allergy among recipients of the mixed wP/aP schedule compared to recipients of the aP-only schedule was 0.01 (-0.02, 0.04; probability [<0] 0.25). There were six serious adverse events (SAEs) among children receiving the aP-only group versus 12 among children receiving the mixed wP/aP schedule; one SAE (hospitalisation for irritability; length of stay < 48 hours) was deemed related to wP vaccine. The trial was stopped early owing to operational reasons. Conclusions There is a low probability of a policy-relevant reduction in food allergy in infants receiving mixed wP/aP versus aP-only pertussis vaccine schedules. Funded by the National Health and Medical Research Council of Australia; ANZCTR number, ACTRN12617000065392p. Clinical implications An early first dose of wP is unlikely to afford a policy-relevant reduction in the probability of developing food allergy, eczema or atopic sensitisation in infants. Capsule summary An early first dose of a 5-in-1 wP combination vaccine is reasonably tolerated but would not be expected to have a material impact on the prevalence of food allergy in infants. Key words Diphtheria-Tetanus-Pertussis Vaccine. Diphtheria-Tetanus-acellular Pertussis Vaccines. Food Hypersensitivity. Infant. Australia.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background Evidence from mechanistic and observational studies suggests that replacing the first acellular pertussis (aP) vaccine dose in early infancy with a whole-cell pertussis (wP)-containing vaccine may reduce the risk of developing IgE-mediated food allergy during childhood. Objective We aimed to determine if a dose of wP at approximately 6 weeks old, in lieu of aP vaccine, could reduce the incidence of food allergy in infants. Methods In this multicentre, randomised, participant and outcome assessor-blinded, parallel, two-stage, Bayesian adaptive trial we assigned Australian infants to one of two pertussis vaccination schedules. These consisted of either a standard homologous priming with a hexavalent combination aP vaccine (diphtheria, tetanus, aP, hepatitis B, inactivated poliovirus types 1, 2, and 3, and Haemophilus influenzae type b; DTaP-HepB-IPV-Hib) at approximately 6 weeks, 4 months and 6 months old ( aP-only&rsquo schedule), or a first dose of a WHO-prequalified pentavalent wP combination vaccine (DTwP-HepB-Hib; Pentabio, PT Bio Farma Indonesia) at approximately 6 weeks old, followed by hexavalent aP combination vaccine at approximately 4 months and 6 months old ( mixed wP/aP&rsquo schedule). The primary outcome was physician-confirmed food allergy by age 12 months requiring both evidence of sensitisation and compatible symptoms in response to either incidental or medically supervised oral food challenge. The initial target sample size was 3,000 enrolments to provide approximately 85% power to detect a policy-relevant 3 percentage point reduction in the risk of the primary outcome. Results A total of 972 infants were enrolled, 486 in each study arm. Of these, 26 of 486 (5.3%) assigned to the aP-only group and 31 of 486 (6.4%) assigned to the mixed wP/aP schedule met the primary endpoint definition. The posterior median difference (95% credible interval) in food allergy among recipients of the mixed wP/aP schedule compared to recipients of the aP-only schedule was 0.01 (-0.02, 0.04; probability [<0] 0.25). There were six serious adverse events (SAEs) among children receiving the aP-only group versus 12 among children receiving the mixed wP/aP schedule; one SAE (hospitalisation for irritability; length of stay < 48 hours) was deemed related to wP vaccine. The trial was stopped early owing to operational reasons. Conclusions There is a low probability of a policy-relevant reduction in food allergy in infants receiving mixed wP/aP versus aP-only pertussis vaccine schedules. Funded by the National Health and Medical Research Council of Australia; ANZCTR number, ACTRN12617000065392p. Clinical implications An early first dose of wP is unlikely to afford a policy-relevant reduction in the probability of developing food allergy, eczema or atopic sensitisation in infants. Capsule summary An early first dose of a 5-in-1 wP combination vaccine is reasonably tolerated but would not be expected to have a material impact on the prevalence of food allergy in infants. Key words Diphtheria-Tetanus-Pertussis Vaccine. Diphtheria-Tetanus-acellular Pertussis Vaccines. Food Hypersensitivity. Infant. Australia.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26367163v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
            "content_type": "application/json",
            "elapsed_ms": 255,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26367163v1?rss=1"
    },
    {
      "id": "7939c146fd6301c50395",
      "title": "Preprint: Participant Outcomes of the Diabetes and WELLbeing 12-Week Psychoeducational Self-Management Programme for Type 2 Diabetes: A Four-Country European Evaluation",
      "content_text": "Introduction: Diabetes self-management education and support (DSMES) improves glycaemic control, but its benefits often fade once programmes end, and psychosocial outcomes are evaluated less often. We evaluated participant outcomes of the Diabetes and WELLbeing (DWELL) programme, a 12-week psychoeducational self-management programme for adults with type 2 diabetes delivered in four European countries. Methods: In this uncontrolled pre-post evaluation, 605 adults with type 2 diabetes were…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "7939c146fd6301c50395",
          "source": "web",
          "type": "change",
          "key": "#31e7757f876eca5d937f",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
          "timestamp": null,
          "observed_at": "2026-11-17T04:06:44Z",
          "data": {
            "change": "added",
            "label": "Preprint: Participant Outcomes of the Diabetes and WELLbeing 12-Week Psychoeducational Self-Management Programme for Type 2 Diabetes: A Four-Country European Evaluation",
            "item_type": "record",
            "summary": "added: Preprint: Participant Outcomes of the Diabetes and WELLbeing 12-Week Psychoeducational Self-Management Programme for Type 2 Diabetes: A Four-Country European Evaluation",
            "after": {
              "title": "Preprint: Participant Outcomes of the Diabetes and WELLbeing 12-Week Psychoeducational Self-Management Programme for Type 2 Diabetes: A Four-Country European Evaluation",
              "authors": "Mukherjee, A.; Shergill, S. S.; Hotham, S.; Vanbosseghem, R.; Gijssel, M.; Manship, S.; Hulbert, S.; Hatzidimitriadou, E.",
              "author_corresponding": "Anurup Mukherjee",
              "author_corresponding_institution": "Kent and Medway Medical School, University of Kent",
              "doi": "10.64898/2026.11.13.26368046",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_no",
              "category": "endocrinology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.13.26368046.source.xml",
              "abstract": "Introduction: Diabetes self-management education and support (DSMES) improves glycaemic control, but its benefits often fade once programmes end, and psychosocial outcomes are evaluated less often. We evaluated participant outcomes of the Diabetes and WELLbeing (DWELL) programme, a 12-week psychoeducational self-management programme for adults with type 2 diabetes delivered in four European countries. Methods: In this uncontrolled pre-post evaluation, 605 adults with type 2 diabetes were recruited in the UK, France, Belgium and the Netherlands. Outcomes were assessed at baseline, at programme completion (12 weeks) and at 6-month follow-up. The primary outcome was diabetes self-care (Summary of Diabetes Self-Care Activities); secondary outcomes included HbA1c, weight, BMI, waist circumference, empowerment, illness perceptions, eating behaviour, health status, physical activity and quality of life. Within-person changes were tested with paired Wilcoxon signed-rank tests. Results: Of 605 participants, 453 were assessed at programme completion and 293 at 6 months. Most self-care behaviours improved by programme completion (for example, dietary self-care rose from a median of 2 to 3 days per week), and all seven self-care measures differed significantly from baseline at 6 months (r=0.41 to 0.82; all p<0.001). By programme completion, weight (median 1.25 kg), waist circumference (2.0 cm) and HbA1c (2.5 mmol/mol) had fallen, and empowerment, illness coherence, emotional and external eating, physical and mental health and quality of life had improved (all p<0.001). At 6 months, all metabolic outcomes remained below baseline, although HbA1c had partly rebounded (1.7 mmol/mol below baseline), and most psychosocial gains were sustained. Conclusions: Participation in DWELL was associated with improvements in self-care, metabolic and psychosocial outcomes that were partly sustained 6 months after the programme ended. As an uncontrolled evaluation, the study cannot establish causation, and controlled studies with longer follow-up are needed.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Introduction: Diabetes self-management education and support (DSMES) improves glycaemic control, but its benefits often fade once programmes end, and psychosocial outcomes are evaluated less often. We evaluated participant outcomes of the Diabetes and WELLbeing (DWELL) programme, a 12-week psychoeducational self-management programme for adults with type 2 diabetes delivered in four European countries. Methods: In this uncontrolled pre-post evaluation, 605 adults with type 2 diabetes were recruited in the UK, France, Belgium and the Netherlands. Outcomes were assessed at baseline, at programme completion (12 weeks) and at 6-month follow-up. The primary outcome was diabetes self-care (Summary of Diabetes Self-Care Activities); secondary outcomes included HbA1c, weight, BMI, waist circumference, empowerment, illness perceptions, eating behaviour, health status, physical activity and quality of life. Within-person changes were tested with paired Wilcoxon signed-rank tests. Results: Of 605 participants, 453 were assessed at programme completion and 293 at 6 months. Most self-care behaviours improved by programme completion (for example, dietary self-care rose from a median of 2 to 3 days per week), and all seven self-care measures differed significantly from baseline at 6 months (r=0.41 to 0.82; all p<0.001). By programme completion, weight (median 1.25 kg), waist circumference (2.0 cm) and HbA1c (2.5 mmol/mol) had fallen, and empowerment, illness coherence, emotional and external eating, physical and mental health and quality of life had improved (all p<0.001). At 6 months, all metabolic outcomes remained below baseline, although HbA1c had partly rebounded (1.7 mmol/mol below baseline), and most psychosocial gains were sustained. Conclusions: Participation in DWELL was associated with improvements in self-care, metabolic and psychosocial outcomes that were partly sustained 6 months after the programme ended. As an uncontrolled evaluation, the study cannot establish causation, and controlled studies with longer follow-up are needed.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368046v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
            "content_type": "application/json",
            "elapsed_ms": 255,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368046v1?rss=1"
    },
    {
      "id": "6cab0f6a18e78c3b38d1",
      "title": "Preprint: Molecular age of Barrett's esophagus indicates onset often occurs decades before diagnosis",
      "content_text": "Background Timely identification of Barrett's esophagus (BE) is crucial for early esophageal adenocarcinoma (EAC) detection. Screening is recommended from age 50 in individuals with additional risk factors, but biological BE onset age remains unknown. Objective Estimate biological BE onset age and duration before clinical diagnosis (dwell time). Design We applied a BE epigenetic clock to 61 samples from 41 patients in a population-representative Northern Ireland cohort and 164 samples from 140…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "6cab0f6a18e78c3b38d1",
          "source": "web",
          "type": "change",
          "key": "#5d526cb36294da9fb04d",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
          "timestamp": null,
          "observed_at": "2026-11-17T04:06:44Z",
          "data": {
            "change": "added",
            "label": "Preprint: Molecular age of Barrett's esophagus indicates onset often occurs decades before diagnosis",
            "item_type": "record",
            "summary": "added: Preprint: Molecular age of Barrett's esophagus indicates onset often occurs decades before diagnosis",
            "after": {
              "title": "Preprint: Molecular age of Barrett's esophagus indicates onset often occurs decades before diagnosis",
              "authors": "Oliveira, T.; Reynolds, S. R.; Scanlon, E.; Child, V.; McManus, D. T.; Johnston, B.; Hu, Z.; Killcoyne, S.; Nutzinger, B.; Devonshire, G.; Fitzgerald, R. C.; Turkington, R. C.; McKnight, A. J.; Coleman, H. G.; Curtius, K.",
              "author_corresponding": "Kit Curtius",
              "author_corresponding_institution": "University of California, San Diego",
              "doi": "10.64898/2026.11.13.26367463",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc",
              "category": "gastroenterology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.13.26367463.source.xml",
              "abstract": "Background Timely identification of Barrett's esophagus (BE) is crucial for early esophageal adenocarcinoma (EAC) detection. Screening is recommended from age 50 in individuals with additional risk factors, but biological BE onset age remains unknown. Objective Estimate biological BE onset age and duration before clinical diagnosis (dwell time). Design We applied a BE epigenetic clock to 61 samples from 41 patients in a population-representative Northern Ireland cohort and 164 samples from 140 patients in an independent UK cohort. BE dwell times were compared between patients with concurrent dysplasia/EAC and age- and sex-matched non-dysplastic BE controls in these cross-sectional studies. In a longitudinal cohort, pre-progression biopsies from 31 future high-grade dysplasia (HGD)/EAC progressors were compared with 35 non-progressors. Results Median estimated BE onset ages in the cross-sectional cohorts were 29.5 (IQR=22.5-45.8) and 29.3 (IQR=20.4-39.0) years, respectively. These estimates were further supported by independent epidemiologic modeling of age-specific BE prevalence data from more than 70,000 BE cases. Estimated dwell times were longer in patients with concurrent dysplasia (median difference 14.3 years; p=0.0042) or EAC (12.5 years; p=0.0002) than matched non-dysplastic BE controls. Dwell time exceeding 19.8 years was associated with higher odds of HGD/EAC progression (OR=12.1, 95% CI 3.7-47.5; p=9.96 x 10-9;). Conclusion BE may arise decades before diagnosis. Although these findings do not justify lowering screening age, they suggest one-time screening from age 50 years may detect existing high-risk BE. Further modeling is warranted to evaluate implications for population-based screening, alongside prospective validation of epigenetic tissue age for progression risk stratification.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background Timely identification of Barrett's esophagus (BE) is crucial for early esophageal adenocarcinoma (EAC) detection. Screening is recommended from age 50 in individuals with additional risk factors, but biological BE onset age remains unknown. Objective Estimate biological BE onset age and duration before clinical diagnosis (dwell time). Design We applied a BE epigenetic clock to 61 samples from 41 patients in a population-representative Northern Ireland cohort and 164 samples from 140 patients in an independent UK cohort. BE dwell times were compared between patients with concurrent dysplasia/EAC and age- and sex-matched non-dysplastic BE controls in these cross-sectional studies. In a longitudinal cohort, pre-progression biopsies from 31 future high-grade dysplasia (HGD)/EAC progressors were compared with 35 non-progressors. Results Median estimated BE onset ages in the cross-sectional cohorts were 29.5 (IQR=22.5-45.8) and 29.3 (IQR=20.4-39.0) years, respectively. These estimates were further supported by independent epidemiologic modeling of age-specific BE prevalence data from more than 70,000 BE cases. Estimated dwell times were longer in patients with concurrent dysplasia (median difference 14.3 years; p=0.0042) or EAC (12.5 years; p=0.0002) than matched non-dysplastic BE controls. Dwell time exceeding 19.8 years was associated with higher odds of HGD/EAC progression (OR=12.1, 95% CI 3.7-47.5; p=9.96 x 10-9;). Conclusion BE may arise decades before diagnosis. Although these findings do not justify lowering screening age, they suggest one-time screening from age 50 years may detect existing high-risk BE. Further modeling is warranted to evaluate implications for population-based screening, alongside prospective validation of epigenetic tissue age for progression risk stratification.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26367463v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/120",
            "content_type": "application/json",
            "elapsed_ms": 255,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26367463v1?rss=1"
    },
    {
      "id": "a17d27c491a3ed9c1e72",
      "title": "Preprint: Dual-platform plasma proteogenomics prioritizes GSTA1 and ARG1 as druggable cross-domain targets in cardiovascular-kidney-metabolic syndrome",
      "content_text": "Background: Cardiovascular-kidney-metabolic (CKM) syndrome reflects shared pathophysiology across metabolic, renal and cardiovascular systems, yet circulating proteins with causal effects spanning multiple CKM domains remain unclear. We aimed to identify and prioritize cross-domain candidate proteins using an integrative, dual-platform plasma proteogenomic framework. Methods: We combined genetic causal inference, statistical colocalization, single-cell expression mapping, and structure-based…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "a17d27c491a3ed9c1e72",
          "source": "web",
          "type": "change",
          "key": "#5c0cb2b17b9495ad0c55",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
          "timestamp": null,
          "observed_at": "2026-11-17T03:09:24Z",
          "data": {
            "change": "added",
            "label": "Preprint: Dual-platform plasma proteogenomics prioritizes GSTA1 and ARG1 as druggable cross-domain targets in cardiovascular-kidney-metabolic syndrome",
            "item_type": "record",
            "summary": "added: Preprint: Dual-platform plasma proteogenomics prioritizes GSTA1 and ARG1 as druggable cross-domain targets in cardiovascular-kidney-metabolic syndrome",
            "after": {
              "title": "Preprint: Dual-platform plasma proteogenomics prioritizes GSTA1 and ARG1 as druggable cross-domain targets in cardiovascular-kidney-metabolic syndrome",
              "authors": "Lan, Y.; Lin, C.; Liu, H.; Zhou, H.; Xie, B.; Chen, J.; Gao, H.; Zheng, Q.; Chen, Y.",
              "author_corresponding": "Yongsong Chen",
              "author_corresponding_institution": "The First Affiliated Hospital of Shantou University Medical College",
              "doi": "10.64898/2026.11.14.26368123",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_no",
              "category": "genetic and genomic medicine",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.14.26368123.source.xml",
              "abstract": "Background: Cardiovascular-kidney-metabolic (CKM) syndrome reflects shared pathophysiology across metabolic, renal and cardiovascular systems, yet circulating proteins with causal effects spanning multiple CKM domains remain unclear. We aimed to identify and prioritize cross-domain candidate proteins using an integrative, dual-platform plasma proteogenomic framework. Methods: We combined genetic causal inference, statistical colocalization, single-cell expression mapping, and structure-based druggability assessment. Cis-protein quantitative trait loci (cis-pQTL) instruments were derived from two independent plasma proteomic platforms, UKB-PPP (2,030 proteins with valid cis instruments) and deCODE (1,640 proteins). Genetic causal inference (two-sample Mendelian randomization) was performed against seven CKM-related outcomes across the metabolic (type 2 diabetes [T2D], body mass index [BMI]), renal (estimated glomerular filtration rate [eGFR], chronic kidney disease) and cardiovascular (coronary artery disease, heart failure, stroke) domains. Proteins showing false discovery rate (FDR)-significant associations in at least two CKM domains independently on both platforms were prioritized, and cross-platform directional concordance was evaluated as a robustness measure. Prioritized proteins were followed by colocalization, and characterization using single-cell expression, disease-association and druggability resources. Structural and ligand-efficiency analyses were performed for the leading candidate using its co-crystallized inhibitor complex. Results: Proteome-wide analysis yielded 9,734 (UKB-PPP) and 8,837 (deCODE) protein-outcome estimates, with 77.9% two-platform directional concordance. Cross-domain prioritization identified six proteins (ARG1, GSTA1, INHBB, ITIH1, NCAN, SHBG), all acting across the metabolic-renal axis. Colocalization provided strong support for GSTA1 with eGFR (posterior probability of a shared causal variant 0.97) and ARG1 with BMI (0.93). Genetically higher GSTA1 was associated with lower eGFR and higher T2D risk, with kidney expression confined to proximal tubule cells. Genetically higher ARG1 was associated with lower BMI and lower T2D risk, consistent with hepatocyte-restricted expression. Both proteins were small-molecule tractable. For GSTA1, the inhibitor-bound structure (PDB 1GSF) showed a deep, enclosed H-site, and three chemotypes with previously reported low-micromolar potency against recombinant hGSTA1-1 (ethacrynic acid and the dietary flavonols fisetin and myricetin) all exceeded the lead-like ligand-efficiency threshold (0.30 kcal mol-1 per heavy atom). Conclusions: Using dual-platform proteogenomics, we identify genetically supported cross-metabolic-renal candidate proteins in CKM syndrome, with GSTA1 and ARG1 emerging as the most robust, pharmacologically tractable candidates. These findings nominate actionable targets and mechanistic entry points for CKM syndrome.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background: Cardiovascular-kidney-metabolic (CKM) syndrome reflects shared pathophysiology across metabolic, renal and cardiovascular systems, yet circulating proteins with causal effects spanning multiple CKM domains remain unclear. We aimed to identify and prioritize cross-domain candidate proteins using an integrative, dual-platform plasma proteogenomic framework. Methods: We combined genetic causal inference, statistical colocalization, single-cell expression mapping, and structure-based druggability assessment. Cis-protein quantitative trait loci (cis-pQTL) instruments were derived from two independent plasma proteomic platforms, UKB-PPP (2,030 proteins with valid cis instruments) and deCODE (1,640 proteins). Genetic causal inference (two-sample Mendelian randomization) was performed against seven CKM-related outcomes across the metabolic (type 2 diabetes [T2D], body mass index [BMI]), renal (estimated glomerular filtration rate [eGFR], chronic kidney disease) and cardiovascular (coronary artery disease, heart failure, stroke) domains. Proteins showing false discovery rate (FDR)-significant associations in at least two CKM domains independently on both platforms were prioritized, and cross-platform directional concordance was evaluated as a robustness measure. Prioritized proteins were followed by colocalization, and characterization using single-cell expression, disease-association and druggability resources. Structural and ligand-efficiency analyses were performed for the leading candidate using its co-crystallized inhibitor complex. Results: Proteome-wide analysis yielded 9,734 (UKB-PPP) and 8,837 (deCODE) protein-outcome estimates, with 77.9% two-platform directional concordance. Cross-domain prioritization identified six proteins (ARG1, GSTA1, INHBB, ITIH1, NCAN, SHBG), all acting across the metabolic-renal axis. Colocalization provided strong support for GSTA1 with eGFR (posterior probability of a shared causal variant 0.97) and ARG1 with BMI (0.93). Genetically higher GSTA1 was associated with lower eGFR and higher T2D risk, with kidney expression confined to proximal tubule cells. Genetically higher ARG1 was associated with lower BMI and lower T2D risk, consistent with hepatocyte-restricted expression. Both proteins were small-molecule tractable. For GSTA1, the inhibitor-bound structure (PDB 1GSF) showed a deep, enclosed H-site, and three chemotypes with previously reported low-micromolar potency against recombinant hGSTA1-1 (ethacrynic acid and the dietary flavonols fisetin and myricetin) all exceeded the lead-like ligand-efficiency threshold (0.30 kcal mol-1 per heavy atom). Conclusions: Using dual-platform proteogenomics, we identify genetically supported cross-metabolic-renal candidate proteins in CKM syndrome, with GSTA1 and ARG1 emerging as the most robust, pharmacologically tractable candidates. These findings nominate actionable targets and mechanistic entry points for CKM syndrome.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368123v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
            "content_type": "application/json",
            "elapsed_ms": 553,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368123v1?rss=1"
    },
    {
      "id": "9bdfe062bd09212cba98",
      "title": "Preprint: Diagnostic performance of rK28- and rK39-based rapid diagnostic tests for Visceral Leishmaniasis in Kenya: Implications for the national diagnostic algorithm",
      "content_text": "Background Visceral Leishmaniasis (VL) is a neglected tropical disease (NTD) caused by Leishmania infantum and L. donovani and transmitted by an infectious bite of a female phlebotomine sandfly. The disease disproportionately affects impoverished and underserved populations, where inadequate access to healthcare. In Kenya, 11 out of the 47 counties are endemic for VL, a fatal disease if untreated. Parasitological methods remain the gold standard for diagnosing VL, however they are invasive and…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "9bdfe062bd09212cba98",
          "source": "web",
          "type": "change",
          "key": "#a75fd42913ee972641d8",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
          "timestamp": null,
          "observed_at": "2026-11-17T03:09:24Z",
          "data": {
            "change": "added",
            "label": "Preprint: Diagnostic performance of rK28- and rK39-based rapid diagnostic tests for Visceral Leishmaniasis in Kenya: Implications for the national diagnostic algorithm",
            "item_type": "record",
            "summary": "added: Preprint: Diagnostic performance of rK28- and rK39-based rapid diagnostic tests for Visceral Leishmaniasis in Kenya: Implications for the national diagnostic algorithm",
            "after": {
              "title": "Preprint: Diagnostic performance of rK28- and rK39-based rapid diagnostic tests for Visceral Leishmaniasis in Kenya: Implications for the national diagnostic algorithm",
              "authors": "Matoke-Muhia, D.; Tuluso, M.; Kimemia, B. B.; Osero, B.; Kamau, L.; Ndungu, J. M.; Ofwete, R.; Thiongo, K.; Maranga, D.",
              "author_corresponding": "Damaris Matoke-Muhia",
              "author_corresponding_institution": "KEMRI Centre for Biotechnology Research and Development",
              "doi": "10.64898/2026.11.13.26368071",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "infectious diseases",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.13.26368071.source.xml",
              "abstract": "Background Visceral Leishmaniasis (VL) is a neglected tropical disease (NTD) caused by Leishmania infantum and L. donovani and transmitted by an infectious bite of a female phlebotomine sandfly. The disease disproportionately affects impoverished and underserved populations, where inadequate access to healthcare. In Kenya, 11 out of the 47 counties are endemic for VL, a fatal disease if untreated. Parasitological methods remain the gold standard for diagnosing VL, however they are invasive and require specialised training and equipment. Serological tests such as Rapid Diagnostic Tests (RDTs) are widely used for screening but can still report positive results way after treatment due to persistence of anti-VL antibodies. It is recommended that VL diagnosis follows an algorithmic approach. This study evaluated diagnostic performance of rK28 and rK39 RDTs (Kala-azar Detect and IT Leish) in various algorithmic combinations against a composite reference standard. Methodology We evaluated rK28 and Kala-azar Detect along with rK39 IT-Leish as index tests, and Direct Agglutination Test (DAT) as the reference test. Participants were recruited from seven health facilities in Marsabit and Turkana counties. Blood samples were collected together with patient demographic data. Treatment followed the national algorithm and health facility routine procedures. Diagnostic test performance was assessed individually, in parallel, and sequential algorithmic combinations. Specificity, sensitivity, balanced accuracy, negative and positive predictive values were statistically estimated. Results A total of 398 participants were recruited, with most reported clinical symptoms being fever and splenomegaly. Individually, the rK28 kit demonstrated 96% sensitivity, 86% specificity, and 91.2% balanced accuracy (BA). The rK39 IT-Leish had 87% sensitivity, specificity 93%, and BA of 90.4%, while Kala-azar Detect had 67% sensitivity, 91% specificity and 79% BA. IT Leish to rK28 algorithm based on negatives had highest BA (90%), with 92% sensitivity and 88% specificity, while rK28 to Kala-azar detect algorithm based on positives showed the lowest BA (80%) with 65% sensitivity and 94.1% specificity. Discussion The rK28 RDT demonstrated high sensitivity (96-98%) and moderate specificity (72-86%), findings broadly consistent with reports elsewhere. In contrast, the rK39-based tests showed higher specificity (91-93%) but lower sensitivity (67-87%), limiting their effectiveness in elimination programs. Parallel testing algorithms combining rK28 and rK39 RDTs improved sensitivity up to 97.7%, whereas sequential approaches increased specificity at the expense of sensitivity when compared to rK28 alone. These approaches were more balanced as compared to sequential which increased overall specificity and reduced sensitivity. This flexibility in combinations provides more options for elimination programs. The performance of rK28 gives it an advantage over rK39 kits, especially with IT Leish facing stockouts. While the study faced limitations including lack of PCR data leading to reliance on DAT as the reference standard, and underpowered secondary analyses, the findings provide strong preliminary evidence guiding national algorithm, supply chain, and policy decisions that may accelerate VL elimination. Conclusion The findings demonstrate that diagnostic algorithms incorporating rK28 provide robust performance for VL diagnosis. They support consideration of rK28 diagnostic kit for VL diagnostic algorithms enhancing case detection for control and elimination efforts in Eastern Africa",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background Visceral Leishmaniasis (VL) is a neglected tropical disease (NTD) caused by Leishmania infantum and L. donovani and transmitted by an infectious bite of a female phlebotomine sandfly. The disease disproportionately affects impoverished and underserved populations, where inadequate access to healthcare. In Kenya, 11 out of the 47 counties are endemic for VL, a fatal disease if untreated. Parasitological methods remain the gold standard for diagnosing VL, however they are invasive and require specialised training and equipment. Serological tests such as Rapid Diagnostic Tests (RDTs) are widely used for screening but can still report positive results way after treatment due to persistence of anti-VL antibodies. It is recommended that VL diagnosis follows an algorithmic approach. This study evaluated diagnostic performance of rK28 and rK39 RDTs (Kala-azar Detect and IT Leish) in various algorithmic combinations against a composite reference standard. Methodology We evaluated rK28 and Kala-azar Detect along with rK39 IT-Leish as index tests, and Direct Agglutination Test (DAT) as the reference test. Participants were recruited from seven health facilities in Marsabit and Turkana counties. Blood samples were collected together with patient demographic data. Treatment followed the national algorithm and health facility routine procedures. Diagnostic test performance was assessed individually, in parallel, and sequential algorithmic combinations. Specificity, sensitivity, balanced accuracy, negative and positive predictive values were statistically estimated. Results A total of 398 participants were recruited, with most reported clinical symptoms being fever and splenomegaly. Individually, the rK28 kit demonstrated 96% sensitivity, 86% specificity, and 91.2% balanced accuracy (BA). The rK39 IT-Leish had 87% sensitivity, specificity 93%, and BA of 90.4%, while Kala-azar Detect had 67% sensitivity, 91% specificity and 79% BA. IT Leish to rK28 algorithm based on negatives had highest BA (90%), with 92% sensitivity and 88% specificity, while rK28 to Kala-azar detect algorithm based on positives showed the lowest BA (80%) with 65% sensitivity and 94.1% specificity. Discussion The rK28 RDT demonstrated high sensitivity (96-98%) and moderate specificity (72-86%), findings broadly consistent with reports elsewhere. In contrast, the rK39-based tests showed higher specificity (91-93%) but lower sensitivity (67-87%), limiting their effectiveness in elimination programs. Parallel testing algorithms combining rK28 and rK39 RDTs improved sensitivity up to 97.7%, whereas sequential approaches increased specificity at the expense of sensitivity when compared to rK28 alone. These approaches were more balanced as compared to sequential which increased overall specificity and reduced sensitivity. This flexibility in combinations provides more options for elimination programs. The performance of rK28 gives it an advantage over rK39 kits, especially with IT Leish facing stockouts. While the study faced limitations including lack of PCR data leading to reliance on DAT as the reference standard, and underpowered secondary analyses, the findings provide strong preliminary evidence guiding national algorithm, supply chain, and policy decisions that may accelerate VL elimination. Conclusion The findings demonstrate that diagnostic algorithms incorporating rK28 provide robust performance for VL diagnosis. They support consideration of rK28 diagnostic kit for VL diagnostic algorithms enhancing case detection for control and elimination efforts in Eastern Africa",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368071v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
            "content_type": "application/json",
            "elapsed_ms": 553,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368071v1?rss=1"
    },
    {
      "id": "483b21ddfff88cfad91b",
      "title": "Preprint: Unified ACLF grading in critically ill patients with cirrhosis: reclassification and mortality in two intensive care databases",
      "content_text": "Abstract Background & Aims. The 2026 unified definition of acute-on-chronic liver failure (ACLF) requires bilirubin [&ge;]5 mg/dL and INR [&ge;]1.5 before extrahepatic organ involvement is graded. Many critically ill patients with cirrhosis have extrahepatic organ failure without such liver failure. How the unified grade classifies them is unknown. Methods.We applied the unified, EASL-CLIF and NACSELD classifications around intensive care unit (ICU) admission to adults with cirrhosis in…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "483b21ddfff88cfad91b",
          "source": "web",
          "type": "change",
          "key": "#a2608994ce231bcb10a5",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
          "timestamp": null,
          "observed_at": "2026-11-17T03:09:24Z",
          "data": {
            "change": "added",
            "label": "Preprint: Unified ACLF grading in critically ill patients with cirrhosis: reclassification and mortality in two intensive care databases",
            "item_type": "record",
            "summary": "added: Preprint: Unified ACLF grading in critically ill patients with cirrhosis: reclassification and mortality in two intensive care databases",
            "after": {
              "title": "Preprint: Unified ACLF grading in critically ill patients with cirrhosis: reclassification and mortality in two intensive care databases",
              "authors": "Hu, Z.; Ye, J.",
              "author_corresponding": "Jihui Ye",
              "author_corresponding_institution": "Department of Critical Care Medicine, The First Affiliated Hospital of Ningbo University, China",
              "doi": "10.64898/2026.11.14.26368094",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "intensive care and critical care medicine",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.14.26368094.source.xml",
              "abstract": "Abstract Background & Aims. The 2026 unified definition of acute-on-chronic liver failure (ACLF) requires bilirubin [&ge;]5 mg/dL and INR [&ge;]1.5 before extrahepatic organ involvement is graded. Many critically ill patients with cirrhosis have extrahepatic organ failure without such liver failure. How the unified grade classifies them is unknown. Methods.We applied the unified, EASL-CLIF and NACSELD classifications around intensive care unit (ICU) admission to adults with cirrhosis in MIMIC-IV, excluding prior or perioperative liver transplantation. The primary outcome was 28-day mortality; in-hospital mortality was examined in eICU. Results. Among 2,972 patients, 33.8% met ACLF criteria by the unified grade, 65.2% by EASL-CLIF and 29.9% by NACSELD. Of EASL-CLIF-positive patients, 1,086 (56.0%) were assigned unified grade 0; 54.7% of them were ventilated, 48.7% received vasopressors, and their 28-day mortality was 32.6% (95% CI, 29.9% to 35.4%), versus 11.8% in patients negative by both definitions. Patients with unified grade 0 accounted for 46.7% of all 28-day deaths. The unified grade discriminated 28-day mortality less well than EASL-CLIF grade (difference in area under the receiver operating characteristic curve [AUC], -0.071; 95% CI, -0.090 to -0.050) and the CLIF-C OF score (-0.105; -0.123 to -0.088). Among 1,883 patients with coded decompensation, 45.8% of those EASL-CLIF-positive were assigned grade 0, with 28-day mortality of 34.3%. In eICU, in-hospital mortality was 28.9% among patients positive by EASL-CLIF alone. Conclusions. In critically ill patients with cirrhosis, the unified grade assigned grade 0 to about half of those meeting EASL-CLIF criteria, and one in three of them died within 28 days. In the ICU, unified grade 0 should not be read as low risk. ACLF types A and B could not be determined.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Abstract Background & Aims. The 2026 unified definition of acute-on-chronic liver failure (ACLF) requires bilirubin [&ge;]5 mg/dL and INR [&ge;]1.5 before extrahepatic organ involvement is graded. Many critically ill patients with cirrhosis have extrahepatic organ failure without such liver failure. How the unified grade classifies them is unknown. Methods.We applied the unified, EASL-CLIF and NACSELD classifications around intensive care unit (ICU) admission to adults with cirrhosis in MIMIC-IV, excluding prior or perioperative liver transplantation. The primary outcome was 28-day mortality; in-hospital mortality was examined in eICU. Results. Among 2,972 patients, 33.8% met ACLF criteria by the unified grade, 65.2% by EASL-CLIF and 29.9% by NACSELD. Of EASL-CLIF-positive patients, 1,086 (56.0%) were assigned unified grade 0; 54.7% of them were ventilated, 48.7% received vasopressors, and their 28-day mortality was 32.6% (95% CI, 29.9% to 35.4%), versus 11.8% in patients negative by both definitions. Patients with unified grade 0 accounted for 46.7% of all 28-day deaths. The unified grade discriminated 28-day mortality less well than EASL-CLIF grade (difference in area under the receiver operating characteristic curve [AUC], -0.071; 95% CI, -0.090 to -0.050) and the CLIF-C OF score (-0.105; -0.123 to -0.088). Among 1,883 patients with coded decompensation, 45.8% of those EASL-CLIF-positive were assigned grade 0, with 28-day mortality of 34.3%. In eICU, in-hospital mortality was 28.9% among patients positive by EASL-CLIF alone. Conclusions. In critically ill patients with cirrhosis, the unified grade assigned grade 0 to about half of those meeting EASL-CLIF criteria, and one in three of them died within 28 days. In the ICU, unified grade 0 should not be read as low risk. ACLF types A and B could not be determined.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368094v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
            "content_type": "application/json",
            "elapsed_ms": 553,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368094v1?rss=1"
    },
    {
      "id": "54642251226287a511e6",
      "title": "Preprint: Sublingual Buprenorphine Is Associated with Increased Caries Experience and Altered Oral Microbial and Salivary Risk Factors",
      "content_text": "Background: Sublingual buprenorphine (SLB) is commonly prescribed to treat opioid use disorder. Pharmacoepidemiologic studies suggest an association between SLB and severe dental caries, yet clinical investigations are lacking. Objective: To assess caries experience and caries-related risk factors among patients taking SLB. Methods: This pilot cross-sectional study enrolled 11 subjects taking SLB films, 10 taking SLB tablets, and 10 age- and sex-matched controls. Demographic, medical, dental…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "54642251226287a511e6",
          "source": "web",
          "type": "change",
          "key": "#38cbe3808eb59fcc988a",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
          "timestamp": null,
          "observed_at": "2026-11-17T03:09:24Z",
          "data": {
            "change": "added",
            "label": "Preprint: Sublingual Buprenorphine Is Associated with Increased Caries Experience and Altered Oral Microbial and Salivary Risk Factors",
            "item_type": "record",
            "summary": "added: Preprint: Sublingual Buprenorphine Is Associated with Increased Caries Experience and Altered Oral Microbial and Salivary Risk Factors",
            "after": {
              "title": "Preprint: Sublingual Buprenorphine Is Associated with Increased Caries Experience and Altered Oral Microbial and Salivary Risk Factors",
              "authors": "Kasparian, K. V.; Katrak, C.; Abernethy, J.; Reed, S.; Martin, K.; Jenkins, R.; Zang, Y.; Hsu, S.-H.; Oliveira, D.; Garcia, B.; Sharma, A.; McCurdy, C. R.; Abranches, J.",
              "author_corresponding": "Jacqueline Abranches",
              "author_corresponding_institution": "University of Florida",
              "doi": "10.64898/2026.11.13.26368056",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_no",
              "category": "addiction medicine",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.13.26368056.source.xml",
              "abstract": "Background: Sublingual buprenorphine (SLB) is commonly prescribed to treat opioid use disorder. Pharmacoepidemiologic studies suggest an association between SLB and severe dental caries, yet clinical investigations are lacking. Objective: To assess caries experience and caries-related risk factors among patients taking SLB. Methods: This pilot cross-sectional study enrolled 11 subjects taking SLB films, 10 taking SLB tablets, and 10 age- and sex-matched controls. Demographic, medical, dental, and behavioral data were collected. Caries examinations were performed. Salivary pH, buffering capacity, and flow rate were measured. Saliva and plaque levels of Mutans streptococci and Candida spp. were determined. Oral pH dynamics and salivary concentrations of buprenorphine, its metabolites, and naloxone were monitored. Results: Caries experience was greater in SLB subjects than controls and higher among tablet versus film subjects (p<0.05). SLB subjects exhibited lower salivary pH and buffering capacity (p<0.05), and elevated salivary levels of Mutans streptococci (p<0.05) and Candida spp. (p<0.001). SLB administration was associated with rapid oral acidification and prolonged recovery. Salivary buprenorphine exposure was elevated and correlated with baseline pH (p<0.01), suggesting ion trapping contributes to oral retention. Conclusion: Patients receiving SLB exhibit increased caries experience likely resulting from localized acidification favoring caries-associated microorganisms and prolonged oral exposure to buprenorphine.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background: Sublingual buprenorphine (SLB) is commonly prescribed to treat opioid use disorder. Pharmacoepidemiologic studies suggest an association between SLB and severe dental caries, yet clinical investigations are lacking. Objective: To assess caries experience and caries-related risk factors among patients taking SLB. Methods: This pilot cross-sectional study enrolled 11 subjects taking SLB films, 10 taking SLB tablets, and 10 age- and sex-matched controls. Demographic, medical, dental, and behavioral data were collected. Caries examinations were performed. Salivary pH, buffering capacity, and flow rate were measured. Saliva and plaque levels of Mutans streptococci and Candida spp. were determined. Oral pH dynamics and salivary concentrations of buprenorphine, its metabolites, and naloxone were monitored. Results: Caries experience was greater in SLB subjects than controls and higher among tablet versus film subjects (p<0.05). SLB subjects exhibited lower salivary pH and buffering capacity (p<0.05), and elevated salivary levels of Mutans streptococci (p<0.05) and Candida spp. (p<0.001). SLB administration was associated with rapid oral acidification and prolonged recovery. Salivary buprenorphine exposure was elevated and correlated with baseline pH (p<0.01), suggesting ion trapping contributes to oral retention. Conclusion: Patients receiving SLB exhibit increased caries experience likely resulting from localized acidification favoring caries-associated microorganisms and prolonged oral exposure to buprenorphine.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368056v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
            "content_type": "application/json",
            "elapsed_ms": 553,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368056v1?rss=1"
    },
    {
      "id": "acb2f20b127bb312add3",
      "title": "Preprint: Immune Defense Protein IDP Improves Cough and Chest Congestion During Cold and Flu Season in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Study",
      "content_text": "Background. Upper respiratory infections are common and carry a greater burden in older adults. IDP (Immune Defense Protein) is a dietary supplement whose active ingredient is a complex of milk-derived bioactive whey proteins. Prior studies of IDP report enhanced antibody response following influenza vaccination, suggesting a potential for reduction of incidence, duration, and severity of upper respiratory symptoms. This study evaluated the effects of IDP supplementation on the incidence, type…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "acb2f20b127bb312add3",
          "source": "web",
          "type": "change",
          "key": "#359eed7219a8c1cb5282",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
          "timestamp": null,
          "observed_at": "2026-11-17T03:09:24Z",
          "data": {
            "change": "added",
            "label": "Preprint: Immune Defense Protein IDP Improves Cough and Chest Congestion During Cold and Flu Season in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Study",
            "item_type": "record",
            "summary": "added: Preprint: Immune Defense Protein IDP Improves Cough and Chest Congestion During Cold and Flu Season in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Study",
            "after": {
              "title": "Preprint: Immune Defense Protein IDP Improves Cough and Chest Congestion During Cold and Flu Season in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Study",
              "authors": "Grant, A. D.; Prideaux, C. S.; Rosales, M.; Capano-Wehrle, L.; Moos, J.; Mkrtytchian, N.; Luna, V.; Krupa, M. C. E.; Craft, N.",
              "author_corresponding": "Azure D Grant",
              "author_corresponding_institution": "People Science Inc",
              "doi": "10.64898/2026.11.09.26367685",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_no",
              "category": "allergy and immunology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.09.26367685.source.xml",
              "abstract": "Background. Upper respiratory infections are common and carry a greater burden in older adults. IDP (Immune Defense Protein) is a dietary supplement whose active ingredient is a complex of milk-derived bioactive whey proteins. Prior studies of IDP report enhanced antibody response following influenza vaccination, suggesting a potential for reduction of incidence, duration, and severity of upper respiratory symptoms. This study evaluated the effects of IDP supplementation on the incidence, type, duration, and severity of upper respiratory symptoms in older adults during cold and flu season, along with rescue medication use and quality of life. Methods. This was a randomized, double-blind, placebo-controlled study with three arms (placebo, standard dose of 50mg IDP /day, and advanced dose of 200mg IDP /day). Participants completed a one-week baseline period followed by a 16-week product use period, reporting daily upper respiratory symptoms via the Wisconsin Upper Respiratory Symptom Survey (WURSS-24). Participants additionally logged quality of life using the Short Form 36 (SF-36). ANCOVA for change from baseline, mixed models for repeated measures (MRMM), as well as Kruskal Wallis (KW) tests of area under the curve of symptom frequency and severity were used to compare trajectories over time. Results. N=255 participants (n=88 Placebo, n=85 50 mg IDP , n=82 200 mg IDP ) were evaluated. Analysis of individual symptom trends over time revealed that chest congestion and cough decreased in severity and duration significantly faster in the 50 mg IDP and 200 mg IDP groups compared to Placebo (KW for Area Under the Curve p<0.05). ANCOVA of baseline to Week-16 change and MRMM of total WURSS-24 symptom frequency, severity and rescue medication use revealed no significant difference between arms (ANCOVA and MRMM p > 0.05). SF-36 quality of life did not differ between arms. Adverse events potentially attributable to product use were infrequent, resolved, and did not differ between arms. Conclusions. Sixteen weeks of daily IDP supplementation was associated with a reduction in duration and severity of cough and chest congestion in older adults. IDP appears safe and tolerable.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background. Upper respiratory infections are common and carry a greater burden in older adults. IDP (Immune Defense Protein) is a dietary supplement whose active ingredient is a complex of milk-derived bioactive whey proteins. Prior studies of IDP report enhanced antibody response following influenza vaccination, suggesting a potential for reduction of incidence, duration, and severity of upper respiratory symptoms. This study evaluated the effects of IDP supplementation on the incidence, type, duration, and severity of upper respiratory symptoms in older adults during cold and flu season, along with rescue medication use and quality of life. Methods. This was a randomized, double-blind, placebo-controlled study with three arms (placebo, standard dose of 50mg IDP /day, and advanced dose of 200mg IDP /day). Participants completed a one-week baseline period followed by a 16-week product use period, reporting daily upper respiratory symptoms via the Wisconsin Upper Respiratory Symptom Survey (WURSS-24). Participants additionally logged quality of life using the Short Form 36 (SF-36). ANCOVA for change from baseline, mixed models for repeated measures (MRMM), as well as Kruskal Wallis (KW) tests of area under the curve of symptom frequency and severity were used to compare trajectories over time. Results. N=255 participants (n=88 Placebo, n=85 50 mg IDP , n=82 200 mg IDP ) were evaluated. Analysis of individual symptom trends over time revealed that chest congestion and cough decreased in severity and duration significantly faster in the 50 mg IDP and 200 mg IDP groups compared to Placebo (KW for Area Under the Curve p<0.05). ANCOVA of baseline to Week-16 change and MRMM of total WURSS-24 symptom frequency, severity and rescue medication use revealed no significant difference between arms (ANCOVA and MRMM p > 0.05). SF-36 quality of life did not differ between arms. Adverse events potentially attributable to product use were infrequent, resolved, and did not differ between arms. Conclusions. Sixteen weeks of daily IDP supplementation was associated with a reduction in duration and severity of cough and chest congestion in older adults. IDP appears safe and tolerable.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.09.26367685v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
            "content_type": "application/json",
            "elapsed_ms": 553,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.09.26367685v1?rss=1"
    },
    {
      "id": "a9582f46dff2f9290bf3",
      "title": "Preprint: Distinct circulating proteomic patterns associated with thoracic aortic diameter and stiffness: A proteome-wide study in the UK Biobank",
      "content_text": "Background: Thoracic aortic aneurysm (TAA) is characterized by abnormal dilation and functional remodelling of the thoracic aorta. Current detection and surveillance rely largely on imaging, limiting population-wide risk stratification. Circulating proteins may provide biological insight into aortic remodelling and support future biomarker development. We aimed to identify circulating proteomic patterns associated with imaging-derived thoracic aortic diameter and aortic stiffness in a large…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "a9582f46dff2f9290bf3",
          "source": "web",
          "type": "change",
          "key": "#3a7f0009b19370e6415a",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
          "timestamp": null,
          "observed_at": "2026-11-17T03:09:24Z",
          "data": {
            "change": "added",
            "label": "Preprint: Distinct circulating proteomic patterns associated with thoracic aortic diameter and stiffness: A proteome-wide study in the UK Biobank",
            "item_type": "record",
            "summary": "added: Preprint: Distinct circulating proteomic patterns associated with thoracic aortic diameter and stiffness: A proteome-wide study in the UK Biobank",
            "after": {
              "title": "Preprint: Distinct circulating proteomic patterns associated with thoracic aortic diameter and stiffness: A proteome-wide study in the UK Biobank",
              "authors": "Choi, A.; Hobbs, A. J.; Tsui, J.; Hingorani, A. D.; Paliwal, N.",
              "author_corresponding": "Nikhil Paliwal",
              "author_corresponding_institution": "Institute of Cardiovascular Science, University College London, London, UK",
              "doi": "10.64898/2026.11.13.26368064",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "cardiovascular medicine",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.13.26368064.source.xml",
              "abstract": "Background: Thoracic aortic aneurysm (TAA) is characterized by abnormal dilation and functional remodelling of the thoracic aorta. Current detection and surveillance rely largely on imaging, limiting population-wide risk stratification. Circulating proteins may provide biological insight into aortic remodelling and support future biomarker development. We aimed to identify circulating proteomic patterns associated with imaging-derived thoracic aortic diameter and aortic stiffness in a large population-based cohort. Methods: A proteome-wide association study was conducted in 6773 UK Biobank participants with available plasma proteomic and cardiac imaging data. A combined thoracic aortic diameter was derived from taking the maximum of standardized ascending and descending measurements, while stiffness was derived using a pressure-free index of aortic wall properties. Associations with 2920 circulating proteins were evaluated using multivariable linear regression with Benjamini-Hochberg false discovery rate (FDR) correction. Functional enrichment analysis was performed using the complete ranked protein list across Hallmark, curated, and Gene Ontology Biological Process collections. Principal component analysis (PCA) was performed as a secondary analysis to explore shared and divergent variation between the two phenotypes. Results: In age- and sex-adjusted analyses, 358 proteins were associated with aortic diameter and 60 with stiffness after FDR correction. Sequential adjustment materially altered these associations; in the primary fully adjusted models, 417 proteins were associated with diameter and six with stiffness. Functional enrichment analyses highlighted complement/coagulation, extracellular matrix organization, and contractile pathways associated with aortic diameter. In contrast, although only a few individual proteins were associated with stiffness, rank-based pathway analysis across the full proteome identified a distinct enrichment pattern involving cytokine signalling, protein processing, and intracellular transport. Aortic diameter and stiffness were only modestly correlated (r = 0.21). Secondary PCA showed that the first principal component (PC1) largely overlapped with the diameter-associated profile, with 310 of 370 PC1-associated proteins also associated with diameter. Four proteins (REN, BCAN, GGH and THY1) were associated with both diameter and stiffness in addition to being associated with PC1. Conclusion: Circulating proteomic profiling identified markedly different and minimally overlapping molecular patterns associated with thoracic aortic diameter and stiffness. Structural dilation was primarily linked to complement/coagulation, extracellular matrix, and contractile pathways, whereas stiffness reflected a smaller, more distinct aspect of aortic remodelling involving cytokine signalling and cellular transport processes. The four shared proteins across both phenotypes (REN, BCAN, GGH and THY1) represent candidates for further biomarker and causal investigation.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background: Thoracic aortic aneurysm (TAA) is characterized by abnormal dilation and functional remodelling of the thoracic aorta. Current detection and surveillance rely largely on imaging, limiting population-wide risk stratification. Circulating proteins may provide biological insight into aortic remodelling and support future biomarker development. We aimed to identify circulating proteomic patterns associated with imaging-derived thoracic aortic diameter and aortic stiffness in a large population-based cohort. Methods: A proteome-wide association study was conducted in 6773 UK Biobank participants with available plasma proteomic and cardiac imaging data. A combined thoracic aortic diameter was derived from taking the maximum of standardized ascending and descending measurements, while stiffness was derived using a pressure-free index of aortic wall properties. Associations with 2920 circulating proteins were evaluated using multivariable linear regression with Benjamini-Hochberg false discovery rate (FDR) correction. Functional enrichment analysis was performed using the complete ranked protein list across Hallmark, curated, and Gene Ontology Biological Process collections. Principal component analysis (PCA) was performed as a secondary analysis to explore shared and divergent variation between the two phenotypes. Results: In age- and sex-adjusted analyses, 358 proteins were associated with aortic diameter and 60 with stiffness after FDR correction. Sequential adjustment materially altered these associations; in the primary fully adjusted models, 417 proteins were associated with diameter and six with stiffness. Functional enrichment analyses highlighted complement/coagulation, extracellular matrix organization, and contractile pathways associated with aortic diameter. In contrast, although only a few individual proteins were associated with stiffness, rank-based pathway analysis across the full proteome identified a distinct enrichment pattern involving cytokine signalling, protein processing, and intracellular transport. Aortic diameter and stiffness were only modestly correlated (r = 0.21). Secondary PCA showed that the first principal component (PC1) largely overlapped with the diameter-associated profile, with 310 of 370 PC1-associated proteins also associated with diameter. Four proteins (REN, BCAN, GGH and THY1) were associated with both diameter and stiffness in addition to being associated with PC1. Conclusion: Circulating proteomic profiling identified markedly different and minimally overlapping molecular patterns associated with thoracic aortic diameter and stiffness. Structural dilation was primarily linked to complement/coagulation, extracellular matrix, and contractile pathways, whereas stiffness reflected a smaller, more distinct aspect of aortic remodelling involving cytokine signalling and cellular transport processes. The four shared proteins across both phenotypes (REN, BCAN, GGH and THY1) represent candidates for further biomarker and causal investigation.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368064v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
            "content_type": "application/json",
            "elapsed_ms": 553,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368064v1?rss=1"
    },
    {
      "id": "2959edf4d53b352e5b26",
      "title": "Preprint: Reconstructing the range-normalized terminal QRS from V1 and V6 using the time-embedded 3D ECG",
      "content_text": "Objective. Can a fixed V1/V6 projection of the time-embedded 3D ECG estimate the final 40 ms of V2-V5 more accurately than a fitted single lead? Methods. We used simultaneous recordings from the Lobachevsky University Electrocardiography Database (LUDB), with cardiologist-annotated QRS complexes in all six chest leads. We fitted both models in 118 patients and tested them in 80 others. Root mean squared error (RMSE) is expressed in percentage points (pp) of the target lead's 10-second amplitude…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "2959edf4d53b352e5b26",
          "source": "web",
          "type": "change",
          "key": "#7d72f69a98e86ee8678d",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
          "timestamp": null,
          "observed_at": "2026-11-17T03:09:24Z",
          "data": {
            "change": "added",
            "label": "Preprint: Reconstructing the range-normalized terminal QRS from V1 and V6 using the time-embedded 3D ECG",
            "item_type": "record",
            "summary": "added: Preprint: Reconstructing the range-normalized terminal QRS from V1 and V6 using the time-embedded 3D ECG",
            "after": {
              "title": "Preprint: Reconstructing the range-normalized terminal QRS from V1 and V6 using the time-embedded 3D ECG",
              "authors": "Bermejo Valdes, A. J.; Archer Jimenez, J.",
              "author_corresponding": "Alejandro Jesús Bermejo Valdés",
              "author_corresponding_institution": "061 Emergency Medical Services Department, La Rioja Health Service",
              "doi": "10.64898/2026.11.14.26368083",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "cardiovascular medicine",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.14.26368083.source.xml",
              "abstract": "Objective. Can a fixed V1/V6 projection of the time-embedded 3D ECG estimate the final 40 ms of V2-V5 more accurately than a fitted single lead? Methods. We used simultaneous recordings from the Lobachevsky University Electrocardiography Database (LUDB), with cardiologist-annotated QRS complexes in all six chest leads. We fitted both models in 118 patients and tested them in 80 others. Root mean squared error (RMSE) is expressed in percentage points (pp) of the target lead's 10-second amplitude range. Results. In 733 test beats, patient-weighted terminal RMSE fell from 12.58 to 10.64 pp (difference 1.94 pp, 95% bootstrap confidence interval 1.30 to 2.55). Reductions were 3.23, 2.85 and 1.35 pp in V3, V4 and V5. In V2 the difference was 0.35 pp (95% interval -0.35 to 1.05). In 702 matched beats from 77 patients, the overall advantage was 2.22 pp at the automatic V1/V6 end and 1.92 pp at the annotated target end. Of 1,498 beat-lead pairs with whole-QRS correlation of at least 0.95, 28.84% still had terminal RMSE of at least 10 pp. Conclusions. A fixed V1/V6 projection improved offline estimates of relative terminal amplitude in V3-V5 without fitting the target lead in the new patient. The gain was largest in V3 and V4 and uncertain in V2. Whether a reconstructed trace preserves a clinically recognizable notch or slur remains untested.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Objective. Can a fixed V1/V6 projection of the time-embedded 3D ECG estimate the final 40 ms of V2-V5 more accurately than a fitted single lead? Methods. We used simultaneous recordings from the Lobachevsky University Electrocardiography Database (LUDB), with cardiologist-annotated QRS complexes in all six chest leads. We fitted both models in 118 patients and tested them in 80 others. Root mean squared error (RMSE) is expressed in percentage points (pp) of the target lead's 10-second amplitude range. Results. In 733 test beats, patient-weighted terminal RMSE fell from 12.58 to 10.64 pp (difference 1.94 pp, 95% bootstrap confidence interval 1.30 to 2.55). Reductions were 3.23, 2.85 and 1.35 pp in V3, V4 and V5. In V2 the difference was 0.35 pp (95% interval -0.35 to 1.05). In 702 matched beats from 77 patients, the overall advantage was 2.22 pp at the automatic V1/V6 end and 1.92 pp at the annotated target end. Of 1,498 beat-lead pairs with whole-QRS correlation of at least 0.95, 28.84% still had terminal RMSE of at least 10 pp. Conclusions. A fixed V1/V6 projection improved offline estimates of relative terminal amplitude in V3-V5 without fitting the target lead in the new patient. The gain was largest in V3 and V4 and uncertain in V2. Whether a reconstructed trace preserves a clinically recognizable notch or slur remains untested.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368083v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
            "content_type": "application/json",
            "elapsed_ms": 553,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368083v1?rss=1"
    },
    {
      "id": "9274217beecd277ed033",
      "title": "Preprint: Integrating Histopathology Foundation Models and PRAME Immunohistochemistry in Melanoma Diagnosis",
      "content_text": "Background: The histopathological diagnosis of challenging melanocytic lesions remains limited by substantial interobserver variability. Although computational pathology foundation models demonstrated promising diagnostic performance, their predictions are often difficult to interpret in terms of established criteria. Objective: We evaluated a diagnostic framework combining foundation-model-based whole-slide image analysis, automated prediction of morphological features, and manually assessed…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "9274217beecd277ed033",
          "source": "web",
          "type": "change",
          "key": "#40fbd2e7d36f458a0c28",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
          "timestamp": null,
          "observed_at": "2026-11-17T03:09:24Z",
          "data": {
            "change": "added",
            "label": "Preprint: Integrating Histopathology Foundation Models and PRAME Immunohistochemistry in Melanoma Diagnosis",
            "item_type": "record",
            "summary": "added: Preprint: Integrating Histopathology Foundation Models and PRAME Immunohistochemistry in Melanoma Diagnosis",
            "after": {
              "title": "Preprint: Integrating Histopathology Foundation Models and PRAME Immunohistochemistry in Melanoma Diagnosis",
              "authors": "Gellrich, F. F.; Kistner, A.; Guenther, C.; Hufnagel, C.; Hobelsberger, S.; Laske, J.; Beissert, S.; Aust, D.; Baretton, G.; Reidow, N.; Sergon, M.; Kather, J. N.; Ghaffari Laleh, N.",
              "author_corresponding": "Frank Friedrich Gellrich",
              "author_corresponding_institution": "Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universitaet Dresden, Dresden, Germany",
              "doi": "10.64898/2026.11.14.26368089",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "dermatology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.14.26368089.source.xml",
              "abstract": "Background: The histopathological diagnosis of challenging melanocytic lesions remains limited by substantial interobserver variability. Although computational pathology foundation models demonstrated promising diagnostic performance, their predictions are often difficult to interpret in terms of established criteria. Objective: We evaluated a diagnostic framework combining foundation-model-based whole-slide image analysis, automated prediction of morphological features, and manually assessed PRAME immunohistochemistry. Methods: Using the Virchow2 foundation model and STAMP framework, we analyzed a retrospective cohort of 1,000 melanocytic lesions undergoing PRAME immunohistochemistry. Models were trained on 800 cases and evaluated on a temporally held-out test cohort of 200 cases. Results: The slide-level malignancy classifier achieved a test AUROC of 0.970 (AUPRC 0.984). Separate models predicted established histopathological criteria with high discrimination, including ulceration (AUROC 0.991) and dermal mitoses (AUROC 0.966). In contrast, predicting PRAME expression from H&E images alone showed lower performance (AUROC 0.776-0.780 for PRAME scores 4 and 0). An integrated model combining the slide-level malignancy score, AI-predicted morphological features, and manual PRAME status achieved an AUROC of 0.972 (AUPRC 0.975), comparable to the standalone classifier. In multivariable analysis, PRAME score 4 versus 0 was strongly associated with malignancy (adjusted OR 35.04, 95% CI 17.39-74.62). Conclusions: These findings demonstrate the feasibility of combining foundation-model-based histopathological analysis with established morphological criteria and PRAME immunohistochemistry. Although the integrated framework did not substantially improve overall discrimination, it provides a structured approach for incorporating complementary histopathological and immunohistochemical information into AI-assisted assessment of melanocytic lesions.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background: The histopathological diagnosis of challenging melanocytic lesions remains limited by substantial interobserver variability. Although computational pathology foundation models demonstrated promising diagnostic performance, their predictions are often difficult to interpret in terms of established criteria. Objective: We evaluated a diagnostic framework combining foundation-model-based whole-slide image analysis, automated prediction of morphological features, and manually assessed PRAME immunohistochemistry. Methods: Using the Virchow2 foundation model and STAMP framework, we analyzed a retrospective cohort of 1,000 melanocytic lesions undergoing PRAME immunohistochemistry. Models were trained on 800 cases and evaluated on a temporally held-out test cohort of 200 cases. Results: The slide-level malignancy classifier achieved a test AUROC of 0.970 (AUPRC 0.984). Separate models predicted established histopathological criteria with high discrimination, including ulceration (AUROC 0.991) and dermal mitoses (AUROC 0.966). In contrast, predicting PRAME expression from H&E images alone showed lower performance (AUROC 0.776-0.780 for PRAME scores 4 and 0). An integrated model combining the slide-level malignancy score, AI-predicted morphological features, and manual PRAME status achieved an AUROC of 0.972 (AUPRC 0.975), comparable to the standalone classifier. In multivariable analysis, PRAME score 4 versus 0 was strongly associated with malignancy (adjusted OR 35.04, 95% CI 17.39-74.62). Conclusions: These findings demonstrate the feasibility of combining foundation-model-based histopathological analysis with established morphological criteria and PRAME immunohistochemistry. Although the integrated framework did not substantially improve overall discrimination, it provides a structured approach for incorporating complementary histopathological and immunohistochemical information into AI-assisted assessment of melanocytic lesions.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368089v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
            "content_type": "application/json",
            "elapsed_ms": 553,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.14.26368089v1?rss=1"
    },
    {
      "id": "62d17e56d2e7f5041bf9",
      "title": "Preprint: Beyond National Averages: Social Contact Patterns in the Upper Midwest",
      "content_text": "Background: Social contact surveys measure how individuals interact with each other, which directly influences disease transmission dynamics. The COVID-19 pandemic substantially altered how people live and work, highlighting the need for up-to-date and sub-national estimates of social contact patterns to inform disease modeling and public health planning. Methods: The Midwest Analytics & Disease Modeling Center (MADMC) conducted an opt-in social contact survey of upper Midwest residents, with…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "62d17e56d2e7f5041bf9",
          "source": "web",
          "type": "change",
          "key": "#7f9a15f3bbb4d7135d9c",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
          "timestamp": null,
          "observed_at": "2026-11-17T03:09:24Z",
          "data": {
            "change": "added",
            "label": "Preprint: Beyond National Averages: Social Contact Patterns in the Upper Midwest",
            "item_type": "record",
            "summary": "added: Preprint: Beyond National Averages: Social Contact Patterns in the Upper Midwest",
            "after": {
              "title": "Preprint: Beyond National Averages: Social Contact Patterns in the Upper Midwest",
              "authors": "Dorelien, A.; Carlson, M.; Wheatley, M. M.; Erickson, L.; Morris, K.; Sweet, K.; Enns, E.",
              "author_corresponding": "Audrey Dorelien",
              "author_corresponding_institution": "University of Washington",
              "doi": "10.64898/2026.11.13.26367651",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc",
              "category": "epidemiology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.13.26367651.source.xml",
              "abstract": "Background: Social contact surveys measure how individuals interact with each other, which directly influences disease transmission dynamics. The COVID-19 pandemic substantially altered how people live and work, highlighting the need for up-to-date and sub-national estimates of social contact patterns to inform disease modeling and public health planning. Methods: The Midwest Analytics & Disease Modeling Center (MADMC) conducted an opt-in social contact survey of upper Midwest residents, with about 60% of participants drawn from Minnesota. Participants reported all interpersonal contacts during the previous day, including the age of their contacts allowing for the analysis of mixing patterns. Detailed demographic information about the participants was also collected, allowing for additional subgroup analyses of contact patterns. Results: Participants in our sample had an average of 6.8 contacts per day (IQR: 2.0 - 8.0), which is within the range of recent post-pandemic US national and European estimates. Contacts varied across demographic groups, with those attending work or school in-person reporting the highest number of contacts. Mixing across most age group pairs was a little lower than in comparable national survey except for younger age groups, who had substantially higher rates of contact with same-age peers. Differences in the contact matrices alone were associated with a 6.7% difference in estimated basic reproduction number(R0). Near the epidemic threshold, even this modest difference could meaningfully affect transmission dynamics. These effects may be amplified or attenuated by pathogen-specific age patterns of susceptibility and infectiousness, leading to larger or smaller differences in R0 estimates derived from national versus regional mixing patterns. Conclusions: These findings provide empirical evidence on post-pandemic social contact patterns in the United States and highlight the potential implications of regional variation in social mixing for infectious disease transmission. The mean 6.8 daily contacts is consistent with evidence of persistent changes in daily routines following the pandemic. Incorporating contemporary, region-specific contact patterns into transmission models may improve their ability to capture geographic variation in transmission risk and inform epidemic forecasting.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background: Social contact surveys measure how individuals interact with each other, which directly influences disease transmission dynamics. The COVID-19 pandemic substantially altered how people live and work, highlighting the need for up-to-date and sub-national estimates of social contact patterns to inform disease modeling and public health planning. Methods: The Midwest Analytics & Disease Modeling Center (MADMC) conducted an opt-in social contact survey of upper Midwest residents, with about 60% of participants drawn from Minnesota. Participants reported all interpersonal contacts during the previous day, including the age of their contacts allowing for the analysis of mixing patterns. Detailed demographic information about the participants was also collected, allowing for additional subgroup analyses of contact patterns. Results: Participants in our sample had an average of 6.8 contacts per day (IQR: 2.0 - 8.0), which is within the range of recent post-pandemic US national and European estimates. Contacts varied across demographic groups, with those attending work or school in-person reporting the highest number of contacts. Mixing across most age group pairs was a little lower than in comparable national survey except for younger age groups, who had substantially higher rates of contact with same-age peers. Differences in the contact matrices alone were associated with a 6.7% difference in estimated basic reproduction number(R0). Near the epidemic threshold, even this modest difference could meaningfully affect transmission dynamics. These effects may be amplified or attenuated by pathogen-specific age patterns of susceptibility and infectiousness, leading to larger or smaller differences in R0 estimates derived from national versus regional mixing patterns. Conclusions: These findings provide empirical evidence on post-pandemic social contact patterns in the United States and highlight the potential implications of regional variation in social mixing for infectious disease transmission. The mean 6.8 daily contacts is consistent with evidence of persistent changes in daily routines following the pandemic. Incorporating contemporary, region-specific contact patterns into transmission models may improve their ability to capture geographic variation in transmission risk and inform epidemic forecasting.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26367651v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
            "content_type": "application/json",
            "elapsed_ms": 553,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26367651v1?rss=1"
    },
    {
      "id": "c1f4cdd7854bd1942ff0",
      "title": "Preprint: Multi-omics models for hypertension prediction using blood pressure PRS and omics scores",
      "content_text": "Background: Hypertension is a major modifiable risk factor for cardiovascular disease, yet the relative contributions of proteomic (ProtS), metabolomic (MetS), and polygenic risk scores (PRS) to incident hypertension risk remain incompletely characterized. Methods: We developed ProtS and MetS for systolic (SBP) and diastolic blood pressure (DBP), and hypertension using Elastic Net regression in the Multi-Ethnic Study of Atherosclerosis (MESA). We incorporated these scores with previously…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "c1f4cdd7854bd1942ff0",
          "source": "web",
          "type": "change",
          "key": "#070fb8290b758e25f725",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
          "timestamp": null,
          "observed_at": "2026-11-17T03:09:24Z",
          "data": {
            "change": "added",
            "label": "Preprint: Multi-omics models for hypertension prediction using blood pressure PRS and omics scores",
            "item_type": "record",
            "summary": "added: Preprint: Multi-omics models for hypertension prediction using blood pressure PRS and omics scores",
            "after": {
              "title": "Preprint: Multi-omics models for hypertension prediction using blood pressure PRS and omics scores",
              "authors": "Wang, Z.; Hrytsenko, Y.; Almogy, S.; Spitzer, B. W.; Purushotham, Y.; Taylor, K.; Lin, H. J. J.; Tahir, U. A.; Raffield, L. M.; Rich, S.; Rotter, J.; Chen, Z. Z.; Sofer, T.",
              "author_corresponding": "Ziqing Wang",
              "author_corresponding_institution": "BIDMC",
              "doi": "10.64898/2026.11.13.26368055",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "epidemiology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.13.26368055.source.xml",
              "abstract": "Background: Hypertension is a major modifiable risk factor for cardiovascular disease, yet the relative contributions of proteomic (ProtS), metabolomic (MetS), and polygenic risk scores (PRS) to incident hypertension risk remain incompletely characterized. Methods: We developed ProtS and MetS for systolic (SBP) and diastolic blood pressure (DBP), and hypertension using Elastic Net regression in the Multi-Ethnic Study of Atherosclerosis (MESA). We incorporated these scores with previously developed BP PRSs into 5 incremental XGBoost models, with external validation in the Jackson Heart Study (JHS). We further applied transfer learning to adapt the MESA-derived models to JHS. Elastic Net selected proteins were prioritized using Mendelian randomization, colocalization, and functional analyses. Results: In MESA, model discrimination improved with the addition of omics scores, with the combined model achieving an area under the curve (AUC) of 0.72 compared with 0.63 for the clinical baseline model. In JHS, ProtS showed the highest AUC of 0.68 and the smallest cross-cohort performance decline, compared to MetS and PRS. Incorporating measured SBP and DBP substantially improved discrimination, with the PRS+BP model achieving an AUC of 0.80 in MESA and the baseline+BP model achieving an AUC of 0.74 in JHS. Among JHS participants with normal baseline BP, ProtS provided the strongest discrimination among models without measured BP (AUC = 0.62), while PRS+BP model achieved an AUC of 0.69. Leaf-weight refreshing consistently improved calibration in JHS while preserving discrimination. Mendelian randomization identified 77 proteins associated with BP traits or hypertension, involved in vascular, inflammatory, renal, and natriuretic pathways. Conclusions: ProtS demonstrated superior predictive performance and cross-cohort transferability among the omics modalities evaluated, while measured BP remained the strongest predictors of incident hypertension. Proteomic and genetic information may provide complementary biological signals for identifying individuals at elevated hypertension risk, particularly before clinically elevated BP is detectable.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background: Hypertension is a major modifiable risk factor for cardiovascular disease, yet the relative contributions of proteomic (ProtS), metabolomic (MetS), and polygenic risk scores (PRS) to incident hypertension risk remain incompletely characterized. Methods: We developed ProtS and MetS for systolic (SBP) and diastolic blood pressure (DBP), and hypertension using Elastic Net regression in the Multi-Ethnic Study of Atherosclerosis (MESA). We incorporated these scores with previously developed BP PRSs into 5 incremental XGBoost models, with external validation in the Jackson Heart Study (JHS). We further applied transfer learning to adapt the MESA-derived models to JHS. Elastic Net selected proteins were prioritized using Mendelian randomization, colocalization, and functional analyses. Results: In MESA, model discrimination improved with the addition of omics scores, with the combined model achieving an area under the curve (AUC) of 0.72 compared with 0.63 for the clinical baseline model. In JHS, ProtS showed the highest AUC of 0.68 and the smallest cross-cohort performance decline, compared to MetS and PRS. Incorporating measured SBP and DBP substantially improved discrimination, with the PRS+BP model achieving an AUC of 0.80 in MESA and the baseline+BP model achieving an AUC of 0.74 in JHS. Among JHS participants with normal baseline BP, ProtS provided the strongest discrimination among models without measured BP (AUC = 0.62), while PRS+BP model achieved an AUC of 0.69. Leaf-weight refreshing consistently improved calibration in JHS while preserving discrimination. Mendelian randomization identified 77 proteins associated with BP traits or hypertension, involved in vascular, inflammatory, renal, and natriuretic pathways. Conclusions: ProtS demonstrated superior predictive performance and cross-cohort transferability among the omics modalities evaluated, while measured BP remained the strongest predictors of incident hypertension. Proteomic and genetic information may provide complementary biological signals for identifying individuals at elevated hypertension risk, particularly before clinically elevated BP is detectable.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368055v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-15/2026-11-17/90",
            "content_type": "application/json",
            "elapsed_ms": 553,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368055v1?rss=1"
    },
    {
      "id": "b10ad2a2411c19440298",
      "title": "Preprint: Timing of First Poststroke Seizure and Risk of Seizure Recurrence by Stroke Subtype",
      "content_text": "Importance: The 7-day cutoff separating acute symptomatic from unprovoked poststroke seizures guides epilepsy diagnosis and long-term antiseizure medication but is consensus based and unvalidated against recurrence risk by stroke subtype. Objective: To determine whether seizure recurrence risk changes abruptly at day 7 and how it varies with first-seizure timing by stroke subtype. Design, Setting, and Participants: This pooled analysis of individual participant data from 36 cohorts in 22…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "b10ad2a2411c19440298",
          "source": "web",
          "type": "change",
          "key": "#f1047d61a337435a32a0",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-14/2026-11-16/60",
          "timestamp": null,
          "observed_at": "2026-11-16T18:16:39Z",
          "data": {
            "change": "added",
            "label": "Preprint: Timing of First Poststroke Seizure and Risk of Seizure Recurrence by Stroke Subtype",
            "item_type": "record",
            "summary": "added: Preprint: Timing of First Poststroke Seizure and Risk of Seizure Recurrence by Stroke Subtype",
            "after": {
              "title": "Preprint: Timing of First Poststroke Seizure and Risk of Seizure Recurrence by Stroke Subtype",
              "authors": "Schubert, K. M.; Berg, I.; Pedrazzetti, M. E.; Delazer, L.; Lindgren, E.; Orlandi, N.; Meletti, S.; Abraira, L.; Campos-Fernandez, D.; Fukuma, K.; Ihara, M.; Dasari, V.; Punia, V.; Landau, B.; Lochner, P.; Winter, Y.; Tsalouchidou, P.-E.; Wang, Y.; Merlino, G.; Valente, M.; Bentes, C.; Alet, M.; Franco, A. C. G.; Oliveira, A. L.; Khoo, C. S.; Helbok, R.; Gruber, J.; Kimiskidis, V. K.; Doerrfuss, J. I.; Leclercq, V.; Gaspard, N.; Heldner, M. R.; Putaala, J.; Aguiar de Sousa, D.; Coutinho, J. M.; Zafra-Sierra, M. P.; Mayor-Romero, L. C.; Keezer, M. R.; Pezzini, A.; Rouhl, R. P. W.; Duncan, J. S.",
              "author_corresponding": "Marian Galovic",
              "author_corresponding_institution": "Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland",
              "doi": "10.64898/2026.11.13.26368030",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "neurology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.13.26368030.source.xml",
              "abstract": "Importance: The 7-day cutoff separating acute symptomatic from unprovoked poststroke seizures guides epilepsy diagnosis and long-term antiseizure medication but is consensus based and unvalidated against recurrence risk by stroke subtype. Objective: To determine whether seizure recurrence risk changes abruptly at day 7 and how it varies with first-seizure timing by stroke subtype. Design, Setting, and Participants: This pooled analysis of individual participant data from 36 cohorts in 22 countries (inclusion, 1994-2025) included adults with a first seizure after ischemic stroke, intracerebral hemorrhage, aneurysmal subarachnoid hemorrhage, or cerebral venous thrombosis. Exposure: Days from stroke onset (or venous thrombosis diagnosis) to first seizure. Main Outcomes and Measures: The 10-year cumulative incidence of unprovoked seizure recurrence, with death as a competing event, from stabilized inverse probability of treatment-weighted Fine-Gray spline models. Risk zones were based on the likelihood of being helped vs harmed and the 60% epilepsy threshold of the International League Against Epilepsy. Results: Of 2434 individuals (median [IQR] age, 63 [49-75] years; 1181 [48.5%] female), 684 (28.1%) had a seizure recurrence. Risk changed gradually with first-seizure timing, without a day-7 transition; overall 10-year risk differed by subtype (cerebral venous thrombosis, 44%; intracerebral hemorrhage, 43%; ischemic stroke, 40%; subarachnoid hemorrhage, 35%; P < .001). At day 7, the 10-year risk was 24% (95% CI, 17%-32%) after ischemic stroke, 30% (95% CI, 22%-38%) after intracerebral hemorrhage, 41% (95% CI, 22%-53%) after subarachnoid hemorrhage, and 58% (95% CI, 44%-71%) after cerebral venous thrombosis. The 60% threshold was crossed from day 71 after ischemic stroke, day 41 after intracerebral hemorrhage, and day 9 after cerebral venous thrombosis; after subarachnoid hemorrhage, only seizures on days 2 to 3 exceeded it. Mortality was inversely related to recurrence risk. Of 800 first seizures after day 7 following ischemic stroke or intracerebral hemorrhage, which would qualify as epilepsy under current criteria, 335 (42%) had a recurrence risk below the 60% diagnostic threshold. Conclusions and Relevance: In this pooled analysis, seizure recurrence risk after stroke rose gradually, not abruptly at day 7, and differed by subtype. After external validation, subtype-specific risk zones could inform individualized decisions about long-term antiseizure medication.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Importance: The 7-day cutoff separating acute symptomatic from unprovoked poststroke seizures guides epilepsy diagnosis and long-term antiseizure medication but is consensus based and unvalidated against recurrence risk by stroke subtype. Objective: To determine whether seizure recurrence risk changes abruptly at day 7 and how it varies with first-seizure timing by stroke subtype. Design, Setting, and Participants: This pooled analysis of individual participant data from 36 cohorts in 22 countries (inclusion, 1994-2025) included adults with a first seizure after ischemic stroke, intracerebral hemorrhage, aneurysmal subarachnoid hemorrhage, or cerebral venous thrombosis. Exposure: Days from stroke onset (or venous thrombosis diagnosis) to first seizure. Main Outcomes and Measures: The 10-year cumulative incidence of unprovoked seizure recurrence, with death as a competing event, from stabilized inverse probability of treatment-weighted Fine-Gray spline models. Risk zones were based on the likelihood of being helped vs harmed and the 60% epilepsy threshold of the International League Against Epilepsy. Results: Of 2434 individuals (median [IQR] age, 63 [49-75] years; 1181 [48.5%] female), 684 (28.1%) had a seizure recurrence. Risk changed gradually with first-seizure timing, without a day-7 transition; overall 10-year risk differed by subtype (cerebral venous thrombosis, 44%; intracerebral hemorrhage, 43%; ischemic stroke, 40%; subarachnoid hemorrhage, 35%; P < .001). At day 7, the 10-year risk was 24% (95% CI, 17%-32%) after ischemic stroke, 30% (95% CI, 22%-38%) after intracerebral hemorrhage, 41% (95% CI, 22%-53%) after subarachnoid hemorrhage, and 58% (95% CI, 44%-71%) after cerebral venous thrombosis. The 60% threshold was crossed from day 71 after ischemic stroke, day 41 after intracerebral hemorrhage, and day 9 after cerebral venous thrombosis; after subarachnoid hemorrhage, only seizures on days 2 to 3 exceeded it. Mortality was inversely related to recurrence risk. Of 800 first seizures after day 7 following ischemic stroke or intracerebral hemorrhage, which would qualify as epilepsy under current criteria, 335 (42%) had a recurrence risk below the 60% diagnostic threshold. Conclusions and Relevance: In this pooled analysis, seizure recurrence risk after stroke rose gradually, not abruptly at day 7, and differed by subtype. After external validation, subtype-specific risk zones could inform individualized decisions about long-term antiseizure medication.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368030v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-14/2026-11-16/60",
            "content_type": "application/json",
            "elapsed_ms": 1619,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368030v1?rss=1"
    },
    {
      "id": "30ec7ba33ad279b6ab84",
      "title": "Preprint: Inter-articulatory Timing of Vocalic Tongue Body and Jaw Movements across Talkers with Dysarthria due to Various Neurological Conditions",
      "content_text": "Purpose: This study compared inter-articulatory timing patterns of the tongue and jaw across talkers with Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), multiple sclerosis (MS), and neurotypical controls (CON) to identify disease-related differences. The study also explored if a talker's tongue body cycle duration, which serve as a proxy for a talker's habitual speech rate, or a talker's reliance on their jaw, as indicated by their jaw movement…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "30ec7ba33ad279b6ab84",
          "source": "web",
          "type": "change",
          "key": "#7bac4702aefd2307ec5c",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-14/2026-11-16/60",
          "timestamp": null,
          "observed_at": "2026-11-16T18:16:39Z",
          "data": {
            "change": "added",
            "label": "Preprint: Inter-articulatory Timing of Vocalic Tongue Body and Jaw Movements across Talkers with Dysarthria due to Various Neurological Conditions",
            "item_type": "record",
            "summary": "added: Preprint: Inter-articulatory Timing of Vocalic Tongue Body and Jaw Movements across Talkers with Dysarthria due to Various Neurological Conditions",
            "after": {
              "title": "Preprint: Inter-articulatory Timing of Vocalic Tongue Body and Jaw Movements across Talkers with Dysarthria due to Various Neurological Conditions",
              "authors": "Thies, T.; Dietrich, M. S.; Mefferd, A.",
              "author_corresponding": "Tabea Thies",
              "author_corresponding_institution": "Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany",
              "doi": "10.64898/2026.11.13.26368039",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "neurology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.13.26368039.source.xml",
              "abstract": "Purpose: This study compared inter-articulatory timing patterns of the tongue and jaw across talkers with Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), multiple sclerosis (MS), and neurotypical controls (CON) to identify disease-related differences. The study also explored if a talker's tongue body cycle duration, which serve as a proxy for a talker's habitual speech rate, or a talker's reliance on their jaw, as indicated by their jaw movement amplitude, could predict their inter-articulatory timing patterns. Method: Using three-dimensional electromagnetic articulography, the movements of the posterior tongue and jaw were examined in 24 talkers with PD, 19 talkers with ALS, 18 talkers with HD, 18 talkers with MS, and 34 CON during a sentence repetition task ('Buy Kaia a kite'). The tongue movement during the segment [kai] served as the reference signal (tongue body cycle) for which the phase angle of the jaw reaching the maximum opening position during [kai] was calculated. Tongue body cycle durations were measured as the time between the tongue body movement onset to the tongue body movement offset. The jaw opening amplitude was measured as the relative positional change from the jaw's maximum closing position associated with [k] to the jaw's maximal opening position at the onset of the diphthong [ai]. Results: A significant group effect was found for phase angles. Pairwise comparisons showed that talkers with ALS had significantly larger phase angles than talkers with PD, MS, HD, and CON, indicating a timing pattern where the tongue reached the target [a] earlier relative to the jaw. No significant differences were found for any other pairwise comparisons. Furthermore, no significant associations were found between tongue body cycle durations and phase angles. A significant association was found between jaw amplitudes and phase angles when considering all talkers [rS(110) = .253, p = .008] and when only considering talkers of the control group [r(34) = .361, p = .036]. Conclusions: Findings suggest that during the production of [kai], tongue-jaw timing patterns of talkers with ALS differ from those of talkers with PD, MS, HD, and CON with the tongue reaching the maximum opening position before the jaw while the opposite pattern was observed for talkers of the other groups. However, the variability in tongue body cycle duration did not significantly contribute to the variability in phase angles and the variability in jaw amplitudes only accounted for 6% of the variability in phase angles across all talkers. Future studies are needed to determine if the observed tongue-jaw timing pattern of talkers with ALS generalizes to other phonetic contexts and determine the underlying factors that contribute to the unique tongue-jaw timing patterns of talkers with ALS.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Purpose: This study compared inter-articulatory timing patterns of the tongue and jaw across talkers with Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), multiple sclerosis (MS), and neurotypical controls (CON) to identify disease-related differences. The study also explored if a talker's tongue body cycle duration, which serve as a proxy for a talker's habitual speech rate, or a talker's reliance on their jaw, as indicated by their jaw movement amplitude, could predict their inter-articulatory timing patterns. Method: Using three-dimensional electromagnetic articulography, the movements of the posterior tongue and jaw were examined in 24 talkers with PD, 19 talkers with ALS, 18 talkers with HD, 18 talkers with MS, and 34 CON during a sentence repetition task ('Buy Kaia a kite'). The tongue movement during the segment [kai] served as the reference signal (tongue body cycle) for which the phase angle of the jaw reaching the maximum opening position during [kai] was calculated. Tongue body cycle durations were measured as the time between the tongue body movement onset to the tongue body movement offset. The jaw opening amplitude was measured as the relative positional change from the jaw's maximum closing position associated with [k] to the jaw's maximal opening position at the onset of the diphthong [ai]. Results: A significant group effect was found for phase angles. Pairwise comparisons showed that talkers with ALS had significantly larger phase angles than talkers with PD, MS, HD, and CON, indicating a timing pattern where the tongue reached the target [a] earlier relative to the jaw. No significant differences were found for any other pairwise comparisons. Furthermore, no significant associations were found between tongue body cycle durations and phase angles. A significant association was found between jaw amplitudes and phase angles when considering all talkers [rS(110) = .253, p = .008] and when only considering talkers of the control group [r(34) = .361, p = .036]. Conclusions: Findings suggest that during the production of [kai], tongue-jaw timing patterns of talkers with ALS differ from those of talkers with PD, MS, HD, and CON with the tongue reaching the maximum opening position before the jaw while the opposite pattern was observed for talkers of the other groups. However, the variability in tongue body cycle duration did not significantly contribute to the variability in phase angles and the variability in jaw amplitudes only accounted for 6% of the variability in phase angles across all talkers. Future studies are needed to determine if the observed tongue-jaw timing pattern of talkers with ALS generalizes to other phonetic contexts and determine the underlying factors that contribute to the unique tongue-jaw timing patterns of talkers with ALS.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368039v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-14/2026-11-16/60",
            "content_type": "application/json",
            "elapsed_ms": 1619,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368039v1?rss=1"
    },
    {
      "id": "997b49a8a96b9e33df16",
      "title": "Preprint: Adrenergic nerve fibers are depleted in adenomyosis myometrium",
      "content_text": "Objective: Uterine dyscontractility in adenomyosis and endometriosis is at the heart of pain symptoms and disease pathogenesis. To elucidate possible causes of dyscontractility, we examined the distribution of smooth muscle, blood vessel, collagen and nerve fibers in full-thickness, serosa-to-endometrium myometrium of adenomyosis patients versus control. Design: Retrospective study. Subjects: Uterine biopsies from patients who underwent hysterectomy for adenomyosis (n = 26) or other…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "997b49a8a96b9e33df16",
          "source": "web",
          "type": "change",
          "key": "#d8bdaeec6d4b3210951a",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-14/2026-11-16/60",
          "timestamp": null,
          "observed_at": "2026-11-16T18:16:39Z",
          "data": {
            "change": "added",
            "label": "Preprint: Adrenergic nerve fibers are depleted in adenomyosis myometrium",
            "item_type": "record",
            "summary": "added: Preprint: Adrenergic nerve fibers are depleted in adenomyosis myometrium",
            "after": {
              "title": "Preprint: Adrenergic nerve fibers are depleted in adenomyosis myometrium",
              "authors": "Chevalier, N. R.; Huon, E.; Segard, O.; Ouali, M.; Plancke, M.; Boer Wigman, C.; Savy, T.; Pujol, T.; Bourdoncle, P.; Dietrich, G.; Petit, E.; Abrahami, Y.; Kouby, J.; Adam, J.; Lamau, M.-C.; Abo, C.",
              "author_corresponding": "Nicolas R Chevalier",
              "author_corresponding_institution": "CNRS",
              "doi": "10.64898/2026.11.16.26368015",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc",
              "category": "obstetrics and gynecology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.16.26368015.source.xml",
              "abstract": "Objective: Uterine dyscontractility in adenomyosis and endometriosis is at the heart of pain symptoms and disease pathogenesis. To elucidate possible causes of dyscontractility, we examined the distribution of smooth muscle, blood vessel, collagen and nerve fibers in full-thickness, serosa-to-endometrium myometrium of adenomyosis patients versus control. Design: Retrospective study. Subjects: Uterine biopsies from patients who underwent hysterectomy for adenomyosis (n = 26) or other non-adenomyosis indications (n=22, mostly myomas). Main Outcome Measures: Density profiles along the serosa-to-endometrium axis of smooth muscle (SMA), endothelium (PECAM), general innervation (PGP9.5) and adrenergic innervation (TH) obtained by immunofluorescence, mosaic epifluorescence imaging and machine-learning assisted segmentation. Fibrous collagen type I&III was quantified by second-harmonic generation microscopy (SHG). Results: The density profiles of smooth muscle, endothelium, collagen and PGP9.5 were similar between both patient groups. Sympathetic adrenergic nerve fiber density radiated from the serosa inwards, with a continuously decreasing density from the outer to the inner myometrium. Adrenergic inhibitory nerve fibers were 4 times less dense in the inner myometrium of adenomyosis uteri compared to controls. Conclusion: The enrichment of inhibitory adrenergic nerve fibers in the outer vs inner myometrium provides a neuro-muscular mechanism by which contractions are restricted to the inner myometrium outside of pregnancy. The depletion of TH fibers in adenomyosis implies that a higher thickness of myometrium is involved in uterine contractions, thus explaining junctional zone thickening and dyscontractility in this pathology. This depletion may be due to defective post-pregnancy adrenergic re-innervation of the myometrium.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Objective: Uterine dyscontractility in adenomyosis and endometriosis is at the heart of pain symptoms and disease pathogenesis. To elucidate possible causes of dyscontractility, we examined the distribution of smooth muscle, blood vessel, collagen and nerve fibers in full-thickness, serosa-to-endometrium myometrium of adenomyosis patients versus control. Design: Retrospective study. Subjects: Uterine biopsies from patients who underwent hysterectomy for adenomyosis (n = 26) or other non-adenomyosis indications (n=22, mostly myomas). Main Outcome Measures: Density profiles along the serosa-to-endometrium axis of smooth muscle (SMA), endothelium (PECAM), general innervation (PGP9.5) and adrenergic innervation (TH) obtained by immunofluorescence, mosaic epifluorescence imaging and machine-learning assisted segmentation. Fibrous collagen type I&III was quantified by second-harmonic generation microscopy (SHG). Results: The density profiles of smooth muscle, endothelium, collagen and PGP9.5 were similar between both patient groups. Sympathetic adrenergic nerve fiber density radiated from the serosa inwards, with a continuously decreasing density from the outer to the inner myometrium. Adrenergic inhibitory nerve fibers were 4 times less dense in the inner myometrium of adenomyosis uteri compared to controls. Conclusion: The enrichment of inhibitory adrenergic nerve fibers in the outer vs inner myometrium provides a neuro-muscular mechanism by which contractions are restricted to the inner myometrium outside of pregnancy. The depletion of TH fibers in adenomyosis implies that a higher thickness of myometrium is involved in uterine contractions, thus explaining junctional zone thickening and dyscontractility in this pathology. This depletion may be due to defective post-pregnancy adrenergic re-innervation of the myometrium.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.16.26368015v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-14/2026-11-16/60",
            "content_type": "application/json",
            "elapsed_ms": 1619,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.16.26368015v1?rss=1"
    },
    {
      "id": "084b4fb7042bae6c623e",
      "title": "Preprint: Attitudes and Perceptions of Generative Artificial Intelligence Chatbots in the Peer Review of Traditional, Complementary, and Integrative Medicine Research: A Large-Scale, International Cross-Sectional Survey",
      "content_text": "Background: Generative artificial intelligence (GenAI) chatbots are being explored for their potential to support the peer review process by improving efficiency and analytical capacity. While early applications show promise, concerns regarding ethics, privacy, and research integrity remain, and their use within traditional, complementary, and integrative medicine (TCIM) remains underexplored. This study examines TCIM researchers' attitudes and perceptions regarding the use of GenAI chatbots in…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "084b4fb7042bae6c623e",
          "source": "web",
          "type": "change",
          "key": "#826dc209a32f9c82b2b3",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-14/2026-11-16/60",
          "timestamp": null,
          "observed_at": "2026-11-16T18:16:39Z",
          "data": {
            "change": "added",
            "label": "Preprint: Attitudes and Perceptions of Generative Artificial Intelligence Chatbots in the Peer Review of Traditional, Complementary, and Integrative Medicine Research: A Large-Scale, International Cross-Sectional Survey",
            "item_type": "record",
            "summary": "added: Preprint: Attitudes and Perceptions of Generative Artificial Intelligence Chatbots in the Peer Review of Traditional, Complementary, and Integrative Medicine Research: A Large-Scale, International Cross-Sectional Survey",
            "after": {
              "title": "Preprint: Attitudes and Perceptions of Generative Artificial Intelligence Chatbots in the Peer Review of Traditional, Complementary, and Integrative Medicine Research: A Large-Scale, International Cross-Sectional Survey",
              "authors": "Ng, J. Y.; Tan, J.; Adapa, K.; Gupta, P. K.; Gupta, M.; Li, S.; Mehta, D. H.; Ring, M.; Shridhar, M.; Souza, J. P.; Yoshino, T.; Lee, M. S.; Cramer, H.",
              "author_corresponding": "Jeremy Y. Ng",
              "author_corresponding_institution": "Institute of General Practice and Interprofessional Care, University Hospital Tubingen, Tubingen, Germany; Robert Bosch Center for Integrative Medicine and Heal",
              "doi": "10.64898/2026.11.12.26366211",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "health policy",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.12.26366211.source.xml",
              "abstract": "Background: Generative artificial intelligence (GenAI) chatbots are being explored for their potential to support the peer review process by improving efficiency and analytical capacity. While early applications show promise, concerns regarding ethics, privacy, and research integrity remain, and their use within traditional, complementary, and integrative medicine (TCIM) remains underexplored. This study examines TCIM researchers' attitudes and perceptions regarding the use of GenAI chatbots in peer review through a large-scale international survey. Methods: Corresponding authors of TCIM-related publications indexed in Ovid MEDLINE were invited to participate in an online, anonymous, international cross-sectional survey distributed via SurveyMonkey. The questionnaire collected data on demographic characteristics, the perceived importance of GenAI in peer review, the likelihood of adoption, and the perceived benefits and concerns. Results: A total of 889 eligible respondents participated. Overall, 40.25% (n=285/708) reported a positive perception of GenAI in peer review, and 41.67% (n=295/708) considered it important to the field. 34.24% researchers reported being likely (n=253/739) or 18.27% (135/739) very likely (totaling 52.51%) to use GenAI in peer review, highlighting a gap between perceived importance and intended adoption. Identified benefits included improved efficiency (50.72%, n=350/690), reduced reviewer workload (51.16%, n=353/690), and generation of constructive feedback (46.30%, n=319/689), reflecting respondents selecting \"agree.\" Concerns included bias (49.85%, n=333/668), lack of transparency (42.86%, n=285/665), inaccuracies (49.40%, n=329/666), accountability challenges (45.20%, n=301/666), and data privacy risks (36.05%, n=239/663). Most respondents believed that peer reviewers require either some training (43.91%, n=310/706) or a lot of training (40.93%, n=289/706) to use GenAI chatbots effectively in peer review. Conclusion: Respondents reported perceived benefits of GenAI in peer review, alongside notable concerns regarding its use. While opinions were mixed, findings suggest both perceived utility and apprehension about potential risks. Further work is needed to understand these perspectives better and to explore how GenAI can be responsibly integrated into peer-review processes.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background: Generative artificial intelligence (GenAI) chatbots are being explored for their potential to support the peer review process by improving efficiency and analytical capacity. While early applications show promise, concerns regarding ethics, privacy, and research integrity remain, and their use within traditional, complementary, and integrative medicine (TCIM) remains underexplored. This study examines TCIM researchers' attitudes and perceptions regarding the use of GenAI chatbots in peer review through a large-scale international survey. Methods: Corresponding authors of TCIM-related publications indexed in Ovid MEDLINE were invited to participate in an online, anonymous, international cross-sectional survey distributed via SurveyMonkey. The questionnaire collected data on demographic characteristics, the perceived importance of GenAI in peer review, the likelihood of adoption, and the perceived benefits and concerns. Results: A total of 889 eligible respondents participated. Overall, 40.25% (n=285/708) reported a positive perception of GenAI in peer review, and 41.67% (n=295/708) considered it important to the field. 34.24% researchers reported being likely (n=253/739) or 18.27% (135/739) very likely (totaling 52.51%) to use GenAI in peer review, highlighting a gap between perceived importance and intended adoption. Identified benefits included improved efficiency (50.72%, n=350/690), reduced reviewer workload (51.16%, n=353/690), and generation of constructive feedback (46.30%, n=319/689), reflecting respondents selecting \"agree.\" Concerns included bias (49.85%, n=333/668), lack of transparency (42.86%, n=285/665), inaccuracies (49.40%, n=329/666), accountability challenges (45.20%, n=301/666), and data privacy risks (36.05%, n=239/663). Most respondents believed that peer reviewers require either some training (43.91%, n=310/706) or a lot of training (40.93%, n=289/706) to use GenAI chatbots effectively in peer review. Conclusion: Respondents reported perceived benefits of GenAI in peer review, alongside notable concerns regarding its use. While opinions were mixed, findings suggest both perceived utility and apprehension about potential risks. Further work is needed to understand these perspectives better and to explore how GenAI can be responsibly integrated into peer-review processes.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.12.26366211v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-14/2026-11-16/60",
            "content_type": "application/json",
            "elapsed_ms": 1619,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.12.26366211v1?rss=1"
    },
    {
      "id": "782866d3b4db3ec697d9",
      "title": "Preprint: Fentanyl dabbing with cannabis retail equipment: an ethnographic and drug-checking study",
      "content_text": "Background: Fentanyl's entrenchment in U.S. West Coast drug markets brought a shift from injecting to smoking illicit opioids. We characterize the next transition: the rise of 'dabbing,' vaporizing fentanyl with equipment sold for cannabis concentrates. Methods: This mixed-methods study combined ethnographic interviewing and participant observation among people who use fentanyl in California and Oregon (2024-2026) with survey data from a Los Angeles drug checking program. After identifying…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "782866d3b4db3ec697d9",
          "source": "web",
          "type": "change",
          "key": "#8141580e1c5db1cbbb6f",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-14/2026-11-16/60",
          "timestamp": null,
          "observed_at": "2026-11-16T18:16:39Z",
          "data": {
            "change": "added",
            "label": "Preprint: Fentanyl dabbing with cannabis retail equipment: an ethnographic and drug-checking study",
            "item_type": "record",
            "summary": "added: Preprint: Fentanyl dabbing with cannabis retail equipment: an ethnographic and drug-checking study",
            "after": {
              "title": "Preprint: Fentanyl dabbing with cannabis retail equipment: an ethnographic and drug-checking study",
              "authors": "Godvin, M.; Cecil, L.; Koncsol, A.; Molina, C. A.; Grabill, M.; Romero, R.; Jalayer, E.; Villanueva, N.; Arellano, O.; Cowan, A.; Buhr, R. G.; Englander, H.; Friedman, J. R.; Bourgois, P.; Shover, C. L.",
              "author_corresponding": "Morgan Godvin",
              "author_corresponding_institution": "Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA",
              "doi": "10.64898/2026.11.13.26367858",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc_nd",
              "category": "addiction medicine",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.13.26367858.source.xml",
              "abstract": "Background: Fentanyl's entrenchment in U.S. West Coast drug markets brought a shift from injecting to smoking illicit opioids. We characterize the next transition: the rise of 'dabbing,' vaporizing fentanyl with equipment sold for cannabis concentrates. Methods: This mixed-methods study combined ethnographic interviewing and participant observation among people who use fentanyl in California and Oregon (2024-2026) with survey data from a Los Angeles drug checking program. After identifying dabbing ethnographically, we added an optional smoking-method item to the survey. Results: Of 108 participants who stated a route of administration, 104 (96%) reported smoking; of 93 who named a smoking method, 81 (87%) reported dabbing. All 11 who first named another method and returned later then reported dabbing. Dabbing was reported at 250 of 405 (62%) encounters with a stated route. We observed participants adapting cannabis equipment. They praised dabbing's discretion, reduced stigma, and convenience, and its capacity for more large hits, more quickly; the same speed led some to call it wasteful, because it went through their fentanyl faster than other methods. Participants described rapidly rising tolerance and frequent dabbing-related burns, which we also observed. Some who had injected said dabbing approximated its \"rush.\" Conclusions: Dabbing has become the dominant way to consume fentanyl among people using drug checking services in Los Angeles, and was observed in every other city where we did fieldwork. Clinicians and programs should ask people how they smoke fentanyl, not only whether they smoke or inject; dabbing may reduce some risks while increasing others.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background: Fentanyl's entrenchment in U.S. West Coast drug markets brought a shift from injecting to smoking illicit opioids. We characterize the next transition: the rise of 'dabbing,' vaporizing fentanyl with equipment sold for cannabis concentrates. Methods: This mixed-methods study combined ethnographic interviewing and participant observation among people who use fentanyl in California and Oregon (2024-2026) with survey data from a Los Angeles drug checking program. After identifying dabbing ethnographically, we added an optional smoking-method item to the survey. Results: Of 108 participants who stated a route of administration, 104 (96%) reported smoking; of 93 who named a smoking method, 81 (87%) reported dabbing. All 11 who first named another method and returned later then reported dabbing. Dabbing was reported at 250 of 405 (62%) encounters with a stated route. We observed participants adapting cannabis equipment. They praised dabbing's discretion, reduced stigma, and convenience, and its capacity for more large hits, more quickly; the same speed led some to call it wasteful, because it went through their fentanyl faster than other methods. Participants described rapidly rising tolerance and frequent dabbing-related burns, which we also observed. Some who had injected said dabbing approximated its \"rush.\" Conclusions: Dabbing has become the dominant way to consume fentanyl among people using drug checking services in Los Angeles, and was observed in every other city where we did fieldwork. Clinicians and programs should ask people how they smoke fentanyl, not only whether they smoke or inject; dabbing may reduce some risks while increasing others.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26367858v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-14/2026-11-16/60",
            "content_type": "application/json",
            "elapsed_ms": 1619,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26367858v1?rss=1"
    },
    {
      "id": "2491745a386aa02976ce",
      "title": "Preprint: Digital cytometry of immune cell types from dried blood microsamples",
      "content_text": "Enumeration of circulating immune cells is an established clinical practice implemented across a plethora of indications. While flow cytometry is the gold standard for this task, cellular deconvolution algorithms provide a robust computational alternative using molecular data. These digital cytometry pipelines typically rely on millilitre-scale venous blood samples. Here, we evaluated the potential of capillary blood microsampling as a patient-centric and minimally invasive approach for the…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "2491745a386aa02976ce",
          "source": "web",
          "type": "change",
          "key": "#5a109830b6947f16ae1c",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-14/2026-11-16/60",
          "timestamp": null,
          "observed_at": "2026-11-16T18:16:39Z",
          "data": {
            "change": "added",
            "label": "Preprint: Digital cytometry of immune cell types from dried blood microsamples",
            "item_type": "record",
            "summary": "added: Preprint: Digital cytometry of immune cell types from dried blood microsamples",
            "after": {
              "title": "Preprint: Digital cytometry of immune cell types from dried blood microsamples",
              "authors": "Ferry, Q. R.; Rajakumar, T.; Zeeck, M.; Chong-Morrison, V.; von Schrenck, T.; Ahmadi-Simab, K.; Steinkraus, B. R.",
              "author_corresponding": "Bruno R Steinkraus",
              "author_corresponding_institution": "Muno GmbH, Hamburg, Germany",
              "doi": "10.64898/2026.11.13.26368027",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc",
              "category": "allergy and immunology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.13.26368027.source.xml",
              "abstract": "Enumeration of circulating immune cells is an established clinical practice implemented across a plethora of indications. While flow cytometry is the gold standard for this task, cellular deconvolution algorithms provide a robust computational alternative using molecular data. These digital cytometry pipelines typically rely on millilitre-scale venous blood samples. Here, we evaluated the potential of capillary blood microsampling as a patient-centric and minimally invasive approach for the digital cytometry of major lymphocyte populations (T cells, B cells, and natural killer cells; TBNK). In a cohort of 200 participants, we compared RNA sequencing based deconvolution performance between matched PAXgene-stabilised venous blood and Mitra capillary blood microsamples. While venous transcriptomes enabled highly accurate TBNK estimation, patient-matched capillary microsamples exhibited a significant reduction in deconvolution accuracy. Computational adaptations, including the integration of capillary-specific single-cell reference profiles, yielded only limited improvements. Instead, our analyses revealed that the performance deficit was primarily driven by the decreased transcriptome complexity of the capillary microsample libraries. This study highlights the critical role of transcript diversity for cellular deconvolution and reveals the current pre-analytical challenges that must be overcome to harness transcriptomics based digital cytometry using dried blood microsamples.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Enumeration of circulating immune cells is an established clinical practice implemented across a plethora of indications. While flow cytometry is the gold standard for this task, cellular deconvolution algorithms provide a robust computational alternative using molecular data. These digital cytometry pipelines typically rely on millilitre-scale venous blood samples. Here, we evaluated the potential of capillary blood microsampling as a patient-centric and minimally invasive approach for the digital cytometry of major lymphocyte populations (T cells, B cells, and natural killer cells; TBNK). In a cohort of 200 participants, we compared RNA sequencing based deconvolution performance between matched PAXgene-stabilised venous blood and Mitra capillary blood microsamples. While venous transcriptomes enabled highly accurate TBNK estimation, patient-matched capillary microsamples exhibited a significant reduction in deconvolution accuracy. Computational adaptations, including the integration of capillary-specific single-cell reference profiles, yielded only limited improvements. Instead, our analyses revealed that the performance deficit was primarily driven by the decreased transcriptome complexity of the capillary microsample libraries. This study highlights the critical role of transcript diversity for cellular deconvolution and reveals the current pre-analytical challenges that must be overcome to harness transcriptomics based digital cytometry using dried blood microsamples.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368027v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-14/2026-11-16/60",
            "content_type": "application/json",
            "elapsed_ms": 1619,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368027v1?rss=1"
    },
    {
      "id": "f7ca050127ce55276cb1",
      "title": "Preprint: Population-level indirect effects of HPV vaccination in high-income settings: a Bayesian modelling study",
      "content_text": "Background Human papillomavirus (HPV) vaccination provides direct protection to vaccinated individuals, but also indirectly protects unvaccinated individuals through reduced HPV transmission. Mechanistic transmission models that predict the magnitude of such effects have been crucial to informing vaccination strategies. However, nearly two decades of post-vaccination experience in high-income countries now allow us to empirically characterise how population-level indirect effects vary with…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "f7ca050127ce55276cb1",
          "source": "web",
          "type": "change",
          "key": "#24682994ba5f49fd0973",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-14/2026-11-16/60",
          "timestamp": null,
          "observed_at": "2026-11-16T18:16:39Z",
          "data": {
            "change": "added",
            "label": "Preprint: Population-level indirect effects of HPV vaccination in high-income settings: a Bayesian modelling study",
            "item_type": "record",
            "summary": "added: Preprint: Population-level indirect effects of HPV vaccination in high-income settings: a Bayesian modelling study",
            "after": {
              "title": "Preprint: Population-level indirect effects of HPV vaccination in high-income settings: a Bayesian modelling study",
              "authors": "Wang, R.; Jit, M.",
              "author_corresponding": "Runze Wang",
              "author_corresponding_institution": "New York University",
              "doi": "10.64898/2026.11.13.26367966",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by",
              "category": "epidemiology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.13.26367966.source.xml",
              "abstract": "Background Human papillomavirus (HPV) vaccination provides direct protection to vaccinated individuals, but also indirectly protects unvaccinated individuals through reduced HPV transmission. Mechanistic transmission models that predict the magnitude of such effects have been crucial to informing vaccination strategies. However, nearly two decades of post-vaccination experience in high-income countries now allow us to empirically characterise how population-level indirect effects vary with vaccine coverage, time since vaccine introduction, and age. Methods We synthesised studies reporting HPV16/18 prevalence before and after vaccine introduction in high-income settings between 2007 and 2025. Indirect effects were estimated as the observed reduction in HPV16/18 prevalence after accounting for expected direct vaccine protection. We used a Bayesian hierarchical model to examine associations with vaccine coverage, time since vaccine introduction, and age at effect assessment across routine, catch-up, and non-targeted vaccination groups. XGBoost was used as a complementary, non-parametric approach. Findings Data from 11 high-income settings were included. Indirect effects increased during the first five to eight years after vaccine introduction and then remained relatively stable. Indirect effects generally decreased with increasing vaccine coverage. Patterns with age differed across vaccination groups. In the routine group, indirect effects increased during adolescence and remained positive at older observed ages. In the catch-up group, indirect effects decreased with age and approached zero or became negative after approximately age 25 years. XGBoost identified similar non-linear patterns. Interpretation Indirect protection against HPV16/18 develops gradually after vaccine introduction and varies with vaccine coverage, age, and vaccination group. This empirical approach can complement transmission models by using real-world evidence to characterise population-level indirect protection. However, making predictions outside the populations and ranges represented in the data should be done cautiously.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Background Human papillomavirus (HPV) vaccination provides direct protection to vaccinated individuals, but also indirectly protects unvaccinated individuals through reduced HPV transmission. Mechanistic transmission models that predict the magnitude of such effects have been crucial to informing vaccination strategies. However, nearly two decades of post-vaccination experience in high-income countries now allow us to empirically characterise how population-level indirect effects vary with vaccine coverage, time since vaccine introduction, and age. Methods We synthesised studies reporting HPV16/18 prevalence before and after vaccine introduction in high-income settings between 2007 and 2025. Indirect effects were estimated as the observed reduction in HPV16/18 prevalence after accounting for expected direct vaccine protection. We used a Bayesian hierarchical model to examine associations with vaccine coverage, time since vaccine introduction, and age at effect assessment across routine, catch-up, and non-targeted vaccination groups. XGBoost was used as a complementary, non-parametric approach. Findings Data from 11 high-income settings were included. Indirect effects increased during the first five to eight years after vaccine introduction and then remained relatively stable. Indirect effects generally decreased with increasing vaccine coverage. Patterns with age differed across vaccination groups. In the routine group, indirect effects increased during adolescence and remained positive at older observed ages. In the catch-up group, indirect effects decreased with age and approached zero or became negative after approximately age 25 years. XGBoost identified similar non-linear patterns. Interpretation Indirect protection against HPV16/18 develops gradually after vaccine introduction and varies with vaccine coverage, age, and vaccination group. This empirical approach can complement transmission models by using real-world evidence to characterise population-level indirect protection. However, making predictions outside the populations and ranges represented in the data should be done cautiously.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26367966v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-14/2026-11-16/60",
            "content_type": "application/json",
            "elapsed_ms": 1619,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26367966v1?rss=1"
    },
    {
      "id": "589d0b9f9e1d89af52bc",
      "title": "Preprint: Nirsevimab effectiveness against RSV hospitalizations in children 8-23 months at risk of severe RSV",
      "content_text": "Importance: Respiratory syncytial virus (RSV) is a leading cause of hospitalization in high-risk young children during their second RSV season. Nirsevimab, a long-acting monoclonal antibody against RSV, is recommended for some children who are at increased risk for severe RSV and entering their second RSV season to prevent severe RSV disease. Because of limited eligibility criteria for second season nirsevimab, estimating its effectiveness is challenging. Objective: We evaluated nirsevimab…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "589d0b9f9e1d89af52bc",
          "source": "web",
          "type": "change",
          "key": "#8ab52a3aecc1f7d47823",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-14/2026-11-16/60",
          "timestamp": null,
          "observed_at": "2026-11-16T18:16:39Z",
          "data": {
            "change": "added",
            "label": "Preprint: Nirsevimab effectiveness against RSV hospitalizations in children 8-23 months at risk of severe RSV",
            "item_type": "record",
            "summary": "added: Preprint: Nirsevimab effectiveness against RSV hospitalizations in children 8-23 months at risk of severe RSV",
            "after": {
              "title": "Preprint: Nirsevimab effectiveness against RSV hospitalizations in children 8-23 months at risk of severe RSV",
              "authors": "Simeone, R. M.; Newhams, M. M.; Payne, A. B.; Orzel-Lockwood, A. O.; Calixte, J.; Halasa, N.; Kamidani, S.; Crandall, H.; Irby, K.; Maddux, A. B.; Zerr, D.; Guzman-Cottrill, J.; Schuster, J.; Chiotos, K.; Kong, M.; Staat, M. A.; Hume, J.; Stockwell, M. S.; Cameron, M.; Hogan, A. H.; Chauhan, J.; Biggs, A.; Levy, E. R.; Bhumbra, S.; Walker, T. C.; Marupudi, N. K.; Prahl, M. K.; Michelson, K. N.; Martin, L.; Brandford, T.; Randolph, A.; Campbell, A. P.; Overcoming RSV Network investigators,  ",
              "author_corresponding": "Regina M Simeone",
              "author_corresponding_institution": "CDC",
              "doi": "10.64898/2026.11.13.26368017",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc0",
              "category": "epidemiology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.13.26368017.source.xml",
              "abstract": "Importance: Respiratory syncytial virus (RSV) is a leading cause of hospitalization in high-risk young children during their second RSV season. Nirsevimab, a long-acting monoclonal antibody against RSV, is recommended for some children who are at increased risk for severe RSV and entering their second RSV season to prevent severe RSV disease. Because of limited eligibility criteria for second season nirsevimab, estimating its effectiveness is challenging. Objective: We evaluated nirsevimab effectiveness against RSV-associated hospitalizations among young children eligible to receive nirsevimab during their second RSV season. Design: This retrospective case control study with a test-negative design was conducted during the 2024-2025 and 2025-2026 RSV seasons. Setting: Enrollment was in 26 hospitals across 24 U.S. states. Participants: Children eligible for nirsevimab during their second RSV season (as recommended in August 2023) were included. Nirsevimab-eligible children 8-23 months old hospitalized with respiratory symptoms were enrolled. Case-patients tested positive for RSV; control-patients tested negative for RSV. Exposures: Receipt of nirsevimab before or during the second RSV season and at least 7 days before symptom onset. Outcomes and measures: RSV-associated hospitalization. We estimated nirsevimab effectiveness using multivariable logistic regression adjusted for age, month and year of hospitalization, census region, and sex comparing the odds of second season nirsevimab receipt among case- and control-patients. Results: One hundred six case-patients and 125 control-patients were analyzed. Distributions of age, sex, race and ethnicity, and region were similar in case- and control-patients. Most case- and control-patients were eligible for nirsevimab because of chronic lung disease of prematurity (84.0% and 69.6%, respectively). Overall, 21 (19.8%) of case-patients and 53 (42.4%) of control-patients received nirsevimab. Adjusted nirsevimab effectiveness against RSV-associated hospitalizations was 78.1% (95% CI, 55.2%-89.3%); the median interval from nirsevimab receipt to symptom onset was 66.5 days (IQR = 30-96 days). Effectiveness was estimated to be higher if nirsevimab was received 8-59 days before symptom onset (88.5%, 95% CI, 63.4%-96.4%). Conclusions: This analysis provides real-world estimates of substantial nirsevimab effectiveness against RSV-associated hospitalizations for high-risk U.S. children in their second RSV season These data support recommendations for nirsevimab as a preventive strategy in this population.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Importance: Respiratory syncytial virus (RSV) is a leading cause of hospitalization in high-risk young children during their second RSV season. Nirsevimab, a long-acting monoclonal antibody against RSV, is recommended for some children who are at increased risk for severe RSV and entering their second RSV season to prevent severe RSV disease. Because of limited eligibility criteria for second season nirsevimab, estimating its effectiveness is challenging. Objective: We evaluated nirsevimab effectiveness against RSV-associated hospitalizations among young children eligible to receive nirsevimab during their second RSV season. Design: This retrospective case control study with a test-negative design was conducted during the 2024-2025 and 2025-2026 RSV seasons. Setting: Enrollment was in 26 hospitals across 24 U.S. states. Participants: Children eligible for nirsevimab during their second RSV season (as recommended in August 2023) were included. Nirsevimab-eligible children 8-23 months old hospitalized with respiratory symptoms were enrolled. Case-patients tested positive for RSV; control-patients tested negative for RSV. Exposures: Receipt of nirsevimab before or during the second RSV season and at least 7 days before symptom onset. Outcomes and measures: RSV-associated hospitalization. We estimated nirsevimab effectiveness using multivariable logistic regression adjusted for age, month and year of hospitalization, census region, and sex comparing the odds of second season nirsevimab receipt among case- and control-patients. Results: One hundred six case-patients and 125 control-patients were analyzed. Distributions of age, sex, race and ethnicity, and region were similar in case- and control-patients. Most case- and control-patients were eligible for nirsevimab because of chronic lung disease of prematurity (84.0% and 69.6%, respectively). Overall, 21 (19.8%) of case-patients and 53 (42.4%) of control-patients received nirsevimab. Adjusted nirsevimab effectiveness against RSV-associated hospitalizations was 78.1% (95% CI, 55.2%-89.3%); the median interval from nirsevimab receipt to symptom onset was 66.5 days (IQR = 30-96 days). Effectiveness was estimated to be higher if nirsevimab was received 8-59 days before symptom onset (88.5%, 95% CI, 63.4%-96.4%). Conclusions: This analysis provides real-world estimates of substantial nirsevimab effectiveness against RSV-associated hospitalizations for high-risk U.S. children in their second RSV season These data support recommendations for nirsevimab as a preventive strategy in this population.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368017v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-14/2026-11-16/60",
            "content_type": "application/json",
            "elapsed_ms": 1619,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26368017v1?rss=1"
    },
    {
      "id": "09bf8ae2bd9832635561",
      "title": "Preprint: Emergent Heterogeneity in Compartmental Disease Models",
      "content_text": "Heterogeneity in infectious disease spread reshapes the risk and severity of outbreaks. This heterogeneity can arise from intrinsic individual-level differences in susceptibility, contact patterns, and infectious durations. Heterogeneity can also emerge from disease dynamics in a canonically homogeneous population, due to the fact that individuals randomly become infected at different times, recover after different intervals, and have access to different numbers of susceptible individuals…",
      "date_published": "2026-11-16T00:00:00Z",
      "_unlimitedpipe": {
        "event": {
          "schema": "unlimitedpipe.event/1",
          "id": "09bf8ae2bd9832635561",
          "source": "web",
          "type": "change",
          "key": "#974e4ef4b87eef8c0b18",
          "source_url": "https://api.biorxiv.org/details/medrxiv/2026-11-14/2026-11-16/60",
          "timestamp": null,
          "observed_at": "2026-11-16T18:16:39Z",
          "data": {
            "change": "added",
            "label": "Preprint: Emergent Heterogeneity in Compartmental Disease Models",
            "item_type": "record",
            "summary": "added: Preprint: Emergent Heterogeneity in Compartmental Disease Models",
            "after": {
              "title": "Preprint: Emergent Heterogeneity in Compartmental Disease Models",
              "authors": "Roswell, M.; Aghaeeyan, A.; Goel, T.; Beckett, S. J.; Weitz, J. S.; Dushoff, J.",
              "author_corresponding": "Jonathan Dushoff",
              "author_corresponding_institution": "McMaster University",
              "doi": "10.64898/2026.11.13.26367950",
              "date": "2026-11-16",
              "version": "1",
              "type": "PUBLISHAHEADOFPRINT",
              "license": "cc_by_nc",
              "category": "epidemiology",
              "jatsxml": "https://www.medrxiv.org/content/early/2026/11/16/2026.11.13.26367950.source.xml",
              "abstract": "Heterogeneity in infectious disease spread reshapes the risk and severity of outbreaks. This heterogeneity can arise from intrinsic individual-level differences in susceptibility, contact patterns, and infectious durations. Heterogeneity can also emerge from disease dynamics in a canonically homogeneous population, due to the fact that individuals randomly become infected at different times, recover after different intervals, and have access to different numbers of susceptible individuals. Here, we explore the mechanisms generating emergent heterogeneity by analyzing secondary case distributions within the SIR model. We show numerically and prove analytically that the variation in secondary cases, calculated over the course of the epidemic, does not change with R0. This is in contrast to the increasing variation in secondary cases in the linearized SIR model, often used to study heterogeneity at the beginning of an outbreak. When we consider forward cohorts of individuals infected at the same time, between-cohort variation increases as R0 increases, while within-cohort variation decreases. We show that these effects balance exactly, leading to the invariance of the variation in secondary cases with respect to R0. These results demonstrate the importance of considering emergent, as well as intrinsic, variation between individuals and of considering heterogeneity of transmission spread over the whole epidemic cycle, including substantive dynamical effects that appear even in the initial outbreak phase.",
              "published": "NA",
              "server": "medRxiv",
              "summary": "Heterogeneity in infectious disease spread reshapes the risk and severity of outbreaks. This heterogeneity can arise from intrinsic individual-level differences in susceptibility, contact patterns, and infectious durations. Heterogeneity can also emerge from disease dynamics in a canonically homogeneous population, due to the fact that individuals randomly become infected at different times, recover after different intervals, and have access to different numbers of susceptible individuals. Here, we explore the mechanisms generating emergent heterogeneity by analyzing secondary case distributions within the SIR model. We show numerically and prove analytically that the variation in secondary cases, calculated over the course of the epidemic, does not change with R0. This is in contrast to the increasing variation in secondary cases in the linearized SIR model, often used to study heterogeneity at the beginning of an outbreak. When we consider forward cohorts of individuals infected at the same time, between-cohort variation increases as R0 increases, while within-cohort variation decreases. We show that these effects balance exactly, leading to the invariance of the variation in secondary cases with respect to R0. These results demonstrate the importance of considering emergent, as well as intrinsic, variation between individuals and of considering heterogeneity of transmission spread over the whole epidemic cycle, including substantive dynamical effects that appear even in the initial outbreak phase.",
              "link": "https://www.medrxiv.org/content/10.64898/2026.11.13.26367950v1?rss=1",
              "published_at": "2026-11-16T00:00:00Z"
            }
          },
          "metadata": {
            "status": 200,
            "final_url": "https://api.biorxiv.org/details/medrxiv/2026-11-14/2026-11-16/60",
            "content_type": "application/json",
            "elapsed_ms": 1619,
            "not_modified": false,
            "method": "json"
          },
          "provenance": [
            {
              "step": "web",
              "version": "0.10.62"
            },
            {
              "step": "filter",
              "version": "0.10.62",
              "args": {
                "expr": "version == \"1\""
              }
            },
            {
              "step": "map",
              "version": "0.10.62",
              "args": {
                "assign": [
                  "title=\"Preprint: \" + title",
                  "summary=abstract",
                  "link=\"https://www.medrxiv.org/content/\" + doi + \"v1?rss=1\"",
                  "published_at=date + \"T00:00:00Z\"",
                  "summary=replace(trim(summary), \"^(Background|Objectives?|Introduction|Aims?|Purpose|Importance|Context|Rationale)(?=[A-Z])\", \"\\\\1: \")"
                ]
              }
            },
            {
              "step": "dedupe",
              "version": "0.10.62",
              "args": {
                "by": [
                  "link"
                ]
              }
            },
            {
              "step": "diff",
              "version": "0.10.62",
              "args": {
                "namespace": "health-papers",
                "only": [
                  "added"
                ],
                "emit_initial": true
              }
            }
          ]
        }
      },
      "url": "https://www.medrxiv.org/content/10.64898/2026.11.13.26367950v1?rss=1"
    }
  ]
}
